Sentence,class,file
"Biol Open 2014; 3:1228-35; PMID:25432514; http://dx.doi.org/ 10.1242/bio.201410132[33] Balzac F, Avolio M, Degani S, Kaverina I, Torti M, Silengo L, Small JV, Retta SF.",OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"J CellSci 2005; 118:4765-83; PMID:16219685; http://dx.doi.org/10.1242/jcs.02584 [34] Retta SF, Balzac F, Avolio M. Rap1: a turnabout for the crosstalk between cadherins and integrins.",OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"Eur J Cell Biol 2006; 85:283-93; PMID:16546572; http://dx.doi.org/10.1016/j.ejcb.2005.09.007 [35] Goitre L, Pergolizzi B, Ferro E, Trabalzini L, Retta SF.",OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"J Signal Trans-duct 2012; 2012:807682; PMID:22203898; http://dx.doi.org/10.1155/2012/807682 [36] Scherz-Shouval R, Elazar Z. ROS, mitochondria and the regulation of autophagy.",Non-OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"Trends Cell Biol 2007;17:422-7; PMID:17804237; http://dx.doi.org/10.1016/j.tcb.2007.07.009 [37] Filomeni G, De Zio D, Cecconi F. Oxidative stress and autophagy: the clash between damage and metabolicneeds.",OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"Cell Death and Differentiation 2015; 22:377-88;PMID:25257172; http://dx.doi.org/10.1038/cdd.2014.150 [38] Zhao Y, Yang J, Liao WJ, Liu XY, Zhang H, Wang S, Wang DL, Feng JN, Yu L, Zhu WG.",OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"Nat Cell Biol 2010; 12:665-U88;PMID:20543840; http://dx.doi.org/10.1038/ncb2069 [39] Liu J, Bi X, Chen T, Zhang Q, Wang SX, Chiu JJ, Liu GS, Zhang Y, Bu P, Jiang F. Shear stress regulates endothelialcell autophagy via redox regulation and Sirt1 expression.",OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"Autophagy 2010; 6:566-7;PMID:20404571; http://dx.doi.org/10.4161/auto.6.4.11950 [41] Lin R, Feng J, Dong S, Pan R, Zhuang H, Ding Z. Regula- tion of autophagy of prostate cancer cells by beta-catenin signaling.",OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"Cell Physiol Biochem 2015; 35:926-32; PMID:25633614; http://dx.doi.org/10.1159/000369749 [42] Mleczak A, Millar S, Tooze SA, Olson MF, Chan EY.",OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"Regulation of autophagosome formation by Rho kinase.Cell Signal 2013; 25:1-11; PMID:22975682; http://dx.doi.org/10.1016/j.cellsig.2012.09.010 [43] Huang J, Lam GY, Brumell JH.",OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"Cell Cycle 2013;12:3317-28; PMID:24036548; http://dx.doi.org/10.4161/cc.26298 [45] Kumar S, Guru SK, Pathania AS, Kumar A, Bhushan S, Malik F. Autophagy triggered by magnolol derivative negatively regulates angiogenesis.",Non-OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"e889; PMID:24176847; http://dx.doi.org/10.1038/ cddis.2013.399 [46] Kim KW, Paul P, Qiao J, Lee S, Chung DH.",OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"Autophagy2013; 9:1579-90; PMID:24108003; http://dx.doi.org/10.4161/auto.25987 [47] Scherz-Shouval R, Elazar Z.",Non-OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"Trends Biochem Sci2011; 36:30-8; PMID:20728362; http://dx.doi.org/10.1016/j.tibs.2010.07.007 [48] Lee J, Giordano S, Zhang J. Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling.",OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"Bio-chem J 2012; 441:523-40; PMID:22187934; http://dx.doi.org/10.1042/BJ20111451 [49] Li DY, Whitehead KJ.",OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"Stroke 2010;41:S92-S4; PMID:20876517; http://dx.doi.org/10.1161/STROKEAHA.110.594929 [50] McDonald DA, Shi CB, Shenkar R, Stockton RA, Liu FF, Ginsberg MH, Marchuk DA, Awad IA.",Non-OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
Stroke 2012; 43:571-4; PMID:22034008; http://dx.doi.org/10.1161/ STROKEAHA.111.625467 [51] Wiseman H. Vitamin D is a membrane antioxidant.,Non-OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"FEBS Lett 1993;326:285-8; PMID:8325381; http://dx.doi.org/10.1016/0014-5793(93)81809-E [52] Aghajanian A, Wittchen ES, Campbell SL, Burridge K. Direct activationofRhoAbyreactiveoxygenspeciesrequiresaredox-sensitive motif.",OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"Plos One 2009; 4:e8045; PMID:19956681;http://dx.doi.org/10.1371/journal.pone.0008045 [53] Adam O, Laufs U. Antioxidative effects of statins.",OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"Arch Toxicol 2008; 82:885-92; PMID:18670762; http://dx.doi.org/10.1007/s00204-008-0344-4 [54] Kuhlmann CR, Gerigk M, Bender B, Closhen D, Less- mann V, Luhmann HJ.",OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"Life Sci2008; 82:1281-7; PMID:18534629; http://dx.doi.org/10.1016/j.lfs.2008.04.017 [55] Ma Z, Zhang J, Ji E, Cao G, Li G, Chu L. Rho kinase inhi- bition by fasudil exerts antioxidant effects in hyper-cholesterolemic rats.",OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"Clin Exp Pharmacol Physiol 2011;38:688-94; PMID:21711379; http://dx.doi.org/10.1111/ j.1440-1681.2011.05561.x [56] Costa D, Gomes A, Reis S, Lima JL, Fernandes E. Hydrogen peroxide scavenging activity by non-steroidal anti-in ﬂam- matory drugs.",OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"Life Sci 2005; 76:2841-8; PMID:15808884;http://dx.doi.org/10.1016/j.lfs.2004.10.052 [57] Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, AndrewsD, Annicchiarico-Petruzzelli M, et al.",OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"Cell Death Differ 2015; 22:58-73; PMID:25236395; http://dx.doi.org/10.1038/cdd.2014.137 [58] Zhang J, Yang Z, Xie L, Xu L, Xu D, Liu X. Statins, autophagy and cancer metastasis.",Non-OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"Int J Biochem Cell Biol2013; 45:745-52; PMID:23147595; http://dx.doi.org/10.1016/j.biocel.2012.11.001 [59] Wei YM, Li X, Xu M, Abais JM, Chen Y, Riebling CR, Boini KM, Li PL, Zhang Y. Enhancement of Autophagy by Simvastatin through Inhibition of Rac1-mTOR Signal-ing Pathway in Coronary Arterial Myocytes.",OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"Cell PhysiolBiochem 2013; 31:925-37; PMID:23817226; http://dx.doi.org/10.1159/000350111 [60] Iorio F, Isacchi A, di Bernardo D, Brunetti-Pierri N. Iden- tiﬁcation of small molecules enhancing autophagic func- tion from drug network analysis.",OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"Autophagy 2010; 6:1204-5; PMID:20930556; http://dx.doi.org/10.4161/ auto.6.8.13551 [61] Gurpinar E, Grizzle WE, Shacka JJ, Mader BJ, Li N, Piazza NA, Russo S, Keeton AB, Piazza GA. A NovelSulindac Derivative Inhibits Lung Adenocarcinoma CellGrowth through Suppression of Akt/mTOR Signalingand Induction of Autophagy.",Non-OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
Molecular Cancer Thera-peutics 2013; 12:663-74; PMID:23443799; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"Biochem Pharmacol 2011; 81:1317-23;PMID:21458423; http://dx.doi.org/10.1016/j.bcp.2011.03.019 [63] Lisse TS, Hewison M. Vitamin D: a new player in the world of mTOR signaling.",Non-OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"Cell Cycle 2011; 10:1888-9; PMID:21558808; http://dx.doi.org/10.4161/cc.10.12.15620 [64] Wu S, Sun J. Vitamin D, vitamin D receptor, and macro- autophagy in in ﬂammation and infection.",OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
J Biol Chem 2010; 285:36387-94; PMID:20851890; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
2016; 92:100-109; PMID:26795600; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/34/93/krad-04-01-1142640.PMC4838318.pdf
"Brain 138(7): 1801-1816. http://dx.doi.org/10 .1093/brain/ awv132 © Kerri J. Kinghorn and Jorge Iv /C19an Castillo-Quan This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/by-nc/3.0/), which per- mits unrestrictednon-commercial use, distribution, and reproductionin any medium, provided the original work is properlycited.",Non-OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"1, e1128616 (14 pages)http://dx.doi.org/10.1080/21675511.2015.1128616",Non-OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Nat Genet 2006; 38:752-4; PMID:16783378; http://dx.doi.org/10.1038/ng1826 [2] Khateeb S, Flusser H, O ﬁr R, Shelef I, Narkis G, Vardi G, Shorer Z, Levy R, Galil A, Elbedour K, et al.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"AmJ Hum Genet 2006; 79:942-8; PMID:17033970; http://dx.doi.org/10.1086/508572 [3] Gregory A, Westaway SK, Holm IE, Kotzbauer PT, Hogarth P, Sonek S, Coryell JC, Nguyen TM, NardocciN, Zorzi G, et al.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Neurology 2008; 71:1402-9; PMID:18799783; http://dx.doi.org/10.1212/01.wnl.0000327094.67726.28 [4] Winstead MV1, Balsinde J, Dennis EA.",Non-OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Bio-chim Biophys Acta 2000; 1488:28-39; PMID:11080674;http://dx.doi.org/10.1016/S1388-1981(00)00107-4 [5] Burke JE, Dennis EA.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Cardiovasc Drugs Ther 2009; 23:49-59; PMID:18931897; http://dx.doi.org/10.1007/s10557-008-6132-9 [6] Ong WY, Yeo JF, Ling SF, Farooqui AA.",Non-OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"J Neurocytol 2005; 34:447-58; PMID:16902765; http://dx.doi.org/10.1007/s11068-006-8730-4 [7] Williams, SD and Gottlieb, RA.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"J Biochem 2002; 362:23-32; http://dx.doi.org/10.1042/bj3620023 [8] Seleznev K, Zhao C, Zhang XH, Song K, Ma ZA.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
J Biol Chem 2006; 281:22275-88;PMID:16728389; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"M604330200[9] Song H1, Bao S, Lei X, Jin C, Zhang S, Turk J, Ramanad- ham S. Evidence for proteolytic processing and stimu-lated organelle redistribution of iPLA(2) b. Biochim Biophys Acta 2010; 1801:547-58; PMID:20132906; http://dx.doi.org/10.1016/j.bbalip.2010.01.006 [10] Balsinde J, Balboa MA.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Cell Signal 2005; 17:1052-62; PMID:15993747; http://dx.doi.org/10.1016/j.cellsig.2005.03.002 [11] Wang Z, Ramanadham S, Ma ZA, Bao S, Mancuso DJ, Gross RW, Turk J.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"J Biol Chem 2005; 280:6840-9; PMID:15576376; http://dx.doi.org/10.1074/jbc.M405287200 [12] Balsinde J1, Bianco ID, Ackermann EJ, Conde-Frieboes K, Dennis EA.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"1999; 269:278-88; PMID:10221999; http://dx.doi.org/10.1006/abio.1999.4053 [14] Balboa MA1, Balsinde J.",Non-OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"J Biol Chem 2002; 277:40384-9; PMID:12181317; http://dx.doi.org/10.1074/jbc.M206155200 [15] Shindou H1, Hishikawa D, Harayama T, Eto M, Shimizu T. Generation of membrane diversity bylysophospholipid acyltran sferases.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
J Biochem 2013; 154:21-8; PMID:23698096; http://dx.doi.org/10.1093/jb/mvt048 [16] Glynn P. Neuronal phospholipid deacylation is essential for axonal and synaptic integrity.,Non-OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Biochim Biophys Acta 2013; 1831:633-41; PMID:22903185; http://dx.doi.org/10.1016/j.bbalip.2012.07.023 [17] Balboa MA, P /C19erez R, Balsinde J. Calcium-independent phospholipase A2 mediates proliferation of humanpromonocytic U937 cells.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"J Biol Chem 2004; 279:40385-91; http://dx.doi.org/10.1074/jbc.M402562200 [19] Malaguti MC, Melzi V, Di Giacopo R, Monfrini E, Di Biase E, Franco G, Borellini L, Trezzi I, Monzio Compag- noni G, Fortis P, et al.",Non-OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Psychiatr Genet 2013; 23:86-9; PMID:23277130;http://dx.doi.org/10.1097/YPG.0b013e32835d700d [21] Ning LF, Yu YQ, GuoJi ET, Kou CG, Wu YH, Shi JP, Ai LZ, Yu Q. Meta-analysis of differentially expressed genesin autism based on gene expression data.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Genet Mol Res2015; 14:2146-55; PMID:25867362; http://dx.doi.org/10.4238/2015.March.27.1 [22] Zhang P, Gao Z, Jiang Y, Wang J, Zhang F, Wang S, Yang Y, Xiong H, Zhang Y, Bao X, et al.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Eur J Neurol 2013; 20:322-30; PMID:22934738; http://dx.doi.org/10.1111/j.1468-1331.2012.03856.x [23] Nardocci N, Zorzi G, Farina L, Binelli S, Scaioli W, Ciano C, Verga L, Angelini L, Savoiardo M, Bugiani O. Infantileneuroaxonal dystrophy: clinical spectrum and diagnosticcriteria.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Neurology 1999; 52:1472-8; PMID:10227637;http://dx.doi.org/10.1212/WNL.52.7.1472 [24] Riku Y, Ikeuchi T, Yoshino H, Mimuro M, Mano K, Goto Y, Hattori N, Sobue G, Yoshida M. Extensive aggregation ofa-synuclein and tau in juvenile-onset neuroaxonal dystrophy: an autopsied individual with a novel mutationin the PLA2G6 gene-splicing site.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Acta NeuropatholCommun 2013; 1:12; PMID:24252552; http://dx.doi.org/10.1186/2051-5960-1-12 [25] Biancheri R, Rossi A, Alpigiani G, Filocamo M, Gandolfo C, Lorini R, Minetti C. Cerebellar atrophy without cere- bellar cortex hyperintensity in infantile neuroaxonal dys- trophy (INAD) due to PLA2G6 mutation.",Non-OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Eur J PaediatrNeurol 2007; 11:175-7; PMID:17254819; http://dx.doi.org/10.1016/j.ejpn.2006.11.013 [26] Kurian MA, Morgan NV, MacPherson L, Foster K, Peake D, Gupta R, Philip SG, Hendriksz C, Morton JE, King-ston HM, et al.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Neurology 2008; 70:1623-9; PMID:18443314; http://dx.doi.org/10.1212/01.wnl.0000310986.48286.8e [27] Arber CE, Li A, Houlden H, Wray S. Insights into molec- ular mechanisms of disease in neurodegeneration withbrain iron accumulation: unifying theories.",Non-OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"NeuropatholAppl Neurobiol 2015; PMID:25870938; http://dx.doi.org/10.1111/nan.12242 [28] Paisan-Ruiz C, Bhatia KP, Li A, Hernandez D, Davis M, Wood NW, Hardy J, Houlden H, Singleton A, Schneider SA.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Ann Neurol 2009; 65:19-23; PMID:18570303; http://dx.doi.org/10.1002/ana.21415 [29] Shi CH, Tang BS, Wang L, Lv ZY, Wang J, Luo LZ, Shen L, Jiang H, Yan XX, Pan Q, et al.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Neurology 2011; 77:75-81; PMID:21700586; http://dx.doi.org/10.1212/WNL.0b013e318221acd3[30] Lu CS1, Lai SC, Wu RM, Weng YH, Huang CL, Chen RS, Chang HC, Wu-Chou YH, Yeh TH.",Non-OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Am J Med Genet B Neuropsy-chiatr Genet 2012; 159B:183-91; PMID:22213678; http://dx.doi.org/10.1002/ajmg.b.32012 [31] Xie F, Cen Z, Ouyang Z, Wu S, Xiao J, Luo W. Homozy- gous p.D331Y mutation in PLA2G6 in two patients with pure autosomal-recessive early-onset parkinsonism: fur-ther evidence of a fourth phenotype of PLA2G6-associ-ated neurodegeneration.",Non-OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Parkinsonism Relat Disord2015; 21:420-2; PMID:25660576; http://dx.doi.org/10.1016/j.parkreldis.2015.01.012 [32] Kimura T, Fujise N, Ono T, Shono M, Yuzuriha T, Katsuragi S, Takamatsu J, Miyakawa T, Kitamura T. Identi ﬁcation of an aging-related spherical inclusion in the human brain.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Pathol Int 2002; 52:636-42; PMID:12445135; http://dx.doi.org/10.1046/j.1440-1827.2002.01402.x [33] Malik I, Turk J, Mancuso DJ, Montier L, Wohltmann M, Wozniak DF, Schmidt RE, Gross RW, Kotzbauer PT.Disrupted membrane homeostasis and accumulation ofubiquitinated proteins in a mouse model of infantile neu- roaxonal dystrophy caused by PLA2G6 mutations.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Am J Pathol 2008; 172:406-16; PMID:18202189; http://dx.doi.org/10.2353/ajpath.2008.070823 [34] Pais /C19an-Ruiz C, Li A, Schneider S, Holton JL, Johnson R, Kidd D, Chataway J, Bhatia KP, Lees AJ, Hardy J, et al.Widespread Lewy body and tau accumulation in child-hood and adult onset dystonia-parkinsonism cases withPLA2G6 mutations.",Non-OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Neurobiol Aging 2012; 33:814-823; http://dx.doi.org/10.1016/j.neurobiolaging.2010.05.009 [35] Beck G, Sugiura Y, Shinzawa K, Kato S, Setou M, Tsuji- moto Y, Sakoda S, Sumi-Akamaru H. Neuroaxonal dys-trophy in calcium-independent phospholipase A2 b deﬁciency results from insuf ﬁcient remodeling and degeneration of mitochondrial and presynaptic mem-branes.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"J Neurosci 2011; 31:11411-20; PMID:21813701;http://dx.doi.org/10.1523/JNEUROSCI.0345-11.2011 [36] Engel LA, Jing Z, O ’Brien DE, Sun M, Kotzbauer PT.",Non-OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"PLoS One 2010; 5:e12897;PMID:20886109; http://dx.doi.org/10.1371/journal.pone.0012897 [37] Gui YX, Xu ZP, Wen-Lv, Liu HM, Zhao JJ, Hu XY.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Parkinsonism Relat Disord 2013; 19:21-6; PMID:23182313; http://dx.doi.org/10.1016/j.parkreldis.2012.07.016 [38] Kagan VE, Borisenko GG, Tyurina YY, Tyurin VA, Jiang J, Potapovich AI, Kini V, Amoscato AA, Fujii Y. Oxida-tive lipidomics of apoptosis: redox catalytic interactionsof cytochrome c with cardiolipin and phosphatidylserine.Free Radic Biol Med 2004; 37:1963-85; PMID:15544916; http://dx.doi.org/10.1016/j.freeradbiomed.2004.08.016RARE DISEASES e1128616-11",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"NatChem Biol 2005; 1:223-32; PMID:16408039; http://dx.doi.org/10.1038/nchembio727 [40] Wada H1, Yasuda T, Miura I, Watabe K, Sawa C, Kami- juku H, Kojo S, Taniguchi M, Nishino I, Wakana S, Yoshida H, et al.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Establishment of an improved mousemodel for infantile neuroaxonal dystrophy that showsearly disease onset and bears a point mutation in Pla2g6.Am J Pathol 2009; 175:2257-63; PMID:19893029; http://dx.doi.org/10.2353/ajpath.2009.090343 [41] Cheon Y, Kim HW, Igarashi M, Modi HR, Chang L, Ma K, Greenstein D, Wohltmann M, Turk J, Rapoport SI, et al.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Biochim Biophys Acta 2012; 1821:1278-86; PMID:22349267; http://dx.doi.org/10.1016/j.bbalip.2012.02.003 [42] Strokin M, Seburn KL, Cox GA, Martens KA, Reiser G. Severe disturbance in the Ca 2Csignaling in astrocytes from mouse models of human infantile neuroaxonal dys- trophy with mutated Pla2g6.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Hum Mol Genet 2012; 21:2807-14; PMID:22442204; http://dx.doi.org/10.1093/hmg/dds108 [43] Zhao Z, Wang J, Zhao C, Bi W, Yue Z, Ma ZA.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"PLoS One 2011; 6:e26991; PMID:22046428; http://dx.doi.org/10.1371/journal.pone.0026991 [44] Shinzawa K, Sumi H, Ikawa M, Matsuoka Y, Okabe M, Sakoda S, Tsujimoto Y. Neuroaxonal dystrophy causedby group VIA phospholipase A2 de ﬁciency in mice: a model of human neurodegenerative disease.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"J Neurosci2008; 28:2212-20; PMID:18305254; http://dx.doi.org/10.1523/JNEUROSCI.4354-07.2008 [45] Kinghorn KJ, Castillo-Quan JI, Bartolome F, Angelova PR, Li L, Pope S, Cochem /C19e HM, Khan S, Asghari S, Bha- tia KP, et al.",Non-OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
Loss of PLA2G6 leads to elevated mitochon- drial lipid peroxidation and mitochondrial dysfunction.Brain 2015; 138:1801-16; PMID:26001724; http://dx.doi.org/10.1093/brain/awv132 [46] Schlame M. Cardiolipin remodeling and the function of tafazzin.,Non-OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Biochim Biophys Acta 2013; 1831:582-8;PMID:23200781; http://dx.doi.org/10.1016/j.bbalip.2012.11.007 [47] Hill S, Hirano K, Shmanai VV, Marbois BN, Vidovic D, Bekish AV, Kay B, Tse V, Fine J, Clarke CF, et al.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Free Radic Biol Med 2011;50:130-8; PMID:20955788; http://dx.doi.org/10.1016/j.freeradbiomed.2010.10.690 [48] Hill S, Lamberson CR, Xu L, To R, Tsui HS, Shmanai VV, Bekish AV, Awad AM, Marbois BN, Cantor CR, et al.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
Free Radic BiolMed 2012; 53:893-906; PMID:22705367; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
Toxicol Lett 2011; 207:97-103; PMID:21906664; http://dx.doi.org/10.1016/j.toxlet.2011.,OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"07.020 [50] Campanella A, Privitera D, Guaraldo M, Rovelli E, Barza- ghi C, Garavaglia B, Santambrogio P, Cozzi A, Levi S.Skin ﬁbroblasts from pantothenate kinase-associated neurodegeneration patients show altered cellular oxida-tive status and have defective iron-handling properties.Hum Mol Genet 2012; 21:4049-59; PMID:22692681; http://dx.doi.org/10.1093/hmg/dds229 [51] Brunetti D, Dusi S, Morbin M, Uggetti A, Moda F, D’Amato I, Giordano C, d ’Amati G, Cozzi A, Levi S, et al.",Non-OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"2012; 21(24):5294-305; PMID:22983956; http://dx.doi.org/10.1093/hmg/dds380 [52] H €ortnagel K, Prokisch H, Meitinger T. An isoform of hPANK2, de ﬁcient in pantothenate kinase-associated neurodegeneration, localizes to mitochondria.",Non-OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Hum MolGenet 2003; 12(3):321-7; PMID:12554685; http://dx.doi.org/10.1093/hmg/ddg026 [53] Rock CO, Calder RB, Karim MA, Jackowski S. Pantothe- nate kinase regulation of the intracellular concentrationof coenzyme A. J Biol Chem 2000; 275:1377-83; PMID:10625688; http://dx.doi.org/10.1074/jbc.275.2.1377 [54] Perry TL, Norman MG, Yong VW, Whiting S, Crich- ton JU, Hansen S, Kish SJ.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Ann Neurol 1985; 18(4):482-9; PMID:4073841; http://dx.doi.org/10.1002/ana.410180411 [55] Bosveld F, Rana A, van der Wouden PE, Lemstra W, Rit- sema M, Kampinga HH, Sibon OC.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"HumMol Genet 2008; 17:2058-69; PMID:18407920; http://dx.doi.org/10.1093/hmg/ddn105 [56] Rana A, Seinen E, Siudeja K, Muntendam R, Srinivasan B, van der Want JJ, Hay ﬂick S, Reijngoud DJ, Kayser O, Sibon OC.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Cell Cycle 2006; 5(12):1292-6; PMID:16760669; http://dx.doi.org/10.4161/cc.5.12.2865 [60] Zhyvoloup A, Nemazanyy I, Babich A, Panasyuk G, Pobigailo N, Vudmaska M, Naidenov V, Kukharenko O,Palchevskii S, Savinska L, et al.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"J BiolChem 2002; 277:22107-10; PMID:11980892; http://dx.doi.org/10.1074/jbc.C200195200 [61] Nemazanyy I, Panasyuk G, Breus O, Zhyvoloup A, Filo- nenko V, Gout IT.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Bio- chem Biophys Res Commun 2006; 341:995-1000; PMID:16460672; http://dx.doi.org/10.1016/j.bbrc.2006.01.051 [62] Dusi S, Valletta L, Haack TB, Tsuchiya Y, Venco P, Pasqua- l a t oS ,G o f f r i n iP ,T i g a n oM ,D e m c h e n k oN ,W i e l a n dT ,Schwarzmayr T, et al.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
Am J Hum Genet 2014; 94:11-22; PMID:24360804; http://dx.doi.org/10.1016/j.ajhg.2013.,OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Proteomic mapping of mitochondriain living cells via spatially restricted enzymatic tagging.Science 2013; 339:1328-1331; PMID:23371551; http://dx.doi.org/10.1126/science.1230593 [64] Zhyvoloup A, Nemazanyy I, Panasyuk G, Valovka T, Fenton T, Rebholz H, Wang ML, Foxon R, Lyzogubov V, Usenko V, et al.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"J Biol Chem 2003; 278:50316-50321; PMID:14514684; http://dx.doi.org/10.1074/jbc.M307763200 [65] Alfonso-Pecchio A, Garcia M, Leonardi R, Jackowski S. Compartmentalization of mammalian pantothenate kin-ases.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Mol Genet Metab 2012; 105:463-71; PMID:22221393; http://dx.doi.org/10.1016/j.ymgme.2011.12.005 [67] Hartig MB, Iuso A, Haack T, Kmiec T, Jurkiewicz E, Heim K, Roeber S, Tarabin V, Dusi S, Krajewska-Walasek M, et al.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Am J HumGenet 2011; 89(4):543-50; http://dx.doi.org/10.1016/j.ajhg.2011.09.007 [68] Gagliardi M, Annesi G, Lesca G, Broussolle E, Iannello G, Vaiti V, Gambardella A, Quattrone A. C19orf12 gene mutations in patients with neurodegeneration with brain iron accumulation.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
Parkinsonism Relat Disord 2015;21:813-6; PMID:25962551; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"JNeurol Sci 2015; 357:115-8; PMID:26187298; http://dx.doi.org/10.1016/j.jns.2015.07.009 [70] Kruer MC, Salih MA, Mooney C, Alzahrani J, Elmalik SA, Kabiraj MM, Khan AO, Paudel R, Houlden H,Azzedine H, et al.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Gene 2014; 537:352-6;PMID:24361204; http://dx.doi.org/10.1016/j.gene.2013.11.039 [71] Landour /C19e G, Zhu PP, Louren ¸co CM, Johnson JO, Toro C, Bricceno KV, Rinaldi C, Meilleur KG, Sangar /C19eM ,D i a l l oO , et al.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Hum Mutat 2013;34:1357-60; PMID:Can ’t; http://dx.doi.org/10.1002/ humu.22378 [72] Hogarth P, Gregory A, Kruer MC, Sanford L, Wagoner W, Natowicz MR, Egel RT, Subramony SH, Goldman JG,Berry-Kravis E, et al.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
Front Genet 2015; 6:185; PMID:26136767; http://dx.doi.org/10.3389/fgene.2015.,OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"PLoS One 2014;9:e89439; PMID:24586779; http://dx.doi.org/10.1371/journal.pone.0089439 [75] Edvardson S, Hama H, Shaag A, Gomori JM, Berger I, Soffer D, Korman SH, Taustein I, Saada A, Elpeleg O.Mutations in the fatty acid 2-hydroxylase gene are associ-ated with leukodystrophy with spastic paraparesis anddystonia.",Non-OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Mutation of FA2H underlies a compli- cated form of hereditary spastic paraplegia (SPG35).Hum Mutat 2010; 31:E1251-60; PMID:20104589; http://dx.doi.org/10.1002/humu.21205 [77] Kruer MC, Gregory A, Hay ﬂick SJ.",Non-OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"J Lipid Res 2008; 49:153-61; PMID:17901466; http://dx.doi.org/10.1194/jlr.M700400-JLR200 [79] Eckhardt M, Yaghootfam A, Fewou SN, Z €oller I, Giesel- mann V. A mammalian fatty acid hydroxylase responsible for the formation of a-hydroxylated galactosylceramide in myelin.",Non-OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Biochem J 2005; 388:245-54; PMID:15658937;http://dx.doi.org/10.1042/BJ20041451 [80] Fukunaga M, Li TQ, van Gelderen P, de Zwart JA, Shmueli K, Yao B, Lee J, Maric D, Aronova MA, ZhangG, et al.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"J Lipid Res 2009; 50:1203-8; PMID:19171550http://dx.doi.org/10.1194/jlr.M800666-JLR200 [82] Kota V, Hama H. 2 0-Hydroxy ceramide in membrane homeostasis and cell signaling.",Non-OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
Adv Biol Regul 2014;54:223-30; PMID:24139861; http://dx.doi.org/; http://dx.,OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"J Biol Chem 2007; 282:13211-9; PMID:17355976; http://dx.doi.org/10.1074/jbc.M611562200 [84] Bras J, Singleton A, Cookson MR, Hardy J.",OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"FEBS J 2008;275:5767-73; PMID:19021754; http://dx.doi.org/10.1111/j.1742-4658.2008.06709.x [85] Lei X, Zhang S, Bohrer A, Bao S, Song H, Ramanadham S. The group VIA calcium-independent phospholipaseA2 participates in ER stress-induced INS-1 insulinoma cell apoptosis by promoting ceramide generation viahydrolysis of sphingomyelins by neutral sphingomyeli-nase.",Non-OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Biochemistry 2007; 46:10170-85; PMID:17685585;http://dx.doi.org/10.1021/bi700017z [86] Ben-David O, Futerman AH.",Non-OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"Neuromolecular Med 2010; 12:341- 50; PMID:20502986; http://dx.doi.org/10.1007/s12017-010-8114-x [87] Levi S, Finazzi D. Neurodegeneration with brain iron accumulation: update on pathogenic mechanisms.FrontPharmacol 2014; 5:99; PMID:24847269; http://dx.doi.org/10.3389/fphar.2014.00099 [88] Horowitz MP, Greenamyre JT.",Non-OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
Biochim Biophys Acta 2014;1842:1282-94; PMID:24060637; http://dx.doi.org/10.1016/j.bbadis.2013.09.007 [91] Murphy MP.,OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
Free Radic Biol Med 2014; 66:20-3; PMID: 23603661; http://dx.doi.org /10.1016/j.freeradbiomed.,OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
Ann N YAcad Sci 2010; 1201:96-103; PMID:20649545; http://dx.doi.org/10.1111/j.1749-6632.2010.05627.xe1128616-14 K. J. KINGHORN AND J. I. CASTILLO-QUAN,OADS,/arxiv_data1/oa_pdf/0a/94/krad-04-01-1128616.PMC4838319.pdf
"1, e1153778 (9 pages)http://dx.doi.org/10.1080/21675511.2016.1153778",Non-OADS,/arxiv_data1/oa_pdf/b9/79/krad-04-01-1153778.PMC4838320.pdf
"Available from: http://www.ncbi.nlm.nih.gov/pubmed/17496168; PMID:17496168; http://dx.doi.org/10.1124/jpet.107.123000 [2] Bordet T, Berna P, Abitbol JL, Pruss RM.",OADS,/arxiv_data1/oa_pdf/b9/79/krad-04-01-1153778.PMC4838320.pdf
Pharmaceuticals 2010; 3:345-68;http://dx.doi.org/10.3390/ph3020345 [3] Colombini M. VDAC: the channel at the interface between mitochondria and the cytosol.,OADS,/arxiv_data1/oa_pdf/b9/79/krad-04-01-1153778.PMC4838320.pdf
"J Bioenerg Biomembr 2008; 40:199-205; PMID:18670869; http://dx.doi.org/10.1007/s10863-008-9142-1 [6] Gouarn /C19e C, Tracz J, Paoli MG, Deluca V, Seimandi M ,T a r d i fG ,X i l o u r iM ,S t e f a n i sL ,B o r d e tT ,P r u s s R M .P r o t e c t i v er o l eo fo l e s o x i m ea g a i n s tw i l d - t y p e a-synuclein-induced toxicity in human neuronally dif- ferentiated SHSY-5Y cells.",Non-OADS,/arxiv_data1/oa_pdf/b9/79/krad-04-01-1153778.PMC4838320.pdf
"Available from: http://doi.wiley.com/10.1111/bph.12939; PMID: 25220617; http://dx.doi.org/10.1111/bph.12939 [7] Gouarn /C19e C, Giraudon-Paoli M, Seimandi M, Biscarrat C, Tardif G, Pruss RM, Bordet T. Olesoxime protects embryonic cortical neurons from camptothecin intoxica- tion by a mechanism distinct from BDNF.",Non-OADS,/arxiv_data1/oa_pdf/b9/79/krad-04-01-1153778.PMC4838320.pdf
"Br J Pharma-col 2013; 168:1975-88; PMID:23278424; http://dx.doi.org/10.1111/bph.12094 [8] Rovini A, Carr /C19eM ,B o r d e tT ,P r u s sR M ,B r a g u e rD .",Non-OADS,/arxiv_data1/oa_pdf/b9/79/krad-04-01-1153778.PMC4838320.pdf
"Biochem Pharmacol 2010; 80:884-94; PMID:20417191; http://dx.doi.org/10.1016/ j.bcp.2010.04.018 [9] Magalon K, Zimmer C, Cayre M, Khaldi J, Bourbon C, Robles I, Tardif G, Viola A, Pruss RM, Bordet T,et al.",OADS,/arxiv_data1/oa_pdf/b9/79/krad-04-01-1153778.PMC4838320.pdf
"Ann Neurol 2012;71:213-26; PMID:22367994; http://dx.doi.org/10.1002/ana.22593 [10] Sunyach C, Michaud M, Arnoux T, Bernard-Marissal N, Aebischer J, Latyszenok V, Gouarn /C19e C, Raoul C, Pruss RM, Bordet T, et al.",OADS,/arxiv_data1/oa_pdf/b9/79/krad-04-01-1153778.PMC4838320.pdf
"Neuropharmacology2012; 62:2346-52; PMID:22369784; http://dx.doi.org/10.1016/j.neuropharm.2012.02.013[11] Richter F, Gao F, Medvedeva V, Lee P, Bove N, Flem- ing SM, Michaud M, Lemesre V, Patassini S, De LaRosa K, et al.",OADS,/arxiv_data1/oa_pdf/b9/79/krad-04-01-1153778.PMC4838320.pdf
"J Phar-macol Exp Ther 2008; 326:623-32; PMID:18492948; http://dx.doi.org/10.1124/jpet.108.139410 [13] Xiao WH, Zheng FY, Bennett GJ, Bordet T, Pruss RM.",OADS,/arxiv_data1/oa_pdf/b9/79/krad-04-01-1153778.PMC4838320.pdf
"Pain 2009; 147:202-9; PMID:19833436;http://dx.doi.org/10.1016/j.pain.2009.09.006 [14] Xiao WH, Zheng H, Bennett GJ.",OADS,/arxiv_data1/oa_pdf/b9/79/krad-04-01-1153778.PMC4838320.pdf
"Neuroscience 2012; 203:194-206; PMID:22200546; http://dx.doi.org/10.1016/j.neuroscience.2011.12.023 [15] Lenglet T, Lacomblez L, Abitbol JL, Ludolph a., Mora JS, Robberecht W, Shaw PJ, Pruss RM, Cuvier V, MeiningerV.",OADS,/arxiv_data1/oa_pdf/b9/79/krad-04-01-1153778.PMC4838320.pdf
"Eur J Neurol 2014; 21:529-36; PMID:24447620; http://dx.doi.org/10.1111/ene.12344 [16] Dessaud E, Carole A, Bruno S, Patrick B, Rebecca P, Cuv- ier V, Hauke W, Enrico B, Mcdonald C, Watson C, et al.A Phase II study to assess safety and ef ﬁcacy of olesoxime (TRO19622) in 3-25 year-old Spinal Muscular Atrophy(SMA) patients.",OADS,/arxiv_data1/oa_pdf/b9/79/krad-04-01-1153778.PMC4838320.pdf
Dysfunction of the cholesterol biosyn-thetic pathway in Huntington ’sd i s e a s e .JN e u r o s c i 2005; 25:9932-9; PMID:16251441; http://dx.doi.org/10.1523/JNEUROSCI.3355-05.2005 [18] Browne SE.,Non-OADS,/arxiv_data1/oa_pdf/b9/79/krad-04-01-1153778.PMC4838320.pdf
"Mitochondria and Huntington ’s disease pathogenesis: insight from genetic and chemical models.Ann N Y Acad Sci 2008; 1147:358-82; PMID:19076457; http://dx.doi.org/10.1196/annals.1427.018 [19] Clemens LE, Weber JJ, Wlodkowski TT, Yu-Taeger L, Michaud M, Calaminus C, Eckert SH, Gaca J, Weiss A,Magg JCD, et al.",OADS,/arxiv_data1/oa_pdf/b9/79/krad-04-01-1153778.PMC4838320.pdf
"Olesoxime suppresses calpain activationand mutant huntingtin fragmentation in the BACHD rat.Brain 2015; 138:3632-53; http://dx.doi.org/10.1093/brain/awv290 [20] Wheeler VC, White JK, Gutekunst CA, Vrbanac V, Weaver M, Li XJ, Li SH, Yi H, Vonsattel JP, Gusella JF, et al.",OADS,/arxiv_data1/oa_pdf/b9/79/krad-04-01-1153778.PMC4838320.pdf
"HumMol Genet 2000; 9:503-13; PMID:10699173; http://dx.doi.org/10.1093/hmg/9.4.503 [21] Trettel F, Rigamonti D, Hilditch-Maguire P, Wheeler VC, Sharp a H, Persichetti F, Cattaneo E, MacDonald ME.Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells.",Non-OADS,/arxiv_data1/oa_pdf/b9/79/krad-04-01-1153778.PMC4838320.pdf
"Hum Mol Genet 2000; 9:2799-809; PMID:11092756; http://dx.doi.org/10.1093/hmg/9.19.2799 [22] Eckmann J, Clemens LE, Eckert SH, Hagl S, Yu-Taeger L, Bordet T, Pruss RM, Muller WE, Leuner K, Nguyen HP,et al.",OADS,/arxiv_data1/oa_pdf/b9/79/krad-04-01-1153778.PMC4838320.pdf
"NeuroRx 2005; 2:465-70; PMID:16389309;http://dx.doi.org/10.1602/neurorx.2.3.465[24] Brustovetsky N, LaFrance R, Purl KJ, Brustovetsky T, Keene CD, Low WC, Dubinsky JM.",OADS,/arxiv_data1/oa_pdf/b9/79/krad-04-01-1153778.PMC4838320.pdf
"J Neuro- chem 2005; 93:1361-70; PMID:15935052; http://dx.doi.org/10.1111/j.1471-4159.2005.03036.x [25] Yu-Taeger L, Petrasch-Parwez E, Osmand AP, Redensek A, Metzger S, Clemens LE, Park L, Howland D, Calaminus C, Gu X, et al.",OADS,/arxiv_data1/oa_pdf/b9/79/krad-04-01-1153778.PMC4838320.pdf
"J Neurosci 2012; 32:15426-38; PMID:23115180;http://dx.doi.org/10.1523/JNEUROSCI.1148-12.2012 [26] Jansson EKH, Clemens LE, Riess O, Nguyen HP.",OADS,/arxiv_data1/oa_pdf/b9/79/krad-04-01-1153778.PMC4838320.pdf
PLoS One 2014; 9:e105662; PMID:25144554; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b9/79/krad-04-01-1153778.PMC4838320.pdf
"PLoS Genet- ics 2015, 11 (8), e1005267; http://dx.doi.org/10.1371/journal.pgen.1005267© Helen Budworth and Cynthia T. McMurrayThis is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/83/6b/krad-04-01-1131885.PMC4838321.pdf
"1, e1131885 (8 pages)http://dx.doi.org/10.1080/21675511.2015.1131885",Non-OADS,/arxiv_data1/oa_pdf/83/6b/krad-04-01-1131885.PMC4838321.pdf
Nat Rev Genet 2010; 11(11):786-99; PMID:20953213; http://dx.doi.org/ 10.1038/nrg2828 [2] Mirkin SM.,OADS,/arxiv_data1/oa_pdf/83/6b/krad-04-01-1131885.PMC4838321.pdf
"Nature 2007 Jun 21; 447(7147):932-40;PMID:17581576; http://dx.doi.org/10.1038/nature05977 [3] Manley K, Shirley TL, Flaherty L, Messer A. Msh2 de ﬁ- ciency prevents in vivo somatic instability of the CAGrepeat in Huntington disease transgenic mice.",Non-OADS,/arxiv_data1/oa_pdf/83/6b/krad-04-01-1131885.PMC4838321.pdf
"Nat Genet- ics 1999; 23(4):p. 471-3; http://dx.doi.org/10.1038/70598 [4] Owen BA, Yang Z, Lai M, Gajec M, Badger II JD, Hayes JJ, Edelman W Kucherlapati R, Wilson TM, McMurrayCT.",OADS,/arxiv_data1/oa_pdf/83/6b/krad-04-01-1131885.PMC4838321.pdf
"Nat StructMol Biol 2005; 12(8):663-70; PMID:16025128; http://dx.doi.org/10.1038/nsmb965 [5] Savouret C, Brisson E, Essers J, Kanaar R, Pastink A, te Riele H, Junien C, Gourdon G. CTG repeat instabilityand size variation timing in DNA repair-de ﬁcient mice.",OADS,/arxiv_data1/oa_pdf/83/6b/krad-04-01-1131885.PMC4838321.pdf
"EMBO J 2003; 22:2264-73; PMID:12727892; http://dx.doi.org/10.1093/emboj/cdg202 [6] van den Broek WJ, Nelen MR, Wansink DG, Coerwinkel MM, te Riele H, Groenen PJ, Wieringa B. Somatic expan-sion behavior of the (CTG)n repeat in myotonic dystro-phy knock-in mice is differentially affected by Msh3 and Msh6 mismatch-repair proteins.",OADS,/arxiv_data1/oa_pdf/83/6b/krad-04-01-1131885.PMC4838321.pdf
"Hum Mol Genet 2002; 11:191-8; PMID:11809728; http://dx.doi.org/10.1093/hmg/11.2.191 [7] Mangiarini L, Sathasivam K, Mahal A, Mott R, Seller M, Bates GP.",OADS,/arxiv_data1/oa_pdf/83/6b/krad-04-01-1131885.PMC4838321.pdf
"Nat Genetics 1997; 15(2):p. 197-200; http://dx.doi.org/10.1038/ng0297-197 [8] Dragileva E, Hendricks A, Teed A, Gillis T, Lopez ET, Friedberg EC, Kucherlapati R, Edelmann W, Lunetta KL,MacDonald ME, Wheeler VC.",OADS,/arxiv_data1/oa_pdf/83/6b/krad-04-01-1131885.PMC4838321.pdf
"Intergenerational andstriatal CAG repeat instability in Huntington ’s disease knock-in mice involve different DNA repair genes.Neuro Biol Dis 2009; 33(1):p. 37-47; PMID:18930147;http://dx.doi.org/10.1016/j.nbd.2008.09.014 [9] Wheeler VC, Lebel LA, Vrbanac V, Teed A, te Riele H, MacDonald ME.",OADS,/arxiv_data1/oa_pdf/83/6b/krad-04-01-1131885.PMC4838321.pdf
"HumMol Genet 2003; 12(3):p. 273-81; PMID:12554681;http://dx.doi.org/10.1093/hmg/ddg056 [10] Bak ST, Sakellariou D, Pena-Diaz J.",OADS,/arxiv_data1/oa_pdf/83/6b/krad-04-01-1131885.PMC4838321.pdf
"Front Genet 2014; 5: p. 287; http://dx.doi.org/10.3389/fgene.2014.00287 [11] Kovtun IV, Liu Y, Bjoras M, Klungland A, Wilson SH, McMurray CT. OGG1 initiates age-dependent CAG tri-nucleotide expansion in somatic cells.",OADS,/arxiv_data1/oa_pdf/83/6b/krad-04-01-1131885.PMC4838321.pdf
"Nature 2007; 447(7143):p. 447-52; PMID:17450122; http://dx.doi.org/10.1038/nature05778 [12] Budworth H, Harris FR, Williams P, Lee do Y, Holt A, Pahnke J, Szczesny B, Acevedo-Torres K, Ayala-Pena S,McMurray CT. Suppression of Somatic Expansion Delays the Onset of Pathophysiology in a Mouse Model of Huntington ’s Disease.",Non-OADS,/arxiv_data1/oa_pdf/83/6b/krad-04-01-1131885.PMC4838321.pdf
"PLoS Genetics 2015; 11(8):p. e1005267; PMID:26247199; http://dx.doi.org/10.1371/journal.pgen.1005267 [13] Mollersen L, Rowe AD, Larsen E, Rognes T, Klungland A.",OADS,/arxiv_data1/oa_pdf/83/6b/krad-04-01-1131885.PMC4838321.pdf
"PLoS Genetics 2010; 6 (12):p. e1001242; PMID:21170307; http://dx.doi.org/ 10.1371/journal.pgen.1001242 [14] Kennedy L, Evans E, Chen CM, Craven L, Detloff PJ, Ennis M, Shelbourne PF.",OADS,/arxiv_data1/oa_pdf/83/6b/krad-04-01-1131885.PMC4838321.pdf
"Hum Mol Genet 2003;12(24):p. 3359-67; PMID:14570710; http://dx.doi.org/10.1093/hmg/ddg352 [15] Shelbourne PF, Keller-McGandy C, Bi WL, Yoon SR, Dubeau L, Veitch NJ, Vonsattel JP, Wexler NS, Arnheim N, Augood SJ.",OADS,/arxiv_data1/oa_pdf/83/6b/krad-04-01-1131885.PMC4838321.pdf
"Hum Mol Genet 1999; 8(1):p. 115-22; PMID:9887339;http://dx.doi.org/10.1093/hmg/8.1.115 [17] Lee JM, Zhang J, Su AI, Walker JR, Wiltshire T, Kang K, Dragileva E, Gillis T, Lopez ET, Boily MJ, Cyr M, KohaneI, Gusella JF, MacDonald ME, Wheeler VC.",OADS,/arxiv_data1/oa_pdf/83/6b/krad-04-01-1131885.PMC4838321.pdf
"BMC Syst Biol 2010; 4:p. 29; PMID:20302627; http://dx.doi.org/10.1186/1752-0509-4- 29 [18] Andrew SE, Goldberg YP, Kremer B, Telenius H, Theil- mann J, Adam S, Starr E, Squitieri F, Lin B, Kalchman MA,et al.",OADS,/arxiv_data1/oa_pdf/83/6b/krad-04-01-1131885.PMC4838321.pdf
"The relationship between trinucleotide (CAG) repeatlength and clinical features of Huntington ’sd i s e a s e .N a tGenetics 1993; 4(4):p. 398-403; http://dx.doi.org/10.1038/ ng0893-398 [19] Kennedy L, Shelbourne PF.",Non-OADS,/arxiv_data1/oa_pdf/83/6b/krad-04-01-1131885.PMC4838321.pdf
Hum Mol Genet2009; 18(16):p. 3039-47; PMID:19465745; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/83/6b/krad-04-01-1131885.PMC4838321.pdf
Based on ARE site ( http://rna.tbi.,OADS,/arxiv_data1/oa_pdf/b4/18/gkv1353.PMC4838338.pdf
"CRISPR guide design, CRISPR /Cas9 transfection and screening Two pairs of gRNAs flanking the −20.9 kb CTCF site and the intron 11 enhancer core were identified using the CRISPR Design Program ( http://crispr.mit.edu ) (Supple- mentary Table S3).",OADS,/arxiv_data1/oa_pdf/82/51/gkv1358.PMC4838340.pdf
"A lack of interactions with all viewpoints beyond the −80.1 and +48.9 kb sites, suggestedthatthesetwoCTCFsitesdefinetheboundaryof aTADorsub-TADatthe CFTRlocus.Toverifythisinter- pretation, we used published human fibroblast Hi-C data(http://www.3dgenome.org ) to define the TADs surround- ingCFTRand observed an identical domain to that illus- trated by our 4C-seq data (Supplementary Figure S1).",OADS,/arxiv_data1/oa_pdf/82/51/gkv1358.PMC4838340.pdf
"3120NucleicAcidsResearch,2016,Vol.44,No.7 available from http://www.bioinformatics.babraham.ac.uk/ projects/fastqc/ .",OADS,/arxiv_data1/oa_pdf/e8/b5/gkv1380.PMC4838343.pdf
Peaking calling and IDR analysis Pseudoreplicates were created using homer-idr v0.1 (avail- able from https://zenodo.org/record/11619# ) for individual and combined IP samples.,OADS,/arxiv_data1/oa_pdf/e8/b5/gkv1380.PMC4838343.pdf
"FormotifanalysisusingthecompleteChIP-Seqdatasets, alternative web-based motif finding tools, RSAT peakmotifs(availablefrom http://floresta.eead.csic.es/rsat/peak- motifs form.cgi)(34) and DREME (available from http: //meme-suite.org/tools/dreme )(35), wereused.",OADS,/arxiv_data1/oa_pdf/e8/b5/gkv1380.PMC4838343.pdf
"To address the issue of inter-species gene nomenclature difference, mouse gene names on the KLF3 MEFs list was converted to the correspond- ing human orthologs using HCOP: Orthology PredictionSearch (available from http://www.genenames.org/cgi-bin/ hcop).TheKLF3FD-AZFHEK293listwasrefinedtocon- tain only the human /mouse orthologous genes.",Non-OADS,/arxiv_data1/oa_pdf/e8/b5/gkv1380.PMC4838343.pdf
A chi- squared value was computed yielding a P-value using GraphPad software available from http://graphpad.com/ quickcalcs/ .,OADS,/arxiv_data1/oa_pdf/e8/b5/gkv1380.PMC4838343.pdf
"(33), and available online for download ( http://www.seas.ucla.edu/ ∼liaoj/downloads.",Non-OADS,/arxiv_data1/oa_pdf/bc/a2/gkv1463.PMC4838348.pdf
"acknowledge infrastructure sup- port from the Norwegian University of Science and Tech- nology.M.N.B.N.,K.S.andR.S.wouldliketoacknowledge National Centre for Biological Sciences, Tata Institute of FundamentalResearch,Bangalore,Indiaforinfrastructure support.FUNDING The Multi-Stress transcriptomic experiments were funded by the European Research Area Network Plant Ge- nomics (ERA-NET PG) ( http://www.erapg.org/ ) project; Biotechnology and Functional Genomics (FUGE) andFRIMEDBIOprogramsoftheNorwegianResearchCoun- cil [RCN184146 and 214329 to A.M.B]; Department of Biotechnology, India for the development of STIF algo-rithm (to K.S., R.S.",OADS,/arxiv_data1/oa_pdf/bc/a2/gkv1463.PMC4838348.pdf
CrossHub is freely available at https://sourceforge.net/projects/ crosshub/ .,OADS,/arxiv_data1/oa_pdf/c7/03/gkv1478.PMC4838350.pdf
"This tool may be a starting point for integrating the data of several major projects such as TCGAandENCODE.Thesoftwarewithdatabasesdumpsis freely available at Sourceforge, http://sourceforge.net/p/ crosshub/ .",OADS,/arxiv_data1/oa_pdf/c7/03/gkv1478.PMC4838350.pdf
"ACKNOWLEDGEMENTS Authors thank the EIMB RAS ‘Genome’ center (http://www.eimb.ru/RUSSIAN NEW/INSTITUTE/ ccugenomec.php), Orekhovich Institute of Biomedical Chemistry and M.M.",Non-OADS,/arxiv_data1/oa_pdf/c7/03/gkv1478.PMC4838350.pdf
"In order to remove sequences that were closely similar to each other, we used the BlastClust tool ( ftp://ftp.ncbi.nih.gov/blast/documents/ blastclust.html )fromtheNCBI–BLASTpackage( 34),with a 50% sequence identity threshold.",OADS,/arxiv_data1/oa_pdf/5d/7b/gkv1479.PMC4838351.pdf
Models generated by SimRNA are available for down-load from ftp://ftp.genesilico.pl/pub/software/simrna/ .,OADS,/arxiv_data1/oa_pdf/5d/7b/gkv1479.PMC4838351.pdf
Com-piled Linux binaries for Intel and AMD (32 bit and 64 bit)areavailablefrom http://genesilico.pl/simrna/ .Themul- tiprocessor code requires openmp.,OADS,/arxiv_data1/oa_pdf/5d/7b/gkv1479.PMC4838351.pdf
Performance evaluation byrealistic simulation studies We generated a list of realistic genomic regions by apply- ing PeakSeq ( 9) to MYC ChIP-seq data acquired from a leukemia study of cell line K562 in the ENCODEproject ( http://genome.ucsc.edu/ENCODE/ ).,OADS,/arxiv_data1/oa_pdf/92/aa/gkv1491.PMC4838354.pdf
"Moreover, by ap- plyingfunctionalenrichmentanalysisusingQIAGEN’sIn- genuity Pathway Analysis ( http://www.ingenuity.com )a n d DAVID ( http://david.abcc.ncifcrf.gov ) on NOTCH3 target genes in the NCI /Nature interaction, QIAGEN pathway andKEGGpathwaydatabases(linkstopathwaydatabasescan be found in Supplementary Material S10), we identi- fied 22 Notch signaling pathway genes from the NOTCH3",Non-OADS,/arxiv_data1/oa_pdf/92/aa/gkv1491.PMC4838354.pdf
NE-501) controlled withacustomPythonscript( https://github.com/AbateLab/ Pump-Control-Program ).,Non-OADS,/arxiv_data1/oa_pdf/95/32/gkv1493.PMC4838355.pdf
"Data were obtained from the on- going Multiple Myeloma Research Foundation (MMRF)CoMMpass Trial (NCT0145429), a longitudinal study in MM relating clinical outcomes to genomic and im- munophenotypic profiles of CD138 selected plasma cellsfrom the bone marrow of newly diagnosed MM patients (7).Datafrom377patientswithavailableclinicaloutcomes, Exome-SeqsomaticmutationsandCNsegmentsandRNA-SeqensembleGEatpre-treatmentweredownloadedbased on the IA6 release of this trial from the MMRF researcher gateway portal ( https://research.themmrf.org ).",OADS,/arxiv_data1/oa_pdf/08/2d/gkv1503.PMC4838358.pdf
"Methods Herein, we adopt The Cancer Genome Atlas (TCGA) nomenclature ( https://tcga-data.nci.nih.gov/tcga/ dataAccessMatrix.htm ) that references a specific data type (RNA-Seq expression, DNA CpG methylation, etc.",Non-OADS,/arxiv_data1/oa_pdf/08/2d/gkv1503.PMC4838358.pdf
The R code to run GISPA is available for down- load at https://github.com/BhaktiDwivedi .,Non-OADS,/arxiv_data1/oa_pdf/08/2d/gkv1503.PMC4838358.pdf
The Bioconductor R pack- ageforSISPAisavailableat https://www.bioconductor.org/ packages/release/bioc/html/SISPA.html .,Non-OADS,/arxiv_data1/oa_pdf/08/2d/gkv1503.PMC4838358.pdf
The software package and source codes of TopDom are available at http://zhoulab.usc.edu/TopDom/ .,OADS,/arxiv_data1/oa_pdf/6d/47/gkv1505.PMC4838359.pdf
Our TopDom program (available via http://zhoulab.usc.,Non-OADS,/arxiv_data1/oa_pdf/6d/47/gkv1505.PMC4838359.pdf
ACCESSION NUMBERS Microarray data have been deposited in EBI ArrayExpress (http://www.ebi.ac.uk/arrayexpress ) under accession num- berE-MTAB-3670.,OADS,/arxiv_data1/oa_pdf/33/39/gkw036.PMC4838363.pdf
"Modeling of secondary and tertiaryRNA structures Secondary structure elements were modeled essen- tially as described ( 40), using probabilistic (Pfold; http://www.daimi.au.dk/ compbio/pfold/ )(41)a n d posterior decoding approaches (CentroidFold; http://www.ncrna.org/centroidfold )(42) and were veri- fied and refined by free energy minimization using Mfold (http://mfold.rna.albany.edu/?q mfold)(43) and pKiss (http://bibiserv2.cebitec.uni-bielefeld.de/pkiss )(44), in all instancesusingdefaultparameters.Computationalanalysis was done usingseries ofoverlapping RNAsequences.",OADS,/arxiv_data1/oa_pdf/44/de/gkw074.PMC4838371.pdf
(2010) http://www.schrodinger.com/ .,Non-OADS,/arxiv_data1/oa_pdf/bd/76/gkw082.PMC4838373.pdf
A web ser- vice that provides all configuration files required to runourelastic-networkguidedsimulationofanarbitraryDNA origamiobjectisavailableat http://bionano.physics.illinois.,OADS,/arxiv_data1/oa_pdf/93/fc/gkw155.PMC4838381.pdf
See http://creativecommons.org/licenses/by-nc/2.0/de/ HHS Public Access Author manuscript Demogr Res .,Non-OADS,/arxiv_data1/oa_pdf/a1/50/nihms-753048.PMC4838405.pdf
"Retrieved from http://data.bls.gov/pdq/SurveyOutputServlet Cancio AS, Evans TD, Maume DJ Jr. Reconsidering the declining significance of race: Racial  differences in early career wages.",OADS,/arxiv_data1/oa_pdf/a1/50/nihms-753048.PMC4838405.pdf
Retrieved from  http://nces.ed.gov/programs/digest/d13/tables/dt13_302.60.asp NCES.,OADS,/arxiv_data1/oa_pdf/a1/50/nihms-753048.PMC4838405.pdf
Retrieved from  http://nces.ed.gov/programs/digest/d13/tables/dt13_504.10.asp NCES.,OADS,/arxiv_data1/oa_pdf/a1/50/nihms-753048.PMC4838405.pdf
"Retrieved from http://nces.ed.gov/programs/digest/d13/tables/ dt13_505.20.asp Newman, KS.",OADS,/arxiv_data1/oa_pdf/a1/50/nihms-753048.PMC4838405.pdf
"Retrieved from http://ncfmr.bgsu.edu/pdf/ family_profiles/file109824.pdf Payne, KK.",Non-OADS,/arxiv_data1/oa_pdf/a1/50/nihms-753048.PMC4838405.pdf
"Key Words: animal models ◼ cardiomyopathy ◼ Drosophila ◼ genetics ◼ proteomics Circ Cardiovasc Genet is available at http://circgenetics.ahajournals.org DOI: 10.1161/CIRCGENETICS.115.001254Received August 31, 2015; accepted January 27, 2016.",Non-OADS,/arxiv_data1/oa_pdf/78/86/hcg-9-119.PMC4838489.pdf
"The Data Supplement is available at http://circgenetics.ahajournals.org/lookup/suppl/doi:10.1161/CIRCGENETICS.115.001254/-/DC1.Correspondence to Paul S. Hartley, PhD, Department of Life and Environmental Science, University of Bournemouth, Talbot Campus, Poole, Dorset  BH12 5BB, United Kingdom.",Non-OADS,/arxiv_data1/oa_pdf/78/86/hcg-9-119.PMC4838489.pdf
"1, 2016G&I    Genomics & InformaticseISSN 2234-0742 Genomics Inform  2016;14(1):1 http://dx.doi.org/10.5808/GI.2016.14.1.1 EDITORIAL *Corresponding author:  Tel: +82-2-2258-7343, Fax: +82-2-537-0572, E-mail: yejun@catholic.ac.kr Copyright © 2016 by the Korea Genome Organization CC It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).Editor’s Introduction to This Issue Yeun-Jun Chung*  IRCGP , College of Medicine, The Catholic University of Korea, Seoul 06591, Korea In the post-genome era, understanding protein biomarkers  is becoming more important.",Non-OADS,/arxiv_data1/oa_pdf/30/87/gni-14-1.PMC4838523.pdf
"For further details, please visit the G&I homepage  (http://www.kogo.or.kr/webapp/kogo_publish/genomics_ and_informatics/).",Non-OADS,/arxiv_data1/oa_pdf/30/87/gni-14-1.PMC4838523.pdf
"G&I    Genomics & InformaticseISSN 2234-0742 Genomics Inform  2016;14(1):12-19 http://dx.doi.org/10.5808/GI.2016.14.1.12 REVIEW ARTICLE Received January 5, 2016; Revised March 2, 2016; Accepted March 3, 2016 *Corresponding author:  Tel: +82-2-958-6422, Fax: +82-2-958-5909, E-mail: jelee9137@kist.re.kr Copyright © 2016 by the Korea Genome Organization CC It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).Neuropeptidomics: Mass Spectrometry-Based  Identification and Quantitation of Neuropeptides Ji Eun Lee* Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul 02792, Korea Neuropeptides produced from pr ohormones by selective action of endopeptidases  are vital signaling molecules, playing a  critical role in a variety of physiological processes, such as  addiction, depression, pain, an d circadian rhythms.",Non-OADS,/arxiv_data1/oa_pdf/71/ab/gni-14-12.PMC4838524.pdf
Approximately 100  different neuropeptides are currently known to function in cell-to-cell signaling (http://www.neuropeptides.nl).,OADS,/arxiv_data1/oa_pdf/71/ab/gni-14-12.PMC4838524.pdf
"There are several software packages that can perform  de novo  sequencing directly on MS/MS data, including  Lutefisk (http://www.hairyfatguy.com/lutefisk/), Mascot",Non-OADS,/arxiv_data1/oa_pdf/71/ab/gni-14-12.PMC4838524.pdf
"Distiller (Matrix Science), and PEAKS (Bioinformatics  Solutions, http://www.bioinformaticssolutions.com/) [30].",OADS,/arxiv_data1/oa_pdf/71/ab/gni-14-12.PMC4838524.pdf
The peptide sequences obtained from de novo  sequencing are  often compared with the nonredundant database of the  National Center for Biotechnology Information to establish  the peptide identities with the Basic Local Alignment Search T ool (http://www.ncbi.nlm.nih.,OADS,/arxiv_data1/oa_pdf/71/ab/gni-14-12.PMC4838524.pdf
"G&I    Genomics & InformaticseISSN 2234-0742 Genomics Inform  2016;14(1):2-11 http://dx.doi.org/10.5808/GI.2016.14.1.2 REVIEW ARTICLE Received November 25, 2015; Revised January 6, 2016; Accepted January 7, 2016 *Corresponding author:  Tel: +82-54-279-2393, Fax: +82-54-279-8409, E-mail: dhhwang@postech.ac.kr Copyright © 2016 by the Korea Genome Organization CC It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).Network-Based Protein Biomarker Discovery Platforms Minhyung Kim, Daehee Hwang* Department of New Biology and Center for Plant Aging Research, Institute for Basic Science,  Daegu Gyeongbuk Institute of Science and Technology, Daegu 42988, Korea The advances in mass spectrometry-based proteomics technolog ies have enabled the generation of global proteome data  from tissue or body fluid samples collected from a broad spec trum of human diseases.",OADS,/arxiv_data1/oa_pdf/08/cc/gni-14-2.PMC4838525.pdf
"Resources for network-based protein biomarker discovery 　 Tool Website Peptide and protein identificationSWISS-Prot or UniProt http://www.ebi.ac.uk/uniprot Mascot http://www.matrixscience.com/ SEQUEST http://fields.scripps.edu/sequest/ MS-GF+ http://bix-lab.ucsd.edu/pa ges/viewpage.action?pageId=1353 3355 Paragon http://sciex.com/products/software/proteinpilot-software PeptideProphet http://peptideprophet.sourceforge.net/ Trans-Proteomic Pipeline (TPP) http://www.proteomecenter.org/software.php Compid http://compid.aavalla.net/ MSblender http://www.marcottelab.org/index.php/MSblender Protein quantitation MaxQuant http://www .coxdocs.org/doku.php?id=maxquant:start Functional enrichment analysisKyoto Encyclopedia of Genes and  Genomes (KEGG)http://www.genome.jp/kegg/ DAVID http://david.ncifcrf.gov/ PANTHER http://pantherdb.org/ MetaCore http://portal.genego.com/ Ingenuity Pathway Analysis  (IPA, QIAGEN Redwood City)http://www.qiagen.com/ingenuity Gene set enrichment analysis (GSEA) http:// software.broadinstitute.org/gsea/index.jsp Signaling pathway impact analysis (SPIA) http://vortex.cs.wayne.edu/projects.htm Network modeling and analysisHuman protein reference databa se (HPRD) http://www.hprd.org/ Biological general repository for interaction datasets (BioGRID)http://thebiogrid.org/ Biomolecular interaction network database (BIND) http://metadatabase.org/wiki/BI ND_-_Biomolecular_Interacti on_Network_Database Search tool for recurring instances of  neighbouring genes (STRING)http://string-db.org/ Molecular INTeraction database (MIN T) http://mint.bio.uniroma2.it/mint/  EdgeExpressDB (FANTOM4-EEDB) http://fantom.gsc.riken.jp/4/edgeexpress/about/ Transcriptional regulatory element database (TRED)http://cb.utdallas.edu/cgi-bin /TRED/tred.cgi?process=home Molecular signatures database (MSigDB) http://software.broadinstitute.org/gsea/msigdb/index.jsp jActiveModules http://apps.cytoscape.org/apps/jactivemodules ResponseNet http://netbio.bgu.ac.il/respnet/ NetWalker https://netwalkersuite.org/ clusterMaker http://apps.cytoscape.org/apps/clustermaker Integrative analysis of proteomic data withother global dataHotNet http://compbio.cs.brown.edu/projects/hotnet/ SteinerNet http://fraenkel.mit.edu/steinernet/ peptide-spectrum match (PSM).",Non-OADS,/arxiv_data1/oa_pdf/08/cc/gni-14-2.PMC4838525.pdf
"For example, the enrichment  analysis of gene ontology biological processes (GOBPs) or Kyoto Encyclopedia of Genes and Genomes (KEGG)  pathways can be applied to the DEPs using DAVID [38] and  PANTHER [39], and commercial tools, such as MetaCore [40] and Ingenuity Pathway Analysis (IPA, QIAGEN  Redwood City, http://www.qiagen.com/ingenuity) (T able  1 ) .",Non-OADS,/arxiv_data1/oa_pdf/08/cc/gni-14-2.PMC4838525.pdf
"A number of the tools have been developed  to understand the subnetworks (network clusters) of the  multi-layered networks whose perturbations are collectively indicated by different types of global datasets, including IPA  (QIAGEN Redwood City, http://www.qiagen.com/ingenuity),  HotNet [62], or SteinerNet (Table 1) [63].",OADS,/arxiv_data1/oa_pdf/08/cc/gni-14-2.PMC4838525.pdf
"G&I    Genomics & InformaticseISSN 2234-0742 Genomics Inform  2016;14(1):20-28 http://dx.doi.org/10.5808/GI.2016.14.1.20 REVIEW ARTICLE Received February 18, 2016; Revised March 14, 2016; Accepted March 14, 2016 *Corresponding author:  Tel: +82-2-2258-7648, Fax: +82-2-2258-8257, E-mail: iychoi@catholic.ac.kr Copyright © 2016 by the Korea Genome Organization CC It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).The OAuth 2.0 Web Authorization Protocol for the  Internet Addiction Bioinformatics (IABio) Database Jeongseok Choi1, Jaekwon Kim1, Dong Kyun Lee2,  Kwang Soo Jang3, Dai-Jin Kim4, In Young Choi2* 1Department of Computer Science and Information Engineering, Inha University, Incheon 22212, Korea, 2Department of Medical Informatics College of Medicine, and Institute of Healthcare Management, The Catholic University of  Korea, Seoul 06591, Korea, 3Department of Information System, Hanyang University, Seoul 04763, Korea, 4Department of Psychiatry, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea Internet addiction (IA) has become a widespread and pr oblematic phenomenon as smar t devices pervade society.",Non-OADS,/arxiv_data1/oa_pdf/21/e3/gni-14-20.PMC4838526.pdf
Available from: http://www.ihe.net/uploadedFiles/Documents/  ITI/IHE_ITI_Suppl_IUA.pdf.,OADS,/arxiv_data1/oa_pdf/21/e3/gni-14-20.PMC4838526.pdf
Available from: http://developer.naver.com/wi- ki/pages/OpenAPI.,Non-OADS,/arxiv_data1/oa_pdf/21/e3/gni-14-20.PMC4838526.pdf
"G&I    Genomics & InformaticseISSN 2234-0742 Genomics Inform  2016;14(1):29-33 http://dx.doi.org/10.5808/GI.2016.14.1.29 ORIGINAL ARTICLE Received December 3, 2015; Revised December 23, 2015; Accepted February 23, 2016 *Corresponding author:  Tel: +82-2-820-0457, Fax: +82-2-824-4383, E-mail: sskimb@ssu.ac.kr Copyright © 2016 by the Korea Genome Organization CC It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/39/96/gni-14-29.PMC4838527.pdf
Supplementary materials Supplementary data including one table can be found with  this article online at http://www.genominfo.org/src/sm/ gni-14-29-s001.pdf.,Non-OADS,/arxiv_data1/oa_pdf/39/96/gni-14-29.PMC4838527.pdf
Available from:  http://www.ncbi.nlm.nih.gov/staff/tao/URLAPI/wwwblast/ node20.html.,OADS,/arxiv_data1/oa_pdf/39/96/gni-14-29.PMC4838527.pdf
"G&I    Genomics & InformaticseISSN 2234-0742 Genomics Inform  2016;14(1):34-40 http://dx.doi.org/10.5808/GI.2016.14.1.34 ORIGINAL ARTICLE Received September 9, 2015; Revised December 30, 2015; Accepted December 30, 2015 *Corresponding author:  Tel: +82-42-879-8116, Fax: +82-42-879-8119, E-mail: kimsy@kribb.re.kr Copyright © 2016 by the Korea Genome Organization CC It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).Non-negligible Occurrence of Errors in Gender  Description in Public Data Sets Jong Hwan Kim1,2, Jong-Luyl Park3, Seon-Young Kim1,2* 1Genome Structure Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Korea,  2Department of Functional Genomics, University of Science and T echnology (UST), Daejeon 34113, Korea,  3Epigenome Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Korea Due to advances in omics technologies,  numerous genome-wide studies on human sa mples have been published, and most  of the omics data with the associated clinical information a re available in public repositories, such as Gene Expression  Omnibus and ArrayExpress.",OADS,/arxiv_data1/oa_pdf/3b/1c/gni-14-34.PMC4838528.pdf
"For DNA methylation, a user-friendly website (https://dnamage.genetics.ucla.edu/) [18] is also available  for researchers.",Non-OADS,/arxiv_data1/oa_pdf/3b/1c/gni-14-34.PMC4838528.pdf
"SUPPLEMENTARY INFORMATION Non-negligible Occurrence of Errors in Gender Description in Public Data Sets Jong Hwan Kim1,2, Jong-Luyl Park3, Seon-Young Kim1,2* 1Genome Structure Research Center, Korea Research In stitute of Bioscience and Biotechnology (KRIBB),  Daejeon 34141, Korea,  2Department of Functional Genomics, University of  Science and Technology (UST), Daejeon34113, Korea, 3Epigenome Research Center, Korea Research Institut e of Bioscience and Biotechnology (KRIBB),Daejeon  34141, Korea http://www.genominfo.org/src/sm/gni-14-34-s001.pdf",Non-OADS,/arxiv_data1/oa_pdf/3b/1c/gni-14-34.PMC4838528.pdf
"THE KOREAN SOCIETY FOR REPRODUCTIVE MEDICINE1 REVIEW http://dx.doi.org/10.5653/cerm.2016.43.1.1 pISSN 2233-8233 · eISSN 2233-8241 Clin Exp Reprod Med 2016;43(1):1-8 Insights into granulosa cell tumors using  spontaneous or genetically engineered mouse  models    So-Youn Kim Division of Reproductive Science in Medicine, Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University,  Chicago, IL, USA Granulosa cell tumors (GCTs) are rare sex cord-stromal tumors that have been studied for decades.",Non-OADS,/arxiv_data1/oa_pdf/1e/1c/cerm-43-1.PMC4838576.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution  Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the  original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/1e/1c/cerm-43-1.PMC4838576.pdf
" http://dx.doi.org/10.5653/cerm.2016.43.1.1 Clin Exp Reprod Med 2016;43(1):1-8 2FOXL2 can alter the fate of granulosa cells, pushing them into uncon - trolled growth, because FOXL2 expression is important for establish - ing and maintaining granulosa cell identity.",Non-OADS,/arxiv_data1/oa_pdf/1e/1c/cerm-43-1.PMC4838576.pdf
 http://dx.doi.org/10.5653/cerm.2016.43.1.1 Clin Exp Reprod Med 2016;43(1):1-8 47.,OADS,/arxiv_data1/oa_pdf/1e/1c/cerm-43-1.PMC4838576.pdf
 http://dx.doi.org/10.5653/cerm.2016.43.1.1 Clin Exp Reprod Med 2016;43(1):1-8 6recurrence.,OADS,/arxiv_data1/oa_pdf/1e/1c/cerm-43-1.PMC4838576.pdf
 http://dx.doi.org/10.5653/cerm.2016.43.1.1 Clin Exp Reprod Med 2016;43(1):1-8 852.,OADS,/arxiv_data1/oa_pdf/1e/1c/cerm-43-1.PMC4838576.pdf
http://dx.doi.org/10.1096/fj.15-280313.,Non-OADS,/arxiv_data1/oa_pdf/1e/1c/cerm-43-1.PMC4838576.pdf
"THE KOREAN SOCIETY FOR REPRODUCTIVE MEDICINE15 ORIGINAL ARTICLE http://dx.doi.org/10.5653/cerm.2016.43.1.15 pISSN 2233-8233 · eISSN 2233-8241 Clin Exp Reprod Med 2016;43(1):15-25 Pregnancy outcomes following the administration of  high doses of dexamethasone in early pregnancy    Hasan Namdar Ahmadabad1, Sabah Kayvan Jafari2, Maryam Nezafat Firizi1, Ali Reza Abbaspour3, Fahime Ghafoori Gharib3,  Yusef Ghobadi4, Samira Gholizadeh4  1Department of Pathobiology and Medical Laboratory Science, School of Medicine, North Khorasan University of Medical Sciences, Bojnord;  2Department of Biology, Payame Noor University of Mashhad, Mashhad; 3Department of Biotechnology and Molecular Sciences, School of Medicine,  North Khorasan University of Medical Sciences, Bojnord; 4Department of Immunology, School of Medicine, Tarbiat Modares University, Tehran, Iran Objective:  In the present study, we aimed to evaluate the effects of high doses of dexamethasone (DEX) in early pregnancy on pregnancy out - comes.",Non-OADS,/arxiv_data1/oa_pdf/dd/95/cerm-43-15.PMC4838577.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution  Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the  original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/dd/95/cerm-43-15.PMC4838577.pdf
" http://dx.doi.org/10.5653/cerm.2016.43.1.15 Clin Exp Reprod Med 2016;43(1):15-25 16Although pharmacological monographs have indicated GCs to be  relatively safe in pregnancy (safety category B), animal studies have  indicated the possibilities of long-term developmental abnormalities  [8,9].",Non-OADS,/arxiv_data1/oa_pdf/dd/95/cerm-43-15.PMC4838577.pdf
 http://dx.doi.org/10.5653/cerm.2016.43.1.15 Clin Exp Reprod Med 2016;43(1):15-25 18on GD 18.5 and their uteri were removed.,OADS,/arxiv_data1/oa_pdf/dd/95/cerm-43-15.PMC4838577.pdf
" http://dx.doi.org/10.5653/cerm.2016.43.1.15 Clin Exp Reprod Med 2016;43(1):15-25 20Uterine macrophages were present in the myometrium, mesometri - um, and decidua basalis (Figure 4), while uNK cells accumulated in  the decidua basalis and around the glandular and luminal epithelial  layers (Figure 5).",OADS,/arxiv_data1/oa_pdf/dd/95/cerm-43-15.PMC4838577.pdf
 http://dx.doi.org/10.5653/cerm.2016.43.1.15 Clin Exp Reprod Med 2016;43(1):15-25 22activation) and LPS-stimulated (due to polyclonal B cell activation)  proliferation of mononuclear cells compared to the DS of the control  group ( p< 0.05) (Figure 2A).,Non-OADS,/arxiv_data1/oa_pdf/dd/95/cerm-43-15.PMC4838577.pdf
 http://dx.doi.org/10.5653/cerm.2016.43.1.15 Clin Exp Reprod Med 2016;43(1):15-25 24gy and Medical Laboratory Science of the North Khorasan University  of Medical Sciences for technical assistance.,Non-OADS,/arxiv_data1/oa_pdf/dd/95/cerm-43-15.PMC4838577.pdf
"THE KOREAN SOCIETY FOR REPRODUCTIVE MEDICINE26 ORIGINAL ARTICLE http://dx.doi.org/10.5653/cerm.2016.43.1.26 pISSN 2233-8233 · eISSN 2233-8241 Clin Exp Reprod Med 2016;43(1):26-30 Usage and perceptions of phosphodiesterase type 5  inhibitors among the male partners of infertile  couples Seung-Hun Song1, Dong Suk Kim1, Sung Han Shim2, Jung Jin Lim3,4,5, Seung Choul Yang1  1Department of Urology, Fertility Center of CHA Gangnam Medical Center, CHA University, Seoul; 2Department of Genetics, CHA University, Seoul,  Korea; 3Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa; 4Department of Obstetrics and Gynecology, University of Ottawa,  Ottawa; 5Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Canada Objective:  We aimed to investigate the prevalence of erectile dysfunction (ED) and the usage of phosphodiesterase type 5 (PDE5) inhibitors for  ED treatment in infertile couples.",Non-OADS,/arxiv_data1/oa_pdf/46/02/cerm-43-26.PMC4838578.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution  Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the  original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/46/02/cerm-43-26.PMC4838578.pdf
 http://dx.doi.org/10.5653/cerm.2016.43.1.26 Clin Exp Reprod Med 2016;43(1):26-30 2810.4% (27/260) (Figure 1).,OADS,/arxiv_data1/oa_pdf/46/02/cerm-43-26.PMC4838578.pdf
 http://dx.doi.org/10.5653/cerm.2016.43.1.26 Clin Exp Reprod Med 2016;43(1):26-30 30tion in vitro.,OADS,/arxiv_data1/oa_pdf/46/02/cerm-43-26.PMC4838578.pdf
"THE KOREAN SOCIETY FOR REPRODUCTIVE MEDICINE31 ORIGINAL ARTICLE http://dx.doi.org/10.5653/cerm.2016.43.1.31 pISSN 2233-8233 · eISSN 2233-8241 Clin Exp Reprod Med 2016;43(1):31-37 The effects of blastocyst morphological score and  blastocoele re-expansion speed after warming on  pregnancy outcomes  Huiqun Yin, Hong Jiang, Ruibing He, Cunli Wang, Jie Zhu, Yang Li   Reproductive Medicine Center, 105th Hospital of PLA, Hefei, China Objective:  The aim of this study was to investigate associations between the morphology score of blastocysts and blastocoele re-expansion  speed after warming with clinical outcomes, which could assist in making correct and cost-effective decisions regarding the appropriate time  to vitrify blastocysts and to transfer vitrified-warmed blastocysts.",Non-OADS,/arxiv_data1/oa_pdf/14/37/cerm-43-31.PMC4838579.pdf
"A meta-analysis comparing vitrified day 6 and day 5 blasto -Received: Nov 28, 2015 ∙ Revised: Dec 23, 2015 ∙ Accepted: Jan 21, 2016 Corresponding author:  Hong Jiang  Reproductive Medicine Center, 105th Hospital of PLA, 424 West Changjiang  Road, Hefei 230031, China Tel: +86-551-65966361 Fax: +86-551-65123513 E-mail: jiangh105@sina.com This is an Open Access article distributed under the terms of the Creative Commons Attribution  Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the  original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/14/37/cerm-43-31.PMC4838579.pdf
 http://dx.doi.org/10.5653/cerm.2016.43.1.31 Clin Exp Reprod Med 2016;43(1):31-37 32cysts showed lower pregnancy rates and live birth rates in vitrified  day 5 blastocysts.,OADS,/arxiv_data1/oa_pdf/14/37/cerm-43-31.PMC4838579.pdf
" http://dx.doi.org/10.5653/cerm.2016.43.1.31 Clin Exp Reprod Med 2016;43(1):31-37 34good-morphology grade 3 blastocysts frozen on day 5 (BL-1 group:  46.7% and 32.2%, respectively), only one good-morphology blasto - cyst (BL-5 group: 47.9% and 31.3%, respectively) and two poor-mor - phology blastocysts (BL-6 group: 35.0% and 20.0%, respectively)  (p< 0.05).",Non-OADS,/arxiv_data1/oa_pdf/14/37/cerm-43-31.PMC4838579.pdf
 http://dx.doi.org/10.5653/cerm.2016.43.1.31 Clin Exp Reprod Med 2016;43(1):31-37 36blastocyst expansion extent) before freezing affected pregnancy  outcomes in vitrified-warmed blastocyst transfer cycles.,Non-OADS,/arxiv_data1/oa_pdf/14/37/cerm-43-31.PMC4838579.pdf
"THE KOREAN SOCIETY FOR REPRODUCTIVE MEDICINE38 ORIGINAL ARTICLE http://dx.doi.org/10.5653/cerm.2016.43.1.38 pISSN 2233-8233 · eISSN 2233-8241 Clin Exp Reprod Med 2016;43(1):38-43 Current status of assisted reproductive technology in  Korea, 2011    Committee for Assisted Reproductive Technology, Statistics, Korean Society for Assisted Reproduction; Gyoung Hoon Lee1,  Hyun Jin Song1, Kyu Sup Lee2, Young Min Choi3,4 1I-one Center, Seoul Women’s Hospital, Bucheon; 2Department of Obstetrics and Gynecology, Pusan National University School of Medicine and  Medical Research Institute, Pusan National University Hospital, Busan; 3Department of Obstetrics and Gynecology, 4The Institute of Reproductive  Medicine and Population, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea Objective:  The number of assisted reproductive technology (ART) clinics, ART cycles, clinical pregnancy rate (CPR), and number of newborns  conceived using ART have steadily increased in South Korea.",Non-OADS,/arxiv_data1/oa_pdf/2b/40/cerm-43-38.PMC4838580.pdf
"Received: Jan 27, 2016 ∙ Revised: Feb 13, 2016 ∙ Accepted: Feb 17, 2016 Corresponding author:  Young Min Choi  Department of Obstetrics and Gynecology, The Institute of Reproductive  Medicine and Population, Medical Research Center, Seoul National University  College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea  Tel: +82-2-2072-2385 Fax: +82-2-762-3599 E-mail: ymchoi@snu.ac.kr This is an Open Access article distributed under the terms of the Creative Commons Attribution  Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the  original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2b/40/cerm-43-38.PMC4838580.pdf
Responses were col - lected online (http://www.ivfkorea.or.kr).,Non-OADS,/arxiv_data1/oa_pdf/2b/40/cerm-43-38.PMC4838580.pdf
" http://dx.doi.org/10.5653/cerm.2016.43.1.38 Clin Exp Reprod Med 2016;43(1):38-43 4090.1% (n = 27,396) successfully transferred their embryos in 2011.",OADS,/arxiv_data1/oa_pdf/2b/40/cerm-43-38.PMC4838580.pdf
" http://dx.doi.org/10.5653/cerm.2016.43.1.38 Clin Exp Reprod Med 2016;43(1):38-43 422) Preimplantation genetic diagnosis and preimplantation   genetic screening Of the 227 cycles of preimplantation genetic diagnosis that were  planned, a total of 39 cases successfully progressed to clinical preg - nancy after ET (179 cycles).",Non-OADS,/arxiv_data1/oa_pdf/2b/40/cerm-43-38.PMC4838580.pdf
"Despite the aforementioned limitations, the KSAR is now launching  an online system to collect information related to other infertility-re - lated procedures, including intrauterine insemination, the miscar - riage rate, preimplantation genetic screening, and oocyte donation  (http://www.ivfkorea.or.kr).",Non-OADS,/arxiv_data1/oa_pdf/2b/40/cerm-43-38.PMC4838580.pdf
Supplemental data can be found at: http://ecerm.org/src/ sm/cerm-43-45-s002.pdf Reference 1.,OADS,/arxiv_data1/oa_pdf/2b/40/cerm-43-38.PMC4838580.pdf
"THE KOREAN SOCIETY FOR REPRODUCTIVE MEDICINE44 ORIGINAL ARTICLE http://dx.doi.org/10.5653/cerm.2016.43.1.44 pISSN 2233-8233 · eISSN 2233-8241 Clin Exp Reprod Med 2016;43(1):44-50 Clinical experience with single-port access  laparoscopic cystectomy and myomectomy Jae-Hyeok Jeong1, Yu-Ri Kim1, Kil-Pyo Hong1, Jae-Eun Ha1, Eun-Jeong Kim1, Da-Kyo Hong1, Kyu-Sup Lee2 1Department of Obstetrics and Gynecology, Hwamyeong Ilsin Christian Hospital, Busan; 2Department of Obstetrics and Gynecology, Pusan National  University School of Medicine, Busan, Korea Objective:  This study was performed to assess our clinical experience with single-port access (SPA) laparoscopic cystectomy and myomectomy  and the surgical outcomes of those procedures at our institution.",Non-OADS,/arxiv_data1/oa_pdf/d2/e5/cerm-43-44.PMC4838581.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution  Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the  original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d2/e5/cerm-43-44.PMC4838581.pdf
" http://dx.doi.org/10.5653/cerm.2016.43.1.44 Clin Exp Reprod Med 2016;43(1):44-50 46Gynecare, Ethicon) was avoided whenever possible.",Non-OADS,/arxiv_data1/oa_pdf/d2/e5/cerm-43-44.PMC4838581.pdf
 http://dx.doi.org/10.5653/cerm.2016.43.1.44 Clin Exp Reprod Med 2016;43(1):44-50 48(41.0%).,OADS,/arxiv_data1/oa_pdf/d2/e5/cerm-43-44.PMC4838581.pdf
 http://dx.doi.org/10.5653/cerm.2016.43.1.44 Clin Exp Reprod Med 2016;43(1):44-50 50terms of surgical results.,Non-OADS,/arxiv_data1/oa_pdf/d2/e5/cerm-43-44.PMC4838581.pdf
"THE KOREAN SOCIETY FOR REPRODUCTIVE MEDICINE51 CASE REPORT http://dx.doi.org/10.5653/cerm.2016.43.1.51 pISSN 2233-8233 · eISSN 2233-8241 Clin Exp Reprod Med 2016;43(1):51-53 Ileo-uterine fistula in a degenerated posterior wall  fibroid after Caesarean  section Ayman Shehata1, Naglaa Hussein1, Ahmed El Halwagy1, Adel El Gergawy1, Mohamed Khairallah2 1Lecturer of Obstetrics and Gynecology, 2Lecturer of Surgery, Tanta University, Tanta, Egypt Uterine fibroids are benign tumors of the myometrium with a diverse range of manifestations.",Non-OADS,/arxiv_data1/oa_pdf/55/a1/cerm-43-51.PMC4838582.pdf
"A biopsy was  taken from the mass for histopathological examination, and it was Received: Oct 16, 2015 ∙ Revised: Dec 4, 2015 ∙ Accepted: Dec 23, 2015 Corresponding author:  Ayman Shehata Lecturer of Obstetrics and Gynecology, Tanta University, Tanta-El Geish Street  31111, Tanta, Egypt Tel: +20-12-2588-0071 Fax: +20-40-3320-4569 E-mail: ayman.dawood@med.tanta.edu.eg This is an Open Access article distributed under the terms of the Creative Commons Attribution  Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the  original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/55/a1/cerm-43-51.PMC4838582.pdf
 http://dx.doi.org/10.5653/cerm.2016.43.1.51 Clin Exp Reprod Med 2016;43(1):51-53 52identified as a degenerated cellular fibroid polyp.,OADS,/arxiv_data1/oa_pdf/55/a1/cerm-43-51.PMC4838582.pdf
"THE KOREAN SOCIETY FOR REPRODUCTIVE MEDICINE54 CASE REPORT http://dx.doi.org/10.5653/cerm.2016.43.1.54 pISSN 2233-8233 · eISSN 2233-8241 Clin Exp Reprod Med 2016;43(1):54-57 Transabdominal follicular aspiration in an in vitro   fertilization cycle: experiences with an unusual but  necessary intervention in a resource-limited setting Abieyuwa Osemwenkha, James Osaikhuwuomwan Department of Obstetrics and Gynaecology, College of Medical Sciences, University of Benin, Benin City, Nigeria Controlled ovarian hyperstimulation is one of the major steps of in vitro  fertilization.",Non-OADS,/arxiv_data1/oa_pdf/69/b5/cerm-43-54.PMC4838583.pdf
"Thus, we instituted a protocol  [6] in which, prior to cycle cancellation for poor ovarian response,  scrupulous attention was paid to proxy indicators of the response  such as estradiol levels, basal follicle-stimulating hormone or anti- Müllerian hormone levels, endometrial thickness, and other individ - ual clinical characteristics before arriving at a final decision.Received: Nov 13, 2015 ∙ Revised: Feb 2, 2016 ∙ Accepted: Feb 6, 2016 Corresponding author:  James Osaikhuwuomwan Department of Obstetrics and Gynaecology, University of Benin, Benin City,  Nigeria Tel: +234-8023634885 E-mail: james.osaikhuwuomwan@uniben.edu This is an Open Access article distributed under the terms of the Creative Commons Attribution  Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the  original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/69/b5/cerm-43-54.PMC4838583.pdf
 http://dx.doi.org/10.5653/cerm.2016.43.1.54 Clin Exp Reprod Med 2016;43(1):54-57 56definitive IVF-ET treatment; she consented and underwent a success - ful myomectomy.,Non-OADS,/arxiv_data1/oa_pdf/69/b5/cerm-43-54.PMC4838583.pdf
"THE KOREAN SOCIETY FOR REPRODUCTIVE MEDICINE58 ACKNOWLEDGMENT http://dx.doi.org/10.5653/cerm.2016.43.1.58 pISSN 2233-8233 · eISSN 2233-8241 Clin Exp Reprod Med 2016;43(1):58 Acknowledgment to Reviewers for 2015  On behalf of the editor and editorial board, we would like to express our sincere gratitude for the reviewers and contributors who have gen - erously endowed with their time and efforts in appraising the manuscripts submitted to Clinical and Experimental Reproductive Medicine  in  2015.",Non-OADS,/arxiv_data1/oa_pdf/96/1d/cerm-43-58.PMC4838584.pdf
"Chen, Shee-Uan  National Taiwan University, Taiwan Cho, Moon-Kyoung  Chonnam National University Cho, Yeon-Jean  Dong-A University Cho, Sihyun  Yonsei University Choi, Doo-Seok  Sungkyunkwan University Choi, Won-Jun  Gyeongsang National University Hospital Chun, Sungwook  Inje University Cui, Xiang-Shun  Chungbuk National University Gye, Myung Chan  Hanyang University Han, Myoungseok  Dong-A University Jang, Kyung Hwan  Dr. Yoo Women’s Hospital Jee, Byung Chul  Seoul National University Joo, Jong Kil  Pusan National University Jun, Jin Hyun  Eulji University Jung, Hyewon  Ewha Womans University Kim, Chung-Hoon  Ulsan University Kim, Eun-Kyung  Fertility Center, CHA Bundang Medical Center Kim, Gi Jin  CHA University Kim, Jin Yeong  CHA University Kim, Yong-Jin  Korea University Kim, You-Shin  CHA University  Kim, Hoon  Seoul National University Kim, Jin Ju  Seoul National University Kim, Jong Hyun  Mizmedi Hospital Kim, Miran  Ajou University This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Kim, Sung Hoon  Ulsan University Koo, Hwa Seon  Dankook University Lee, Eun Sil  Soonchunhyang University Lee, Heejun  CHA University Lee, Joongyeup  Hamchoon Women’s Clinic Lee, Jung Ryeol  Seoul National University Lee, Kyung-Ah  CHA University Lee, Sung Ki  Konyang University Lim, Jung Jin  Fertility Center of CHA, Gangnam Medical Center Lim, Hyunjung Jade  Konkuk University Park, Chan Woo  Dankook University Park, Hyun-Tae  Korea University Park, Joon Cheol  Keimyung University Rhee, Jeong Ho  Keimyung University Rhee, Kunsoo  Seoul National University Ruy, Sangwoo  CHA University Seo, Seok-Kyo  Yonsei University Seo, Ju Tae  Dankook University Shin, Im Hee  Catholic University Of Daegu Song, Seung Hun  CHA University Yang, Kwang Moon  Dankook University Yoon, Sang Ho  Dongguk University Yoon, Sook-Young  CHA University Youm, Hyewon  Seoul National University Bundang Hospital",Non-OADS,/arxiv_data1/oa_pdf/96/1d/cerm-43-58.PMC4838584.pdf
"THE KOREAN SOCIETY FOR REPRODUCTIVE MEDICINE9 ORIGINAL ARTICLE http://dx.doi.org/10.5653/cerm.2016.43.1.9 pISSN 2233-8233 · eISSN 2233-8241 Clin Exp Reprod Med 2016;43(1):9-14 Vitrification, in vitro  fertilization, and development of  Atg7  deficient mouse oocytes Soyoung Bang1*, Geun-Kyung Lee1*, Hyejin Shin1, Chang Suk Suh2, Hyunjung Jade Lim1,3 1Department of Biomedical Science and Technology, Institute of Biomedical Science and Technology, Konkuk University, Seoul; 2Department of  Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam; 3Department of Veterinary Medicine, Konkuk University, Seoul,  Korea Objective:  Autophagy contributes to the clearance and recycling of macromolecules and organelles in response to stress.",Non-OADS,/arxiv_data1/oa_pdf/d6/09/cerm-43-9.PMC4838585.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution  Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the  original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d6/09/cerm-43-9.PMC4838585.pdf
" http://dx.doi.org/10.5653/cerm.2016.43.1.9 Clin Exp Reprod Med 2016;43(1):9-14 10Lipidation of LC3, i.e., the conversion of LC3-I to LC3-II, is often used as  a marker of autophagic flux [1].",Non-OADS,/arxiv_data1/oa_pdf/d6/09/cerm-43-9.PMC4838585.pdf
"1.50b (National Institutes  of Health, Bethesda, ME, USA, http://imagej.nih.gov/ij/).",Non-OADS,/arxiv_data1/oa_pdf/d6/09/cerm-43-9.PMC4838585.pdf
 http://dx.doi.org/10.5653/cerm.2016.43.1.9 Clin Exp Reprod Med 2016;43(1):9-14 122.,OADS,/arxiv_data1/oa_pdf/d6/09/cerm-43-9.PMC4838585.pdf
" http://dx.doi.org/10.5653/cerm.2016.43.1.9 Clin Exp Reprod Med 2016;43(1):9-14 14what brought about such an outcome, which warrants further inves - tigation.",Non-OADS,/arxiv_data1/oa_pdf/d6/09/cerm-43-9.PMC4838585.pdf
http://dx.doi.org/10.5713/ajas.15.0762.,Non-OADS,/arxiv_data1/oa_pdf/d6/09/cerm-43-9.PMC4838585.pdf
"The Ganoderma  strains listed in Table 1 were obtained from the Korean Collection for Type Culture (KTCT, Jeongeup,Korea), the American Type Culture Collection (ATCC,Rockville, MD, USA), the Korean Agricultural CultureCollection (KACC, Suwon, Korea), the Mushroom DivisionResearch Article Mycobiology 2016 March, 44(1): 1-6 http://dx.doi.org/10.5941/MYCO.2016.44.1.1 pISSN 1229-8093  eISSN 2092-9323© The Korean Society of Mycology *Corresponding author E-mail: cslee@kku.ac.kr †These authors contributed equally to this work.",Non-OADS,/arxiv_data1/oa_pdf/b4/c8/mb-44-1.PMC4838586.pdf
The sequences of the ITS rDNAwere aligned for phylogenetic analysis using the programBioEdit (http://www.mbio.ncsu.edu/bioedit/bioedit.html).,OADS,/arxiv_data1/oa_pdf/b4/c8/mb-44-1.PMC4838586.pdf
Available from: http://www.ncbi.nlm.nih.gov/books/NBK92773/.,Non-OADS,/arxiv_data1/oa_pdf/b4/c8/mb-44-1.PMC4838586.pdf
"Sizes are represented by the range between thesmallest and largest single values.Research Article Mycobiology 2016 March, 44(1): 14-20 http://dx.doi.org/10.5941/MYCO.2016.44.1.14 pISSN 1229-8093  eISSN 2092-9323 © The Korean Society of Mycology *Corresponding author E-mail: jshur1@sunchon.ac.kr Received  October 26, 2015 Revised  February 26, 2016 Accepted  March 2, 2016 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/3.0/) which permits unrestrictednon-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e4/cc/mb-44-14.PMC4838587.pdf
Chain convergence was determined using Tracerv1.5 (http://tree.bio.ed.ac.uk/software/tracer/) to ensuresufficiently large effective sample size (ESS) values.,OADS,/arxiv_data1/oa_pdf/e4/cc/mb-44-14.PMC4838587.pdf
"Measurements of microscopic characteristicsResearch Article Mycobiology 2016 March, 44(1): 21-28 http://dx.doi.org/10.5941/MYCO.2016.44.1.21 pISSN 1229-8093  eISSN 2092-9323 © The Korean Society of Mycology *Corresponding author E-mail: hansk75@korea.kr Received  January 31, 2016 Revised  March 3, 2016 Accepted  March 10, 2016 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/3.0/) which permits unrestrictednon-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/57/bc/mb-44-21.PMC4838588.pdf
"[7] revised the classiﬁcation of AbsidiaResearch Article Mycobiology 2016 March, 44(1): 29-37 http://dx.doi.org/10.5941/MYCO.2016.44.1.29 pISSN 1229-8093  eISSN 2092-9323 © The Korean Society of Mycology *Corresponding author E-mail: hblee@jnu.ac.kr Received  March 22, 2016 Revised  March 25, 2016 Accepted  March 27, 2016 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/3.0/) which permits unrestrictednon-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/cf/c1/mb-44-29.PMC4838589.pdf
"During this period,most of the total fungal biomass accumulates in the wheatmesophyll tissue [7], and the strategy of survival of M. graminicola  largely employs a biotrophic mode of nutrientResearch Article Mycobiology 2016 March, 44(1): 38-47 http://dx.doi.org/10.5941/MYCO.2016.44.1.38 pISSN 1229-8093  eISSN 2092-9323 © The Korean Society of Mycology *Corresponding author E-mail: Steve.Goodwin@ARS.USDA.gov Received  November 12, 2015 Revised  January 12, 2016 Accepted  January 17, 2016 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/3.0/) which permits unrestrictednon-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2a/99/mb-44-38.PMC4838590.pdf
"We searched for homologs of the CREA , AREA , and NOXa  genes in M. graminicola using the genomic database (http://genome.jgi-psf.org/Mycgr3/Mycgr3.home.html).",OADS,/arxiv_data1/oa_pdf/2a/99/mb-44-38.PMC4838590.pdf
"Inpreliminary experiments, we screened wood rotting fungiResearch Article Mycobiology 2016 March, 44(1): 48-53 http://dx.doi.org/10.5941/MYCO.2016.44.1.48 pISSN 1229-8093  eISSN 2092-9323 © The Korean Society of Mycology *Corresponding author E-mail: tslee@incheon.ac.kr Received  January 31, 2016 Revised  March 22, 2016 Accepted  March 23, 2016 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/3.0/) which permits unrestrictednon-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/81/e7/mb-44-48.PMC4838591.pdf
"PCR product were purified and sequenced by Solgent Co. (Daejeon, Korea).The fungal isolate was identified based on sequence homologywith fungal sequences retrieved from GenBank databaseusing BLAST program (http://www.ncbi.nlm.nih.gov/BLAST).",OADS,/arxiv_data1/oa_pdf/81/e7/mb-44-48.PMC4838591.pdf
"The sperm-rich fractionResearch Note Mycobiology 2016 March, 44(1): 54-57 http://dx.doi.org/10.5941/MYCO.2016.44.1.54 pISSN 1229-8093  eISSN 2092-9323 © The Korean Society of Mycology *Corresponding author E-mail: yiyj@jbnu.ac.kr (Y.-J.",Non-OADS,/arxiv_data1/oa_pdf/3b/cc/mb-44-54.PMC4838592.pdf
"1B~1D).Research Note Mycobiology 2016 March, 44(1): 58-62 http://dx.doi.org/10.5941/MYCO.2016.44.1.58 pISSN 1229-8093  eISSN 2092-9323© The Korean Society of Mycology *Corresponding author E-mail: hdshin@korea.ac.kr (H.-D. Shin),        kjam@jbnu.ac.kr (J.-A.",Non-OADS,/arxiv_data1/oa_pdf/68/68/mb-44-58.PMC4838593.pdf
"The possible identityof the isolates was established by comparing their ITSsequences with those in the GenBank database (NationalCenter for Biotechnology Information [NCBI] US NationalInstitute of Health, Bethesda, MD, USA; http://www.ncbi.nlm.nih.gov/BLAST).",OADS,/arxiv_data1/oa_pdf/68/68/mb-44-58.PMC4838593.pdf
"When each strain was incubated in PDB at 20 oC in anResearch Note Mycobiology 2016 March, 44(1): 63-65 http://dx.doi.org/10.5941/MYCO.2016.44.1.63 pISSN 1229-8093  eISSN 2092-9323 © The Korean Society of Mycology *Corresponding author E-mail: jungle@dau.ac.kr (J. Lee), lsh750409@korea.kr (S.-H. Lee) Received  February 25, 2016 Revised  March 19, 2016 Accepted  March 19, 2016 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/3.0/) which permits unrestrictednon-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b8/d0/mb-44-63.PMC4838594.pdf
"S. granulatus , which belongs to the family of Boletaceae, forms symbiotic ectomycorrhizas with pine tree roots, and has aResearch Article Mycobiology 2016 March, 44(1): 7-13 http://dx.doi.org/10.5941/MYCO.2016.44.1.7 pISSN 1229-8093  eISSN 2092-9323 © The Korean Society of Mycology *Corresponding author E-mail: koocdm@chungbuk.ac.kr Received  November 6, 2015 Revised  December 9, 2015 Accepted  February 22, 2016 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/3.0/) which permits unrestrictednon-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f4/af/mb-44-7.PMC4838595.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/e2/75/bmjgast-2016-000076.PMC4838659.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/ac/0a/bmjdrc-2015-000166.PMC4838662.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjdrc-2015- 000160).,Non-OADS,/arxiv_data1/oa_pdf/55/55/bmjdrc-2015-000160.PMC4838663.pdf
"U.S. Agency for Healthcare Research and Quality, 2014. https://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp#overview 19.",Non-OADS,/arxiv_data1/oa_pdf/55/55/bmjdrc-2015-000160.PMC4838663.pdf
"To view please visit the journal (http://dx.doi.org/ 10.1136/bmjdrc-2015-000154) Received 21 September 2015 Revised 12 February 2016 Accepted 24 February 2016 1HealthCore Inc., Wilmington, Delaware, USA 2AstraZeneca R&D, Fort Washington, Pennsylvania, USA 3Bristol-Myers Squibb Company, Plainsboro, New Jersey, USA Correspondence to Mr Bingcao Wu; bwu@healthcore.comABSTRACT Objective: To describe the estimated prevalence and temporal trends of chronic kidney disease (CKD)treatment patterns, and the association between CKDand potential factors for type 2 diabetes mellitus(T2DM) in different demographic subgroups.",Non-OADS,/arxiv_data1/oa_pdf/53/ca/bmjdrc-2015-000154.PMC4838667.pdf
http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf.,Non-OADS,/arxiv_data1/oa_pdf/53/ca/bmjdrc-2015-000154.PMC4838667.pdf
2014. http://emedicine.medscape.com/article/238946-overview(accessed 23 Jun 2014).,Non-OADS,/arxiv_data1/oa_pdf/53/ca/bmjdrc-2015-000154.PMC4838667.pdf
http://www.cdc.gov/nchs/data/nhis/ earlyrelease/earlyrelease201306_14.pdf (accessed 4 Apr 2015).,OADS,/arxiv_data1/oa_pdf/53/ca/bmjdrc-2015-000154.PMC4838667.pdf
2015. http://www.cdc.gov/nchs/tutorials/dietary/surveyorientation/surveydesign/intro.htm (accessed 3 Jan 2015).,OADS,/arxiv_data1/oa_pdf/53/ca/bmjdrc-2015-000154.PMC4838667.pdf
2015. http://www2.kidney.org/professionals/KDOQI/ guideline_diabetes/guide3.htm (accessed 5 Jan 2015).,Non-OADS,/arxiv_data1/oa_pdf/53/ca/bmjdrc-2015-000154.PMC4838667.pdf
1991:769. http://www.cabdirect.org/abstracts/19920311043.html;jsessionid=6E0E 2C4EFA900 F98B428AFAE994F14E4 20.,Non-OADS,/arxiv_data1/oa_pdf/62/61/bmjgast-2015-000058.PMC4838668.pdf
"San Diego, CA: GraphPad Software Inc., 1999:379. http://www.graphpad.com 38.",Non-OADS,/arxiv_data1/oa_pdf/62/61/bmjgast-2015-000058.PMC4838668.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2015- 009778).,Non-OADS,/arxiv_data1/oa_pdf/91/31/bmjopen-2015-009778.PMC4838674.pdf
Underlying population mortality rates in GA were deter- mined using SEER*Stat software (http://seer.cancer.gov/seerstat) and were used to calculate expected death counts.,OADS,/arxiv_data1/oa_pdf/91/31/bmjopen-2015-009778.PMC4838674.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/91/31/bmjopen-2015-009778.PMC4838674.pdf
http://www.iarc.fr/en/publications/pdfs-online/stat/sp82/SP82_vol2 –3.pdf (accessed 20 Jul 2015).,Non-OADS,/arxiv_data1/oa_pdf/91/31/bmjopen-2015-009778.PMC4838674.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2016- 011913).,Non-OADS,/arxiv_data1/oa_pdf/ed/d7/bmjopen-2016-011913.PMC4838677.pdf
An example of a tool that is based on robust research evidence and effectively dis-seminated is the Fracture Risk Assessment Tool (FRAX) (http://www.shef.ac.uk/FRAX/index.aspx).,Non-OADS,/arxiv_data1/oa_pdf/ed/d7/bmjopen-2016-011913.PMC4838677.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2015- 010106).,Non-OADS,/arxiv_data1/oa_pdf/2d/0d/bmjopen-2015-010106.PMC4838678.pdf
"36 37In add- ition, a new approach to integrating quantity and quality ofphysical activity has been developed using a patient- derived concept, 38through the European Innovative Medicines Initiative project, PROactive (http://www.proactivecopd.com).",Non-OADS,/arxiv_data1/oa_pdf/2d/0d/bmjopen-2015-010106.PMC4838678.pdf
A full list of sites can be obtained at https://clinical-trials.gov.,Non-OADS,/arxiv_data1/oa_pdf/2d/0d/bmjopen-2015-010106.PMC4838678.pdf
2014. http://www.goldcopd.org/uploads/users/files/GOLD_Report2014_Feb07.pdf (accessed 22 Jul 2015).,OADS,/arxiv_data1/oa_pdf/2d/0d/bmjopen-2015-010106.PMC4838678.pdf
2013. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM367411.pdf (accessed 22 Jan 2016).43.,Non-OADS,/arxiv_data1/oa_pdf/2d/0d/bmjopen-2015-010106.PMC4838678.pdf
2015. http://www.livingwellwithcopd.com/ en/home.html (accessed 12 Jan 2015).,Non-OADS,/arxiv_data1/oa_pdf/2d/0d/bmjopen-2015-010106.PMC4838678.pdf
"10Founder mutations, however, drive allele frequencies higher in Ashkenazi Jewish (2.9%)11and Icelandic populations (5.6%).7Current National Comprehensive Cancer Network (NCCN) guidelines suggest screening for BRCA1 and BRCA2 mutations (also known as hereditary breast and ovarian cancer (HBOC)syndrome) if they present with a high Gleason score (≥7) and there is a close relative with breast ( ≤50 years), ovarian, pancreas or prostate cancer (also Gleason score≥7) (http://www.nccn.org/).",Non-OADS,/arxiv_data1/oa_pdf/0b/9d/bmjopen-2015-010332.PMC4838679.pdf
Reads were aligned to the hg19 reference genome using Novoalign (http://novocraft.com; VN: V2.07.13) with the following options: --hdrhd off -v 120Table 1 Descriptive statistics of the cohort Deleterious mutation Yes No p Value Age At primary diagnosis 64 66 0.047At ADT 69.4 69.5 0.958At the developmentof mCRPC73.9 73.7 0.923 Family history Yes 10 45 0.785*No 3 11 Histology Adenocarcinoma 5 28 0.877 † Poorly differentiatedcarcinoma NOS18 Small-cell carcinoma 0 1 Unknown 7 20 Gleason score 7 0 2 0.054*80 1 592 610 4 13NS 7 21 *Linear model ANOVA.,Non-OADS,/arxiv_data1/oa_pdf/0b/9d/bmjopen-2015-010332.PMC4838679.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2015-009134).,Non-OADS,/arxiv_data1/oa_pdf/ee/b3/bmjopen-2015-009134.PMC4838680.pdf
"The patient has to arrange the appointment with the GP .The GP does not receive information about the ERACORI study protocol or the study hypothesis, but is of course free to search for the study in http://www.clinicaltrials.gov.All patients will ﬁll out the short form 12-items health survey (SF-12) and Changes in Sexual Functioning Questionnaires (CSFQ), and disease activityscore C-reactive protein (DAS28-CRP) will be registered using the Danish Danbio registry.",Non-OADS,/arxiv_data1/oa_pdf/ee/b3/bmjopen-2015-009134.PMC4838680.pdf
"The GP does not receive information about the ERACORI study protocol or thestudy hypothesis, but is of course free to search for the study in http://www.clinicaltrials.gov.",Non-OADS,/arxiv_data1/oa_pdf/ee/b3/bmjopen-2015-009134.PMC4838680.pdf
2012. http://www.danskreumatologiskselskab.dk/date(accessed 8 June 2013).,OADS,/arxiv_data1/oa_pdf/ee/b3/bmjopen-2015-009134.PMC4838680.pdf
"Dansk Hypertensions Selskab, 2009. http://www.dahs.dk/date(accessed 8 Jun 2013).",Non-OADS,/arxiv_data1/oa_pdf/ee/b3/bmjopen-2015-009134.PMC4838680.pdf
http://www.endocrinology.dk/date (accessed 8 Jun 2013).,Non-OADS,/arxiv_data1/oa_pdf/ee/b3/bmjopen-2015-009134.PMC4838680.pdf
http://www.heartscore.org/Date (access 8 June 2013).33.,Non-OADS,/arxiv_data1/oa_pdf/ee/b3/bmjopen-2015-009134.PMC4838680.pdf
http://www.wma.net/en/30publications/ 10policies/b3date (accessed 8 Jun 2013).,Non-OADS,/arxiv_data1/oa_pdf/ee/b3/bmjopen-2015-009134.PMC4838680.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2015-010911).,Non-OADS,/arxiv_data1/oa_pdf/73/9a/bmjopen-2015-010911.PMC4838681.pdf
Competing interests All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/coi_disclosure.pdf and declare: financial support for the submitted work from GlaxoSmithKline.,Non-OADS,/arxiv_data1/oa_pdf/73/9a/bmjopen-2015-010911.PMC4838681.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2016- 011286).,Non-OADS,/arxiv_data1/oa_pdf/e6/f0/bmjopen-2016-011286.PMC4838682.pdf
Depression in adults with a chronic physical health problem: full guideline.Retrieved 21 May 2013. http://www.nice.org.uk/guidance/cg91/evidence/cg91-depression-with-a-chronic-physical-health-problem-full-guideline2 13.,Non-OADS,/arxiv_data1/oa_pdf/e6/f0/bmjopen-2016-011286.PMC4838682.pdf
"Roth A, Pilling S. A competence framework for psychological interventions with people with persistent physical health conditions.Retrieved 29 April 2015. http://www.ucl.ac.uk/clinical-psychology/CORE/Docs/physical-health-conditions-competences/Working%20with%20physical%20health%20conditions%20Background%20document%20for%20web%2013th%20April%202015.pdf 35.",Non-OADS,/arxiv_data1/oa_pdf/e6/f0/bmjopen-2016-011286.PMC4838682.pdf
Retrieved 27 April 2015. http://www.nice.org.uk/article/pmg9/resources//non-guidance-guide-to-the-methods-of-technology-appraisal-2013-pdf 38.,Non-OADS,/arxiv_data1/oa_pdf/e6/f0/bmjopen-2016-011286.PMC4838682.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2015-010564).,Non-OADS,/arxiv_data1/oa_pdf/78/40/bmjopen-2015-010564.PMC4838683.pdf
10 April 2015. http://www.sbct.org.br/ pdf/livro_virtual/bronquiectasias.pdf 15.,Non-OADS,/arxiv_data1/oa_pdf/78/40/bmjopen-2015-010564.PMC4838683.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2015-009956).,Non-OADS,/arxiv_data1/oa_pdf/4b/3e/bmjopen-2015-009956.PMC4838684.pdf
Data collection and microbiological sampling We designed a CRF using the Epi-Info free softwarepackage (http://wwwn.cdc.gov/epiinfo/).,OADS,/arxiv_data1/oa_pdf/4b/3e/bmjopen-2015-009956.PMC4838684.pdf
"aida-project.eu) which has been designed to analyse the clinical effectiveness and optimal dosing of older antibio-tics, including colistin, fosfomycin, nitrofurantoin, minocy- cline and rifampicin (see http://www.aida-project.eu).",Non-OADS,/arxiv_data1/oa_pdf/4b/3e/bmjopen-2015-009956.PMC4838684.pdf
Improving surveillance for ventilator-associated events in adults 2012. http://www.cdc.gov/nhsn/PDFs/vae/CDC_VAE_CommunicationsSummary-for-compliance_20120313.pdf (accessed 22 Jul 2015).,Non-OADS,/arxiv_data1/oa_pdf/4b/3e/bmjopen-2015-009956.PMC4838684.pdf
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/10/news_detail_002194.,Non-OADS,/arxiv_data1/oa_pdf/4b/3e/bmjopen-2015-009956.PMC4838684.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2016-011165).,Non-OADS,/arxiv_data1/oa_pdf/b8/7f/bmjopen-2016-011165.PMC4838685.pdf
http://www.mext.go.jp/component/a_menu/education/detail/__icsFiles/afieldfile/2015/11/17/1324090_ 19.pdf 18.,Non-OADS,/arxiv_data1/oa_pdf/b8/7f/bmjopen-2016-011165.PMC4838685.pdf
http://www.mhlw.go.jp/stf/shingi/2r98520000032oxz-att/2r98520000032p1w_1.pdf 25.,Non-OADS,/arxiv_data1/oa_pdf/b8/7f/bmjopen-2016-011165.PMC4838685.pdf
http://www.mhlw.go.jp/general/sikaku/successlist/siken01/about.html 26.,Non-OADS,/arxiv_data1/oa_pdf/b8/7f/bmjopen-2016-011165.PMC4838685.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2015-009881).,Non-OADS,/arxiv_data1/oa_pdf/93/4c/bmjopen-2015-009881.PMC4838686.pdf
http://www.who.int/chp/steps/en/ 16.,Non-OADS,/arxiv_data1/oa_pdf/93/4c/bmjopen-2015-009881.PMC4838686.pdf
http://www.csa.org.lb/cms/assets/questionnaire_nncd_rf_lebanon.pdf 17.,OADS,/arxiv_data1/oa_pdf/93/4c/bmjopen-2015-009881.PMC4838686.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2015-010773).,Non-OADS,/arxiv_data1/oa_pdf/54/ed/bmjopen-2015-010773.PMC4838687.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/54/ed/bmjopen-2015-010773.PMC4838687.pdf
http://www.cdc.gov/vaccines/vpd-vac/measles/faqs-dis-vac-risks.htm(accessed 19 Mar 2015).,Non-OADS,/arxiv_data1/oa_pdf/54/ed/bmjopen-2015-010773.PMC4838687.pdf
"Pediatric vaccinations in Italy: vaccination coverage, 2014. http://www.salute.gov.it/imgs/C_17_tavole_20_allegati_iitemAllegati_2_fileAllegati_itemFile_0_file.pdf (accessed 4Dec 2015).",Non-OADS,/arxiv_data1/oa_pdf/54/ed/bmjopen-2015-010773.PMC4838687.pdf
http://www.salute.,Non-OADS,/arxiv_data1/oa_pdf/54/ed/bmjopen-2015-010773.PMC4838687.pdf
"Socio-demographic indicators, 2015. http://www.istat.it/it/archivio/149003 (accessed 15Feb 2016).",Non-OADS,/arxiv_data1/oa_pdf/54/ed/bmjopen-2015-010773.PMC4838687.pdf
"Geneva, Switzerland, 2013. http://apps.who.int/iris/ handle/10665/92455 (accessed 20 Feb 2016).",Non-OADS,/arxiv_data1/oa_pdf/bf/57/bmjopen-2015-010417.PMC4838688.pdf
"Geneva, Switzerland, 2002. http://www.who.int/ medicines/publications/traditionalpolicy/en/ (accessed 20 Feb 2016).",Non-OADS,/arxiv_data1/oa_pdf/bf/57/bmjopen-2015-010417.PMC4838688.pdf
"Geneva, Switzerland, 2000. http://apps.who.int/medicinedocs/en/d/Jwhozip42e/ (accessed 20 Feb 2016).",Non-OADS,/arxiv_data1/oa_pdf/bf/57/bmjopen-2015-010417.PMC4838688.pdf
"Abuja, Nigeria, Rockville, MD, USA: NPC and ICF International, 2014.http://www.population.gov.ng/images/ndhs_data/ndhs_2013/2013_ndhs_final_report.pdf (accessed 20 Feb 2016).",OADS,/arxiv_data1/oa_pdf/bf/57/bmjopen-2015-010417.PMC4838688.pdf
"Geneva, Switzerland, 2012. http://apps.who.int/iris/bitstream/10665/44844/1/9789241564441_eng.pdf?ua=1 (accessed 20 Feb 2016).",Non-OADS,/arxiv_data1/oa_pdf/bf/57/bmjopen-2015-010417.PMC4838688.pdf
"Washington DC, USA, 2015. https://openknowledge.worldbank.org/handle/10986/21634 (accessed 20 Feb 2016).",Non-OADS,/arxiv_data1/oa_pdf/bf/57/bmjopen-2015-010417.PMC4838688.pdf
"Côte d ’Ivoire, 2011. http://www.afro.",Non-OADS,/arxiv_data1/oa_pdf/bf/57/bmjopen-2015-010417.PMC4838688.pdf
http://www.idrc.ca/en/aboutus/donor_ partnerships/pages/nehsi.aspx (accessed 20 Feb 2016).,Non-OADS,/arxiv_data1/oa_pdf/bf/57/bmjopen-2015-010417.PMC4838688.pdf
http://media.wix.com/ugd/cb47c9_50ec344bc3144a9f85886 cce64c9425e.pdf (accessed 20 Feb 2016).,Non-OADS,/arxiv_data1/oa_pdf/bf/57/bmjopen-2015-010417.PMC4838688.pdf
2015. http://en.wikipedia.org/wiki/CIETmap (accessed 30 Nov 2015).25.,Non-OADS,/arxiv_data1/oa_pdf/bf/57/bmjopen-2015-010417.PMC4838688.pdf
http://media.wix.com/ugd/ cb47c9_d790340d497847e58f5505518c122b24.pdf (accessed 20Feb 2016).,Non-OADS,/arxiv_data1/oa_pdf/bf/57/bmjopen-2015-010417.PMC4838688.pdf
http://www.ncbi.nlm.nih.gov/pubmed/23304931 37.,Non-OADS,/arxiv_data1/oa_pdf/bf/57/bmjopen-2015-010417.PMC4838688.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2015-010757).,Non-OADS,/arxiv_data1/oa_pdf/b6/44/bmjopen-2015-010757.PMC4838689.pdf
Data sharing statement RTI data in Nepal are accessible on the traffic police website (http://traffic.nepalpolice.gov.np/) and in a document prepared by thedepartment of roads (http://www.dor.gov.np/documents/Status_Paper%20_ 2013.pdf).,OADS,/arxiv_data1/oa_pdf/b6/44/bmjopen-2015-010757.PMC4838689.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2015-010699).,Non-OADS,/arxiv_data1/oa_pdf/fc/ca/bmjopen-2015-010699.PMC4838690.pdf
29. http://www.asha.org/policy/KS2004-00080/#r4 30.,Non-OADS,/arxiv_data1/oa_pdf/fc/ca/bmjopen-2015-010699.PMC4838690.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2015-010482).,Non-OADS,/arxiv_data1/oa_pdf/cc/c5/bmjopen-2015-010482.PMC4838691.pdf
18. http://optn.transplant.hrsa.gov/ContentDocuments/OPTN_Policies.,Non-OADS,/arxiv_data1/oa_pdf/cc/c5/bmjopen-2015-010482.PMC4838691.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2015-010054).,Non-OADS,/arxiv_data1/oa_pdf/30/05/bmjopen-2015-010054.PMC4838693.pdf
http://www.un.org/disabilities/convention/conventionfull.shtml(accessed 3 Sep 2015).,Non-OADS,/arxiv_data1/oa_pdf/ca/89/bmjopen-2015-009929.PMC4838694.pdf
http://www.unisdr.,Non-OADS,/arxiv_data1/oa_pdf/ca/89/bmjopen-2015-009929.PMC4838694.pdf
Countermeasures for the Great East Japan Earthquake 2015. http://www.npa.go.jp/archive/keibi/biki/ index_e.htm (accessed 3 Sep 2015).,OADS,/arxiv_data1/oa_pdf/ca/89/bmjopen-2015-009929.PMC4838694.pdf
2010. http://www.fema.gov/pdf/about/odic/fnss_guidance.pdf (accessed 3 Sep 2015).,OADS,/arxiv_data1/oa_pdf/ca/89/bmjopen-2015-009929.PMC4838694.pdf
"10Social classes were de ﬁned accord- ing to the National Readership Survey classi ﬁcations (available from http://www.nrs.co.uk/nrs-print/lifestyle-and-classi ﬁcation-data/social-grade/) and ranged from A to E, with A de ﬁned as being the highest social class and E the lowest.",Non-OADS,/arxiv_data1/oa_pdf/35/5a/bmjopen-2015-010790.PMC4838698.pdf
The full breakdown of answers is publicly availableat http://www.comres.co.uk/poll/1028/gbs-vaccination- survey.htm.,Non-OADS,/arxiv_data1/oa_pdf/35/5a/bmjopen-2015-010790.PMC4838698.pdf
2nd Edition published 01 July 2012. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg36/(accessed 02 Feb 2016).,Non-OADS,/arxiv_data1/oa_pdf/35/5a/bmjopen-2015-010790.PMC4838698.pdf
2015: PHE publications gateway number: 2015046. published May 2015. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/429612/Seasonal_Flu_GP_Patient_Groups_Annual_Report_2014_15.pdf (accessed 14 Apr 2016).,Non-OADS,/arxiv_data1/oa_pdf/35/5a/bmjopen-2015-010790.PMC4838698.pdf
"2015, PHEpublications gateway number 2015282. published September 2015.https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/457733/PrenatalPertussis_Final.pdf (accessed 14 Apr 2016).9.",Non-OADS,/arxiv_data1/oa_pdf/35/5a/bmjopen-2015-010790.PMC4838698.pdf
http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-286348 12.,Non-OADS,/arxiv_data1/oa_pdf/35/5a/bmjopen-2015-010790.PMC4838698.pdf
2013. https://www.gov.uk/government/publications/ pertussis-immunisation-in-pregnancy-vaccine-coverage-estimates- in-england-october-2013-to-march-2014/pertussis-vaccination-programme-for-pregnant-women-vaccine-coverage-estimates-in-england-october-2013-to-march-2014 (accessed 6 Feb 2016).,Non-OADS,/arxiv_data1/oa_pdf/35/5a/bmjopen-2015-010790.PMC4838698.pdf
Updated March 2014. http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/WhoopingCough/ImmunisationForPregnantWomen/ 17.,Non-OADS,/arxiv_data1/oa_pdf/35/5a/bmjopen-2015-010790.PMC4838698.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2015-009920).,Non-OADS,/arxiv_data1/oa_pdf/b6/da/bmjopen-2015-009920.PMC4838700.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2015-010136).,Non-OADS,/arxiv_data1/oa_pdf/3a/40/bmjopen-2015-010136.PMC4838701.pdf
This study was undertaken by ASiT (http://www.asit.,Non-OADS,/arxiv_data1/oa_pdf/3a/40/bmjopen-2015-010136.PMC4838701.pdf
org) and BOTA (http://www.bota.org.uk).,Non-OADS,/arxiv_data1/oa_pdf/3a/40/bmjopen-2015-010136.PMC4838701.pdf
"Twitter Follow Rhiannon Harries at @rhiharries, Vimal Gokani at @VimalGokani, Edward Fitzgerald at @DrEdFitzgerald and Peter Smitham at @PeteSmitham Follow http://www.asit.org, http://www.bota.org.uk, http://twitter.com/ ASiTofficial @ASiTofficial, http://twitter.com/bota_uk @bota_uk Acknowledgements The authors gratefully acknowledge the Royal College of Physicians and Surgeons of Glasgow (RCPSG), the Royal College ofSurgeons of Edinburgh (RCSEd), and the Royal College of Surgeons of England (RCSEng) Women in Surgery group for distributing the survey to their trainee members.",Non-OADS,/arxiv_data1/oa_pdf/3a/40/bmjopen-2015-010136.PMC4838701.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/3a/40/bmjopen-2015-010136.PMC4838701.pdf
2011. http://www.gmc-uk.org/Less_than_full_time_training___GMC_position_statement___18_October_2011.pdf_45023470.pdf (accessed 18 Jun 2015).,Non-OADS,/arxiv_data1/oa_pdf/3a/40/bmjopen-2015-010136.PMC4838701.pdf
2013. http://www.gmc-uk.org/20131004_Chapter_1_SoMEP.pdf_53706030.pdf (accessed 15 Jun 2015).,Non-OADS,/arxiv_data1/oa_pdf/3a/40/bmjopen-2015-010136.PMC4838701.pdf
2013. http://www.rcsi.ie/files/surgery/docs/20140407123804_Guide to Flexible Training Nov.pdf (accessed 18Jun 2015).,Non-OADS,/arxiv_data1/oa_pdf/3a/40/bmjopen-2015-010136.PMC4838701.pdf
"Workforce Census, 2011. https://catalogue.ic.",OADS,/arxiv_data1/oa_pdf/3a/40/bmjopen-2015-010136.PMC4838701.pdf
2013. http://www.asit.org/assets/documents/UB_Statement_ASiT_Final_2.pdf (accessed 18 Jun 2015).,Non-OADS,/arxiv_data1/oa_pdf/3a/40/bmjopen-2015-010136.PMC4838701.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2015-010650).,Non-OADS,/arxiv_data1/oa_pdf/5d/97/bmjopen-2015-010650.PMC4838702.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2015-009342).,Non-OADS,/arxiv_data1/oa_pdf/2d/e6/bmjopen-2015-009342.PMC4838703.pdf
"A/58/227.New York, 2003:4. http://daccess-dds-ny.un.org/doc/UNDOC/GEN/N03/461/70/PDF/N0346170.pdf?OpenElement 7.",Non-OADS,/arxiv_data1/oa_pdf/2d/e6/bmjopen-2015-009342.PMC4838703.pdf
"Geneva: WHO, 1986. http://www.who.int/healthpromotion/conferences/previous/ottawa/en/8.",Non-OADS,/arxiv_data1/oa_pdf/2d/e6/bmjopen-2015-009342.PMC4838703.pdf
To view these files please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2015-010900).,Non-OADS,/arxiv_data1/oa_pdf/3d/de/bmjopen-2015-010900.PMC4838705.pdf
http://www.nationaltraumainstitute.org/ home/trauma_statistics.html (accessed 18 Nov 2014).,Non-OADS,/arxiv_data1/oa_pdf/3d/de/bmjopen-2015-010900.PMC4838705.pdf
http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/demo62f-eng.htm (accessed 18 Nov 2014).,OADS,/arxiv_data1/oa_pdf/3d/de/bmjopen-2015-010900.PMC4838705.pdf
http://www.ramq.gouv.qc.ca/fr/donnees-statistiques/sur-demande/donnees-msss/Pages/bdm-sirtq.aspx# (accessed 19 Nov 2014).,Non-OADS,/arxiv_data1/oa_pdf/3d/de/bmjopen-2015-010900.PMC4838705.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2015- 008986).,Non-OADS,/arxiv_data1/oa_pdf/94/59/bmjopen-2015-008986.PMC4838706.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2016- 011258).,Non-OADS,/arxiv_data1/oa_pdf/f5/e5/bmjopen-2016-011258.PMC4838707.pdf
2011. https://geoportal.statistics.gov.uk/Docs/Lookups/Postcodes_(Enumeration)_(2011)_to_output_areas_(2011)_to_lower_layer_SOA_(2011)_to_middle_layer_SOA_(2011)_to_ local_authority_districts_(2011)_E+W_lookup.zip 19.,OADS,/arxiv_data1/oa_pdf/e4/08/bmjopen-2016-011092.PMC4838708.pdf
2015. https://www.gov.uk/government/statistics/english-indices-of-deprivation-2015 20.,Non-OADS,/arxiv_data1/oa_pdf/e4/08/bmjopen-2016-011092.PMC4838708.pdf
2015. https://geoportal.statistics.gov.uk/Docs/Boundaries/Clinical_commissioning_groups_(Eng)_Jul_2015_Boundaries_(Full_Extent)_V2.zip 21.,OADS,/arxiv_data1/oa_pdf/e4/08/bmjopen-2016-011092.PMC4838708.pdf
2013. http://CRAN.R-project.org/package=maptools 22.,Non-OADS,/arxiv_data1/oa_pdf/e4/08/bmjopen-2016-011092.PMC4838708.pdf
"2015. http://www.hscic.gov.uk/ catalogue/PUB18887 23. de Lusignan S, Hague N, van Vlymen J, et al.",Non-OADS,/arxiv_data1/oa_pdf/e4/08/bmjopen-2016-011092.PMC4838708.pdf
2015. http://www.hscic.gov.uk/catalogue/PUB17274/pres-cost-anal-eng-2014-rep.pdf 25.,Non-OADS,/arxiv_data1/oa_pdf/e4/08/bmjopen-2016-011092.PMC4838708.pdf
2015. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/428971/Seasonal_Flu_Jan15_acc2.pdf 26.,Non-OADS,/arxiv_data1/oa_pdf/e4/08/bmjopen-2016-011092.PMC4838708.pdf
29. http://www.integrateproject.org.uk30.,Non-OADS,/arxiv_data1/oa_pdf/e4/08/bmjopen-2016-011092.PMC4838708.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2015-010270).,Non-OADS,/arxiv_data1/oa_pdf/f8/e3/bmjopen-2015-010270.PMC4838710.pdf
"2008, 2013: http://www.melaniebarwick.com/KTTemplate_dl.php Kapadia MZ, et al.BMJ Open 2016; 6:e010270.",Non-OADS,/arxiv_data1/oa_pdf/f8/e3/bmjopen-2015-010270.PMC4838710.pdf
"Acknowledgements This study is supported by the National Natural Science Foundation of China (http://www.nsfc.gov.cn, grant no 81574045), the Collaboration Innovation Center for Rehabilitation Technology (2015003-Collaboration), the Fujian Provincial Rehabilitation Industrial Institution and the Fujian Key Laboratory of Rehabilitation Technology.",Non-OADS,/arxiv_data1/oa_pdf/ab/fa/bmjopen-2015-010602.PMC4838712.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2015-010453).,Non-OADS,/arxiv_data1/oa_pdf/d3/10/bmjopen-2015-010453.PMC4838713.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/f9/3f/bmjopen-2015-010341.PMC4838715.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2015- 010663).,Non-OADS,/arxiv_data1/oa_pdf/51/d7/bmjopen-2015-010663.PMC4838716.pdf
"No appointment needed: the resurgence of urgent care centers in the United States: CaliforniaHealthCare Foundation, 2007. http://www.chcf.org/publications/2007/09/no-appointment-needed-the-resurgence-of-urgent-care-centers-in-the-united-states (accessed Aug 2014).",Non-OADS,/arxiv_data1/oa_pdf/51/d7/bmjopen-2015-010663.PMC4838716.pdf
http://www.nytimes.com/2014/07/ 10/business/race-is-on-to-profit-from-rise-of-urgent-care.html?_r=0 11.,Non-OADS,/arxiv_data1/oa_pdf/51/d7/bmjopen-2015-010663.PMC4838716.pdf
2011 http://c.ymcdn.com/sites/www.ucaoa.org/resource/resmgr/Files/WhitePaperTheCaseforUrgentCa.pdf (accessed Aug 2014).,Non-OADS,/arxiv_data1/oa_pdf/51/d7/bmjopen-2015-010663.PMC4838716.pdf
2012.http://factfinder.census.gov/faces/tableservices/jsf/pages/productview.xhtml?src=bkmk (accessed Aug 2014).,OADS,/arxiv_data1/oa_pdf/51/d7/bmjopen-2015-010663.PMC4838716.pdf
http://www.ers.usda.gov/briefing/Rurality/RuralUrbanCommutingAreas/ 19.,Non-OADS,/arxiv_data1/oa_pdf/51/d7/bmjopen-2015-010663.PMC4838716.pdf
http://bhpr.hrsa.gov/shortage/ 23.,Non-OADS,/arxiv_data1/oa_pdf/51/d7/bmjopen-2015-010663.PMC4838716.pdf
"Before searching for publications, we searched for trial registration in the largest and most widely used clinical trials database (http://www.clinicaltrials.gov), to identify the unique trial registration number (NCTnumber) used in the database if the trial was registered there.",OADS,/arxiv_data1/oa_pdf/06/5e/bmjopen-2015-010535.PMC4838717.pdf
http://druginfo.nlm.nih.gov/drugportal/(accessed 14 Feb 2014).,OADS,/arxiv_data1/oa_pdf/06/5e/bmjopen-2015-010535.PMC4838717.pdf
http://jcr.incites.thomsonreuters.com/ (accessed 14 Oct 2014).,Non-OADS,/arxiv_data1/oa_pdf/06/5e/bmjopen-2015-010535.PMC4838717.pdf
http://www.isiknowledge.com (accessed 25 Mar 2015).,Non-OADS,/arxiv_data1/oa_pdf/06/5e/bmjopen-2015-010535.PMC4838717.pdf
http://www.whocc.no/atc_ddd_index/ (accessed 1 Nov2015).,OADS,/arxiv_data1/oa_pdf/06/5e/bmjopen-2015-010535.PMC4838717.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2016-011589).,Non-OADS,/arxiv_data1/oa_pdf/70/bf/bmjopen-2016-011589.PMC4838718.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2015-009052).,Non-OADS,/arxiv_data1/oa_pdf/c1/96/bmjopen-2015-009052.PMC4838722.pdf
http://www.atlasti.com 2012).,Non-OADS,/arxiv_data1/oa_pdf/c1/96/bmjopen-2015-009052.PMC4838722.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1. van Rosse F, Essink-Bot ML, Stronks K, et al.",Non-OADS,/arxiv_data1/oa_pdf/c1/96/bmjopen-2015-009052.PMC4838722.pdf
"Bevolkingstrends [Population trends].2011:59. http://www.cbs.nl/nr/rdonlyres/476f84a8-b876-43b4-aa21- 350338c052eb/0/2011k1b15pub.pdf 5. van Rosse F, de Bruijne MC, Wagner C, et al.",OADS,/arxiv_data1/oa_pdf/c1/96/bmjopen-2015-009052.PMC4838722.pdf
Joint Commission International 2013. http://www.jointcommissioninternational.org/assets/3/7/Hospital-5E-Standards-Only-Mar2014.pdf (accessed 4 Apr 2016).,Non-OADS,/arxiv_data1/oa_pdf/c1/96/bmjopen-2015-009052.PMC4838722.pdf
"ISBN: 3-900051-07-0, http://www.R-project.org).",Non-OADS,/arxiv_data1/oa_pdf/31/d2/bmjopen-2015-010810.PMC4838723.pdf
"A European birth cohort registry lists 87 large birth cohorts worldwide, encompassing close tohalf a million children (http://www.birthcohorts.net/ bch2), and of these, only 9 include infectious diseases as important exposures.",Non-OADS,/arxiv_data1/oa_pdf/31/d2/bmjopen-2015-010810.PMC4838723.pdf
"We had chosen to nest this trial within our prospective cohort in part due to current and local interest in TC exposure.With this study, we will be able to explore the ef ﬁcacy of TC-containing compared with plain soaps in preventing reported illness; this analysis will be particularly timely inthe light of current interest in TCs by the United States Environmental Protection A gency (EPA) and the United States Food and Drug Administration (FDA; http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm378393.",Non-OADS,/arxiv_data1/oa_pdf/31/d2/bmjopen-2015-010810.PMC4838723.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/31/d2/bmjopen-2015-010810.PMC4838723.pdf
2014. http://www.cdc.gov/nchs/ data/hestat/obesity_adult_11_12/obesity_adult_11_12.pdf 2.,Non-OADS,/arxiv_data1/oa_pdf/31/d2/bmjopen-2015-010810.PMC4838723.pdf
http://www.cdc.gov/nchs/data/hestat/obesity_child_07_08/obesity_child_07_08.pdf 3.,Non-OADS,/arxiv_data1/oa_pdf/31/d2/bmjopen-2015-010810.PMC4838723.pdf
"2014. http://www.cdc.gov/nchs/ data/hestat/obesity_child_11_12/obesity_child_11_12.pdf Ley C, et al.BMJ Open 2016; 6:e010810.",Non-OADS,/arxiv_data1/oa_pdf/31/d2/bmjopen-2015-010810.PMC4838723.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2015-009081).,Non-OADS,/arxiv_data1/oa_pdf/c5/a8/bmjopen-2015-009081.PMC4838724.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/c5/a8/bmjopen-2015-009081.PMC4838724.pdf
2015. http://www.moh.gov.cn/yzygj/s7653/201503/9aa3cc022c744b28845c121209166491.shtml 5.,Non-OADS,/arxiv_data1/oa_pdf/bc/35/bmjopen-2016-011061.PMC4838725.pdf
2013. http://www.v2020la.org/images/CSR_2012.pdf 7.,Non-OADS,/arxiv_data1/oa_pdf/bc/35/bmjopen-2016-011061.PMC4838725.pdf
2010. http://www.haiweb.org/medicineprices/manual/documents.html 12.,Non-OADS,/arxiv_data1/oa_pdf/bc/35/bmjopen-2016-011061.PMC4838725.pdf
2014. http://www.who.int/en/18.,Non-OADS,/arxiv_data1/oa_pdf/bc/35/bmjopen-2016-011061.PMC4838725.pdf
2015. http://www.nhfpc.gov.cn/zhuzhan/index.shtml 22.,Non-OADS,/arxiv_data1/oa_pdf/bc/35/bmjopen-2016-011061.PMC4838725.pdf
2013. http://www.gzstats.gov.cn/tjgb/qstjgb/201304/t20130401_32641.htm 26.,Non-OADS,/arxiv_data1/oa_pdf/bc/35/bmjopen-2016-011061.PMC4838725.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2015- 010998).,Non-OADS,/arxiv_data1/oa_pdf/b3/26/bmjopen-2015-010998.PMC4838726.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2015-010991).,Non-OADS,/arxiv_data1/oa_pdf/ab/d0/bmjopen-2015-010991.PMC4838728.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2015-010480).,Non-OADS,/arxiv_data1/oa_pdf/11/b9/bmjopen-2015-010480.PMC4838729.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/11/b9/bmjopen-2015-010480.PMC4838729.pdf
http://www.bbc.co.uk/news/ uk-england-oxfordshire-26334445 (accessed 30 Apr 2015).,Non-OADS,/arxiv_data1/oa_pdf/11/b9/bmjopen-2015-010480.PMC4838729.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2016-011207).,Non-OADS,/arxiv_data1/oa_pdf/65/27/bmjopen-2016-011207.PMC4838730.pdf
"To assess changethat might result from enhanced participation, and which patients might consider important in terms of quality of life and well-being, 19we used the Stroke and Aphasia Quality of Life Scale (SAQOL-39g).28To measure patient satisfaction with staff communication in ways that might reﬂect the quality of support for patient engagement and participation we used the Communicative Access Measure for Stroke (CAMS3): patient satisfaction instrument devel- oped by the Aphasia Institute in Toronto (http://www.aphasia.ca/).",Non-OADS,/arxiv_data1/oa_pdf/65/27/bmjopen-2016-011207.PMC4838730.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2016-011088).,Non-OADS,/arxiv_data1/oa_pdf/d6/63/bmjopen-2016-011088.PMC4838731.pdf
http://mdgs.un.org/unsd/ mdg/Metadata.aspx?IndicatorId=0&SeriesId=762 5.,OADS,/arxiv_data1/oa_pdf/d6/63/bmjopen-2016-011088.PMC4838731.pdf
"Calverton, Maryland, USA, 2011. http://www.measuredhs.com/pubs/pdf/FR229/FR229.pdf.",Non-OADS,/arxiv_data1/oa_pdf/d6/63/bmjopen-2016-011088.PMC4838731.pdf
Information about the wider programme of the PHRC is available from http://phrc.lshtm.ac.uk.,Non-OADS,/arxiv_data1/oa_pdf/b9/35/bmjopen-2016-011044.PMC4838732.pdf
http://www.cls.,Non-OADS,/arxiv_data1/oa_pdf/b9/35/bmjopen-2016-011044.PMC4838732.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2015-010213).,Non-OADS,/arxiv_data1/oa_pdf/57/14/bmjopen-2015-010213.PMC4838733.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/57/14/bmjopen-2015-010213.PMC4838733.pdf
http://www.who.int/wer/2014/wer8925/en/ 3.,Non-OADS,/arxiv_data1/oa_pdf/57/14/bmjopen-2015-010213.PMC4838733.pdf
http://www.who.int/immunization/givs/en/10.,Non-OADS,/arxiv_data1/oa_pdf/57/14/bmjopen-2015-010213.PMC4838733.pdf
http://www.cdc.gov/shingles/hcp/diagnosis-testing.html 14.,Non-OADS,/arxiv_data1/oa_pdf/57/14/bmjopen-2015-010213.PMC4838733.pdf
http://data.worldbank.org/about/country-and-lending-groups 18.,Non-OADS,/arxiv_data1/oa_pdf/57/14/bmjopen-2015-010213.PMC4838733.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2015-010965).,Non-OADS,/arxiv_data1/oa_pdf/d4/a7/bmjopen-2015-010965.PMC4838735.pdf
http://www.mortality.org/ 11.,Non-OADS,/arxiv_data1/oa_pdf/d4/a7/bmjopen-2015-010965.PMC4838735.pdf
"Baltimore, MD: John Hopkins University, 2014. http://omim.org/ 32.",Non-OADS,/arxiv_data1/oa_pdf/d4/a7/bmjopen-2015-010965.PMC4838735.pdf
"We will use acentralised web-based, secure randomisation service for clinical trials (http://www.randomize.net/).",Non-OADS,/arxiv_data1/oa_pdf/d6/36/bmjopen-2016-011659.PMC4838736.pdf
"We will disseminate results to key stakeholders (eg, critical care clinicians, critical caretriallists, research funders and the public) through con- ference presentations, peer-review journal publications, trial registry (clinicaltrials.gov) and the CYCLE trialwebsite (http://www.icucycle.ca).",Non-OADS,/arxiv_data1/oa_pdf/d6/36/bmjopen-2016-011659.PMC4838736.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/d6/36/bmjopen-2016-011659.PMC4838736.pdf
2010. http://www.icmje.org/recommendations/.,Non-OADS,/arxiv_data1/oa_pdf/d6/36/bmjopen-2016-011659.PMC4838736.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1. WHO.,Non-OADS,/arxiv_data1/oa_pdf/83/f7/bmjopen-2015-010158.PMC4838737.pdf
2012. https://www.gov.uk/government/publications/nhs-reference-costs-2012-to-2013 17.,Non-OADS,/arxiv_data1/oa_pdf/83/f7/bmjopen-2015-010158.PMC4838737.pdf
"Kent: Personal Social Services Research Unit, University of Kent, Canterbury, 2012. http://www.pssru.ac.uk/archive/pdf/uc/uc2012/full-with-covers.pdf 18.",Non-OADS,/arxiv_data1/oa_pdf/83/f7/bmjopen-2015-010158.PMC4838737.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2015- 010301).,Non-OADS,/arxiv_data1/oa_pdf/b0/82/bmjopen-2015-010301.PMC4838738.pdf
Theprincipal objective of the study was to analyse fivehealth-risk assessment strategies and health indicatorsused in the five regions participating in the AdvancingCare Coordination and Telehealth Deployment (ACT)programme (http://www.act-programme.eu).,Non-OADS,/arxiv_data1/oa_pdf/b0/82/bmjopen-2015-010301.PMC4838738.pdf
"The current study was carried out within the frame of the Advancing Care Coordination and T elehealth (ACT) programme (http://www.act-programme.eu)9involving ﬁve leading European Union (EU) regions in terms of scaling up integrated care: Basque Country (ES), Scotland (UK), Lombardy (I), Groningen (NL) andCatalonia (ES).",Non-OADS,/arxiv_data1/oa_pdf/b0/82/bmjopen-2015-010301.PMC4838738.pdf
"Geneva: World Health Organization (WHO/MNC/CCH/02.01), 2002. http://www.who.int/chp/knowledge/publications/icccreport/en/(accessed 17 Jul 2014).",Non-OADS,/arxiv_data1/oa_pdf/b0/82/bmjopen-2015-010301.PMC4838738.pdf
https://www.consilium.europa.eu/uedocs/ cms_data/docs/pressdata/en/lsa/118282.pdf 5.,Non-OADS,/arxiv_data1/oa_pdf/b0/82/bmjopen-2015-010301.PMC4838738.pdf
European Scaling-up Strategy in Active and Healthy Ageing 2014. http://ec.europa.eu/research/innovation-union/pdf/active-healthy-ageing/scaling_up_strategy.pdf#view=fit&pagemode=none 6.,Non-OADS,/arxiv_data1/oa_pdf/b0/82/bmjopen-2015-010301.PMC4838738.pdf
http://www.act-programme.eu/ 10.,Non-OADS,/arxiv_data1/oa_pdf/b0/82/bmjopen-2015-010301.PMC4838738.pdf
http://www.opimec.org/ (accessed 31 Jul2015).,Non-OADS,/arxiv_data1/oa_pdf/b0/82/bmjopen-2015-010301.PMC4838738.pdf
Health Aff Blog 2015. http://healthaffairs.org/blog/ 2015/04/06/what-are-we-talking-about-when-we-talk-about-population-health/?utm_source=Sailthru&utm_medium=email&utm_term=Healthcare Dive&utm_campaign=Issue: 2015-04-06 Healthcare Dive(accessed 7 Apr 2015).,Non-OADS,/arxiv_data1/oa_pdf/b0/82/bmjopen-2015-010301.PMC4838738.pdf
2012: http://webarchive.nationalarchives.gov.uk/20130513181011/http://www.nigb.nhs.uk/ pubs/guidance/riskpred.pdf.,Non-OADS,/arxiv_data1/oa_pdf/b0/82/bmjopen-2015-010301.PMC4838738.pdf
"Generalitat de Catalunya-Departament de Salut, Agenciade Qualitat i Avaluació Sanitàrias de Catalunya, 2015: http://aquas.gencat.cat/es/projectes/visc/.",Non-OADS,/arxiv_data1/oa_pdf/b0/82/bmjopen-2015-010301.PMC4838738.pdf
"To cite a current, relevant example, TheMedical Board of Australia (MBA) has recently commis- sioned research to establish whether or not there is an evidence base for the validity of validation systems incomparable countries (http://www.medicalboard.gov.",Non-OADS,/arxiv_data1/oa_pdf/ed/54/bmjopen-2015-010368.PMC4838739.pdf
Version 4.2.5 Updated May 2005. http://community-archive.cochrane.org/sites/default/files/uploads/glossary.pdf(accessed 7 Apr 2014).,OADS,/arxiv_data1/oa_pdf/ed/54/bmjopen-2015-010368.PMC4838739.pdf
2011. http://www.gmc-uk.org/static/documents/content/CPD___The_International_Perspective_Jul_11.pdf_44810902.pdf (accessed 3Sept 2014).,Non-OADS,/arxiv_data1/oa_pdf/ed/54/bmjopen-2015-010368.PMC4838739.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2015-010422).,Non-OADS,/arxiv_data1/oa_pdf/d1/d9/bmjopen-2015-010422.PMC4838741.pdf
http://fabry-database.org17.,OADS,/arxiv_data1/oa_pdf/d1/d9/bmjopen-2015-010422.PMC4838741.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2015-010795).,Non-OADS,/arxiv_data1/oa_pdf/ac/57/bmjopen-2015-010795.PMC4838742.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2015-009058).,Non-OADS,/arxiv_data1/oa_pdf/34/1d/bmjopen-2015-009058.PMC4838743.pdf
The web link to the module is http://cpax.ocbmedia.com.,Non-OADS,/arxiv_data1/oa_pdf/ac/37/bmjopen-2015-010614.PMC4838744.pdf
"Great Britain, 2009. http://www.nice.",Non-OADS,/arxiv_data1/oa_pdf/ac/37/bmjopen-2015-010614.PMC4838744.pdf
http://www.rehabmeasures.org/default.aspx (accessed Aug 2015).,Non-OADS,/arxiv_data1/oa_pdf/ac/37/bmjopen-2015-010614.PMC4838744.pdf
To view these files please visit the journal online (http://dx.doi.org/10.1136/ rmdopen-2016-000241).,Non-OADS,/arxiv_data1/oa_pdf/1e/df/rmdopen-2016-000241.PMC4838760.pdf
doi:10.1136/vetreco-2015- 000164 ▸Prepublication history for this paper is available online.To view these files please visit the journal online (http://dx.doi.org/10.1136/ vetreco-2015-000164).,Non-OADS,/arxiv_data1/oa_pdf/1b/7b/vetreco-2015-000164.PMC4838762.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ rmdopen-2015-000179).,Non-OADS,/arxiv_data1/oa_pdf/4f/a2/rmdopen-2015-000179.PMC4838763.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/rmdopen-2015- 000210).,Non-OADS,/arxiv_data1/oa_pdf/5f/97/rmdopen-2015-000210.PMC4838764.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/vetreco-2015- 000163).,Non-OADS,/arxiv_data1/oa_pdf/e4/65/vetreco-2015-000163.PMC4838766.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/vetreco-2015-000146).,Non-OADS,/arxiv_data1/oa_pdf/36/58/vetreco-2015-000146.PMC4838767.pdf
To view please visit the journal (http://dx.doi.org/10.1136/rmdopen-2016- 000246).,Non-OADS,/arxiv_data1/oa_pdf/ff/8f/rmdopen-2016-000246.PMC4838769.pdf
The major discovery of my dissertation research was that under  This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/07/73/nihms745004.PMC4838774.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2015-010580).,Non-OADS,/arxiv_data1/oa_pdf/05/10/bmjopen-2015-010580.PMC4838778.pdf
7 This study represents the preliminary component of an NIHR-funded study which includes a randomised controlled trial (RCT) (PRE-EMPT) (http://www.controlled-trials.com/ISRCTN97865475).,Non-OADS,/arxiv_data1/oa_pdf/05/10/bmjopen-2015-010580.PMC4838778.pdf
"The model structure was based on the NIHR-funded (PRE-EMPT study) RCT design,which was informed by a review of existing evidence and clinical input (http://www.controlled-trials.com/ ISRCTN97865475).",Non-OADS,/arxiv_data1/oa_pdf/05/10/bmjopen-2015-010580.PMC4838778.pdf
2013. http://www.eshre.eu/~/media/Files/ESHRE%20guideline%20on%20endometriosis%202013%20v1.pdf 4.,Non-OADS,/arxiv_data1/oa_pdf/05/10/bmjopen-2015-010580.PMC4838778.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/95/43/rjw052.PMC4838900.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c1/2b/main.PMC4838904.pdf
"There is some evidence of improvements in nutrition beyond infancy(Adair, 1999 ;Mani, 2012 ;Schott, Crookston, Lundeen, Stein &Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/ssmphSSM -Population Health http://dx.doi.org/10.1016/j.ssmph.2016.01.003 2352-8273/ &2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/c1/2b/main.PMC4838904.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c1/2b/main.PMC4838904.pdf
"© 2016 Surgical Neurology International | Published by Wolters Kluwer - MedknowEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comSir, Spontaneous chemical meningitis in craniopharyngioma  is a rare phenomenon.",Non-OADS,/arxiv_data1/oa_pdf/bc/10/SNI-7-41.PMC4838913.pdf
"Surgical Neurology International 2016, 7:41  http://www.surgicalneurologyint.com/content/7/1/41patients’ vision improved in the right eye but there was  no improvement on the left side.",Non-OADS,/arxiv_data1/oa_pdf/bc/10/SNI-7-41.PMC4838913.pdf
"Surgical Neurology International 2016, 7:41  http://www.surgicalneurologyint.com/content/7/1/41The exact mechanism of cyst rupture in these tumors  is not clearly known, but it may be induced by the  progressive enlargement of the cyst causing weakness of  the cyst wall and finally rupture.",Non-OADS,/arxiv_data1/oa_pdf/bc/10/SNI-7-41.PMC4838913.pdf
"Editor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.com © 2016 Surgical Neurology International | Published by Wolters Kluwer - MedknowAbstract Background:   Cauda equina paragangliomas (CEPs) are rare spinal tumors that  are mostly misdiagnosed preoperatively as ependymomas or schwannomas on  magnetic resonance imaging (MRI).",Non-OADS,/arxiv_data1/oa_pdf/fe/ae/SNI-7-37.PMC4838918.pdf
"Surg Neurol  Int 2016;7:37. http://surgicalneurologyint.com/Apoplectic-presentation-of-a-cauda-equina- paraganglioma/This is an open access article distributed under the terms of the Creative Commons  Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix,  tweak, and build upon the work non-commercially, as long as the author is credited and  the new creations are licensed under the identical terms.",Non-OADS,/arxiv_data1/oa_pdf/fe/ae/SNI-7-37.PMC4838918.pdf
"Surgical Neurology International 2016, 7:37  http://www.surgicalneurologyint.com/content/7/1/37gadolinium‑diethylene‑triamine pentaacetic acid showed  thin rim of peripheral enhancement at the superior pole.",Non-OADS,/arxiv_data1/oa_pdf/fe/ae/SNI-7-37.PMC4838918.pdf
"Surgical Neurology International 2016, 7:37  http://www.surgicalneurologyint.com/content/7/1/37characterized by the presence of “zellballen,” or a nesting  of cell groups, and trabecular cords of cells within thin  fibrovascular stroma.",Non-OADS,/arxiv_data1/oa_pdf/fe/ae/SNI-7-37.PMC4838918.pdf
"Editor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.com © 2016 Surgical Neurology International | Published by Wolters Kluwer - MedknowSir, Spontaneous discharging sinus due to a bony lesion is  not an unknown entity.",Non-OADS,/arxiv_data1/oa_pdf/23/0a/SNI-7-40.PMC4838919.pdf
Surg Neurol Int  2016;7:40. http://surgicalneurologyint.com/Empirical-antitubercular-therapy-even-in-endemic- area-should-be-started-with-caution:-Missed-case-of-calvarial-epidermoid- presenting-with-discharging-sinus/ Figure 1: (a) Whitish discharge from the wound.,Non-OADS,/arxiv_data1/oa_pdf/23/0a/SNI-7-40.PMC4838919.pdf
"Surgical Neurology International 2016, 7:40  http://www.surgicalneurologyint.com/content/7/1/40wound healed completely [ Figure  3c] and there is no  recurrence at 6 months follow‑up.",Non-OADS,/arxiv_data1/oa_pdf/23/0a/SNI-7-40.PMC4838919.pdf
"Surgical Neurology International 2016, 7:40  http://www.surgicalneurologyint.com/content/7/1/40Commentary In general, I do not believe in the Western World this  article would be contributing much to neurosurgery.",Non-OADS,/arxiv_data1/oa_pdf/23/0a/SNI-7-40.PMC4838919.pdf
"Editor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.com © 2016 Surgical Neurology International | Published by Wolters Kluwer - MedknowAbstract Background:  Spinal cord stimulators (SCSs) are gaining increasing indications and  utility in an expanding variety of clinical conditions.",Non-OADS,/arxiv_data1/oa_pdf/36/22/SNI-7-33.PMC4838920.pdf
"http://surgicalneurologyint.com/Are-there-a-guidelines-for-implantable-spinal-cord-stimulator-therapy-in-patients-using-chronic-anticoagulation-therapy?---A-review-of- decision-making-in-the-high-risk-patient/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and  build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.",Non-OADS,/arxiv_data1/oa_pdf/36/22/SNI-7-33.PMC4838920.pdf
"Surgical Neurology International 2016, 7:33  http://www.surgicalneurologyint.com/content/7/1/33INTRODUCTION The utility of spinal cord stimulator (SCS) has proven  to be excellent when  compared to conservative medical  management (CMM) or reoperation for failed back  surgery syndrome (FBSS) patients.",Non-OADS,/arxiv_data1/oa_pdf/36/22/SNI-7-33.PMC4838920.pdf
"Surgical Neurology International 2016, 7:33  http://www.surgicalneurologyint.com/content/7/1/33therapy, IDDS, surgical decompression and fusion with  surgical lead SCS implantation, or percutaneous SCS  therapy at the thoracic level.",Non-OADS,/arxiv_data1/oa_pdf/36/22/SNI-7-33.PMC4838920.pdf
"Surgical Neurology International 2016, 7:33  http://www.surgicalneurologyint.com/content/7/1/33which may carry with it severe morbidity and mortality  among elderly patients, and the proximity to the spinal  cord water shadow zone has a potential for a high risk of  permanent paralysis.",Non-OADS,/arxiv_data1/oa_pdf/36/22/SNI-7-33.PMC4838920.pdf
"Surgical Neurology International 2016, 7:33  http://www.surgicalneurologyint.com/content/7/1/33Heparins (unfractionated heparin or low‑molecular‑weight  heparin [LMWH]) carry the greatest risk of epidural  hematoma with high dosing or close timing of therapy to  intervention.",Non-OADS,/arxiv_data1/oa_pdf/36/22/SNI-7-33.PMC4838920.pdf
"Surgical Neurology International 2016, 7:33  http://www.surgicalneurologyint.com/content/7/1/33of patients.",Non-OADS,/arxiv_data1/oa_pdf/36/22/SNI-7-33.PMC4838920.pdf
"Surgical Neurology International 2016, 7:33  http://www.surgicalneurologyint.com/content/7/1/33should differ from current evidence supported guidelines  regarding neuraxial injections and minor procedures.",Non-OADS,/arxiv_data1/oa_pdf/36/22/SNI-7-33.PMC4838920.pdf
"© 2016 Surgical Neurology International | Published by Wolters Kluwer - MedknowEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comAbstract Background:  Neural tube defects (NTDs) are the most common congenital  malformations affecting the brain and spinal cord and have a multifactorial etiology.",Non-OADS,/arxiv_data1/oa_pdf/0c/be/SNI-7-35.PMC4838921.pdf
"Surg Neurol Int  2016;7:35. http://surgicalneurologyint.com/Epidemiology-of-the-neural-tube-defects-in-Kashmir-Valley/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and  build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.",Non-OADS,/arxiv_data1/oa_pdf/0c/be/SNI-7-35.PMC4838921.pdf
"Surgical Neurology International 2016, 7:35  http://www.surgicalneurologyint.com/content/7/1/35 INTRODUCTION Neural tube defects in Kashmir valley Neural tube defects (NTDs) are the most common  congenital malformations affecting the brain and spinal  cord.",Non-OADS,/arxiv_data1/oa_pdf/0c/be/SNI-7-35.PMC4838921.pdf
"Surgical Neurology International 2016, 7:35  http://www.surgicalneurologyint.com/content/7/1/35OBSERVATIONS AND RESULTS Kashmir Valley is topographically and geographically  different from the rest of India.",Non-OADS,/arxiv_data1/oa_pdf/0c/be/SNI-7-35.PMC4838921.pdf
"Surgical Neurology International 2016, 7:35  http://www.surgicalneurologyint.com/content/7/1/35gave history of diabetes.",Non-OADS,/arxiv_data1/oa_pdf/0c/be/SNI-7-35.PMC4838921.pdf
"Surgical Neurology International 2016, 7:35  http://www.surgicalneurologyint.com/content/7/1/35to be less, in our study, could be that anencephaly is not  compatible with life and most of the babies with it die  immediately after birth.",Non-OADS,/arxiv_data1/oa_pdf/0c/be/SNI-7-35.PMC4838921.pdf
"Surgical Neurology International 2016, 7:35  http://www.surgicalneurologyint.com/content/7/1/35our study Grewal et al.,[14] in their study, found women  who did not graduate from high school and lived in  low‑SES neighborhoods exhibited a significantly higher  risk for NTD pregnancy than women with high school or  higher education who lived in the same neighborhood.",Non-OADS,/arxiv_data1/oa_pdf/0c/be/SNI-7-35.PMC4838921.pdf
"Surgical Neurology International 2016, 7:35  http://www.surgicalneurologyint.com/content/7/1/35Commentary Study of the “Prevalence of Neural T ube Defects in  India” is important as a higher incidence is presumed  to occur compared to the western world, and a wide  variation in various regions within the country has been  reported.",Non-OADS,/arxiv_data1/oa_pdf/0c/be/SNI-7-35.PMC4838921.pdf
"© 2016 Surgical Neurology International | Published by Wolters Kluwer ‑ MedknowEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comAbstract Background:  To identify the role of the hypercholesterolemia as a starting factor in  discovertebral degeneration that ultimately causes lower back pain, and investigate  the role of Vitamin E in this process.",Non-OADS,/arxiv_data1/oa_pdf/3d/4e/SNI-7-36.PMC4838922.pdf
"Surg Neurol Int 2016;7:36. http://surgicalneurologyint.com/Effect-of-a-hypercholesterolemia-as-a-starting-factor-on-spinal-degeneration-in-rabbits-and-role-of-Vitamin-E-( α-tocopherol)/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and  build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.",Non-OADS,/arxiv_data1/oa_pdf/3d/4e/SNI-7-36.PMC4838922.pdf
"Surgical Neurology International 2016, 7:36  http://www.surgicalneurologyint.com/content/7/1/36INTRODUCTION Low back pain resulting from lumbar degenerative disc  disease is a common cause of morbidity and deterioration  of the quality of life.",Non-OADS,/arxiv_data1/oa_pdf/3d/4e/SNI-7-36.PMC4838922.pdf
"Surgical Neurology International 2016, 7:36  http://www.surgicalneurologyint.com/content/7/1/36were assayed for αT by HPLC.",Non-OADS,/arxiv_data1/oa_pdf/3d/4e/SNI-7-36.PMC4838922.pdf
"Surgical Neurology International 2016, 7:36  http://www.surgicalneurologyint.com/content/7/1/36was statistically insignificant ( P > 0.05).",Non-OADS,/arxiv_data1/oa_pdf/3d/4e/SNI-7-36.PMC4838922.pdf
"Surgical Neurology International 2016, 7:36  http://www.surgicalneurologyint.com/content/7/1/36cholesterol diet for 4 weeks and with a normal diet for  the next 4 weeks) were statistically similar ( P > 0.05).",Non-OADS,/arxiv_data1/oa_pdf/3d/4e/SNI-7-36.PMC4838922.pdf
"Surgical Neurology International 2016, 7:36  http://www.surgicalneurologyint.com/content/7/1/36that Vitamin E was insufficient to diminish foam cells,  despite its effect on atherosclerotic lesions in large vessels  for this treatment period [ Figure  4b].",Non-OADS,/arxiv_data1/oa_pdf/3d/4e/SNI-7-36.PMC4838922.pdf
"Surgical Neurology International 2016, 7:36  http://www.surgicalneurologyint.com/content/7/1/36evoke radicular pain.",Non-OADS,/arxiv_data1/oa_pdf/3d/4e/SNI-7-36.PMC4838922.pdf
"Surgical Neurology International 2016, 7:36  http://www.surgicalneurologyint.com/content/7/1/36of the bone, and an increase in osteoclast number.",Non-OADS,/arxiv_data1/oa_pdf/3d/4e/SNI-7-36.PMC4838922.pdf
"Surgical Neurology International 2016, 7:36  http://www.surgicalneurologyint.com/content/7/1/36has been studied widely.",Non-OADS,/arxiv_data1/oa_pdf/3d/4e/SNI-7-36.PMC4838922.pdf
"Surgical Neurology International 2016, 7:36  http://www.surgicalneurologyint.com/content/7/1/3616.",Non-OADS,/arxiv_data1/oa_pdf/3d/4e/SNI-7-36.PMC4838922.pdf
"Editor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.com © 2016 Surgical Neurology International | Published by Wolters Kluwer - MedknowAbstract Low back pain (LBP) is a common medical problem with high morbidity and  healthcare costs.",Non-OADS,/arxiv_data1/oa_pdf/54/5d/SNI-7-38.PMC4838923.pdf
"Surg Neurol  Int 2016;7:38. http://surgicalneurologyint.com/The-role-of-surgery-for-treatment-of-low-back-pain:- insights-from-the-randomized-controlled-Spine-Patient-Outcomes-Research-Trials/This is an open access article distributed under the terms of the Creative Commons  Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix,  tweak, and build upon the work non-commercially, as long as the author is credited and  the new creations are licensed under the identical terms.",Non-OADS,/arxiv_data1/oa_pdf/54/5d/SNI-7-38.PMC4838923.pdf
"Surgical Neurology International 2016, 7:38  http://www.surgicalneurologyint.com/content/7/1/38across the country to investigate the clinical efficacy of  surgery as treatment for the three common causes of  lower back pain and neurogenic claudication, including  lumbar disc herniation, DS, and spinal stenosis.",Non-OADS,/arxiv_data1/oa_pdf/54/5d/SNI-7-38.PMC4838923.pdf
"Surgical Neurology International 2016, 7:38  http://www.surgicalneurologyint.com/content/7/1/38at 2 years: SF‑36 bodily pain = 1.5, [95% CI, −4.2–7.3],  SF‑36 physical function = 1.9, [95% CI, −3.7–7.5],  ODI = 2.2, [95% CI, −2.3–6.8]).",Non-OADS,/arxiv_data1/oa_pdf/54/5d/SNI-7-38.PMC4838923.pdf
"Surgical Neurology International 2016, 7:38  http://www.surgicalneurologyint.com/content/7/1/38the efficacy of commonly employed treatment strategies  for patients with similar disorders can be established  and compared.",Non-OADS,/arxiv_data1/oa_pdf/54/5d/SNI-7-38.PMC4838923.pdf
"Surgical Neurology International 2016, 7:38  http://www.surgicalneurologyint.com/content/7/1/38treatment alternative.",Non-OADS,/arxiv_data1/oa_pdf/54/5d/SNI-7-38.PMC4838923.pdf
"Surgical Neurology International 2016, 7:38  http://www.surgicalneurologyint.com/content/7/1/38results of surgical intervention would likely be more clearly  confirmed.",Non-OADS,/arxiv_data1/oa_pdf/54/5d/SNI-7-38.PMC4838923.pdf
"Surgical Neurology International 2016, 7:38  http://www.surgicalneurologyint.com/content/7/1/38SURGICAL VERSUS NONOPERATIVE  TREATMENT FOR LUMBAR DEGENERATIVE  SPONDYLOLISTHESIS; 4‑YEAR RESULTS  IN THE SPINE PATIENT OUTCOMES  RESEARCH TRIAL Weinstein et al.",Non-OADS,/arxiv_data1/oa_pdf/54/5d/SNI-7-38.PMC4838923.pdf
"Surgical Neurology International 2016, 7:38  http://www.surgicalneurologyint.com/content/7/1/38Spine Patient Outcomes Research Trial (SPORT).",Non-OADS,/arxiv_data1/oa_pdf/54/5d/SNI-7-38.PMC4838923.pdf
"Surgical Neurology International 2016, 7:38  http://www.surgicalneurologyint.com/content/7/1/38opinion (e.g., self‑reported surveys of patient satisfaction  conducted by mail or telephone contacts) recorded,  for example, by newly designed but largely unproven  instruments for quantifying pain.",Non-OADS,/arxiv_data1/oa_pdf/54/5d/SNI-7-38.PMC4838923.pdf
"Surgical Neurology International 2016, 7:38  http://www.surgicalneurologyint.com/content/7/1/38prior history of periodic limiting episodes of back pain,  recovered very well with decompressive surgery regardless  of the degenerative diagnosis––lumbar intervertebral disc  herniation, degenerative lumbar spondylolistheses (usually  with a stable slippage of 25% or less), and spinal stenosis.",Non-OADS,/arxiv_data1/oa_pdf/54/5d/SNI-7-38.PMC4838923.pdf
"Surgical Neurology International 2016, 7:38  http://www.surgicalneurologyint.com/content/7/1/38However, a final conclusion of the authors of the  review on which I wish to comment is revealing: “The  importance of the SPORT studies to the neurosurgical  and spine community cannot be overstated” (line 144).",Non-OADS,/arxiv_data1/oa_pdf/54/5d/SNI-7-38.PMC4838923.pdf
"© 2016 Surgical Neurology International | Published by Wolters Kluwer - MedknowEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comThe article titled, “Solid hemangioblastoma in the cerebellopontine angle: Importance of external carotid blood supply  with regard to the probable site of origin and preoperative embolization” published in pages S1‑4, Supplement 1, vol.",Non-OADS,/arxiv_data1/oa_pdf/6f/68/SNI-7-42.PMC4838924.pdf
"Editor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.com © 2016 Surgical Neurology International | Published by Wolters Kluwer - MedknowAbstract Background:  Gangliogliomas are rare low grade, typically well‑differentiated,  tumors that are composed of mature ganglion cells and neoplastic glial cells.",Non-OADS,/arxiv_data1/oa_pdf/a0/87/SNI-7-39.PMC4838925.pdf
"Surg Neurol Int 2016;7:39. http://surgicalneurologyint.com/Bilateral-internal-auditory-canal-gangliogliomas- mimicking-neurofibromatosis-Type-II/This is an open access article distributed under the terms of the Creative Commons  Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix,  tweak, and build upon the work non-commercially, as long as the author is credited and  the new creations are licensed under the identical terms.",Non-OADS,/arxiv_data1/oa_pdf/a0/87/SNI-7-39.PMC4838925.pdf
"Surgical Neurology International 2016, 7:39  http://www.surgicalneurologyint.com/content/7/1/39for vestibular schwannomas in the setting of  neurofibromatosis T ype II (NFII).",Non-OADS,/arxiv_data1/oa_pdf/a0/87/SNI-7-39.PMC4838925.pdf
"Surgical Neurology International 2016, 7:39  http://www.surgicalneurologyint.com/content/7/1/39morphology with Antoni A or B histology and no Verocay  bodies.",Non-OADS,/arxiv_data1/oa_pdf/a0/87/SNI-7-39.PMC4838925.pdf
"Surgical Neurology International 2016, 7:39  http://www.surgicalneurologyint.com/content/7/1/39course and MRI can aid the diagnosis of gangliogliomas  affecting cranial nerves before surgery.",Non-OADS,/arxiv_data1/oa_pdf/a0/87/SNI-7-39.PMC4838925.pdf
"Editor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.com © 2016 Surgical Neurology International | Published by Wolters Kluwer - MedknowFollowing the publication of the first part of this article,  “Bioethics – Should they encourage the killing of  unwanted newborn infants?” dealing with bioethics and  infanticide,[6] I received correspondence from a former  colleague, Dr. Richard L. Elliot, Director of Medical  Ethics at Mercer University, contending there is little  difference among medical and biomedical ethicists; that  my characterization of bioethicists as utilitarian moralists  (useful agents of the state) may not be accurate; and that  autonomy (and personal choice) is given “high priority”  by bioethicists.",Non-OADS,/arxiv_data1/oa_pdf/88/8a/SNI-7-34.PMC4838926.pdf
"Surg Neurol Int 2016;7:34. http://surgicalneurologyint.com/Bioethics-–-Part-2:-Is-it-compassion,-personal- autonomy,-or-ulterior-utilitarian-motives-at-heart?/",Non-OADS,/arxiv_data1/oa_pdf/88/8a/SNI-7-34.PMC4838926.pdf
"Surgical Neurology International 2016, 7:34  http://www.surgicalneurologyint.com/content/7/1/34a “responsibility to end one’s life in the absence of  any terminal illness… a duty to die when one would  prefer to live… even those who want to live can face  a duty to die.",Non-OADS,/arxiv_data1/oa_pdf/88/8a/SNI-7-34.PMC4838926.pdf
Available from: http://khn.org/daniel-callahan- limits-on-health-care/ [Last accessed on 2016 Jan 29].,Non-OADS,/arxiv_data1/oa_pdf/88/8a/SNI-7-34.PMC4838926.pdf
Available from: http://www.haciendapub.com/articles/bioethics-%E2%80%94- should-they-encourage-killing-unwanted-newborn-infants#comment-1360.,Non-OADS,/arxiv_data1/oa_pdf/88/8a/SNI-7-34.PMC4838926.pdf
Available from: http://www.theatlantic.com/ magazine/archive/2014/10/why-i-hope-to-die-at-75/379329/.,Non-OADS,/arxiv_data1/oa_pdf/88/8a/SNI-7-34.PMC4838926.pdf
Available from: http://www.haciendapub.com/medicalsentinel/ euthanasia-medical-science-and-road-genocide.,Non-OADS,/arxiv_data1/oa_pdf/88/8a/SNI-7-34.PMC4838926.pdf
"In this comprehensive article, Hardwig goes to great lengths to defend his  rationalization for “the duty to die” and enumerates all of the criteria for  death, ""even for those individuals who would prefer to live.” Available from:  http://web.utk.edu/~jhardwig/dutydie.htm [Last accessed on 2016 Jan 29].",Non-OADS,/arxiv_data1/oa_pdf/88/8a/SNI-7-34.PMC4838926.pdf
Available from: http://www.utilitarian.net/singer/by/200509--.htm.,Non-OADS,/arxiv_data1/oa_pdf/88/8a/SNI-7-34.PMC4838926.pdf
"© 2016 Surgical Neurology International | Published by Wolters Kluwer - MedknowEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comMeningiomas are common tumors, constituting about  20% of all primary brain tumors.",Non-OADS,/arxiv_data1/oa_pdf/3b/3f/SNI-7-32.PMC4838929.pdf
Surg Neurol Int 2016;7:32. http://surgicalneurologyint.com/Pathological-correlation-of-Magnetic-Resonance- Imaging-features-in-a-classical-case-of-lipomatous-meningioma/,Non-OADS,/arxiv_data1/oa_pdf/3b/3f/SNI-7-32.PMC4838929.pdf
"Surgical Neurology International 2016, 7:32  http://www.surgicalneurologyint.com/content/7/1/32on fat‑suppressed T1‑weighted imaging.",Non-OADS,/arxiv_data1/oa_pdf/3b/3f/SNI-7-32.PMC4838929.pdf
"Surgical Neurology International 2016, 7:32  http://www.surgicalneurologyint.com/content/7/1/322.",Non-OADS,/arxiv_data1/oa_pdf/3b/3f/SNI-7-32.PMC4838929.pdf
The presence of car- bapenemase was identi ﬁ ed by the modi ﬁ ed Hodge test  (MHT) as described by Center for Disease Control and Prevention (http://www.cdc.gov/HAI/pdfs/labSettings/HodgeTest_Carbapenamase_ Enterobacteriaceae.pdf).,OADS,/arxiv_data1/oa_pdf/06/05/eujmi-06-40.PMC4838984.pdf
Available from: http://www.bacterio.net 8.,Non-OADS,/arxiv_data1/oa_pdf/61/19/eujmi-06-67.PMC4838987.pdf
EPI-NYT 2012; available from: URL: http://www.ssi.dk/Aktuelt/  Nyhedsbreve/EPI-NYT/2012/Uge%2051b%20-%202012.aspx 7.,OADS,/arxiv_data1/oa_pdf/c0/bb/eujmi-06-81.PMC4838988.pdf
EPI-NYT 2002; available from: URL: http://www.ssi.dk/~/media/Indhold/DK%20-%20dansk/Aktuelt/Ny-hedsbreve/EPI-NYT/EPI-NYT-Arkiv/2002/2002%20pdf/EPI-NYT%20-%202002%20-%20uge%2046.ashx 8.,Non-OADS,/arxiv_data1/oa_pdf/c0/bb/eujmi-06-81.PMC4838988.pdf
NBV  2014 May 2; available from: URL: http://nbv.cardio.dk/  endocarditis 10.,Non-OADS,/arxiv_data1/oa_pdf/c0/bb/eujmi-06-81.PMC4838988.pdf
Diagnostisk Hånd-bog 2014 August 25; available from: URL: http://www.ssi.dk/Diagnostik/DiagnostiskHaandbog/600-699/695.aspx 11.,Non-OADS,/arxiv_data1/oa_pdf/c0/bb/eujmi-06-81.PMC4838988.pdf
EPI-NYT 2014 September 24; available from: URL: http://www.ssi.dk/~/media/Indhold/DK%20-%20dansk/Vacci-nation/Risikogrupper/Pneumokokvaccination%20uden%20for%20brnevaccinationsprogrammet%20i%20Danmark%20v13.ashx,Non-OADS,/arxiv_data1/oa_pdf/c0/bb/eujmi-06-81.PMC4838988.pdf
"This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlikelicence (http://creativecommons.org/licenses/by-nc-sa/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the same Creative Commons licence is included and the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b1/ff/S0007114516000957a.PMC4839003.pdf
Data ﬁles for the ﬁrst 4 years (2008/2009 –2011/2012) of the NDNS rolling programme were obtained from the UKData Archives (http://discover.ukdataservice.ac.uk/catalogue?sn=6533).,OADS,/arxiv_data1/oa_pdf/b1/ff/S0007114516000957a.PMC4839003.pdf
https://www.gov.,Non-OADS,/arxiv_data1/oa_pdf/b1/ff/S0007114516000957a.PMC4839003.pdf
https://www.gov.uk/ government/uploads/system/uploads/attachment_data/ ﬁle/ 265266/familyfood-method-rni-12dec13.pdf (accessed April 2015).,Non-OADS,/arxiv_data1/oa_pdf/b1/ff/S0007114516000957a.PMC4839003.pdf
https://www.gov.uk/government/uploads/system/uploads/attachment_data/ ﬁle/445503/SACN_ Carbohydrates_and_Health.pdf (accessed December 2015).,Non-OADS,/arxiv_data1/oa_pdf/b1/ff/S0007114516000957a.PMC4839003.pdf
http://www.efsa.europa.eu/en/ndatopics/docs/ndstolerableuil.pdf (accessed June 2015).,Non-OADS,/arxiv_data1/oa_pdf/b1/ff/S0007114516000957a.PMC4839003.pdf
https://www.gov.uk/government/uploads/system/uploads/attachment_data/ ﬁle/447402/ Draft_SACN_Vitamin_D_and_Health_Report.pdf (accessed December 2015).,Non-OADS,/arxiv_data1/oa_pdf/b1/ff/S0007114516000957a.PMC4839003.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 InternationalLicense (http://creativecommons.org/licenses/by-nc/4.0/), which per- mits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the originalauthor(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/de/2c/40263_2016_Article_328.PMC4839032.pdf
A signal of cardiac valve calcification leading to valve incompetence associated with exposure to bisphosphonates was found in the post ‐authorisa- tion analysis of EudraVigilance ( http://eudravigilance.ema.,Non-OADS,/arxiv_data1/oa_pdf/2a/d3/198_2015_Article_3441.PMC4839043.pdf
Accessible at: http://www.ema.europa.eu/docs/en_GB/ document_library/Report/2013/06/WC500144560.pdf (2013) 5.,Non-OADS,/arxiv_data1/oa_pdf/2a/d3/198_2015_Article_3441.PMC4839043.pdf
http://www.whocc.no/ddd/ definition_and_general_considera/ 33.,Non-OADS,/arxiv_data1/oa_pdf/2a/d3/198_2015_Article_3441.PMC4839043.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original au-thor(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/06/50/198_2015_Article_3452.PMC4839047.pdf
http://nof.org/news/ 2948 .,Non-OADS,/arxiv_data1/oa_pdf/3d/e8/198_2015_Article_3445.PMC4839051.pdf
BMC Nurs 9(1) http://www.biomedcentral.,Non-OADS,/arxiv_data1/oa_pdf/3d/e8/198_2015_Article_3445.PMC4839051.pdf
http://nof.org/articles/7 .,Non-OADS,/arxiv_data1/oa_pdf/3d/e8/198_2015_Article_3445.PMC4839051.pdf
"This is an Open Access article distributed under the terms o f the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use , distribution, and reproduction in any medium, provided the original work is prop erly cited.",Non-OADS,/arxiv_data1/oa_pdf/97/ed/msw003.PMC4839214.pdf
"Overlapping these gene re- gions with 171 known pigmentation genes from the human genome (Color Genes database, http://www.espcr.org/mice mut/ , last accessed September 03, 2015) yielded three gene- sets (15, 21 and 19 genes, respectively), among which threepigmentation genes ( OCA2 ,EDAR ,a n d PAH )s h o w e dc o n s i s - tent signals ( supplementary table S2 ,Supplementary Material online).",OADS,/arxiv_data1/oa_pdf/97/ed/msw003.PMC4839214.pdf
"This mis-sense mutation is located in the melanosomal cytoplasmictopological domain ( http://www.uniprot.org/ , last accessed September 15, 2015).",Non-OADS,/arxiv_data1/oa_pdf/97/ed/msw003.PMC4839214.pdf
"The geographic distribution of this SNP across world populations (data from HGDP database: http://hgdp.uchicago.edu , last accessed July 10, 2015) showed that the derived G allele of rs1800414 is highly prev-alent in most East Asian populations (G allele 450% in Han Chinese), as well as in American Indians, but is in low fre-quency in A-A populations (G allele = 16.0% [A-A fromChina]; 21.3% [A-A from Cambodia]), totally absent inAfricans, and absent or extremely rare in western Europeans (G allele <0.3%) ( ﬁg.",Non-OADS,/arxiv_data1/oa_pdf/97/ed/msw003.PMC4839214.pdf
"9 3/C210 /C072)(http://mendel.stan- ford.edu/SidowLab , last accessed October 20, 2015; Cooper et al.",OADS,/arxiv_data1/oa_pdf/97/ed/msw003.PMC4839214.pdf
"Data of the other populations were from the HGDP database ( http://hgdp.uchicago.edu/ , last accessed July 10, 2015).",OADS,/arxiv_data1/oa_pdf/97/ed/msw003.PMC4839214.pdf
"The protein sequences were from NCBI ( http://www.ncbi.nlm.nih.gov/ , last accessed July 10, 2015).",OADS,/arxiv_data1/oa_pdf/97/ed/msw003.PMC4839214.pdf
"Overlapping with 171 known pigmentation genes from the human genome (Color Genes database, http://www.espcr.org/micemut/ ,l a s t accessed September 20, 2015) yielded 15 (CHB vs. A-A), 21 (CHB vs. YRI), and 19 (YRI vs. A-A) pigmentation gene regions with large divergence ( FST, top 1% gene regions).",OADS,/arxiv_data1/oa_pdf/97/ed/msw003.PMC4839214.pdf
"Targeted Gene Modification Experiment in Mouse Using a CRISPR design tool ( http://crispr.mit.edu/ ,l a s t accessed July 10, 2015), we selected the sgRNA target se- quence (TAAAGCACAGGATTTCAGAC) for murine Oca2 to direct Cas9 cleavage.",Non-OADS,/arxiv_data1/oa_pdf/97/ed/msw003.PMC4839214.pdf
"We have made the Spanish population variant server web page that contains population frequency information for the complete list of 170,888 variant positions we found publicly available (http://spv.babelomics.org/), We show that it if fundamental to determine population-speciﬁc variant frequencies to distinguish real disease associations frompopulation-speciﬁc polymorphisms.",Non-OADS,/arxiv_data1/oa_pdf/80/bb/msw005.PMC4839216.pdf
"This is an Open Access article distribut ed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by- nc/4.0/), which permits non-commercial re- use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/80/bb/msw005.PMC4839216.pdf
"The individuals were used as controls in the Medical GenomeProject (MGP; http://www.med icalgenomeproject.com, last accessed January 28, 2016), a pub lic–private partnership which aims to discover disease genes and mutations.",Non-OADS,/arxiv_data1/oa_pdf/80/bb/msw005.PMC4839216.pdf
"Sequence data has been deposited at the European Genome- phenome Archive (EGA, see http://ega.crg.eu, last accessed January 28, 2016), under accession number EGAS00001000938.",OADS,/arxiv_data1/oa_pdf/80/bb/msw005.PMC4839216.pdf
"The Spanish population variant server web page contains the complete list of 170,888 variant positions found in the Spanish MGP population sequenced inthis study, which can be interactively queried (http://spv.babe lomics.org/, last accessed January 28, 2016).",OADS,/arxiv_data1/oa_pdf/80/bb/msw005.PMC4839216.pdf
"To foster research about other pathologies, we have made pub licly available through the Spanish population variant server web page (http://spv.babelomics.org/, last accessed January 28, 2016) all the relevant information on population frequencies for the 170,888 vari- ant positions found in this study.",OADS,/arxiv_data1/oa_pdf/80/bb/msw005.PMC4839216.pdf
"2015 ) were obtained from the repository of this study (http://www.healthdata.org/gbd, last accessed January 28, 2016).",OADS,/arxiv_data1/oa_pdf/80/bb/msw005.PMC4839216.pdf
"This is an Open Access article distribut ed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by- nc/4.0/), which permits non-commercial re- use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5f/c6/msw007.PMC4839217.pdf
2004 ) obtained from http://ancestor.bio info.uqam.ca/programs/anc.tar.,OADS,/arxiv_data1/oa_pdf/5f/c6/msw007.PMC4839217.pdf
Phylogeny was taken from UCSC (phyloP44wayPlacMammal) available at http://hgdownload.cse.ucsc.edu/goldenPath/hg18/phastCons44way/vertebrate.,OADS,/arxiv_data1/oa_pdf/5f/c6/msw007.PMC4839217.pdf
Supplementary Material Supplementary figures S1–S5 and tables S1–S21 are available atMolecular Biology and Evolution online (http://www.mbe.,OADS,/arxiv_data1/oa_pdf/5f/c6/msw007.PMC4839217.pdf
"This is an Open Access article distribut ed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by- nc/4.0/), which permits non-commercial re- use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/da/b9/msw013.PMC4839219.pdf
"Embryo images, raw profiles, extracted boundaries, and integrated expression profiles for both fly species are available from the SuperFly database (http://superfly.crg.eu, last accessed February 8, 2016) ( Cicin-Sain et al.",OADS,/arxiv_data1/oa_pdf/da/b9/msw013.PMC4839219.pdf
"Computational Tools Image processing and extractio n/measurement of expression domain boundary positions was performed with the Java ap- plication FlyGUI (https://subversion.assembla.com/svn/flygui, last accessed February 8, 2016) ( Crombach, Cicin-Sain, et al.",OADS,/arxiv_data1/oa_pdf/da/b9/msw013.PMC4839219.pdf
Our gene expression data sets are available from the SuperFly website (http://superfly.crg.eu) ( Cicin-Sain et al.,OADS,/arxiv_data1/oa_pdf/da/b9/msw013.PMC4839219.pdf
"Simulation and optimization code is implemented in C, using MPI for parallelization, SUNDIALS (http://computation.llnl.gov/casc/sundials) for numerical solvers ( Hindmarsh et al.",OADS,/arxiv_data1/oa_pdf/da/b9/msw013.PMC4839219.pdf
"2005 ), and the GNU Scientific Library (GSL, http://www.gnu.org /software/gsl) for data inter- polation (https://subversion.assembla.com/svn/flysa).",OADS,/arxiv_data1/oa_pdf/da/b9/msw013.PMC4839219.pdf
"This is an Open Access article distribut ed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by- nc/4.0/), which permits non-commercial re- use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2d/ad/msw017.PMC4839221.pdf
"Phylogenetic Tree We constructed a neighbor-joining tree using pairwise geneticdistances matrix data of all indi viduals, calculated by TreeBest (http://treesoft.sourceforge.net/treebest.shtml).",OADS,/arxiv_data1/oa_pdf/2d/ad/msw017.PMC4839221.pdf
"This is an Open Access article distribut ed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by- nc/4.0/), which permits non-commercial re- use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a1/32/msw021.PMC4839222.pdf
"This is an Open Access article distribut ed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by- nc/4.0/), which permits non-commercial re- use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b1/16/msw025.PMC4839223.pdf
"We further developed a user-friendly population genetics gateway, the RhesusBase PopGateway (http://www.rhesusbase.org/popGateway, last accessed February 13, 2016), toexpedite the visualization of these macaque population ge- netics annotations ( fig.",OADS,/arxiv_data1/oa_pdf/b1/16/msw025.PMC4839223.pdf
"For advanced users, all data in the RhesusBase PopGateway could also be downloaded from our table browser (http://browser.rhesusbase.org/cgi-bin/hgTables, last accessed February 13, 2016) and download page (http://www.rhesusbase.org/download/download.jsp, last accessedFebruary 13, 2016).",OADS,/arxiv_data1/oa_pdf/b1/16/msw025.PMC4839223.pdf
Supplementary Material Supplementary methods and tables S1–S8 are available at Molecular Biology and Evolution online (http://www.mbe.,Non-OADS,/arxiv_data1/oa_pdf/b1/16/msw025.PMC4839223.pdf
"This is an Open Access article distribut ed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by- nc/4.0/), which permits non-commercial re- use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/35/8c/msw039.PMC4839224.pdf
Available from: http://www.nof.org/professionals/clinical‑guidelines.,Non-OADS,/arxiv_data1/oa_pdf/2b/b2/UA-8-123.PMC4839225.pdf
http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf 	 [Last accessed 2015 Aug 06].,Non-OADS,/arxiv_data1/oa_pdf/eb/8d/UA-8-131.PMC4839226.pdf
"Appendix 1: Surveillance following surgery adapted from European Association of Urology Risk profile Treatment Surveillance 6 months 1 year 2 years 3 years 4 years 5 years After 5 years Low RN/PN US CT US CT US CT Discharge Intermediate RN/PN/cryoablation/RFA CT US CT US CT CT CT alternate 2 years High RN/PN/cryoablation/RFA CT CT CT CT CT CT CT alternate years CT: Computed tomography, RN: Radical nephrectomy, PN: Partial nephrectomy, RFA: radiofrequency ablation, US: UltrasoundAPPENDIX Author Help: Online submission of the manuscripts Articles can be submitted online from http://www.journalonweb.com.",Non-OADS,/arxiv_data1/oa_pdf/aa/20/UA-8-136.PMC4839227.pdf
"The Surveillance, Epidemiology and End Results (SEER)  online database (SEER, http://seer.cancer.gov/) was utilized  to determine the tumor incidence for many of these tumor  types; this incidence rate was converted from their standard  number/100,000 to a comparable number in 1584 persons;  this number is given in the final column of T able 1.",OADS,/arxiv_data1/oa_pdf/42/7c/UA-8-163.PMC4839232.pdf
The SEER  registries included approximately 26% of the US population  (http://seer.cancer.gov/data/).,OADS,/arxiv_data1/oa_pdf/bf/a2/UA-8-178.PMC4839235.pdf
We then used the macro provided on the SEER‑Medicare  website to assess comorbidity characterized by the Charlson  comorbidity index (http://healthservices.cancer.gov/,Non-OADS,/arxiv_data1/oa_pdf/bf/a2/UA-8-178.PMC4839235.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Neurologic disordersGhanaDemographySpectrum 1.,Non-OADS,/arxiv_data1/oa_pdf/dc/86/main.PMC4839267.pdf
http://dx.doi.org/10.1016/j.ensci.2016.03.003 2405-6502/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/dc/86/main.PMC4839267.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/dc/86/main.PMC4839267.pdf
Contents lists available at ScienceDirect eNeurologicalSci journal homepage: http://ees.elsevier.com/ensci/,Non-OADS,/arxiv_data1/oa_pdf/dc/86/main.PMC4839267.pdf
"Sarfo, J. Akassi, D. Awuah, et al., Trends in stroke admission and mortality rates from 1983 to 2013 in central Ghana, J Neurol Sci (2015), http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/dc/86/main.PMC4839267.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/15/e3/nihms-754602.PMC4839301.pdf
"3, e1095435 (3 pages)http://dx.doi.org/10.1080/2162402X.2015.1095435",Non-OADS,/arxiv_data1/oa_pdf/b4/d7/koni-05-03-1095435.PMC4839312.pdf
Nat Rev Clin Oncol 2014; 11:509- 24; PMID:25001465; http://dx.doi.org/10.1038/nrclinonc.2014.111 2.,Non-OADS,/arxiv_data1/oa_pdf/b4/d7/koni-05-03-1095435.PMC4839312.pdf
Nat Rev Cancer 2014; 14:135-46; PMID:24457417; http://dx.doi.org/10.1038/nrc36704.,Non-OADS,/arxiv_data1/oa_pdf/b4/d7/koni-05-03-1095435.PMC4839312.pdf
Oncoimmunology 2013; 2:e25772; PMID:24244904; http://dx.doi.org/10.4161/onci.25772 5.,Non-OADS,/arxiv_data1/oa_pdf/b4/d7/koni-05-03-1095435.PMC4839312.pdf
Oncoimmunology 2015; 4:e974411;PMID:26137405; http://dx.doi.org/10.4161/2162402X.2014.974411 6.,Non-OADS,/arxiv_data1/oa_pdf/b4/d7/koni-05-03-1095435.PMC4839312.pdf
J Clin Invest 2015; 125:3401-12;PMID:26214521; http://dx.doi.org/10.1172/JCI80009 7.,Non-OADS,/arxiv_data1/oa_pdf/b4/d7/koni-05-03-1095435.PMC4839312.pdf
Drug Discov Today 2012; 17(15-16):850-60; PMID:22465171; http://dx.doi.org/10.1016/j.drudis.2012.03.002 8.,OADS,/arxiv_data1/oa_pdf/b4/d7/koni-05-03-1095435.PMC4839312.pdf
Cancer Res 2015; 75:3020-31; PMID:26116496; http://dx.doi.org/10.1158/0008-5472.CAN-14-3017ONCOIMMUNOLOGY e1095435-3,Non-OADS,/arxiv_data1/oa_pdf/b4/d7/koni-05-03-1095435.PMC4839312.pdf
"4, e1115940 (10 pages)http://dx.doi.org/10.1080/2162402X.2015.1115940",Non-OADS,/arxiv_data1/oa_pdf/30/5d/koni-05-04-1115940.PMC4839314.pdf
N Engl J Med 2014; 371(16):1507-17; PMID:25317870; http://dx.doi.org/10.1056/NEJMoa14072222.,Non-OADS,/arxiv_data1/oa_pdf/30/5d/koni-05-04-1115940.PMC4839314.pdf
ISRN Oncol 201 2; 2012:278093; PMID:23304553; http://dx.doi.org/10.5402/2012/278093 3.,Non-OADS,/arxiv_data1/oa_pdf/30/5d/koni-05-04-1115940.PMC4839314.pdf
Mol Ther 2015; 23(4):769-78; PMID:25582824; http://dx.doi.org/10.1038/mt.2015.4 4.,Non-OADS,/arxiv_data1/oa_pdf/30/5d/koni-05-04-1115940.PMC4839314.pdf
J Hematol Oncol 2013; 6:47; PMID:23829929; PMID: 24353912; http://dx.doi.org/10.1186/1756-8722-6-47 5.,Non-OADS,/arxiv_data1/oa_pdf/30/5d/koni-05-04-1115940.PMC4839314.pdf
Oncoimmunology 2013; 2(10):e26286; PMID:24353912; http://dx.doi.org/10.4161/onci.26286 6.,Non-OADS,/arxiv_data1/oa_pdf/30/5d/koni-05-04-1115940.PMC4839314.pdf
Expert Rev Anticancer Ther 2010; 10 (10):1663-72; PMID:20942636;http://dx.doi.org/10.1586/era.10.135 7.,Non-OADS,/arxiv_data1/oa_pdf/30/5d/koni-05-04-1115940.PMC4839314.pdf
Sci- ence 2014; 343(6168): 301-5; PMID:24292625; http://dx.doi.org/ 10.1126/science.1244851 8.,OADS,/arxiv_data1/oa_pdf/30/5d/koni-05-04-1115940.PMC4839314.pdf
Br J Hae-matol 2014; 164(6):811-21; PMID:24328678; http://dx.doi.org/ 10.1111/bjh.12708 9.,Non-OADS,/arxiv_data1/oa_pdf/30/5d/koni-05-04-1115940.PMC4839314.pdf
Blood 2004; 103(5):1787-90; PMID:14512311; http://dx.doi.org/10.1182/blood-2003-02-0361 10.,Non-OADS,/arxiv_data1/oa_pdf/30/5d/koni-05-04-1115940.PMC4839314.pdf
J Exp Med 1998; 187(11):1885-92; PMID:9607928; http://dx.doi.org/10.1084/jem.187.11.1885 12.,Non-OADS,/arxiv_data1/oa_pdf/30/5d/koni-05-04-1115940.PMC4839314.pdf
Cancer Res 2007; 67(2):746-55; PMID:17234786; http://dx.doi.org/10.1158/0008-5472.CAN-06-2317 14.,Non-OADS,/arxiv_data1/oa_pdf/30/5d/koni-05-04-1115940.PMC4839314.pdf
Blood 2010; 116 (17):3227-37; PMID:20651070; http://dx.doi.org/10.1182/blood-2010- 04-279893 15.,Non-OADS,/arxiv_data1/oa_pdf/30/5d/koni-05-04-1115940.PMC4839314.pdf
Leukemia 2008; 22(10):1925-32;PMID:18596740; http://dx.doi.org/10.1038/leu.2008.174ONCOIMMUNOLOGY e1115940-9,Non-OADS,/arxiv_data1/oa_pdf/30/5d/koni-05-04-1115940.PMC4839314.pdf
Blood 2012; 120 (7):1412-21; PMID:22547582; http://dx.doi.org/10.1182/blood-2012-02-411678 18.,Non-OADS,/arxiv_data1/oa_pdf/30/5d/koni-05-04-1115940.PMC4839314.pdf
Cancer Immunol Immunother 2009; 58(7):1033- 45; PMID:19009291; http://dx.doi.org/10.1007/s00262-008-0620-4 19.,Non-OADS,/arxiv_data1/oa_pdf/30/5d/koni-05-04-1115940.PMC4839314.pdf
"Kneppers E, van der Holt B, Kersten MJ, Zweegman S, Meijer E, Huls G, Cornelissen JJ, Janssen JJ, Huisman C, Cornelisse PB et al., Lenali-domide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.Blood 2011; 118(9):2413-9; PMID:21690556; http://dx.doi.org/10.1182/blood-2011-04-348292 20.",Non-OADS,/arxiv_data1/oa_pdf/30/5d/koni-05-04-1115940.PMC4839314.pdf
Leukemia 2014; 28(2):329-37; PMID: 23765229; http://dx.doi.org/10.1038/leu.2013.177 21.,Non-OADS,/arxiv_data1/oa_pdf/30/5d/koni-05-04-1115940.PMC4839314.pdf
J Infect Dis 2003; 187 (6):946-55; PMID:12660941; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/30/5d/koni-05-04-1115940.PMC4839314.pdf
J ClinInvest 1994; 93(5):2134-40; PMID:8182145; http://dx.doi.org/10.1172/JCI117209 23.,Non-OADS,/arxiv_data1/oa_pdf/30/5d/koni-05-04-1115940.PMC4839314.pdf
Science 2014; 346(6213):1123-7; PMID: 25430770; http://dx.doi.org/10.1126/science.1260044 24.,Non-OADS,/arxiv_data1/oa_pdf/30/5d/koni-05-04-1115940.PMC4839314.pdf
Blood 2012; 119(17):3940-50; PMID:22308288; http://dx.doi.org/10.1182/blood-2011-10-387969 25.,Non-OADS,/arxiv_data1/oa_pdf/30/5d/koni-05-04-1115940.PMC4839314.pdf
J Hematol Oncol 2013; 6:47; PMID:23829929; http://dx.doi.org/10.1186/1756-8722-6-47e1115940-10 P. OT /C19AHAL ET AL.,OADS,/arxiv_data1/oa_pdf/30/5d/koni-05-04-1115940.PMC4839314.pdf
"3, e1091555 (12 pages)http://dx.doi.org/10.1080/2162402X.2015.1091555",Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Eur J Immunol 1987; 17:105-11;PMID:3102250; http://dx.doi.org/10.1002/eji.1830170118 3.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Nature 1985; 314:628-31; PMID:2859527; http://dx.doi.org/10.1038/314628a0 5.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Br J Cancer 2007;97:315-21; PMID:17622246; http://dx.doi.org/10.1038/sj.bjc.6603881 6.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
J Cancer 2011; 2:309-16; PMID:21716847; http://dx.doi.org/10.7150/jca.2.309 7.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Drugs 2015; 75:321- 27; PMID:25637301; http://dx.doi.org/10.1007/s40265-015-0356-3 8.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Science 2008; 321:974-77; PMID:18703743; http://dx.doi.org/10.1126/ science.1158545 9.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Nat Rev Drug Discov 2014; 13:799-801; PMID:25359367; http://dx.doi.org/10.1038/nrd4478 10.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
"Mol Immunol 2015; 67(2 Pt A):95-106, EPub ahead of print; PMID:25637431; http://dx.doi.org/ 10.1016/j.molimm.2015.01.003 11.",Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
J Clin Oncol 2011; 29:2493-98; PMID:21576633; http://dx.doi.org/10.1200/JCO.2010.32.7270 12.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Mol Immunol 2006; 43:763- 71; PMID:16360021; http://dx.doi.org/10.1016/j.molimm.2005.03.007 13.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Immunobiology 2009; 214:441-53; PMID:19157637; http://dx.doi.org/10.1016/j.imbio.2008.11.014 14.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Int J Cancer 2005; 115:98-104; PMID:15688411; http://dx.doi.org/10.1002/ijc.20908 15.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Mol Immunol 2006; 43:1129-43; PMID:16139892;http://dx.doi.org/10.1016/j.molimm.2005.07.034 16.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Cancer Chemother Pharmacol 2015:1065-73; PMID:25814216; http://dx.doi.org/10.1007/s00280- 015-2728-5 17.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Am J Physiol Renal Physiol 2006; 291:F1132- 41; PMID:16774906; http://dx.doi.org/10.1152/ajprenal.00063.2006 18.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
J Gerontol A Biol Sci Med Sci 2009; 64:1146-53; PMID:19692671; http://dx.doi.org/10.1093/gerona/glp118 19.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Dev Dyn 2004;231:425-31; PMID:15366020; http://dx.doi.org/10.1002/dvdy.20142 20.,OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Int J Cancer 2014:2206-14; PMID:24710653; http://dx.doi.org/10.1002/ijc.28857 21.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
His- topathology 2012; 61:1043-56; PMID:22803571; http://dx.doi.org/ 10.1111/j.1365-2559.2012.04314.x 24.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Prenat Diagn 2012; 32:742-51; PMID:22570279;http://dx.doi.org/10.1002/pd.3894 25.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Nat Commun 2013; 4:1992;PMID:23778593; http://dx.doi.org/10.1038/ncomms2992 26.,OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
BRAIN PATHOL2010; 20:140-50; PMID:19220299; http://dx.doi.org/10.1111/j.1750-3639.2008.00255.x 27.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Am J Surg Pathol 2012; 36:73-80; PMID:21989342; http://dx.doi.org/10.1097/PAS.0b013e31822cfa7e 28.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Diagn Pathol 2013; 8:133; PMID:23919729; http://dx.doi.org/ 10.1186/1746-1596-8-133 29.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Diagn Pathol 2013; 8:190; PMID:24245968; http://dx.doi.org/10.1186/1746-1596-8-19030.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
APMIS 2010; 118:640-47; PMID:20718715; http://dx.doi.org/10.1111/j.1600-0463.2010.02638.x 31.,OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
"J Clin Oncol, 2015 ASCO Meeting Abstracts; 33:15_suppl 2015: 5537); http://meeting.ascopubs.",Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
J Immunother 2007; 30:798-807; PMID:18049331; http://dx.doi.org/10.1097/CJI.0b013e318156750c 34.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Dev Dynam 2008; 237:504-12; PMID:18213590; http://dx.doi.org/10.1002/dvdy.21437 35.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Stem Cells 2007; 25:961-73; PMID:17204602; http://dx.doi.org/10.1634/stemcells.2006-0352 36.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Dev Dyn2001; 222:292-300; PMID:11668606; http://dx.doi.org/10.1002/dvdy.1174 37.,OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Methods and compositions for diagnosis and treatment ofcancer: Google Patents; 2010. http://www.google.ga/patents/ WO2010094499A1?cl Den 39.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
J Virol 2007; 81:12465-71; http://dx.doi.org/10.1128/ JVI.01457-07 40.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
"J Clin Oncol 2014; ASCO Meeting Abstracts; 32:15_suppl, 2014: TPS5623; http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS5623?sid=86b60114-f2ab-4a71-9649-e785cb232e0d 41.",Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
PLoS ONE 2013; 8:e60186; PMID:23555918;http://dx.doi.org/10.1371/journal.pone.0060186 43.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Curr Opin Immunol 2012; 24:207-12; PMID:22236695; http://dx.do i.org/10.1016/j.coi.2011.12.009 44.,OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Cancer Metastasis Rev 2010; 29:309-16; PMID:20405169; http://dx.doi.org/10.1007/s10555-010-9223-6 46.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Cytokine Growth Factor Rev 2010; 21:3-10; PMID:20005150; http://dx.doi.org/10.1016/j.cytogfr.2009.11.002ONCOIMMUNOLOGY e1091555-11,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Genes Dev 2011;25:2559-72; PMID:22190457; http://dx.doi.org/10.1101/gad.169029.111 48.,OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
Cancer Cell 2008; 13:23-35; PMID:18167337; http://dx.doi.org/10.1016/j.ccr.2007.12.004 49.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
"Erdeljan M, Hubner B, Koslowski M, Kreuzberg M, Sahin U, T €ureci €O, Walter K, Weichel M, W €oll S. Antibodies for treatment of cancerexpressing claudin 6: Google Patents; 2012. https://www.google.ga/pat ents/WO2012156018A1?cl Den 50.",Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
BMC Cancer 2013; 13:570; PMID:24304549; http://dx.doi.org/10.1186/1471-2407-13-570e1091555-12 C. R. STADLER ET AL.,Non-OADS,/arxiv_data1/oa_pdf/32/dc/koni-05-03-1091555.PMC4839326.pdf
"4, e1117738 (12 pages)http://dx.doi.org/10.1080/2162402X.2015.1117738",Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Cell 2006; 127:679-95; PMID:17110329; http://dx.doi.org/10.1016/j.cell.2006.11.001 2.,OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Nat Med 2013; 19:1438-49; PMID:24202396; http://dx.doi.org/10.1038/nm.3336 3.,OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Cancer Res 2006; 66:8319-26; PMID:16951136; http://dx.doi.org/10.1158/0008-5472.CAN-06-0410 4.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Cell 2009; 138:645-59; PMID:19682730;http://dx.doi.org/10.1016/j.cell.2009.06.034 5.,OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Kinase switching in mesenchymal-like non-small cell lung cancer lines con- tributes to EGFR inhibitor resistance through pathway redundancy.Clin Exp Metastasis 2008; 25:843-54; PMID:18696232; http://dx.doi.org/10.1007/s10585-008-9200-4 6.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Dev Dyn 2004; 229:201-18; PMID:14699590; http://dx.doi.org/ 10.1002/dvdy.10480 8.,OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Cancer Res 2011; 71:5296-306; PMID:21653678; http://dx.doi.org/10.1158/0008-5472.CAN-11-0156 9.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
J Clin Invest 2010;120:533-44; PMID:20071775; http://dx.doi.org/10.1172/JCI38379 10.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Clin Cancer Res 2007;13:2471-8; PMID:17438107; http://dx.doi.org/10.1158/1078-0432.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
J Natl Cancer Inst 2014; 106(5); pii:dju054;PMID:24815864; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Clin Cancer Res 2012; 18:3868-79; PMID:22611028; http://dx.doi.org/10.1158/1078-0432.CCR-11-3211 13.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Clin Cancer Res 2014; 20:4949-61; PMID:25009296; http://dx.doi.org/10.1158/1078-0432.CCR-14-0421 14.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
20(Suppl 3):S509-16; PMID:23456319; http://dx.doi.org/10.1245/ s10434-013-2914-9 15.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Am J Surg Pathol 2008; 32:572-80; PMID:18301055; http://dx.doi.org/ 10.1097/PAS.0b013e31815b693a 16.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
J Pathol 2006; 209:157-65; PMID:16538613; http://dx.doi.org/10.1002/path.1969 17.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Hum Genet 2014; 133:1289-97; PMID:24990759; http://dx.doi.org/10.1007/s00439-014-1463-z 18.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Nat Genet 2009; 41:1176-8; PMID:19801981; http://dx.doi.org/10.1038/ng.454 19.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Dis Markers 2014; 2014:514753; PMID:24591762; http://dx.doi.org/10.1155/2014/514753 20.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Am J Surg Pathol 2012; 36:1052-7; PMID:22446946; http://dx.doi.org/10.1097/PAS.0b013e31824f4ce3 21.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Cell Death Dis 2013; 4:e682;PMID:23788039; http://dx.doi.org/10.1038/cddis.2013.208 22.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Mol Cancer Ther 2013; 12:1805-15;PMID:23783250; http://dx.doi.org/10.1158/1535-7163.MCT-12-1007 2 3 .,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Eur J Cancer 2011; 47:1080-5; PMID:21220197; http://dx.doi.org/ 10.1016/j.ejca.2010.11.015 24.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Cancer Immunol Res 2015; 3(11):1248-56;PMID:26130065; http://dx.doi.org/10.1158/2326-6066.CIR-15-0119 25.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
http://www.clinicaltrials.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Cancer Res 2014; 74:2510-9;PMID:24626094; http://dx.doi.org/10.1158/0008-5472.CAN-13-1894 27.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Nat Rev Cancer 2009; 9:874-85; PMID:19935676; http://dx.doi.org/10.1038/nrc2761 28.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Oncogene 2013; 32:1073-81; PMID:22580612; http://dx.doi.org/10.1038/onc.2012.158 29.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
MolCancer Ther 2011; 10:806-16; PMID:21421804; http://dx.doi.org/ 10.1158/1535-7163.MCT-10-1050 30.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Oncogene 2014; 33:1680-9; PMID:23584475; http://dx.doi.org/10.1038/onc.2013.114 31.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Oncotarget 2014; 5:8893-905; PMID:25245423; http://dx.doi.org/10.18632/oncotarget.2360 32.,OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Oncogene 2015; 34(40):5187-97; PMID:25659581; http://dx.doi.org/10.1038/onc.2014.442 33.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Oncogene 2011; 30:1449-59; PMID:21102519; http://dx.doi.org/10.1038/onc.2010.526 34.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
"Alam M, Rajabi H, Ahmad R, Jin C, Kufe D. Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells.Oncotarget 2014; 5:2622-34; PMID:24770886; http://dx.doi.org/ 10.18632/oncotarget.1848 35.",Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Cancer Cell 2004; 5:163-75; PMID:14998492; http://dx.doi.org/10.1016/S1535-6108(04) 00020-0 36.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
J Biol Chem 2012; 287:20866-75; PMID: 22544745; http://dx.doi.org/10.1074/jbc.M112.357293 37.,OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Expert Opin Biol Ther 2013; 13:35-49; PMID:22998452; http://dx.doi.org/ 10.1517/14712598.2012.725719 38.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Mol Cancer Ther 2007; 6:532-41; PMID:17308052; http://dx.doi.org/10.1158/1535-7163.MCT-06-0462 40.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Cell Death Dis 2013; 4:e915; PMID:24201814; http://dx.doi.org/10.1038/cddis.2013.442 41.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Cancer Res 2015; 75:1789-800;PMID:25744723; http://dx.doi.org/10.1158/0008-5472.CAN-14-2535 42.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Genes Cancer 2010; 1:62-8; PMID:20729973; http://dx.doi.org/10.1177/1947601909357933 43.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Cancer Res 2010; 70:378-87;PMID:19996288; http://dx.doi.org/10.1158/0008-5472.CAN-09-2021 44.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Int J Oncol 2010; 37:61-9; PMID:20514397; http://dx.doi.org/10.3892/ijo_00000653 45.,OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Cancer Res 2008; 68:6136-44; PMID:18676836; http://dx.doi.org/10.1158/0008-5472.CAN-08-0464ONCOIMMUNOLOGY e1117738-11,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Toxicol Pathol 2007; 35:495-516; PMID:17562483; http://dx.doi.org/10.1080/01926230701320337 47.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Biochem Biophys Res Commun 1993; 197:40-5; PMID:8250945; http://dx.doi.org/10.1006/bbrc.1993.2438 48.,OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
J Biol Chem 2002; 277:39209-16;PMID:12161443; http://dx.doi.org/10.1074/jbc.M206400200 50.,OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Cancer Lett 2014; 346:225-36; PMID:24384091; http://dx.doi.org/10.1016/j.canlet.2013.12.029 51.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Nature 2001; 412:95-9; PMID:11452314; http://dx.doi.org/10.1038/35083620 52.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Nature 1999; 397:441-6; PMID:9989411; http://dx.doi.org/10.1038/17135 53.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
"Cancer Prevention Res (Philadelphia, Pa)2010; 3:438-46; PMID:20332301; http://dx.doi.org/10.1158/1940- 6207.CAPR-09-0194 5 4 .",Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
J Cancer Res Clin Oncol2011; 137:1337-42; PMID:21744082; http://dx.doi.org/10.1007/ s00432-011-1003-3 55.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Clin Cancer Res 2011; 17:7164-73; PMID:22068656; http://dx.doi.org/10.1158/1078-0432.CCR-11-064956.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Annals Surg 2013; 258:879-86; PMID:23657083; http://dx.doi.org/10.1097/SLA.0b013e318292919e 57.,OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Cancer Immunol Immunotherapy 2014;63:161-74; PMID:24233342; http://dx.doi.org/10.1007/s00262-013- 1494-7 58.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Oncotarget 2013; 4:1777- 90; PMID:24125763; http://dx.doi.org/10.18632/oncotarget.1295 59.,OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Clin Exp Metastasis 2013; 30:393-405; PMID:23143679; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Cancer Cell 2009; 15:195-206; PMID:19249678;http://dx.doi.org/10.1016/j.ccr.2009.01.023 61.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Cancer Res 2013; 73:2418-27;PMID:23436798; http://dx.doi.org/10.1158/0008-5472.CAN-12-2432 62.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Cancer Res 2009; 69:5133-41; PMID:19491255; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Mol Cancer Ther 2009; 8:3056-65; PMID:19887552; http://dx.doi.org/10.1158/1535-7163.MCT-09-0646 6 4 .,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Clin Cancer Res 2015; 21:2338-47;PMID:25712682; http://dx.doi.org/10.1158/1078-0432.CCR-14- 3000 65.,Non-OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
Onco- target 2015; 6:4853-62; PMID:25605015; http://dx.doi.org/ 10.18632/oncotarget.3086e1117738-12 J. M. DAVID ET AL.,OADS,/arxiv_data1/oa_pdf/3f/ae/koni-05-04-1117738.PMC4839328.pdf
"4, e1071008 (13 pages)http://dx.doi.org/10.1080/2162402X.2015.1071008",Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
AnnuRev Med 2013; 64:71-90; PMID:23092383; http://dx.doi.org/10.1146/ annurev-med-112311-083918 3.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
New Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/ NEJMoa1001294 4.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
J Immunol 2014; 193:1006-11; PMID:25049431; http://dx.doi.org/10.4049/jimmunol.1400703 5.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
Nat Rev Immunol 2014; 14:195-208; PMID:24566916; http://dx.doi.org/10.1038/nri3622 6.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
PloS One 2009; 4:e4942;PMID:19319200; http://dx.doi.org/10.1371/journal.pone.0004942 7.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
J Immunol Methods 2002;270:211-26; PMID:12379326; http://dx.doi.org/10.1016/S0022-1759 (02)00330-7 8.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
Cancer Res 2010; 70:1281-5; PMID:20145139; http://dx.doi.org/10.1158/0008-5472.CAN-09-32769.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
J Trans Med 2005; 3:10; PMID:15740633; http://dx.doi.org/10.1186/ 1479-5876-3-10 10.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
J Trans Med 2005; 3:9; PMID:15723705; http://dx.doi.org/10.1186/1479-5876-3-9 11.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
J Clin Oncol 2008; 26:3552-9; PMID:18506026; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
AnnOncol 2014; 25:1283-93; PMID:24351398; http://dx.doi.org/10.1093/ annonc/mdt529 13.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
J Clin Oncol 2012; 30:2046-54;PMID:22547592; http://dx.doi.org/10.1200/JCO.2011.38.4032 14.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
Blood 2005; 106:216-23; PMID:15790784; http://dx.doi.org/10.1182/blood-2005-01-0220 15.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
Immunol Lett 2003; 89:125-31; PMID:14556969; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
JImmunother 2011; 34:65-75; PMID:21150714; http://dx.doi.org/10.1097/CJI.0b013e3181fe535b 17.,OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
"Blood Cells, Mol Dis 2005; 35:89-93; PMID:15990342; http://dx.doi.org/10.1016/j.bcmd.2005.05.003 18.",OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
Oncoimmunology 2013; 2:e25205; PMID:24073380; http://dx.doi.org/10.4161/onci.25205 19.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
Science 1994; 265:106-9; PMID:8016643; http://dx.doi.org/10.1126/science.8016643 20.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
FASEB J: Off Pub Federat Am Soc Exp Biol 2012; 26:104-16; PMID:21940994; http://dx.doi.org/10.1096/fj.11-189670 21.,OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
J Immunol 2002; 169:1326-33; PMID:12133955; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
Immunity 2007; 27:965-74; PMID:18055229; http://dx.doi.org/10.1016/j.immuni.2007.10.010 23.,OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
Blood; 2013; 122:394-404; PMID:23687088; http://dx.doi.org/10.1182/blood-2013-01-481705 24.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
Sci Transl Med 2015; 7:283ra55; PMID:25877893; http://dx.doi.org/10.1126/scitranslmed.aaa2327; in press 25.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
Cancer Res 2011; 71:5412-22; PMID:21708957; http://dx.doi.org/10.1158/0008-5472.CAN-10-4179 26.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
Histopathol- ogy 2009; 55:301-12; PMID:19723145; http://dx.doi.org/10.1111/ j.1365-2559.2009.03379.x 27.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
J Thorac Cardiovasc Sur 2001; 121:1058-63; PMID:11385371; http://dx.doi.org/ 10.1067/mtc.2001.113026 28.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
Mol Ther: J Am Soc Gene Ther 2013; 21:895-903;PMID:23459515; http://dx.doi.org/10.1038/mt.2013.14 29.,OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
Blood 2013; 121:3658-65; PMID:23509156; http://dx.doi.org/10.1182/blood-2013-01-476606 30.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
Cell Mol Life Sci: CMLS 2014; 71:1829-37; PMID:24305946; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
Cell Mol LifeSci: CMLS 2009; 66:1998-2004; PMID:19357808; http://dx.doi.org/ 10.1007/s00018-009-9198-z 32.,OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
EMBO J 2001;20:1033-41; PMID:11230127; http://dx.doi.org/10.1093/emboj/ 20.5.1033 33.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
Cancer Res 2005; 65:7942-9; PMID:16140966; http://dx.doi.org/10.1158/0008-5472.CAN-05-0377 34.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
Cancer Res 2005; 65:5238-47; PMID:15958569; http://dx.doi.org/10.1158/0008-5472.CAN-04-3804 35.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
PloS One 2008; 3:e3377; PMID:18852879; http://dx.doi.org/10.1371/journal.pone.0003377 36.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
Cell Stress Chaperon 2003; 8:348-60; PMID:15115287; http://dx.doi.org/10.1379/1466-1268(2003)008%3c0348:HSPRIA%3e2.0.CO;2 37.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
Biol Chem 2003; 384:267-79; PMID:12675520; http://dx.doi.org/10.1515/BC.2003.030 38.,OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
Immunol Rev 2008; 221:163-81; PMID:18275481; http://dx.doi.org/10.1111/j.1600- 065X.2008.00591.x 39.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
Nat Med 2011; 17:700-7; PMID:21552268; http://dx.doi.org/10.1038/nm.2366 40.,OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
Int J Cancer 2015; 136:138-51; PMID:24839182; http://dx.doi.org/10.1002/ ijc.28980 41.,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
J Exp Med 2007;204:831-40; PMID:17389240; http://dx.doi.org/10.1084/jem.20062387ONCOIMMUNOLOGY e1071008-13,Non-OADS,/arxiv_data1/oa_pdf/9d/d0/koni-05-04-1071008.PMC4839329.pdf
"3, e1066062 (11 pages)http://dx.doi.org/10.1080/2162402X.2015.1066062",Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Semin Immunopathol 2011; 33:353-67; PMID:21274535; http://dx.doi.org/10.1007/s00281- 011-0246-z 3.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
J Clin Oncol 2003; 21:2636-44;PMID:12860938; http://dx.do i.org/10.1200/JCO.2003.11.136 4.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
J Pain Palliat Care Pharmacother 2007; 21:69-76; PMID:18032321; http://dx.doi.org/10.1080/J354v21n04_14 5.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Nat Clin Pract Rheumatol 2008; 4:525-33; PMID:18762788; http://dx.doi.org/10.1038/ncprheum0898 6.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Autoimmun Rev 2011; 10:305-10; PMID:21224015; http://dx.doi.org/10.1016/j.autrev.2010.11.009 8.,OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Nature 1999; 397:263-6; PMID:9930702; http://dx.doi.org/10.1038/16717 10.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Nat Rev Immunol 2003; 3:939-51; PMID:14647476; http://dx.doi.org/10.1038/nri1248 11.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Immunity 2002; 16:759-67;PMID:12121658; http://dx.doi.org/10.1016/S1074-7613(02)00322-9 12.,OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Immunity 2008; 28:710-22; PMID:18468462;http://dx.doi.org/10.1016/j.immuni.2008.02.020 13.,OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Front Immunol 2014; 5:131; PMID:24744755; http://dx.doi.org/10.3389/ ﬁmmu.2014.00131 14.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Immunology 2013; 140:22-30; PMID:23621371; http://dx.doi.org/10.1111/imm.12117 15.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Arch Neurol 2001; 58:91-7;PMID:11176941; http://dx.doi.org/10.1001/archneur.58.1.91 16.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
J Exp Med 2006; 203:189-201; PMID:16390935; http://dx.doi.org/10.1084/jem.20050433 17.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Nat Rev Immunol 2006; 6:295-307; PMID:16557261; http://dx.doi.org/10.1038/nri1806 18.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Cancer Immunol Immunother 2012; 62:529-39;PMID:23069871; http://dx.doi.org/10.1007/s00262-012-1360-zONCOIMMUNOLOGY e1066062-9,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
J Immunol 2002; 169:2756-61; PMID:12193750; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Cancer Res 2005; 65:2457-64; PMID:15781662; http://dx.doi.org/10.1158/0008-5472.CAN-04-3232 25.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
IntImmunopharmacol 2006; 6:2002-10; PMID:17161354; http://dx.doi.org/10.1016/j.intimp.2006.07.019 26.,OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
J Immunol 2006; 177:7398-405; PMID:17082659;http://dx.doi.org/10.4049/jimmunol.177.10.7398 27.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Cancer 2006; 107:2866-72; PMID:17099880; http://dx.doi.org/10.1002/cncr.22282 28.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Nat Med 2004; 10:942-9;PMID:15322536; http://dx.doi.org/10.1038/nm1093 30.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
J ClinOncol 2006; 24:5373-80; PMID:17135638; http://dx.doi.org/10.1200/ JCO.2006.05.9584 31.,OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Clin Can-cer Res 2006; 12:5423-34; PMID:17000676; http://dx.doi.org/10.1158/1078-0432.CCR-06-0369 33.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
J Clin Oncol 2007; 25:2586-93;PMID:17577038;http://dx.doi.org/10.1200/JCO.2006.09.4565 34.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Int J Cancer 2009; 125:1640-8; PMID:19569243; http://dx.doi.org/10.1002/ijc.24556 35.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
ClinCancer Res 2008; 14:2028-2035; PMID:18381941; http://dx.doi.org/ 10.1158/1078-0432.CCR-07-4554 36.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Clin Cancer Res 2008; 14:6770-9; PMID:18980970; http://dx.doi.org/10.1158/1078-0432.CCR-08-1156 37.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Eur J Immunol 2004; 34:859-69; PMID:14991616; http://dx.doi.org/10.1002/eji.200324506 39.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
J Steroid Biochem Mol Biol 2010; 120:69-75; PMID:20346397; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
J Immunol 2008; 180:5172-6; PMID:18390698;http://dx.doi.org/10.4049/jimmunol.180.8.5172 41.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Clin Immunol 2013; 149:400-10; PMID:24211714; http://dx.doi.org/10.1016/j.clim.2013.09.008 42.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Ann Rheum Dis 2006; 65:1512-7; http://dx.doi.org/10.1136/ard.2005.049924 43.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Blood 2012; 120:2417-27; PMID:22806892; http://dx.doi.org/10.1182/blood-2012-02-411124 44.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
J Exp Med 2002; 195:603-16; PMID:11877483; http://dx.doi.org/10.1084/jem.20011629 45.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Am J Transpl: Off J Am Soc Transpl Am Soc Transpl Surg 2008; 8:517-28;PMID:18294148; http://dx.doi.org/10.1111/j.1600-6143.2007.02106.x 46.,OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
J Vet Intern Med 2010; 24:1118-23;PMID:20666983; http://dx.doi.org/10.1111/j.1939-1676.2010.0557.x 47.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
J Exp Med 2000; 191:1499-512; PMID:10790425; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
J Exp Med 1998; 187:1395-402; PMID:9565632; http://dx.doi.org/10.1084/jem.187.9.1395e1066062-10 A M. COOK ET AL.,OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Immunopharmacology 1999; 41:235-43; PMID:10428652; http://dx.doi.org/10.1016/S0162-3109(99)00037-5 51.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Transplanta-tion 1999; 67:1342-7; PMID:10360588; http://dx.doi.org/10.1097/ 00007890-199905270-00009 53.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
J Clin Invest 1996; 98:142-7; PMID:8690786; http://dx.doi.org/10.1172/JCI118759 54.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Eur J Immunol 1995; 25:2818 /C024; PMID:7589077;http://dx.doi.org/10.1002/eji.1830251016 55.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Blood 2007; 109:3820-9; PMID:17209058; http://dx.doi.org/10.1182/blood-2006-07-035576 56.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
"ZabaLC,Fuentes-DuculanJ,SteinmanRM,KruegerJG,LowesMA.Normal h u m a nd e r m i sc o n t a i n sd i s t i n c tp o p u l a t i o n so fC D 1 1 c CBDCA-1 Cden- driticcellsandCD163 CFXIIIACmacrophages.JClinInvest2007;117:2517- 25;PMID:17786242;http://dx.doi.org/10.1172/JCI32282 57.",Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
J Immunol 2006; 176:5730-34; PMID:16670277; http://dx.doi.org/10.4049/jimmunol.176.10.5730 58.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
J Invest Dermatol 1998; 111:841-9; PMID:9804348; http://dx.doi.org/10.1046/j.1523-1747.1998.00375.x 59.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
J Exp Med 1977; 145:455-9; PMID:299883; http://dx.doi.org/10.1084/jem.145.2.455 60.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Cell Immunol 1979; 48:339-45; PMID:228870; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
J Clin Invest 2000; 105:1045-7; PMID:10772648; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Cancer Immunol Immun 2012; 62:383-91; http://dx.doi.org/10.1007/s00262-012-1343-0 66.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
"Cancer Immunol, Immunother: CII 2007; 56:641-8; PMID:16960692; http://dx.doi.org/10.1007/s00262-006-0225-8 68.",Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Curr Opin Immunol 2007; 19:224-31; PMID:17303400; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Blood 2006; 108:1435-40; PMID:16684955; http://dx.doi.org/10.1182/blood-2006-03-006403 70.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Int Rev Immu-nol 2012; 31:246-66; PMID:22804570; http://dx.doi.org/10.3109/ 08830185.2012.698338 72.,OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Eur J Immunol 2000; 30:1233-42; PMID:10760813; http://dx.doi.org/10.1002/(SICI)1521-4141(200004)30:4%3c1233:: AID-IMMU1233%3e3.0.CO;2-F 73.,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
EMBO Rep 2006; 7:1023-9;PMID:16888650; http://dx.doi.org/10.1038/sj.embor.7400775 74.,OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
J Biol Chem 2009; 284:31860-71; PMID:19776014; http://dx.doi.org/10.1074/jbc.M109.005579 75.,OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
Ann Oncol 2004; 15:257-60; PMID:14760119;http://dx.doi.org/10.1093/annonc/mdh059ONCOIMMUNOLOGY e1066062-11,Non-OADS,/arxiv_data1/oa_pdf/66/e6/koni-05-03-1066062.PMC4839331.pdf
"Published with license by Taylor & Francis Group, LLC © De-Kuan Chang, Eric Peterson, Jiusong Sun, Calum Goudie, Ronny I. Drapkin, Joyce F. Liu, Ursula Matulonis, Quan Zhu, and Wayne A. Marasco This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/ ), which permits unre- stricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
"3, e1090075 (14 pages)http://dx.doi.org/10.1080/2162402X.2015.1090075",Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Nat Rev Cancer 2003; 3:502-16;PMID:12835670; http://dx.doi.org/10.1038/nrc1123 3.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Gynecol Oncol 2003; 90:S24-32; PMID:12928003; http://dx.doi.org/ 10.1016/S0090-8258(03)00341-X 4.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Hematol Oncol Clin North Am 2003; 17:1075-85; PMID:12959192; http://dx.doi.org/10.1016/S0889-8588(03)00054-6 5.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Cancer Res 2013; 73:3591-603; PMID:23633484; http://dx.doi.org/10.1158/0008- 5472.CAN-12-4100 7.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
J Immunother 2015; 38:1-11; PMID:25415283; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
ClinCancer Res 2015; 21:976-84; PMID:25733707; http://dx.doi.org/ 10.1158/1078-0432.CCR-14-1187 11.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Annu Rev Immunol1994; 12:337-65; PMID:8011285; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Nat Rev Immunol 2003; 3:199-210; PMID:12658268; http://dx.doi.org/10.1038/nri1027 14.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Cancer Res 2006;66:4488-95; PMID:16618776; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Nat Med 2004; 10:942-9;PMID:15322536; http://dx.doi.org/10.1038/nm1093 17.,OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Semin Cancer Biol 2006; 16:98-105; PMID:16378733; http://dx.doi.org/10.1016/j.semcancer.2005.11.003 18.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
N Engl J Med 2003; 348:203-13; PMID:12529460; http://dx.doi.org/10.1056/NEJMoa020177 19.,OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
J Thorac Oncol 2015; 10:74-83;PMID:25325779; http://dx.doi.org/10.1097/JTO.0000000000000364 20.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
PloS one 2013; 8:e80063; PMID:24244610; http://dx.doi.org/10.1371/journal.pone.0080063 21.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Mol Cancer Ther 2012; 11:2451-61; PMID:22869555; http://dx.doi.org/10.1158/1535-7163.MCT-12-0278 22.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Nat Immunol 2003; 4:330-6; PMID:12612578; http://dx.doi.org/10.1038/ni904 24.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Blood 2009; 113:3716-25; PMID:19018092; http://dx.doi.org/10.1182/blood- 2008-09-179754 25.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Nat Commun 2013; 4:2126; PMID:23839242; http://dx.doi.org/10.1038/ncomms3126 26.,OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Nat Rev Immunol 2008; 8:523-32; PMID:18566595; http://dx.doi.org/ 10.1038/nri2343 27.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
J Immunol 2004; 172:7761-70; http://dx.doi.org/10.4049/jimmunol.172.12.7761 31.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
J Exp Med 2014; 211:2497-505; PMID:25488980; http://dx.doi.org/10.1084/jem.20140987 32.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
PloS One 2009; 4:e7980;PMID:19956753; http://dx.doi.org/10.1371/journal.pone.0007980 33.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
J In ﬂamm 2009; 6:31; PMID:19878594; http://dx.doi.org/10.1186/1476-9255-6-31 34.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
J Immunol 2004; 173:1681-8; PMID:15265897; http://dx.doi.org/10.4049/jimmunol.173.3.1681 35.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Oncoimmunology 2012; 1:717-25; PMID:22934263; http://dx.doi.org/ 10.4161/onci.20068 36.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Nat Rev Cancer 2005; 5:263-74; PMID:15776005; http://dx.doi.org/10.1038/nrc1586 37.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Cancer Sci 2011; 102:44-50; PMID:21044233; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Cancer Res 2004; 64:2127-33;PMID:15026353; http://dx.doi.org/10.1158/0008-5472.CAN-03-2068 39.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
PloS one2012; 7:e44455; PMID:22973452; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Cancer Immunol Immunother 2009; 58:1195-206;PMID:19048251; http://dx.doi.org/10.1007/s00262-008-0632-0 41.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Int J Cancer 2007; 120:2052-7;PMID:17278106; http://dx.doi.org/10.1002/ijc.22536 42.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Br J Haematol 2004; 126:81-4; PMID:15198736; http://dx.doi.org/10.1111/j.1365-2141.2004.04999.x 43.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Clin Cancer Res 2015; 21:274-85; PMID:25376389; http://dx.doi.org/10.1158/1078-0432.CCR-14-0830 44.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Trends Pharmacol Sci 2012;33:17-27; PMID:22032986; http://dx.doi.org/10.1016/j.tips.2011.09.003 45.,OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Nat Rev Drug Discov 2008; 7:339-57; PMID:18382464; http://dx.doi.org/10.1038/nrd2518 46.,OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Nature 2009; 459:356-63; PMID:19458711; http://dx.doi.org/10.1038/nature08144 47.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Curr Opin Phar- macol 2010; 10:775-81; PMID:20933468; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
J Immunol 2014; 192:3419-27; http://dx.doi.org/10.4049/jimmunol.1300232; PMID:24563252 49.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
PloS One 2013; 8:e81465; PMID:24339934; http://dx.doi.org/10.1371/ journal.pone.008146550.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Science 2006; 311:1924-7; PMID:16484453; http://dx.doi.org/10.1126/science.1122927 51.,OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Cell Res 2015; 25:208-24; PMID:25582080; http://dx.doi.org/10.1038/cr.2015.3 52.,OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Immunology 2010; 131:371-6; PMID:20518821; http://dx.doi.org/10.1111/j.1365-2567.2010.03308.x 53.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Nat Med 2011; 17:604-9; PMID:21532597; http://dx.doi.org/10.1038/nm.2365 54.,OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Nat Rev Neurol 2013; 9:394-404; PMID:23732529; http://dx.doi.org/10.1038/nrneurol.2013.95 55.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Blood 2008; 112:610-8; PMID:18519811; http://dx.doi.org/10.1182/blood-2008-01-135319 57.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
PloS one 2008; 3:e1983; PMID:18431473; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
PloS one 2013; 8:e83139; PMID:24376655; http://dx.doi.org/10.1371/journal.pone.0083139 59.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
J Exp Med 2013; 210:1695-710; PMID:23897981; http://dx.doi.org/10.1084/jem.20130579 60.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
N Engl J Med 2015; 372:311-9; PMID:25482239; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
N Engl J Med 2013; 369:122-33; PMID:23724867; http://dx.doi.org/10.1056/ NEJMoa1302369 63.,OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Mol Immunol 2015 Oct; 67(2 Pt A):4-17; PMID:25749122; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
J Mol Recognit 2012; 25:147-54; PMID:22407978;http://dx.doi.org/10.1002/jmr.2155 65.,OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Cancer Immunol Res 2015; 3(6):620-30; PMID:25701326; http://dx.doi.org/10.1158/2326-6066.CIR-14-0201.66.,Non-OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
Adv Drug Deliv Rev 2014; 79-80:222-37; PMID:25305336; http://dx.doi.org/10.1016/j.addr.2014.09.009.,OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
J Immunol 2015; 194:950-9; http://dx.doi.org/10.4049/jimmunol.1401686e1090075-14 D. K. CHANG ET AL.,OADS,/arxiv_data1/oa_pdf/57/08/koni-05-03-1090075.PMC4839340.pdf
"4, e1102827 (12 pages)http://dx.doi.org/10.1080/2162402X.2015.1102827",Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Nat Rev Cancer 2005; 5:591-602; PMID:16056258; http://dx.doi.org/10.1038/nrc1670 2.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
CurrOpin Oncol 1994; 6:106-13; PMID:7515692; http://dx.doi.org/ 10.1097/00001622-199401000-00015 3.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Curr Opin Cell Biol 2001; 13:555-62; PMID:11544023; http://dx.doi.org/10.1016/S0955- 0674(00)00251-9 4.,OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
J Biol Chem 2006; 281:17758-67; PMID:16632475; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Onco- gene 2005; 24:1338-47; PMID:15592498; http://dx.doi.org/10.1038/sj.onc.1208337 6.,OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Nat Rev Clin Oncol 2010; 7:693- 701; PMID:20956980; http://dx.doi .org/10.1038/nrclinonc.2010.171 7.,OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Nat Rev Mol Cell Biol 2014; 15:178-96; PMID:24556840; http://dx.doi.org/10.1038/nrm3758 8.,OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
J Clin Oncol 2011; 29:1508- 11; PMID:21422428; http://dx.doi.org/10.1200/JCO.2010.34.0026 9.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
J Clin Oncol 2005; 23:1623-6; PMID:15755968; http://dx.doi.org/10.1200/JCO.2005.10.073 10.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
N Engl J Med 2004; 351:781-91; PMID:15317891; http://dx.doi.org/10.1056/NEJMoa040766 12.,OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Int J Cancer 2012; 130:1590-7; PMID:21469140; http://dx.doi.org/10.1002/ijc.26111 13.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Breast Cancer Res Treat 2009;118:523-30; PMID:19597704; http://dx.doi.org/10.1007/s10549-009-0461-7 14.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Gynecol Oncol 2011; 122:356-60; PMID:21605893; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Breast Cancer Res Treat 2012;132:121-9; PMID:21562707; http://dx.doi.org/10.1007/s10549-011- 1569-0 16.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Breast Cancer Res 2009; 11:R59; PMID:19664291; http://dx.doi.org/10.1186/bcr2349 17.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
2009; 118:455-68; PMID:19115104; http://dx.doi.org/10.1007/s10549- 008-0290-0 18.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
BMC Cancer 2010; 10:666;PMID:21129172; http://dx.doi.org/10.1186/1471-2407-10-666 19.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Breast Cancer Res Treat 2008; 110:235-44;PMID:17899371; http://dx.doi.org/10.1007/s10549-007-9716-3 20.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
"Int JCancer 1997; 72:1-22; PMID:9212216; http://dx.doi.org/10.1002/(SICI)1097-0215(19970703)72:1%3c1::AID-IJC1%3e3.0.CO;2-Z 21. de Witte JH, Foekens JA, Brunner N, Heuvel JJ, van Tienoven T, Look MP, Klijn JG, Geurts-Moespot A, Grebenchtchikov N, Benraad Tet al.",OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Cardiovasc Res 2012; 94:125-35;PMID:22287577; http://dx.doi.org/10.1093/cvr/cvs017 24.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Pancreas 2008; 36:160-7; PMID:18376307; http://dx.doi.org/10.1097/MPA.0b013e31815750f0 25.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
J Biol Chem 2007; 282:35594-603; PMID:17923479; http://dx.doi.org/10.1074/jbc.M705867200 26.,OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Oncogene 2002; 21:5127-34;PMID:12140763; http://dx.doi.org/10.1038/sj.onc.1205657 28.,OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
J Clin Oncol 2005; 23:1011-27; PMID:15585754; http://dx.doi.org/10.1200/JCO.2005.06.081 29.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Cancer Res 2006; 66:46-51;PMID:16397214; http://dx.doi.org/10.1158/0008-5472.CAN-05-3086 30.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Mol Cell Biol2006; 26:489-501; PMID:16382141; http://dx.doi.org/10.1128/ MCB.26.2.489-501.2006 31.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Mol Syst Biol 2008; 4:188; PMID:18414489; http://dx.doi.org/10.1038/msb.2008.25 32.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Cancer Res 2004; 64:5702-11;PMID:15313910; http://dx.doi.org/10.1158/0008-5472.CAN-04-0389 35.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
BMC Cancer 2011; 11:418; PMID:21957977; http://dx.doi.org/10.1186/ 1471-2407-11-418 36.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Cancer Lett 2010; 288:99-106; PMID:19619935; http://dx.doi.org/10.1016/j.canlet.2009.06.027 37.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Oncogene 2008; 27:2276-88; PMID:18391970; http://dx.doi.org/10.1038/onc.2008.21 38.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Curr Cancer Drug Targets2011; 11:536-47; PMID:21486223; http://dx.doi.org/10.2174/ 156800911795655930 40.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
J Mol Cell Biol2011; 3:276-82; PMID:21669942; http://dx.doi.org/10.1093/jmcb/mjr013 41.,OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Drugs 2012; 72 Suppl1:28-36; PMID:22712795; http://dx.doi.org/10.2165/1163012-S0- 000000000-00000 42.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Hum Mutat 2000; 16:109-22; PMID:10923032; http://dx.doi.org/10.1002/1098-1004(200008)16:2%3c109::AID-HUMU3%3e3.0.CO;2-0 43.,OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Nature 2005; 434:917-21;PMID:15829967;http://dx.doi.org/10.1038/nature03445 44.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Nature 2005; 434:913-7; PMID:15829966; http://dx.doi.org/10.1038/ nature03443 45.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Annu Rev Cell Dev Biol 2001; 17:615-75; PMID:11687500; http://dx.doi.org/10.1146/annurev.cellbio.17.1.615 4 6 .,OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Apoptosis 2004; 9:667-76; PMID:15505410; http://dx.doi.org/10.1023/B:APPT.0000045801.15585.dd 47.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Br J Cancer 2000; 83:1688-95; PMID:11104567; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Immunity 2011; 35:871-82; PMID:22195744; http://dx.doi.org/10.1016/j.immuni.2011.09.021 49.,OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Immu-nity 2009; 30:832-44; PMID:19538929; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
2012; 1:252-4; PMID:22720261; http://dx.doi.org/10.4161/ onci.1.2.18241 5 1 .,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Expert Opin Biol Ther 2007; 7:449-60; PMID:17373897; http://dx.doi.org/10.1517/14712598.7.4.449 52.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
PloS One 2013; 8:e71590;PMID:23977081; http://dx.doi.org/10.1371/journal.pone.007159053.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Nucleic Acids Res 2012; 40:e51; PMID:22228834;http://dx.doi.org/10.1093/nar/gkr1259 54.,OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
Clin Chem 2009; 55:611-22; PMID:19246619; http://dx.doi.org/10.1373/clinchem.2008.112797e1102827-12 M. HENSLER ET AL.,OADS,/arxiv_data1/oa_pdf/f9/0a/koni-05-04-1102827.PMC4839342.pdf
"3, e1115177 (17 pages)http://dx.doi.org/10.1080/2162402X.2015.1115177",Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Lancet 2006; 368:629-30; PMID:16920452; http://dx.doi.org/10.1016/S0140-6736(06)69225-8 2.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Ann Oncol 2012; 23 Suppl 6:vi7-12; PMID:23012306; http://dx.doi.org/10.1093/annonc/mds187 3.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Ann Oncol 2012; 23 Suppl 6:vi56-65; PMID:23012305; http://dx.doi.org/10.1093/annonc/mds196 4.,OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Nature 2008; 454:436-44; PMID:18650914; http://dx.doi.org/ 10.1038/nature07205 5.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
J Clin Pathol 2012; 65:159-63; PMID:22049225; http://dx.doi.org/ 10.1136/jclinpath-2011-200355 7.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Curr Opin Immunol 2010; 22:231-7; PMID:20144856; http://dx.doi.org/10.1016/j.coi.2010.01.009 8.,OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Trends Immunol 2002; 23:549-55; PMID:12401408; http://dx.doi.org/10.1016/S1471-4906(02)02302-59.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
J Exp Med 1992;176:287-92; PMID:1613462; http://dx.doi.org/10.1084/jem.176.1.287 10.,OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Blood 2009; 114:901-14;PMID:19383967; http://dx.doi.org/10.1182/blood-2009-01-200931 11.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
J Immunol 2000; 164:762-7; PMID:10623821; http://dx.doi.org/10.4049/jimmunol.164.2.762 12.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Nature 2008;456:814-8; PMID:18997773; http://dx.doi.org/10.1038/nature07445 13.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
J ExpMed 2001; 193:727-40; PMID:11257139; http://dx.doi.org/10.1084/ jem.193.6.727 14.,OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Cancer Res 2004; 64:5378-84; PMID:15289345; http://dx.doi.org/10.1158/0008-5472.CAN-04-0961 15.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Cancer Res 2006;66:4349-56; PMID:16618760; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
PLoS One 2013; 8:e54302; PMID:23372702; http://dx.doi.org/10.1371/journal.pone.0054302 17.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Nat Med 2013; 19:1264-72; PMID:24056773; http://dx.doi.org/10.1038/nm.3337 18.,OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
"Cancer Cell, 2014; 25(6):846-59; PMID: 24898549; http://dx.doi.org/10.1016/j.ccr.2014.05.016 19.",Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
J Leukoc Biol 2006;80:862-9; PMID:16895973; http://dx.doi.org/10.1189/jlb.0605297 21.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Exp Hematol 2002;30:495-501; PMID:12031657; http://dx.doi.org/10.1016/S0301-472X (02)00785-3 23.,OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Sci Rep 2015; 5:9188; PMID:25776849; http://dx.doi.org/10.1038/srep09188 24.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Oncogene 2014; 33:1485-94; PMID:23584474; http://dx.doi.org/10.1038/onc.2013.105 26.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
J Clin Invest 2011; 121:2750-67; PMID:21633166; http://dx.doi.org/10.1172/JCI45014 2 7 .,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
BMC Cancer 2012; 12:306; PMID:22824040; http://dx.doi.org/10.1186/1471-2407-12-306 29.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
PLoS One 2011; 6:e27690; PMID:22110722; http://dx.doi.org/10.1371/journal.pone.0027690 31.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Blood 2003; 101:2990-5; PMID:12672695; http://dx.doi.org/10.1182/blood.V101.8.2990 32.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Proc Natl Acad Sci U S A 2009; 106:6742-7; PMID:19346489; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Can cer Immunol Res 2014; 2:765-76; PMID:25005824; http://dx.doi.org/10.1158/2326-6066.CIR-13-0190 35.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
J Immunol 2005; 175:7085-91; PMID:16301609; http://dx.doi.org/10.4049/jimmunol.175.11.7085 36.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Cancer Res 2007;67:5479-88; PMID:17545630; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Auris Nasus Larynx 2007; 34:267-71; PMID:17097253; http://dx.doi.org/10.1016/j.anl.2006.07.014 38.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Br J Cancer 2014; 110:1211-20; PMID:24448357;http://dx.doi.org/10.1038/bjc.2013.822 41.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Ann Oncol 2009; 20:1913-27; PMID:19901010; http://dx.doi.org/10.1093/ annonc/mdp492 44.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Cancer 2010; 116:1234-42; PMID:20082448; http://dx.doi.org/ 10.1002/cncr.24816 45.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Nat Med 2013; 19:1114-23; PMID:23913124; http://dx.doi.org/10.1038/nm.3291 46.,OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Cancer Cell 2011; 20:300-14; PMID:21907922; http://dx.doi.org/10.1016/j.ccr.2011.08.012 47.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Immunity 2011; 34:85-95; PMID:21194983; http://dx.doi.org/ 10.1016/j.immuni.2010.12.011 48.,OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Cancer Sci 2013; 104:1237-44; PMID:23734742; http://dx.doi.org/10.1111/cas.12212 49.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
CancerCell 2006; 10:515-27; PMID:17157791; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Int J Cancer 2007; 120:2411-7; PMID:17294444; http://dx.doi.org/10.1002/ijc.22376 52.,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
Cancer Res2010; 70:5728-39; PMID:20570887; http://dx.doi.org/10.1158/0008- 5472.CAN-09-4672ONCOIMMUNOLOGY e1115177-17,Non-OADS,/arxiv_data1/oa_pdf/29/86/koni-05-03-1115177.PMC4839343.pdf
"dsRNA such as PolyIC- derivatives are currently tested in clinical trials as vaccine adju-vants or intratumorally as immunostimulants for different solidcancers 1(https://clinicaltrials.gov, NCT01984892).",Non-OADS,/arxiv_data1/oa_pdf/74/d2/koni-05-04-1075695.PMC4839344.pdf
"4, e1075695 (3 pages)http://dx.doi.org/10.1080/2162402X.2015.1075695",Non-OADS,/arxiv_data1/oa_pdf/74/d2/koni-05-04-1075695.PMC4839344.pdf
Current Pharm Des 2014; 20:6555-64; PMID:25341932; http://dx.doi.org/10.2174/1381612820666140826153347 2.,Non-OADS,/arxiv_data1/oa_pdf/74/d2/koni-05-04-1075695.PMC4839344.pdf
J Virol 2005; 79:14852-62; PMID:16282485; http://dx.doi.org/10.1128/JVI.79.23.14852-14862.2005 5.,Non-OADS,/arxiv_data1/oa_pdf/74/d2/koni-05-04-1075695.PMC4839344.pdf
J Immunol 2000; 165:1939-48; PMID:10925276; http://dx.doi.org/10.4049/jimmunol.165.4.1939 7.,Non-OADS,/arxiv_data1/oa_pdf/74/d2/koni-05-04-1075695.PMC4839344.pdf
Int J Cancer 2014; 134:2061-73; PMID:24136650; http://dx.doi.org/10.1002/ijc.28549 8 .,Non-OADS,/arxiv_data1/oa_pdf/74/d2/koni-05-04-1075695.PMC4839344.pdf
Cancer Res 2011; 71:87-97; PMID:21199798; http://dx.doi.org/10.1158/0008-5472.CAN-10- 21939.,Non-OADS,/arxiv_data1/oa_pdf/74/d2/koni-05-04-1075695.PMC4839344.pdf
Cell 2012; 148:213-27; PMID:22265413; http://dx.doi.org/10.1016/j.cell.2011.11.031ONCOIMMUNOLOGY e1075695-3,Non-OADS,/arxiv_data1/oa_pdf/74/d2/koni-05-04-1075695.PMC4839344.pdf
"3, e1136044 (8 pages)http://dx.doi.org/10.1080/2162402X.2015.1136044",Non-OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
N Eng J Med2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466 2.,OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
J Clin Oncol 2014; 32:1020-30; PMID:24590637; http://dx.doi.org/10.1200/ JCO.2013.53.0105 3.,Non-OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
N EngJ Med 2012; 367:1694-703; PMID:23020132; http://dx.doi.org/10.1056/NEJMoa1210093 4.,OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
N Eng J Med 2012; 366:707-14; PMID:22356324; http://dx.doi.org/10.1056/ NEJMoa1112302 5.,OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
N Eng J Med 2011; 364:2507-16; PMID:21639808; http://dx.doi.org/10.1056/NEJMoa1103782 6.,OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
N Eng J Med 2015; 372(26):2521-32;PMID:25891173; http://dx.doi.org/10.1056/NEJMoa1503093 7.,Non-OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
Cancer Discov 2014; 4:1377-86; PMID:25395294; http://dx.doi.org/10.1158/2159-8290.CD-14-0477 8.,Non-OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
Lancet 2015; 386(9992):444-51; PMID:26037941; http://dx.doi.org/10.1016/S0140-6736(15)60898-4 10.,Non-OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
Lancet 2012; 380:358-65; PMID:22735384; http://dx.doi.org/10.1016/S0140-6736(12)60868-X 11.,OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
J Clin Oncol 2015; 33(17):1889-94; PMID:25667295; http://dx.doi.org/10.1200/JCO.2014.56.2736 12.,Non-OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
Cancer 2014; 120:1695-701; PMID:24577748; http://dx.doi.org/10.1002/cncr.28620 13.,Non-OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
Cancer Invest 2014; 32:144-9;PMID:24484235; http://dx.doi.org/10.3109/07357907.2014.88598414.,Non-OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
Cancer 2014; 120:1617-9;PMID:24577788; http://dx.doi.org/10.1002/cncr.28622 15.,Non-OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
Melanoma Res 2015; 25:68-74; PMID:25396684;http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
"JAMA Oncol 2015; 1:433-40;PMID:26181250; http://dx.doi.org/10.1001/jamaoncol.2015.1184 17. Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW et al.",OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
Cancer Immunol Res 2014; 2:643-54;PMID:24903021; http://dx.doi.org/10.1158/2326-6066.CIR-13-0215 18.,Non-OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
Nature 2014; 515:568-71; PMID:25428505; http://dx.doi.org/10.1038/ nature13954 19.,Non-OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.PloS One 2014; 9:e87705; PMID:24498358; http://dx.doi.org/10.1371/journal.pone.0087705 20.,Non-OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
"Clin Cancer Res 2013; 19:1225-31; PMID:23307859; http://dx.doi.org/10.1158/1078-0432.CCR-12-1630 21. Cooper ZA, Frederick DT, Juneja VR, Sullivan RJ, Lawrence DP, Piris A, Sharpe AH, Fisher DE, Flaherty KT, Wargo JA.",Non-OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
Oncoimmunol 2013; 2:e26615; PMID:24251082; http://dx.doi.org/10.4161/onci.26615 2 2 .,Non-OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
N Eng J Med 2013; 369:134-44; PMID:23724846; http://dx.doi.org/10.1056/NEJMoa1305133 23.,OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
Proc Natl Acad Sci US A 2012; 109:2796-801; PMID:21825174; http://dx.doi.org/10.1073/ pnas.1104303108 24.,OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
Clin Cancer Res 2012; 18:1386-94; PMID:22156613; http://dx.doi.org/ 10.1158/1078-0432.CCR-11-2479 25.,Non-OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
Clin Cancer Res 2015;21(14):3140-8; PMID:25609064; http://dx.doi.org/10.1158/1078-0432.,Non-OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
Oncoimmunol 2014; 3:e954956; PMID:25941608; http://dx.doi.org/10.4161/21624011.2014.954956 27.,Non-OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
Cancer Res 2012; 72:917-27; PMID:22186141; http://dx.doi.org/10.1158/0008-5472.CAN-11-1620ONCOIMMUNOLOGY e1136044-7,Non-OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
Semin Oncol 2015; 42 Suppl 3:S12-9; PMID:26598055; http://dx.doi.org/10.1053/j.seminoncol.2015.10.002 29.,Non-OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
J Clin Invest 2015; 125:2046-58; PMID:25866972; http://dx.doi.org/10.1172/JCI80445 30.,Non-OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
Trends Cancer 2015; 1:36-43; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/14/2c/koni-05-03-1136044.PMC4839346.pdf
"3, e1091146 (24 pages)http://dx.doi.org/10.1080/2162402X.2015.1091146",Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Cell Stem Cell 2013; 13:392-402; PMID:24094322; http://dx.doi.org/10.1016/j.stem.2013.09.006 2.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Annu Rev Immunol 2013; 31:285- 316; PMID:23298209; http://dx.doi.org/10.1146/annurev-immunol-032712-095919 3.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Nat Rev Immunol 2012; 12:383-96;PMID:22531326; http://dx.doi.org/10.1038/nri3209 4.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
J Immunol 2007; 179:1595-604; PMID:17641026; http://dx.doi.org/10.4049/jimmunol.179.3.1595 6.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
J Clin Immunol 2010; 30:607-19; PMID:20405178; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Exp Cell Res 2010; 316:2713-22; PMID:20451516; http://dx.doi.org/ 10.1016/j.yexcr.2010.04.032 9.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Trends Immunol 2001; 22:199-204; PMID:11274925; http://dx.doi.org/10.1016/S1471-4906(01)01863-4 10.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Nat Rev Cancer 2006; 6:392-401; PMID:16572188; http://dx.doi.org/10.1038/nrc1877 11.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
J Immunol 2007; 178:5552-62; PMID:17442937; http://dx.doi.org/10.4049/jimmunol.178.9.5552 12.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Annu Rev Immunol 2008; 26:677-704; PMID:18173375; http://dx.doi.org/10.1146/annurev.immunol.26.021607.090331 1 3 .,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
J Immunol 2004; 173:945-54; PMID:15240681; http://dx.doi.org/10.4049/jimmunol.173.2.945 14.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Autoimmun Rev 2013; 12:1091-100; PMID:23792703; http://dx.doi.org/10.1016/j.autrev.2013.05.003 15.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
N Engl J Med 2013; 369:134-44; PMID:23724846; http://dx.doi.org/10.1056/NEJMoa1305133ONCOIMMUNOLOGY e1091146-21,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690 19.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Nature 2014;515:568-71; PMID:25428505; http://dx.doi.org/10.1038/nature13954 20.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Nature 2014; 515:563-7; PMID:25428504; http://dx.doi.org/10.1038/nature14011 21.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Nature 2014; 515:558-62; PMID:25428503; http://dx.doi.org/10.1038/ nature13904 22.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Clin Cancer Res 2014;20:5064-74; PMID:24714771; http://dx.doi.org/10.1158/1078-0432.CCR-13-3271 23.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Microcirculation 2002; 9:133-45; PMID:11932780; http://dx.doi.org/ 10.1080/713774061 24.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Blood 2012; 120:4772-82;PMID:22993390; http://dx.doi.org/10.1182/blood-2012-04-427013 25.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
J Exp Med 2006;203:883-95; PMID:16606670; http://dx.doi.org/10.1084/jem.20051776 26.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Immunol Lett 2004; 94:215-22; PMID:15275969; http://dx.doi.org/10.1016/j.imlet.2004.05.007 27.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Nat Immunol 2001; 2:261-8; PMID:11224527; http://dx.doi.org/10.1038/85330 28.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
ClinDev Immunol 2012; 2012:656340; PMID:22611421; http://dx.doi.org/ 10.1155/2012/656340 29.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Biochem Biophys Res Commun 2003; 307:672-7; PMID:12893276; http://dx.doi.org/10.1016/S0006-291X(03)01257-9 30.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Eur J Immunol 2005; 35:1482-90; PMID:15827960; http://dx.doi.org/10.1002/eji.200425405 31.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
J Dermatol Sci 2005; 40:95-103; PMID:16085391; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
"Gastroenterol 2008; 135:1228-37, 1237; PMID:18760278; http://dx.doi.org/10.1053/j.gastro.2008.07.016 33.",Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
J Invest Dermatol 2014; 134:736-45; PMID:24005055; http://dx.doi.org/10.1038/jid.2013.368 34.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
J Cell Mol Med 2014; 18:1184-93; PMID:24655362; http://dx.doi.org/10.1111/jcmm.12264 36.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Tissue Eng Part C Methods 2015; 21:212 –22; PMID:24918644; http://dx.doi.org/10.1089/ten.TEC.2013.0766 37.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Int Immunol 2010; 22:651-60; PMID:20587542; http://dx.doi.org/10.1093/intimm/dxq049 3 8 .,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
PLoS Biol 2010; 8:e1000514; PMID:21049082; http://dx.doi.org/10.1371/journal.pbio.1000514 39.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Int J Oncol 2011; 39:989-99; PMID:21814715; http://dx.doi.org/10.3892/ijo.2011.1132 40.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Nat Pro- toc 2009; 4:1798-806; PMID:20010931; http://dx.doi.org/10.1038/nprot.2009.191 41.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Nat Rev Immunol 2013; 13:649-65; PMID:23969736; http://dx.doi.org/10.1038/nri3499 42.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
PLoS One 2012; 7:e42596; PMID:22880047; http://dx.doi.org/10.1371/journal.pone.0042596 44.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Cell Immunol 2014; 290:72-9; PMID:24908630; http://dx.doi.org/10.1016/j.cellimm.2014.05.006 45.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Hum Immunol 2013; 74:267-76; PMID:23261407; http://dx.doi.org/ 10.1016/j.humimm.2012.12.011 46.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Immunol Lett 2008; 115:50-8; PMID:18022251; http://dx.doi.org/ 10.1016/j.imlet.2007.10.002e1091146-22 C. DEZUTTER-DAMBUYANT ET AL.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
StemCells 2006; 24:2466-77; PMID:17071860; http://dx.doi.org/10.1634/ stemcells.2006-0071 48.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
J Neuroimmunol 2004; 155:172-82; PMID:15342209; http://dx.doi.org/10.1016/j.jneuroim.2004.06.013 49.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Cancer Discov 2013; 3:1355-63; PMID:24078774; http://dx.doi.org/10.1158/2159-8290.CD-13-0310 50.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Scand J Immunol2014; 80:71-2; PMID:24684652; http://dx.doi.org/10.1111/sji.12177 51.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
J Infect Dis 2006; 193:404-12; PMID:16388488;http://dx.doi.org/10.1086/499275 53.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
J Hepatol 2006; 45:520-8; PMID:16876901; http://dx.doi.org/ 10.1016/j.jhep.2006.05.007 54.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
J Immunol 2008; 181:6738-46; PMID:18981091; http://dx.doi.org/10.4049/jimmunol.181.10.6738 55.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
NatMed 2003; 9:562-7; PMID:12704383; http://dx.doi.org/10.1038/nm863 57.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Int J Cancer 2011; 128:887-96; PMID:20473887; http://dx.doi.org/10.1002/ijc.25397 58.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Br J Cancer 1996; 74:352-8; PMID:8695348; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
J Immu-nol 2005; 175:2000-9; PMID:16034145; http://dx.doi.org/10.4049/jimmunol.175.3.2000 60.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
"Pang G, Couch L, Batey R, Clan cy R, Cripps A. GM-CSF, IL-1 a,I L - 1 b,I L - 6 ,I L - 8 ,I L - 1 0 ,I C A M - 1a n dV C A M - 1g e n ee x p r e s s i o na n dc y t o - kine production in human duodenal ﬁbroblasts stimulated with lipopoly- saccharide, IL-1 aand TNF- a. Clin Exp Immunol 1994; 96:437-43; PMID:8004813; http://dx.doi.org/10.1111/j.1365-2249.1994.tb06048.x 61.",Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Exp Cell Res 2005; 305:33-41; PMID:15777785; http://dx.doi.org/10.1016/j.yexcr.2004.12.013 62.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
J Cell Biochem 2003; 90:206-17; PMID:12938169; http://dx.doi.org/10.1002/jcb.10593 63.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Cell 2010; 141:52-67;PMID:20371345; http://dx.doi.org/10.1016/j.cell.2010.03.015 64.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
J Invest Dermatol 2007; 127:49-59; PMID:16917496; http://dx.doi.org/10.1038/sj.jid.5700500 65.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Cytokine 2011; 56:231-8; PMID:21733718; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Clin Cancer Res 2011;17:1915-23; PMID:21355078; http://dx.doi.org/10.1158/1078-0432.CCR-10-0250 67.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Acta Biochim Biophys Sin(Shanghai) 2004; 36:284-9; PMID:15253154; http://dx.doi.org/10.1093/abbs/36.4.284 68.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Trends Immunol 2008; 29:75-82;PMID:18182322; http://dx.doi.org/10.1016/j.it.2007.10.009 69.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Science 2000; 289:1202-6;PMID:10947989; http://dx.doi.org/10.1126/science.289.5482.1202 70.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Eur J Biochem 2003; 270:3739-49; PMID:12950257; http://dx.doi.org/ 10.1046/j.1432-1033.2003.03760.x 71.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Biochem Biophys Res Commun 2003;310:889-96; PMID:14550288; http://dx.doi.org/10.1016/j.bbrc.2003.09.098 72.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Nature 1997; 385:729-33; PMID:9034190; http://dx.doi.org/10.1038/385729a0 73.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Nat Immunol 2006; 7:1293-8; PMID:17072319; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
"LogueEC,BakkourS,MurphyMM,NollaH,ShaWC.ICOS-inducedB7hshed- dingonBcellsisinhibitedbyTLR7/8andTLR9.JImmunol2006;177:2356-64; PMID:16887997;http://dx.doi.org/10.4049/jimmunol.177.4.2356 75.",OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Cancer Immunol Immunother 2010; 59:1163-71; PMID:20333377; http://dx.doi.org/ 10.1007/s00262-010-0841-1 7 6 .,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Immunology 2008; 123:538-46; PMID:18194267; http://dx.doi.org/10.1111/j.1365-2567.2007.02723.xONCOIMMUNOLOGY e1091146-23,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Cancer Res 2014; 74:3429-40; PMID:24780758; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Blood 2010; 116:1291-8; PMID:20472828; http://dx.doi.org/10.1182/blood-2010-01-265975 79.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
J Exp Med 2000; 192:1027-34; PMID:11015443; http://dx.doi.org/10.1084/ jem.192.7.1027 80.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Science 2001; 291:319- 22; PMID:11209085; http://dx.doi.org/10.1126/science.291.5502.319 81.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Cell Death Dis 2015; 6:e1792; PMID:26086965; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Methods 2013; 59:S20-3; PMID:23036330; http://dx.doi.org/10.1016/j.ymeth.2012.09.012 84.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
Anal Chem 2011; 83:8604-10;PMID:22035192; http://dx.doi.org/10.1021/ac202028ge1091146-24 C. DEZUTTER-DAMBUYANT ET AL.,OADS,/arxiv_data1/oa_pdf/ed/c2/koni-05-03-1091146.PMC4839348.pdf
"4, e1062968 (13 pages)http://dx.doi.org/10.1080/2162402X.2015.1062968",Non-OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
In silico predic- tion of putative miR-23a target genes using the TargetScan database(http://www.targetscan.org) revealed the presence of an miR-23a binding site at position116/C0123 in the 3 0-UTR of the CD107a gene ( Fig.,OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
(C) Mapping of has-miR-23a on the mRNA 3 0-UTR of LAMP1 (source TargetScan: http://www.targetscan.org).,OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
Trends Pharmacol Sci 2012; 33:207- 14; PMID:22398146; http://dx.doi.org/10.1016/j.tips.2012.01.005 2.,OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
Crit Rev Immunol 2011; 31:357-77; PMID:22142164; http://dx.doi.org/10.1615/CritRevImmunol.v31.i5.10 3.,Non-OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
Front Immunol 2012; 3:21; PMID:22566905; http://dx.doi.org/10.3389/ ﬁmmu.2012.00021 4.,Non-OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
CancerRes 2014; 74:6820-32; PMID:25297632; http://dx.doi.org/10.1158/ 0008-5472.CAN-14-0303 5.,Non-OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
Autophagy 2014; 10:173-5; PMID:24248158; http://dx.doi.org/ 10.4161/auto.26924 7.,Non-OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
J Exp Med 2014; 211:781-90; PMID:24778419; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
Nat Immunol 2013; 14:1014-22; PMID:24048123; http://dx.doi.org/10.1038/ni.270310.,Non-OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
Gen Dev 2012; 26:1287-99; PMID:22713869;http://dx.doi.org/10.1101/gad.192351.112 12.,Non-OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
Curr Opin Oncol 2013; 25:66-75;PMID:23165142; http://dx.doi.org/10.1097/CCO.0b013e32835b7c81 13.,Non-OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
Semin Immunopathol 2011; 33:393-4; PMID:21590325; http://dx.doi.org/10.1007/s00281-011-0276-6 1 4 .,Non-OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
Lancet 2002; 360:295- 305; PMID:12147373; http://dx.do i.org/10.1016/S0140-6736(02)09552-1 15.,OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
Nat Med 2001; 7:297-303; PMID:11231627; http://dx.doi.org/ 10.1038/85438 16.,OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
J Biol Chem 2012; 287:15874-85; PMID:22396543; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
Blood Cells Mol Dis 2005; 34:206-13; PMID:15885603; http://dx.doi.org/10.1016/j.bcmd.2005.03.003 18.,OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
Haematologica 2011; 96:1302-9; PMID:21606166; http://dx.doi.org/10.3324/haematol.2010.039743 19.,Non-OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
Biochem SocTrans 2013; 41:245-51; PMID:23356291; http://dx.doi.org/10.1042/ BST20120265 20.,OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
BMC cancer 2012; 12:421; PMID:22998595; http://dx.doi.org/10.1186/1471-2407-12-421 21.,Non-OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
J Immunol 2009; 182:3510-21; PMID:19265129; http://dx.doi.org/10.4049/jimmunol.0800854 24.,Non-OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
Nat protoc 2012; 7:2112-26; PMID:23154783; http://dx.doi.org/10.1038/nprot.2012.131 25.,Non-OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
Nat Immunol 2008; 9:503-10; PMID:18425107;http://dx.doi.org/10.1038/ni1582 26.,Non-OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
Ann Rev Immunol 2013; 31:227-58; PMID:23516982;http://dx.doi.org/10.1146/annurev-immunol-020711-075005e1062968-12 G. BERCHEM ET AL.,Non-OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
Neuro-oncology 2010; 12:7-13;PMID:20150362; http://dx.doi.org/10.1093/neuonc/nop009 28.,Non-OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
Cancer Res 2012; 72:4629-41; PMID:22962263; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
Pro- tein Cell 2013; 4:932-41; PMID:24203759; http://dx.doi.org/10.1007/s13238-013-3092-z 30.,Non-OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
PloS one 2013; 8: e74654; PMID:24040308; http://dx.doi.org/10.1371/journal.pone.0074654 31.,Non-OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
Clin Exp Immunol 2014; 178(1):79-85; PMID:24894428; http://dx.doi.org/10.1111/cei.12392 32.,Non-OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
Curr Pharm Des 2014; 20(33):5246-59; PMID:24479804; http://dx.doi.org/10.2174/ 1381612820666140128210105 33.,Non-OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
Method Mol Biol 2014; 1102:287-324; PMID:24258985; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
PloS one 2014; 9:e88557;PMID:24551119; http://dx.doi.org/10.1371/journal.pone.0088557 36.,Non-OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
J Immunol Method 2004; 294:15-22; PMID:15604012; http://dx.doi.org/10.1016/j.jim.2004.08.008 37.,Non-OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
Nat Med 2001; 7:1118-22; PMID:11590434; http://dx.doi.org/10.1038/nm1001-1118 38.,OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
Cancer Cell 2005; 8:369-80; PMID:16286245; http://dx.doi.org/10.1016/j.ccr.2005.10.012 39.,OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
Biochem Biophys Res Commun 2003; 300:980-5;PMID:12559970; http://dx.doi.org/10.1016/S0006-291X(02)02939-X 40.,OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
J Leukoc Biol 2014; 96(4):633-45; PMID:25030422; http://dx.doi.org/10.1189/jlb.3A0114- 025RONCOIMMUNOLOGY e1062968-13,Non-OADS,/arxiv_data1/oa_pdf/a6/5e/koni-05-04-1062968.PMC4839360.pdf
"3, e1086060 (14 pages)http://dx.doi.org/10.1080/2162402X.2015.1086060",Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
J Surg Oncol 2009; 100:619-34;PMID:20017157; http://dx.doi.org/10.1002/jso.21364 2.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Radiofrequency ablation of liver tumors: a systematic review.Arch Surg 2006; 141:181-90; PMID:16490897; http://dx.doi.org/10.1001/archsurg.141.2.181 3.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Hepatology 2003; 37:429-42; PMID:12540794; http://dx.doi.org/10.1053/jhep.2003.50047 4.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Oncogene 2006; 25:3866-84; PMID:16799628; http://dx.doi.org/10.1038/sj.onc.1209550 5.,OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Lancet 2000; 356:802-7; PMID:11022927; http://dx.doi.org/10.1016/S0140-6736(00)02654-4 6.,OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
J Cancer 2011; 2:363-8; PMID:21716717; http://dx.doi.org/10.7150/jca.2.363 7.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Immunol Res 2014; 58:300-6; PMID:24791943; http://dx.doi.org/10.1007/s12026-014-8507-2 8.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Expansion of cytolytic CD8( C) natural killer T cells with limited capacity for graft- versus-host disease induction due to interferon gamma production.Blood 2001; 97:2923-31; PMID:11342413; http://dx.doi.org/10.1182/ blood.V97.10.2923 9.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Expert Opin Biol Ther 2012; 12:673-84; PMID:22500889; http://dx.doi.org/10.1517/14712598.2012.675323 10.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
J Immunother 2012; 35:579-86; PMID:22892454; http://dx.doi.org/10.1097/CJI.0b013e31826b1fd9e1086060-12 X.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
J Immunother 2008; 31:63- 71; PMID:18157013; http://dx.doi.org/10.1097/CJI.0b013e31815a121b 12.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Cancer Biol Ther 2011; 11:450-6; PMID:21258206; http://dx.doi.org/10.4161/cbt.11.5.14669 13.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
J Immunother 2013; 36:287-93;PMID:23719239; http://dx.doi.org/10.1097/CJI.0b013e3182948452 14.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Cell Cycle 2013; 12:3743-8; PMID:24270846; http://dx.doi.org/10.4161/cc.27305 15.,OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
J Stem Cells 2013; 8:135-49; PMID:24699023; http://dx.doi.org/jsc.2014.8.3/4.135.,OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Carcinogenesis 2015; 36:177-85; PMID:25504149; http://dx.doi.org/10.1093/carcin/bgu243 17.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Cell Stem Cell 2014; 14:275-91; PMID:24607403; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Carcinogenesis 2014; 35:1196-208; PMID:24658181; http://dx.doi.org/10.1093/carcin/bgu073 20.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Onco- gene 2014; 33:4967-77; PMID:24240682; http://dx.doi.org/10.1038/ onc.2013.492 21.,OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Oncogene 2014; 33:4451-63; PMID:24096485; http://dx.doi.org/10.1038/onc.2013.411 22.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
J Clin Invest 2013; 123:1911-8; PMID:23635789; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Contemp Oncol 2015; 19:A52-9; PMID:25691822; http://dx.doi.org/10.5114/wo.2014.47129 24.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Clin Cancer Res 2013; 19:4347-58; PMID:23794732; http://dx.doi.org/10.1158/1078-0432.CCR-13-0061 25.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas.Cancer Res 2014; 74:119-29; PMID:24356422; http://dx.doi.org/ 10.1158/0008-5472.CAN-13-1559 26.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Cancer Res 2013; 73:1219-31; PMID:23269272; http://dx.doi.org/10.1158/0008- 5472.CAN-12-1408 27.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
PloS one 2014; 9:e101330;PMID:24992599; http://dx.doi.org/10.1371/journal.pone.010133028.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Cell Cycle 2013; 12:1119-27; PMID:23466707; http://dx.doi.org/10.4161/ cc.24164 2 9 .,OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Biotechnol Lett 2014; 36:9-20; PMID:24068500; http://dx.doi.org/10.1007/s10529-013-1327-y 30.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
PloS one 2015; 10:e0118417; PMID:25799309;http://dx.doi.org/10.1371/journal.pone.0118417 31.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Genes Dev 2003;17:1253-70; PMID:12756227; http://dx.doi.org/10.1101/gad.1061803 32.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
PLoS Pathog 2010; 6:e1000940; PMID:20532215; http://dx.doi.org/10.1371/journal.ppat.1000940 33.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Oncogene 2012; 31:2614-26; PMID:21996747; http://dx.doi.org/ 10.1038/onc.2011.439 34.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
J Clin Oncol 2008; 26:2901-10; PMID:18539971; http://dx.doi.org/10.1200/JCO.2008.16.9573 36.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Nat Protoc 2009; 4:1192-201;PMID:19617890; http://dx.doi.org/10.1038/nprot.2009.100 38.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
J Immunol 2005; 175:7819- 28; PMID:16339517; http://dx.doi.org/10.4049/jimmunol.175.12.7819.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Nat Rev Cancer 2008; 8:755-68; PMID:18784658; http://dx.doi.org/10.1038/nrc2499 42.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Cell Stem Cell 2012; 10:717-28;PMID:22704512; http://dx.doi.org/10.1016/j.stem.2012.05.007 43.,OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
J Clin Oncol2008; 26:2901-10; PMID:18539971; http://dx.doi.org/10.1200/JCO.2008.16.9573 44.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Nat Protoc 2009; 4:1192-201;PMID:19617890; http://dx.doi.org/10.1038/nprot.2009.100 46.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Med Hypotheses 2015; 84:159-61; PMID:25636604;http://dx.doi.org/10.1016/j.mehy.2014.08.022 47.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Arch Pharm Res 2009; 32:781-7;PMID:19471894; http://dx.doi.org/10.1007/s12272-009-1518-1 48.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Mol Ther 2013; 21:2268-77; PMID:23985696; http://dx.doi.org/10.1038/mt.2013.192.,OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
J Immunother 2013; 36:181-9; PMID:23502765; http://dx.doi.org/10.1097/CJI.0b013e318-288f8c1 51.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Haematologica 2010; 95:2144-52; PMID:20713459; http://dx.doi.org/ 10.3324/haematol.2010.026310 52.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Leukemia 2014; 28:1596-605; PMID:24504024;http://dx.doi.org/10.1038/leu.2014.62 53.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Clin Dev Immunol 2012; 2012:238924; PMID:22481963; http://dx.doi.org/10.1155/2012/238924 54.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Br J Haematol 2013; 161:389-401; PMID:23432359; http://dx.doi.org/ 10.1111/bjh.12282 55.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Clin Cancer Res 2006; 12:1859-67; PMID:16551871; http://dx.doi.org/10.1158/1078-0432.CCR-05-2019 56.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Clin Immunol 2013; 149:156-68; PMID:23994769; http://dx.doi.org/10.1016/j.clim.2013.07.006 57.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
Cancer Immunol Immunother 2007; 56:1911-20; PMID:17487487;http://dx.doi.org/10.1007/s00262-007-0333-0 59.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
CancerRes 2011; 71:225-33; PMID:21199804; http://dx.doi.org/10.1158/ 0008-5472.CAN-10-1850e1086060-14 X.,Non-OADS,/arxiv_data1/oa_pdf/b2/cf/koni-05-03-1086060.PMC4839362.pdf
"3, e1086862 (7 pages)http://dx.doi.org/10.1080/2162402X.2015.1086862",Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690 2.,OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2010; 363:711-23; PMID:20525992; http://dx.doi.org/ 10.1056/NEJMoa1003466 3.,OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2011; 208:2005-16; PMID:21930765; http://dx.doi.org/10.1084/ jem.20101159 4.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2013; 13:847-61; PMID:23421934; http://dx.doi.org/10.1517/14712598.2013.770836 5.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2013; 5:169-81; PMID:23634195; http://dx.doi.org/10.1177/1758834012475152 6.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2015; 51:12-5; PMID:25459157; http://dx.doi.org/10.1016/j.oraloncology.2014.10.010 7.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2009; 69:3077-85; PMID:19293190; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2013; 5:200ra116; PMID:23986400; http://dx.doi.org/10.1126/ scitranslmed.3006504 9.,OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
Nature2014; 515:568-71; PMID:25428505; http://dx.doi.org/10.1038/ nature13954 11.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2014; 2; PMID:24829760; http://dx.doi.org/10.1186/2051-1426-2-3 12.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
Science 2015; 348:69-74; PMID:25838375; http://dx.doi.org/10.1126/science.aaa4971 13.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2014;371:2189-99; PMID:25409260; http://dx.doi.org/10.1056/NEJMoa1406498 14.,OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
Sci- ence 2015; PMID:25765070; http://dx.doi.org/10.1126/science.,OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
Immunity 2014; 41:830-42; PMID:25517615; http://dx.doi.org/10.1016/j.immuni.2014.10.017 17.,OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2010; 207:823- 36; PMID:20351058; http://dx.doi.org/10.1084/jem.20091627 18.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2012; 21:402-17; PMID:22439936; http://dx.doi.org/10.1016/j.ccr.2012.01.008 19.,OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2013; 14:1014-22;PMID:24048123; http://dx.doi.org/10.1038/ni.2703 20.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2014; 124:687-95;PMID:24382348; http://dx.doi.org/10.1172/JCI67313 21.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
Cell Rep. 2015; 11:1018-30; PMID:25959818; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2014; 134:563-74; PMID:23873187; http://dx.doi.org/10.1002/ijc.28391 23.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2012; 72:1070- 80; PMID:22266112; http://dx.doi.org/10.1158/0008-5472.CAN-11- 3218e1086862-6 S. SPRANGER AND T. F. GAJEWSKI,OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2015; in press; PMID:26109379; http://dx.doi.org/10.1038/ ncomms8458 25.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
Nature 2015; PMID:25970248; http://dx.doi.org/10.1038/nature14404 26.,OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
Genesis 2006; 44:262-7; PMID:16676322; http://dx.doi.org/10.1002/dvg.20205 27.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2011; 20:741-54; PMID:22172720; http://dx.doi.org/10.1016/j.ccr.2011.10.030 28.,OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2009; 41:544-52; PMID:19282848; http://dx.doi.org/ 10.1038/ng.356 29.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2008; 68:9459-68; PMID:19010921; http://dx.doi.org/10.1158/0008-5472.CAN-08-2634 30.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2002; 3:991-8; PMID:12407406; http://dx.doi.org/10.1038/ni1102-991 31.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2004; 10:48-54; PMID:14702634; http://dx.doi.org/10.1038/nm976 32.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2005; 174:3925-31; PMID:15778348;http://dx.doi.org/10.4049/jimmunol.174.7.3925 33.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
Cell Rep. 2014; 9:75-89; PMID:25263564; http://dx.doi.org/10.1016/j.celrep.2014.08.044 34.,OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2012;72:2990-9; PMID:22659452; http://dx.doi.org/10.1158/0008-5472.CAN-11-4062 35.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
Nature2007; 445:656-60; PMID:17251933; http://dx.doi.org/10.1038/ nature05529 36.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2013; 210:2057-69; PMID:24043758; http://dx.doi.org/10.1084/jem.20130783 37.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2015; 13:493-501; PMID:25351767; http://dx.doi.org/10.1158/1541-7786.MCR-14-0387 38.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2006; 25:6817-30; PMID:17072330; http://dx.doi.org/10.1038/sj.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2012; 246:327-45; PMID:22435564; http://dx.doi.org/10.1111/j.1600-065X.2012.01095.x 40.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
Nature 2004; 431:461-6; PMID:15329734; http://dx.doi.org/10.1038/nature02924 41.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2004; 118:285-96;PMID:15294155; http://dx.doi.org/10.1016/j.cell.2004.07.013 42.,OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2012; 72:3735-43;PMID:22593190; http://dx.doi.org/10.1158/0008-5472.CAN-11-4136 43.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2011; 19:715-27; PMID:21665146; http://dx.doi.org/10.1016/j.ccr.2011.04.016 44.,OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
Science 2013; 339:286-91; PMID:23329041; http://dx.doi.org/10.1126/science.1232227 45.,OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
Nat Med.2015; 21:117-9; PMID:25654601; http://dx.doi.org/10.1038/nm.3794 46.,OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2014; 2:361-70; PMID:24764583; http://dx.doi.org/10.1158/2326- 6066.CIR-13-0127 47.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2005; 79:3675-83; PMID:15731261; http://dx.doi.org/10.1128/ JVI.79.6.3675-3683.2005 48.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2015; 7:271ps1; PMID:25609166; http://dx.doi.org/ 10.1126/scitranslmed.3010473 49.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
Oncoimmunology 2012; 1:520-5;PMID:22754772; http://dx.doi.org/10.4161/onci.19531 50.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2012; 10:170; PMID:22909381; http://dx.doi.org/10.1186/1479-5876-10-170 51.,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
2015; 112:2841-6; PMID:25730878; http://dx.doi.org/10.1073/ pnas.1424869112ONCOIMMUNOLOGY e1086862-7,Non-OADS,/arxiv_data1/oa_pdf/d5/d2/koni-05-03-1086862.PMC4839364.pdf
"3, e1091147 (5 pages)http://dx.doi.org/10.1080/2162402X.2015.1091147",Non-OADS,/arxiv_data1/oa_pdf/0f/d9/koni-05-03-1091147.PMC4839365.pdf
Cell 2011; 144:646 –74; PMID:21376230; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/0f/d9/koni-05-03-1091147.PMC4839365.pdf
Nat Rev Immunol 2006; 6:836 –48; PMID:17063185; http://dx.doi.org/10.1038/nri1961 4.,Non-OADS,/arxiv_data1/oa_pdf/0f/d9/koni-05-03-1091147.PMC4839365.pdf
Nat Immunol 2002; 3:991 –8; PMID:12407406; http://dx.doi.org/ 10.1038/ni1102-991 5.,Non-OADS,/arxiv_data1/oa_pdf/0f/d9/koni-05-03-1091147.PMC4839365.pdf
J Exp Med 2011; 208:1989 –2003; PMID:21930769; http://dx.doi.org/10.1084/jem.20101158 6 .,Non-OADS,/arxiv_data1/oa_pdf/0f/d9/koni-05-03-1091147.PMC4839365.pdf
Nat Immunol 2005; 6:722 –9; PMID:15951814; http://dx.doi.org/ 10.1038/ni1213 7.,Non-OADS,/arxiv_data1/oa_pdf/0f/d9/koni-05-03-1091147.PMC4839365.pdf
Eur J Immunol 1986; 16:370 –5; PMID:2422040; http://dx.doi.org/10.1002/eji.1830160410 8.,Non-OADS,/arxiv_data1/oa_pdf/0f/d9/koni-05-03-1091147.PMC4839365.pdf
Acta Oncol 2006; 45:389 –99; PMID:16760174; http://dx.doi.org/10.1080/02841860600630954 10.,Non-OADS,/arxiv_data1/oa_pdf/0f/d9/koni-05-03-1091147.PMC4839365.pdf
Lancet Oncol 2011; 12:419; PMID:21536217; http://dx.doi.org/10.1016/S1470-2045(11)70107-3 11.,Non-OADS,/arxiv_data1/oa_pdf/0f/d9/koni-05-03-1091147.PMC4839365.pdf
Vaccine 2007; 25 Suppl 2:B97 –B109; PMID:17916465; http://dx.doi.org/10.1016/j.vaccine.2007.06.067 12.,Non-OADS,/arxiv_data1/oa_pdf/0f/d9/koni-05-03-1091147.PMC4839365.pdf
Proc Natl Acad SciU S A 2008; 105:3005 –10; PMID:18287062; http://dx.doi.org/10.1073/ pnas.0712237105 13.,Non-OADS,/arxiv_data1/oa_pdf/0f/d9/koni-05-03-1091147.PMC4839365.pdf
Ann Oncol 2013; 24(8):2174 –80; PMID:25210016; http://dx.doi.org/ 10.1093/annonc/mdu441 14.,Non-OADS,/arxiv_data1/oa_pdf/0f/d9/koni-05-03-1091147.PMC4839365.pdf
J Clin Oncol 2010; 28:1099 –105; PMID:20100959; http://dx.doi.org/10.1200/JCO.2009.25.0597 16.,Non-OADS,/arxiv_data1/oa_pdf/0f/d9/koni-05-03-1091147.PMC4839365.pdf
Cancer Immunol Immunother 2013; 62:1547 –51; PMID:23979447; http://dx.doi.org/10.1007/s00262- 013-1458-y 18.,Non-OADS,/arxiv_data1/oa_pdf/0f/d9/koni-05-03-1091147.PMC4839365.pdf
Cancer 2015; 121:335 –8; PMID:25278175; http://dx.doi.org/10.1002/cncr.29031ONCOIMMUNOLOGY e1091147-5,Non-OADS,/arxiv_data1/oa_pdf/0f/d9/koni-05-03-1091147.PMC4839365.pdf
"Evidence of clinical and © Archana Thakur and Lawrence G Lum *Correspondence to: Archana Thakur; Email: thakur@karmanos.orgSubmitted: 05/20/2015; Accepted: 05/21/2015 http://dx.doi.org/10.1080/2162402X.2015.1055061 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/86/75/koni-05-03-1055061.PMC4839366.pdf
N Engl J Med 2013; 368:1509-18; PMID:23527958; http://dx.doi.org/10.1056/NEJMoa1215134 2.,OADS,/arxiv_data1/oa_pdf/86/75/koni-05-03-1055061.PMC4839366.pdf
Blood 2010; 116:4099- 102; PMID:20668228; http://dx.doi.org/10.1182/blood-2010-04-281931 3.,Non-OADS,/arxiv_data1/oa_pdf/86/75/koni-05-03-1055061.PMC4839366.pdf
Sci- ence 2015; 348:62-8; PMID:25838374; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/86/75/koni-05-03-1055061.PMC4839366.pdf
Cancer 2007; 110:973-9;PMID:17647245; http://dx.doi.org/10.1002/ cncr.22867 5.,Non-OADS,/arxiv_data1/oa_pdf/86/75/koni-05-03-1055061.PMC4839366.pdf
J Hematother Stem Cell Res 2001; 10:247-60; PMID:11359672; http://dx.doi.org/ 10.1089/15258160151134944 6.,Non-OADS,/arxiv_data1/oa_pdf/86/75/koni-05-03-1055061.PMC4839366.pdf
Clin Prostate Cancer 2004; 3:112-21;PMID:15479495; http://dx.doi.org/10.3816/ CGC.2004.n.021 7.,Non-OADS,/arxiv_data1/oa_pdf/86/75/koni-05-03-1055061.PMC4839366.pdf
Clin Cancer Res 2015; 21:2305-14;PMID:25688159; http://dx.doi.org/10.1158/1078- 0432.CCR-14-2280 8.,Non-OADS,/arxiv_data1/oa_pdf/86/75/koni-05-03-1055061.PMC4839366.pdf
Cancer Res 2013; 73:3489-93; PMID:23740771; http://dx.doi.org/ 10.1158/0008-5472.CAN-13-0260 9.,Non-OADS,/arxiv_data1/oa_pdf/86/75/koni-05-03-1055061.PMC4839366.pdf
Clinl Cancer Res 2006; 12:569-76; PMID:16428502; http://dx.doi.org/10.1158/1078-0432.CCR-05-2005 10.,Non-OADS,/arxiv_data1/oa_pdf/86/75/koni-05-03-1055061.PMC4839366.pdf
J Transl Med 2013; 11:35; PMID:23394575; http://dx.doi.org/10.1186/1479- 5876-11-35 www.tandfonline.com e1055061-3 OncoImmunology,Non-OADS,/arxiv_data1/oa_pdf/86/75/koni-05-03-1055061.PMC4839366.pdf
"4, e1105429 (11 pages)http://dx.doi.org/10.1080/2162402X.2015.1105429",Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Science 1996; 274:373-6; PMID:8832876; http://dx.doi.org/10.1126/ science.274.5286.373 2.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Nat Med 2000; 6:1134-9; PMID:11017145; http://dx.doi.org/10.1038/80474 3.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Mol Ther 2011; 19:1558-68; PMID:21468000; http://dx.doi.org/10.1038/mt.2011.29 4.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Mol Ther 2007; 15:386-92; PMID:17235318; http://dx.doi.org/10.1038/sj.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Cancer Res 2010;70:4297-309; PMID:20484030; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Mol Ther 2011; 19:1737-46; PMID:21673660; http://dx.doi.org/10.1038/mt.2011.113 7.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
PLoS One 2013; 8:e67512;PMID:23844018; http://dx.doi.org/10.1371/journal.pone.0067512 8.,OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Hum Gene Ther 2015; 26(3):134-44;PMID:25557131; http://dx.doi.org/10.1089/hum.2014.069 9.,OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Cancer Res 2012; 72:2327-38; PMID:22396493; http://dx.doi.org/10.1158/0008-5472.CAN-11-2975 10.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Cancer Gene Ther 2014; 21:95- 102; PMID:24481488; http://dx.doi.org/10.1038/cgt.2014.2 11.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Int J Cancer 2012; 130:1937-47; PMID:21630267; http://dx.doi.org/10.1002/ijc.26216 12.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Mol Ther 2010; 18:1874-84; PMID:20664527; http://dx.doi.org/10.1038/mt.2010.161e1105429-10 C. CAPASSO ET AL.,OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Eur J Immunol 2009; 39:2725-36; PMID:19637230; http://dx.doi.org/10.1002/eji.200939543 14.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Clin Diagn Lab Immunol 2004; 11:351-7;PMID:15013987; http://dx.doi.org/10.1128/CDLI.11.2.351 –357.2004 15.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
J Cell Biochem 2009; 108:778-90; PMID:19711370; http://dx.doi.org/10.1002/jcb.22328 16.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
J Biol Chem 1997; 272:6479-89; PMID:9045673; http://dx.doi.org/10.1074/jbc.272.10.6479 17.,OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Cell 1988; 54:777-85; PMID:3261634; http://dx.doi.org/10.1016/S0092-8674(88)91043-4 18.,OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Mol Ther 2012; 20:2076-86; PMID:22828500; http://dx.doi.org/10.1038/mt.2012.137 20.,OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
J Exp Med 1998; 188:277-86; PMID:9670040; http://dx.doi.org/10.1084/jem.188.2.277 21.,OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Curr Protoc Immunol 2001; Chapter 20:Unit 20 1;PMID:18432774; http://dx.doi.org/10.1002/0471142735.im2001s39 22.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Oncoim- munology 2013; 2:e24850; PMID:24073369; http://dx.doi.org/10.4161/onci.24850 23.,OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Oncoimmunology 2013; 2:e26621;PMID:24498550; http://dx.doi.org/10.4161/onci.26621 24.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
TrialWatch: Adoptive cell transfer for anticancer immunotherapy.Oncoimmunology 2014; 3:e28344; PMID:25050207; http://dx.doi.org/ 10.4161/onci.28344 25.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
J Pharm Sci 2013; 102:1981-93; PMID:23592439;http://dx.doi.org/10.1002/jps.2355627.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Nat Rev Immunol 2001; 1:126-34; PMID:11905820;http://dx.doi.org/10.1038/35100512 28.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Nat Rev Immunol 2012; 12:557-69; PMID:22790179; http://dx.doi.org/10.1038/nri3254 29.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
J Immunol 2009; 182:4601-7; PMID:19342634; http://dx.doi.org/10.4049/jimmunol.0803806 30.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Viruses 2014; 6:832-55; PMID:24549268; http://dx.doi.org/10.3390/v6020832 31.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Viruses 2010; 2:468-502; PMID:21994645; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
J Pharm Sci 2011; 100:388-401; PMID:20740674; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
JImmunother 2013; 36:11-9; PMID:23211625; http://dx.doi.org/ 10.1097/CJI.0b013e3182787f5e 34.,OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Cancer Lett 2012; 325:155-64; PMID:22809568; http://dx.doi.org/10.1016/j.canlet.2012.07.012 36.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Nat Med 2012; 18(8):1254-61; PMID:22842478; http://dx.doi.org/10.1038/nm.2883 37.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Immunogenetics 2008; 60:439-47; PMID:18545995; http://dx.doi.org/10.1007/s00251-008-0303-5 38.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
J Natl Cancer Inst 2006; 98:625-36; PMID:16670388; http://dx.doi.org/ 10.1093/jnci/djj161 39.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Mol Ther 2013; 21:1212-23;PMID:23546299; http://dx.doi.org/10.1038/mt.2013.51 40.,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
Mol Ther 2003; 8:449-58; PMID:12946318;http://dx.doi.org/10.1016/S1525-0016(03)00200-4ONCOIMMUNOLOGY e1105429-11,Non-OADS,/arxiv_data1/oa_pdf/59/6e/koni-05-04-1105429.PMC4839367.pdf
"4, e1115178 (11 pages)http://dx.doi.org/10.1080/2162402X.2015.1115178",Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Bone Marrow Trans- plant 2013; 48:433-8; PMID:22941380; http://dx.doi.org/10.1038/ bmt.2012.162 2.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Blood 2005; 105:3051-7;PMID:15632206; http://dx.doi.org/10.1182/blood-2004-07-2974 3.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Science 2002; 295:2097-100; PMID:11896281; http://dx.doi.org/10.1126/science.1068440 4.,OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Front Immunol 2013; 4:15; PMID:23378843; http://dx.doi.org/10.3389/ ﬁmmu.2013.00015 5.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Oncoimmunology 2014; 3:e28147; PMID:25340009; http://dx.doi.org/ 10.4161/onci.28147 6.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Front Pharmacol 2015; 6:21; PMID:25729364; http://dx.doi.org/10.3389/fphar.2015.00021 7.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
J Immunother 2010; 33:200-10; PMID:20145545;http://dx.doi.org/10.1097/CJI.0b013e3181bb46f7 8.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
PloS One 2011; 6:e27351; PMID:22096557; http://dx.doi.org/10.1371/journal.pone.00273519.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Eur J Immu- nol 2010; 40:3255-67; PMID:21061445; http://dx.doi.org/10.1002/ eji.201040568 10.,OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Oncoimmunology 2013; 2: e26097; PMID:24353908; http://dx.doi.org/10.4161/onci.26097 11.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Cancer Immunol Immunother 2014; 63:821-33; PMID:24806448; http://dx.doi.org/10.1007/s002- 62-014-1556-5 12.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
J Cell Mol Med 2012; 16:569-81; PMID:21595822; http://dx.doi.org/10.1111/j.1582-4934.2011.01343.x 13.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Mol Ther 2015; 23:330-8; PMID:25373520; http://dx.doi.org/10.1038/mt.2014.219 14.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Cytotherapy 2010; 12:750-63; PMID:20491532; http://dx.doi.org/10.3109/14653241003786155 15.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Transfusion 2009; 49: 362-71; PMID:19389215; http://dx.doi.org/10.1111/j.1537-2995.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Blood 2008; 111:3155-62; PMID:18192509;http://dx.doi.org/10.1182/blood-2007-09-110312 17.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Cytotherapy 2010; 12:1044-55; PMID:20795758; http://dx.doi.org/10.3109/14653249.2010.504770 18.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
2015 Jun; 17(6):739-48; http://dx.doi.org/10.1016/j.jcyt.2015.03.005 19.,OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
PloS One 2010; 5:e9221; PMID:20169160; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
"Cany J, van der Waart AB, Spanholtz J, Tordoir M, Jansen JH, van der Voort R, Schaap NM, Dolstra H. Combined IL-15 and IL-12 drives the generation of CD34-derived natural killer cells with superior mat-uration and alloreactivity potential following adoptive transfer.Oncoimmunology 2015; 4:e1017701; PMID:26140247; http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
PloS One 2011; 6:e20740; PMID:21698239; http://dx.doi.org/10.1371/journal.pone.00-20740e1115178-8 U. KOEHL ET AL.,OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Front Immunol 2014;5:95; PMID:24672522; http://dx.doi.org/10.3389/ ﬁmmu.2014.00095 23.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
PloS One 2013; 8:e76781; PMID:24204673; http://dx.doi.org/10.1371/journal.pone.0076781 25.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Blood2014; 124:403-11; PMID:24891320; http://dx.doi.org/10.1182/blood- 2013-05-499707 26.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Adv Exp Med Biol 2014; 804:341-53; PMID:24924184; http://dx.doi.org/10.1007/ 978-3-319-04843-7_19 27.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Cytother- apy 2011; 13:98-107; PMID:20849361; http://dx.doi.org/10.3109/14653249.2010.515582 28.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Cancer ImmunolImmunother 2010; 59:1739-44; PMID:20680271; http://dx.doi.org/ 10.1007/s00262-010-0896-z 29.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Clin Cancer Res 2013; Jul 15; 19(14):3844-55; PMID:23690482; http://dx.doi.org/10.1158/1078-0432.CCR-13-0505 30.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Hematology Am Soc Hematol Educ Program 2013; 2013:247-53; PMID:24319187; http://dx.doi.org/10.1182/asheducation-2013.1.247 31.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
PloS One 2015; 10:e0123416;PMID:26062124; http://dx.doi.org/10.1371/journal.pone.0123416 32.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
JImmunol 2011; 187:6227-34; PMID:22084431; http://dx.doi.org/ 10.4049/jimmunol.1101640 34.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Front Immunol 2013; 4:408; PMID:24324471; http://dx.doi.org/10.3389/ ﬁmmu.2013.00408 35.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Leukemia 2005; 19:835-40; PMID: 15744340; http://dx.doi.org/10.1038/sj.leu.2403704 37.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Cytother- apy 2013; 15:1563-70; PMID:24094496; http://dx.doi.org/10.1016/j.jcyt.2013.06.017 38.,OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Cytotherapy 2015; 17:245-9; PMID:25533934; http://dx.doi.org/10.1016/j.jcyt.2014.09.007 39.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Cytotherapy 2003; 5:259-72; PMID:12850795; http://dx.doi.org/10.1080/14653240310001523 40.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Cytotherapy 2013; 15:1185-94; PMID:23768925;http://dx.doi.org/10.1016/j.jcyt.2013.03.011 41.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Transfusion2013; 53:398-403; PMID:22574659; http://dx.doi.org/10.1111/j.1537- 2995.2012.03695.x 42.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Transfusion 2013; 53:412-8; quiz 1; PMID:22738379; http://dx.doi.org/10.1111/j.1537-2995.2012.03764.x 43.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Oncoimmunology 2012; 1:1223-5; PMID:23243584; http://dx.doi.org/10.4161/onci.21335 44.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Immunotherapy 2014; 6:95-106; PMID:24341888; http://dx.doi.org/ 10.2217/imt.13.152 45.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Blood 2011; 118:3273-9; PMID:21791425; http://dx.doi.org/10.1182/blood-2011-01-329508 46.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Clin Cancer Res 2014; 20:3390-400; PMID:24987108; http://dx.doi.org/10.1158/1078-0432.CCR-13-1766 47.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Br J Haematol 2011; 155:14-29; PMID:21812770; http://dx.doi.org/10.1111/j.1365- 2141.2011.08823.x 48.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
J Immunol 2004; 172:644-50; PMID:14688377; http://dx.doi.org/10.4049/jimmunol.172.1.644 49.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Eur JImmunol 2014; 44:2192-6; PMID:24723455; http://dx.doi.org/ 10.1002/eji.201444464 50.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Blood2010; 116:2411-9; PMID:20581313; http://dx.doi.org/10.1182/blood-2010-05-283051 51.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
J ClinOncol 2013; 31:3782-90; PMID:24043749; http://dx.doi.org/10.1200/ JCO.2012.47.4007 52.,OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Clin Cancer Res 2014; 20:5986-94;PMID:25281696; http://dx.doi.org/10.1158/1078-0432.CCR-14-0479 53.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
J Immunol 2014; 192:4592-600; PMID:24748496; http://dx.doi.org/10.4049/jimmunol.1302517 54.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Immunol Rev 2014; 258:45-63; PMID:24517425; http://dx.doi.org/10.1111/imr.12157 55.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
J Immunol 2005; 174:6540-5; PMID:15879158; http://dx.doi.org/10.4049/jimmunol.174.10.6540 56.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Blood2009; 114:5182-90; PMID:19828694; http://dx.doi.org/10.1182/blood- 2009-07-231977 57.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Blood 2002; 99:754-8; PMID:11806974; http://dx.doi.org/ 10.1182/blood.V99.3.754 58.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Clin Cancer Res 2011; 17:6287-97; PMID:21844012; http://dx.doi.org/10.1158/1078-0432.CCR-11-1347 59.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
CancerRes 2009; 69:4010-7; PMID:19383914; http://dx.doi.org/10.1158/ 0008-5472.CAN-08-3712 60.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Cytother- apy 2009; 11:341-55; PMID:19308771; http://dx.doi.org/10.1080/14653240902807034 61.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
J Cancer 2011; 2:383-5;PMID:21750690; http://dx.doi.org/10.7150/jca.2.383 62.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
J Hematother Stem Cell Res 2002; 11:651-7; PMID:12201953;http://dx.doi.org/10.1089/15258160260194794 63.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Cyto-therapy 2008; 10:625-32; PMID:18836917; http://dx.doi.org/10.1080/ 14653240802301872 64.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Cytotherapy 2004; 6:15-22; PMID: 14985163; http://dx.doi.org/10.1080/14653240310004548 65.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Cytotherapy 2003; 5:479-84; PMID:14660043; http://dx.doi.org/ 10.1080/14653240310003558 66.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
PloS One 2013; 8:e53611; PMID:23326467;http://dx.doi.org/10.1371/journal.pone.005361167.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Front Oncol 2013; 3:118; PMID:23730623; http://dx.doi.org/10.3389/fonc.2013.00118 68.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Cyto- therapy 2012; 14:1131-43; PMID:22900959; http://dx.doi.org/10.3109/14653249.2012.700767 69.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Leukemia 2012; 26:1149-52; PMID:22143670;http://dx.doi.org/10.1038/leu.2011.345 70.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Cyto-therapy 2015; 17:621-32; PMID:25881519; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Leukemia 2004; 18:1835-8; PMID:15457184; http://dx.doi.org/10.1038/sj.leu.2403524 72.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
J Clin Oncol2010; 28:955-9; PMID:20085940; http://dx.doi.org/10.1200/JCO.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Clin Cancer Res 2006; 12:6079-86; PMID:17028247; http://dx.doi.org/10.1158/1078-0432.CCR-06-0114 74.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Clin Cancer Res 2004; 10:3699- 707; PMID:15173076; http://dx.doi.org/10.1158/1078-0432.CCR-03- 0683 75.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Bone Marrow Transplant 2010; 45:1038-46; PMID: 19881555; http://dx.doi.org/10.1038/bmt.2009.304 76.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Immunotherapy 2009; 1:753-64; PMID:20636021; http://dx.doi.org/10.2217/imt.09.47 77.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Blood Cells Mol Dis 2004; 33:261-6; PMID:15528141;http://dx.doi.org/10.1016/j.bcmd.2004.08.013 78.,OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
J Immunother 2015; 38:24-36; PMID: 25415285; http://dx.doi.org/10.1097/CJI.0000000000000059 79.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Cancer Immunol Immun- other 2010; 59:1781-9; PMID:20703455; http://dx.doi.org/10.1007/s00262-010-0904-3e1115178-10 U. KOEHL ET AL.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Blood 2015; 125:784-92; PMID:25452614; http://dx.doi.org/10.1182/blood-2014-07-592881 81.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Blood 2015; 125:744-5; PMID:25634612; http://dx.doi.org/10.1182/blood-2014-12- 616359 82.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Cytotherapy 2011; 13(6):767-8; PMID:21375422; http://dx.doi.org/10.3109/14653249.2011.563295.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
J Exp Med 2012; 209:2351-65; http://dx.doi.org/10.1084/jem.2012094486.,OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
Cytometry B Clin Cytom 2013; 84:135-42; PMID:23554222;http://dx.doi.org/10.1002/cyto.b.21079 88.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
J Immunol Methods 2005; 296:63-76; PMID:15680151; http://dx.doi.org/10.1016/j.jim.2004.10.014 89.,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
J Immu- nol Methods 2007; 325:140-7; PMID:17663991; http://dx.doi.org/10.1016/j.jim.2007.06.013ONCOIMMUNOLOGY e1115178-11,Non-OADS,/arxiv_data1/oa_pdf/7d/1c/koni-05-04-1115178.PMC4839369.pdf
"4, e1093276 (13 pages)http://dx.doi.org/10.1080/2162402X.2015.1093276",Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
34ULBP2 harbors several single nucleotide polymorphismsresulting in amino acid substitutions (see http://www.ncbi.nlm.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
AnnNeurol 2011; 70:9-21; PMID:21786296; http://dx.doi.org/10.1002/ana.22425 2.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Front Oncol 2013; 3:275; PMID:24273748; http://dx.doi.org/10.3389/fonc.2013.00275 3.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Oncoimmunology 2013; 2: e26097; PMID:24353908; http://dx.doi.org/10.4161/onci.26097 5.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Immunol Rev 2010; 235:267-85; PMID:20536569; http://dx.doi.org/10.1111/j.0105-2896.2010.00893.x 6.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Ann Rev Immunol 2013; 31:413-41; PMID:23298206; http://dx.doi.org/10.1146/ annurev-immunol-032712-095951 7.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Onco- gene 2008; 27:5944-58; PMID:18836475; http://dx.doi.org/10.1038/ onc.2008.272ONCOIMMUNOLOGY e1093276-11,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
NeuroOncol 2010; 12:7-13; PMID:20150362; http://dx.doi.org/10.1093/neuonc/nop009 10.,OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
J Exp Med 2013; 210:2675-92; PMID:24190430; http://dx.doi.org/10.1084/jem.20122292 11.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Cancer Res 2008; 68:6368-76; PMID:18676862; http://dx.doi.org/10.1158/0008-5472.CAN-07-6768 12.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Int J Cancer 2013; 133:1557-66; PMID:23526433; http://dx.doi.org/10.1002/ijc.28174 13.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
NeuroOncol 2014; 16:382-91;PMID:24327582; http://dx.doi.org/10.1093/neuonc/not232 14.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Scand J Immunol 2013; 78:120-9;PMID:23679194; http://dx.doi.org/10.1111/sji.12072 15.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
CurrMolPharmacol 2012; 5:102-14;PMID:22122467; http://dx.doi.org/10.2174/1874467211205010102 16.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
PloS One 2013; 8:e51805; PMID:23326319; http://dx.doi.org/10.1371/journal.pone.0051805 17.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Blood 2012; 120:2269-79; PMID:22767497; http://dx.doi.org/10.1182/blood-2012-05-430470 18.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Nat Immunol 2013; 14:908-16; PMID:23872678; http://dx.doi.org/10.1038/ni.2665 19.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
J Immunol 2013; 191:1029-42; PMID:23833237; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
J Exp Med 2003; 197:163-8; PMID:12538656; http://dx.doi.org/10.1084/jem.20021500 21.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Cancer Res 2007; 67:5-8; PMID:17210676; http://dx.doi.org/10.1158/0008-5472.CAN-06-3069 22.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Scand J Immunol 2007; 66:320-8; PMID:17635809; http://dx.doi.org/10.1111/j.1365-3083.2007.01963.x 23.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
J Neurooncol 2011; 101:179-88;PMID:20532954; http://dx.doi.org/10.1007/s11060-010-0245-2 24.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Cancer Res 2010; 70:481-9; PMID:20068167; http://dx.doi.org/10.1158/0008-5472.CAN-09-1688 25.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Blood 2003; 102:1186-95; PMID:12714508; http://dx.doi.org/10.1182/blood-2002-12-3775 27.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
NeuroOn- col 2009; 11:357-67; PMID:19211933; http://dx.doi.org/10.1215/15228517-2008-111 28.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Immunology 2009; 128:1-6; PMID:19689730; http://dx.doi.org/10.1111/j.1365-2567.2009.03147.x 31.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
J Immunol 2009; 182:4800-8; PMID:19342658; http://dx.doi.org/10.4049/jimmunol.0800713 32.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Eur J Immunol2011; 41:3667-76; PMID:21928280; http://dx.doi.org/10.1002/ eji.201141645 33.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Crit Rev Biochem- MolBiol 2010; 45:146-69; PMID:20184396; http://dx.doi.org/10.3109/ 10409231003628015 34.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Genes Dev 2003; 17:7-30; PMID:12514095; http://dx.doi.org/10.1101/gad.1039703 35.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Front Biosci 2008; 13:3448-56;PMID:18508446; http://dx.doi.org/10.2741/2939 37.,OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
"J Transl Med 2012; 10:134;PMID:22738135; http://dx.doi.org/10.1186/1479-5876-10-134 3 8 .J i n u s h iM ,H o d iF S ,D r a n o f fG .T herapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppres-sion and stimulate antitumor cytotoxicity.",Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Proc Nat AcadSci USA2006; 103:9190-5; PMID:16754847; http://dx.doi.org/10.1073/ pnas.0603503103 39.,OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Leukemia 2007; 21:2103-8; PMID:17625602;http://dx.doi.org/10.1038/sj.leu.2404862e1093276-12 G. CHITADZE ET AL.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Modulation of NKG2D- ligand cell surface expression enhances immune cell therapy of cancer.J Immunother 2011; 34:289-96; PMID:21389869; http://dx.doi.org/10.1097/CJI.0b013e31820e1b0d 41.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
J Cancer Res ClinOncol 2005; 131:41-8; PMID:15565459; http://dx.doi.org/10.1007/s00432- 004-0619-y 42.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Clin Cancer Res 2009; 15:1140-4; PMID:19228719; http://dx.doi.org/10.1158/1078-0432.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Cancer Res 2008; 68:7083-9;PMID:18757423; http://dx.doi.org/10.1158/0008-5472.CAN-08-0739 44.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
J ClinOncol 2002; 20:1383-8; PMID:11870183; http://dx.doi.org/10.1200/JCO.20.5.1383 45.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
J Neurooncol 2006; 80:83-90; PMID:16639492; http://dx.doi.org/10.1007/s11060-006-9160-y 46.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Phar- macol Res 2013; 71:19-22; PMID:23415892; http://dx.doi.org/10.1016/ j.phrs.2013.01.012 47.,OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Sci-ence 2015; 348:136-9; PMID:25745066; http://dx.doi.org/10.1126/science.1258867 48.,OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
J LeukocBiol 2011; 89: 75-84; PMID:20952657; http://dx.doi.org/10.1189/jlb.0710413 49.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Cancer Res 2009; 69:8710-7; PMID:19887600; http://dx.doi.org/10.1158/0008-5472.CAN-09-1602 50.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Eur J Immunol 2009; 39:1361-8;PMID:19404979; http://dx.doi.org/10.1002/eji.200838409 51.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
NeuroOncol 2011; 13:393-400; PMID:21339188; http://dx.doi.org/10.1093/neuonc/noq204 52.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Oncol Rep 2011; 25:33- 9; PMID:21109954; http://dx.doi.org/10.3892/or_00001038 53.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Cancer ImmunolImmunother 2008;57:1599-609; PMID:18301889; http://dx.doi.org/10.1007/s00262-008-0491-8 5 4 .,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
ExpHematol 2009; 37:956-68; PMID:19409955; http://dx.doi.org/10.1016/j.exphem.2009.04.008 55.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Cancer ImmunolImmunother 2007;56:469-76; PMID:16850345; http://dx.doi.org/10.1007/s00262-006-0199-6 56.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Br J Cancer 2011; 105:778-86; PMID:21847128; http://dx.doi.org/10.1038/bjc.2011.293 57.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Cancer Res 2014; 74:1349-60; PMID:24448235; http://dx.doi.org/10.1158/ 0008-5472.CAN-13-0675 58.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
Blood 2003; 102:1389-96; PMID:12714493; http://dx.doi.org/10.1182/blood-2003-01-0019 59.,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
ClinDiagnLaboImmunol 2001; 8:1131-5; PMID:11687452; http://dx.doi.org/10.1128/CDLI.8.6.1131 –1135.2001ONCOIMMUNOLOGY e1093276-13,Non-OADS,/arxiv_data1/oa_pdf/09/e5/koni-05-04-1093276.PMC4839372.pdf
"3, e1100791 (15 pages)http://dx.doi.org/10.1080/2162402X.2015.1100791",Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Cancer Res 2007; 67:10669-76;PMID:18006808; http://dx.doi.org/10.1158/0008-5472.CAN-07-0539 2.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
J Transl Med 2013; 11:145; PMID:23758773; http://dx.doi.org/10.1186/1479-5876-11-145 3.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Genome Biol 2007; 8:R157; PMID:17683518; http://dx.doi.org/10.1186/gb-2007-8- 8-r157 4.,OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
J Clin Oncol 2011; 29:1949-55; PMID:21483002; http://dx.doi.org/10.1200/JCO.2010.30.5037 5.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Cancer Res 2013; 73:4629-40; PMID:23722543; http://dx.doi.org/10.1158/0008-5472.CAN-12-3058 6.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Cancer Res 2012; 72:5188-97; PMID:22836755; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Int J Cancer 2013; 133:771-8; PMID:23389942; http://dx.doi.org/10.1002/ijc.28072 8.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Cancer Res 2011; 71:6143- 52; PMID:21852386; http://dx.doi.org/10.1158/0008-5472.CAN-11-0573 9.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Cancer Res 2012; 72:6130-41; PMID:23026134; http://dx.doi.org/10.1158/0008-5472.CAN-12-2409 10.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Cancer Res 2009; 69:2000-9;PMID:19244125; http://dx.doi.org/10.1158/0008-5472.CAN-08-2360 11.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Oncoimmunology 2012; 1:432-40; PMID:22754761; http://dx.doi.org/10.4161/onci.19545ONCOIMMUNOLOGY e1100791-13,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Eur J Cancer 2013; 49:1673-82; PMID:23265706; http://dx.doi.org/10.1016/j.ejca.2012.11.028 14.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Breast Cancer Res Treat 1993; 26:77-88; PMID:8400326; http://dx.doi.org/10.1007/BF00682702 15.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
BreastCancer Res Treat 2005; 91:163-71; PMID:15868444; http://dx.doi.org/ 10.1007/s10549-004-7048-0 16.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Cancer Immunol Immunother 1999; 48:435-42; PMID:10550548; http://dx.doi.org/10.1007/s002620050620 17.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
J Transl Med 2013; 11:16; PMID:23320561; http://dx.doi.org/10.1186/1479-5876-11-16 18.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Br J Can- cer 2009; 100:1061-7; PMID:19277040; http://dx.doi.org/10.1038/sj.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
"Piccioli D, Tavarini S, Borgogni E, Steri V, Nuti S, Sammicheli C, Bar- delli M, Montagna D, Locatelli F, Wack A. Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets.Blood 2007; 109:5371-9; PMID:17332250; http://dx.doi.org/10.1182/blood-2006-08-038422 20.",Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
J Immunol 2014; 193:1622-35; PMID:25009205; http://dx.doi.org/10.4049/jimmunol.1401243 21.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
J Exp Med 2010; 207:2703-17; PMID:20975040; http://dx.doi.org/10.1084/jem.20092720 22.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
J Exp Med 2010; 207:1273-81; PMID:20479115; http://dx.doi.org/10.1084/jem.20100348 23.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Int J Cancer 2015; 136:1085-94; PMID:25046660; http://dx.doi.org/10.1002/ijc.29087 24.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
J Exp Med 2010; 207:1247-60; PMID:20479116; http://dx.doi.org/10.1084/jem.20092140 25.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
J Exp Med 2010; 207:1261-71; PMID:20479117; http://dx.doi.org/10.1084/jem.20092618 26.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Annu Rev Immunol 2011; 29:163-83; PMID:21219184; http://dx.doi.org/10.1146/annurev- immunol-031210-101345 27.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Br J Can-cer 2003; 89:1463-72; PMID:14562018; http://dx.doi.org/10.1038/sj.bjc.6601243 28.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Cancer Immunol Immunother 2004; 53:1146-52;PMID:15185014; http://dx.doi.org/10.1007/s00262-004-0556-2 29.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Annu Rev Immunol 2015; 33:445-74; PMID:25622193; http://dx.doi.org/10.1146/annurev-immunol-032414-112043 30.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
J Exp Med 2002; 195:327-33; PMID:11828007;http://dx.doi.org/10.1084/jem.20010938 31.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Immunol Rev 2006; 214:219-28;PMID:17100887; http://dx.doi.org/10.1111/j.1600-065X.2006.00450.x 32.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
J Clin Invest 2011; 121:3609- 22; PMID:21841316; http://dx.doi.org/10.1172/JCI45816 33.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Immunity 2014; 41:815-29;PMID:25453823; http://dx.doi.org/10.1016/j.immuni.2014.09.014 34.,OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
J Leukoc Biol 2012; 92:673-82; PMID:22636320; http://dx.doi.org/10.1189/jlb.0112048 35.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
J Immunol Methods 2008; 339:153-64; PMID:18835394; http://dx.doi.org/10.1016/j.jim.2008.09.009 36.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Immunity 2014; 40:436-50; PMID:24656047; http://dx.doi.org/10.1016/j.immuni.2014.03.002 37.,OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
J Leukoc Biol 2013; 93:599-609; PMID:23341538; http://dx.doi.org/10.1189/jlb.0912452 38.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
J Immunol Methods 2006; 310:86-99; PMID:16455104; http://dx.doi.org/10.1016/j.jim.2005.12.008 39.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
BMC Med Res Methodol 2012; 12:112; PMID:22853196; http://dx.doi.org/10.1186/1471-2288-12-112 40.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
J Immunol Methods 2012; 376:79-88; PMID:22155193; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
J Immunol Methods 2008; 336:183-92; PMID:18565537; http://dx.doi.org/10.1016/j.jim.2008.04.013 4 2 .,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Cytometry A 2008; 73:975-83; PMID:18785267; http://dx.doi.org/10.1002/cyto.a.20643 43.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Blood 2010; 116:e74-e80; PMID:20628149; http://dx.doi.org/10.1182/blood-2010-02-258558 44.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
J Immunol 2010; 185:2080-8;PMID:20639488; http://dx.doi.org/10.4049/jimmunol.1000532 45.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Int Immunol 2006; 18:1115-26; PMID:16728430; http://dx.doi.org/10.1093/intimm/dxl046 46.,OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Immunology 2006; 117:38-46; PMID:16423039; http://dx.doi.org/10.1111/j.1365-2567.2005.02261.x 47.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Mol Ther 2008; 16:1300-7; PMID:18443600; http://dx.doi.org/10.1038/mt.2008.88 48.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Exp Hematol 2009; 37:838-48; PMID:19446661; http://dx.doi.org/10.1016/ j.exphem.2009.04.003 49.,OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
J Immunol 2005; 174:727-34; PMID:15634892; http://dx.doi.org/10.4049/jimmunol.174.2.727 50.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Immunity 2012; 37:60- 73; PMID:22795876; http://dx.doi.org/10.1016/j.immuni.2012.04.012 51.,OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Blood 2003; 101:4500- 4; PMID:12560217; http://dx.doi.org/10.1182/blood-2002-11-3569 52.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Eur J Immunol 2001; 31:3026-37;PMID:11592079; http://dx.doi.org/10.1002/1521-4141(2001010) 31:10%3c3026::AID-IMMU3026%3e3.0.CO;2-H 53.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
J Clin Invest 2006; 116:1310-6; PMID:16670770;http://dx.doi.org/10.1172/JCI21404 54.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Annu Rev Immunol 2000; 18:143-64; PMID:10837055; http://dx.doi.org/10.1146/annurev.immunol.18.1.143 55.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
J Leukoc Biol 2006; 79:1286-94; PMID:16624932; http://dx.doi.org/10.1189/jlb.1205742 56.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
J Immunol 2007; 178:1534-41; PMID:17237402; http://dx.doi.org/10.4049/ jimmunol.178.3.1534 58.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Curr Dir Autoimmun 2010; 11:105-18; PMID:20173390; http://dx.doi.org/10.1159/000289200 60.,OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
Biochem Biophys Res Commun 2007; 360:702-7; PMID:17618911;http://dx.doi.org/10.1016/j.bbrc.2007.06.126 61.,OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
J Gene Med 2006; 8:90-9; PMID:16097036; http://dx.doi.org/10.1002/ jgm.817 62.,OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
J Immunol 2013; 190:3977-84; PMID:23479229; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
J Immunol 2006; 177:120-9; PMID:16785506; http://dx.doi.org/10.4049/jimmunol.177.1.120ONCOIMMUNOLOGY e1100791-15,Non-OADS,/arxiv_data1/oa_pdf/f1/f8/koni-05-03-1100791.PMC4839376.pdf
"3, e1091554 (10 pages)http://dx.doi.org/10.1080/2162402X.2015.1091554",Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Nat Rev Immunol (2012); 12:269-81; PMID:22437939; http://dx.doi.org/10.1038/nri3191 2.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Immunity (2013); 39:61-73; PMID:23890064; http://dx.doi.org/10.1016/j.immuni.2013.07.005 3.,OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Semin Immunol (2010);22:173-82; PMID:20409732; http://dx.doi.org/10.1016/j.smim.2010.03.002 4.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Nat Rev Cancer (2012); 12:252-64; PMID:22437870;http://dx.doi.org/10.1038/nrc3239 5.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Cancer Res (2012); 72:1651-60; PMID:22315352; http://dx.doi.org/10.1158/0008-5472.CAN-11-2788 6.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Cancer Res (2012); 72:2327-38; PMID:22396493; http://dx.doi.org/10.1158/0008-5472.CAN-11-2975 7.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Cancer Res (2009); 69:7713-20; PMID:19773437; http://dx.doi.org/10.1158/0008- 5472.CAN-09-1013 8.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
N Engl J Med (2003); 348:203-13; PMID:12529460; http://dx.doi.org/10.1056/NEJMoa020177 10.,OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Oncogene (2010); 29:1093-102; PMID:19946335; http://dx.doi.org/10.1038/onc.2009.41612.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Oncogene (2008); 27:5904-12; PMID:18836471;http://dx.doi.org/10.1038/onc.2008.271 13.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Nat Immunol (2013); 14:1014-22; PMID:24048123; http://dx.doi.org/10.1038/ni.2703 14.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Mol Cancer (2013); 12:103; PMID:24020520; http://dx.doi.org/10.1186/1476-4598-12-103 15.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Cancer Immunol Res (2014); 2:295-300; PMID:24764576; http://dx.doi.org/10.1158/2326-6066.CIR-14-0015 16.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Nat Rev Cancer (2014); 14:559-67; PMID:24990523; http://dx.doi.org/10.1038/nrc3770 17.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Oncoimmunology (2014); 3:e28694; PMID:25097804; http://dx.doi.org/10.4161/onci.28694 18.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Nat Immunol (2008); 9:970-80; PMID:18711434; http://dx.doi.org/10.1038/ni.f.213 19.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Cell (1999); 99:23-33; PMID:10520991; http://dx.doi.org/10.1016/ S0092-8674(00)80059-8 20.,OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Cancer Res (2009); 69:6331-8; PMID:19602595; http://dx.doi.org/10.1158/0008-5472.CAN-08-4329 21.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
J Exp Med (1998); 187:2009-21; PMID:9625760;http://dx.doi.org/10.1084/jem.187.12.2009 24.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
J Immunother (2005);28:343-51; PMID:16000952; http://dx.doi.org/10.1097/01.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Scand J Immunol (2004); 59:246-54; PMID:15030574; http://dx.doi.org/10.1111/j.0300- 9475.2004.01391.x 26.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Cancer ImmunolImmunother (2007); 56:359-70; PMID:16783574; http://dx.doi.org/ 10.1007/s00262-006-0190-2 27.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Mol Ther (2011); 19:650-7; PMID:21266959; http://dx.doi.org/10.1038/mt.2010.312 29.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Cell Adh Migr (2010); 4:153-61; PMID:20179421; http://dx.doi.org/10.4161/cam.4.1.11361 30.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Cancer Res (2012); 72:2473-80; PMID:22414581; http://dx.doi.org/10.1158/0008-5472.CAN-12-0122 31.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Clin Cancer Res (2007); 13:5256-61; PMID:17875753; http://dx.doi.org/10.1158/1078-0432.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Cancer Res (2012); 72:2159-61; PMID:22549945; http://dx.doi.org/10.1158/0008-5472.CAN-11-3538 33.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Gut (2010); 59:1416-26; PMID:20675696; http://dx.doi.org/10.1136/gut.2009.196519 34.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Gene Ther (2013);20:7-15; PMID:22170342; http://dx.doi.org/10.1038/gt.2011.205 35.,OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Cancer Res (2012); 72:2609-21;PMID:22461509; http://dx.doi.org/10.1158/0008-5472.CAN-11-3185 36.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Clin Cancer Res (2013); 19:1147-58; PMID:23339127; http://dx.doi.org/10.1158/1078-0432.CCR-12-2733 37.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Oncoimmunology (2013); 2:e24212; PMID:23762802; http://dx.doi.org/10.4161/onci.24212 38.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
J Biol Chem (2001); 276:21083-8; PMID:11279246; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Cancer Res (2005); 65:9991-8; PMID:16267024; http://dx.doi.org/10.1158/0008-5472.CAN-05-1630 40.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Mol Ther (2013); 21:2074-86; PMID:23985697; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Front Oncol (2014); 4:74; PMID:24782985; http://dx.doi.org/10.3389/ fonc.2014.00074.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Mol Ther (2014); 22:251-6; PMID:24048442;http://dx.doi.org/10.1038/mt.2013.220 43.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
J Immunol (2013); 190:5866-73; PMID:23610140; http://dx.doi.org/10.4049/ jimmunol.1203470 44.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Tumour immu- nity: effector response to tumour and role of the microenvironment.Lancet (2008); 371:771-83; PMID:18275997; http://dx.doi.org/ 10.1016/S0140-6736(08)60241-X 45.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Cancer Res(2012); 72:917-27; PMID:22186141; http://dx.doi.org/10.1158/0008-5472.CAN-11-1620 46.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
NatMed (2013); 19:329-36; PMID:23396206; http://dx.doi.org/10.1038/ nm.3089 47.,OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
J Clin Oncol (2015); 33:2780-8;PMID:26014293; http://dx.doi.org/10.1200/JCO.2014.58.3377 48.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Mol Ther (2015); 23:202-14;PMID:25292189; http://dx.doi.org/10.1038/mt.2014.194 49.,Non-OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Int JCancer (1992); 52:881-6; PMID:1459729; http://dx.doi.org/10.1002/ ijc.2910520609 50.,OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
Mol Ther (2013); 21:1024-33; PMID:23439499; http://dx.doi.org/10.1038/mt.2013.27e1091554-10 Z. LIU ET AL.,OADS,/arxiv_data1/oa_pdf/f8/28/koni-05-03-1091554.PMC4839379.pdf
"3, e1090077 (3 pages)http://dx.doi.org/10.1080/2162402X.2015.1090077",Non-OADS,/arxiv_data1/oa_pdf/cf/e4/koni-05-03-1090077.PMC4839380.pdf
Nat Biotechnol 2010; 28:1069-78; PMID:20944599; http://dx.doi.org/10.1038/nbt.1678 2.,OADS,/arxiv_data1/oa_pdf/cf/e4/koni-05-03-1090077.PMC4839380.pdf
Cell 2015; 162:974-86; PMID:26317466;http://dx.doi.org/10.1016/j.cell.2015.07.011 3.,OADS,/arxiv_data1/oa_pdf/cf/e4/koni-05-03-1090077.PMC4839380.pdf
Cell 2015; 162:961-973; PMID:26317465; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cf/e4/koni-05-03-1090077.PMC4839380.pdf
Genome Biol 2001; 2:reviews1017.1-.5; PMID:11423012; http://dx.doi.org/10.1186/gb-2001-2-6-reviews10175.,OADS,/arxiv_data1/oa_pdf/cf/e4/koni-05-03-1090077.PMC4839380.pdf
Sci- ence 2013; 339:543-8; PMID:23239622; http://dx.doi.org/10.1126/ science.1227670 6.,OADS,/arxiv_data1/oa_pdf/cf/e4/koni-05-03-1090077.PMC4839380.pdf
Nat Med 2014; 20:29-36; PMID:24292392; http://dx.doi.org/10.1038/nm.3418 7.,OADS,/arxiv_data1/oa_pdf/cf/e4/koni-05-03-1090077.PMC4839380.pdf
"Nat Immunol 2015; 16:802-9; PMID:26194286; http://dx.doi.org/10.1038/ni.3212 8 .B u r k a r tC ,A r i m o t oC I ,T a n gT ,C o n gX ,X i a oN ,L i uY C , Kotenko SV, Ellies LG, Zang DE.",OADS,/arxiv_data1/oa_pdf/cf/e4/koni-05-03-1090077.PMC4839380.pdf
EMBO Mol Med 2013; 5:967-82; PMID:23681607; http://dx.doi.org/10.1002/emmm.201201864 9.,Non-OADS,/arxiv_data1/oa_pdf/cf/e4/koni-05-03-1090077.PMC4839380.pdf
Cancer Discov 2011; 1:598-607; PMID:22586682; http://dx.doi.org/; http://dx.doi.org/10.1158/2159- 8290.CD-11-0214ONCOIMMUNOLOGY e1090077-3,Non-OADS,/arxiv_data1/oa_pdf/cf/e4/koni-05-03-1090077.PMC4839380.pdf
"3, e1082705 (14 pages)http://dx.doi.org/10.1080/2162402X.2015.1082705",Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Original detailed protocols for recombineering can also be found at the recombineering website (http://recombineering.ncifcrf).,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Clin Breast Cancer 2008; 8:38-49; PMID:18501058; http://dx.doi.org/10.3816/CBC.2008.n.002 2.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Science 1988; 240:1795-8; PMID:3289120; http://dx.doi.org/10.1126/science.3289120 3.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Science 1989; 244:707-12; PMID:2470152; http://dx.doi.org/10.1126/science.2470152 4.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Nat Rev Mol Cell Biol 2001; 2:127-37; PMID:11252954; http://dx.doi.org/10.1038/35052073 6.,OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Ann Oncol 2003; 14:1346-63;PMID:12954573; http://dx.doi.org/10.1093/annonc/mdg365 7.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Oncogene 2000; 19:6102-14; PMID:11156523;http://dx.doi.org/10.1038/sj.onc.1203973 8.,OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
N Engl J Med 2007; 357:39-51; PMID:17611206; http://dx.doi.org/10.1056/NEJMra043186 9.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Cancer J 2007; 13:141-7; PMID:17620762; http://dx.doi.org/10.1097/ PPO.0b013e318074dc6f 10.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Br J Cancer 2010; 102:134-43; PMID:19920829; http://dx.doi.org/10.1038/sj.bjc.6605448 11.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Cancer Res 2004; 64:2858-64; PMID:15087404;http://dx.doi.org/10.1158/0008-5472.CAN-03-2962 13.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
J Clin Invest 2004; 113:709-17; PMID:14991069; http://dx.doi.org/10.1172/JCI19850 14.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Cancer Res 2006; 66:7734-40; PMID:16885376; http://dx.doi.org/ 10.1158/0008-5472.CAN-06-1432 15.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
JImmunol 2006; 177:7626-33; PMID:17114432; http://dx.doi.org/ 10.4049/jimmunol.177.11.7626 16.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
J Exp Med2009; 206:849-66; PMID:19332877; http://dx.doi.org/10.1084/jem.20081382 19.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Nat Med 2006; 12:198-206; PMID:16444264; http://dx.doi.org/10.1038/nm1363 20.,OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Cancer Chemother Biol Response Modif 2005; 22:769-87; PMID:16110640; http://dx.doi.org/10.1016/S0921-4410(04)22036-1 21.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Cancer Res 2010; 70:2604-12; PMID:20332241; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Cancer Res 2010; 70:119-28; PMID:20048073; http://dx.doi.org/10.1158/0008-5472.CAN-09-2554 24.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
J Virol Methods 2002; 101:49- 61; PMID:11849683; http://dx.doi.org/10.1016/S0166-0934(01)00419-0 25.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Establishment of a bovine herpesvi- rus 4 based vector expressing a secreted form of the bovine viraldiarrhoea virus structural glycoprotein E2 for immunization purposes.BMC Biotechnol 2007; 7:68; PMID:17945009; http://dx.doi.org/ 10.1186/1472-6750-7-68 26.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Vaccine 2008; 26:6031-42; PMID:18812200; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Clin Vaccine Immu-nol 2009; 16:1675-86; PMID:19793901; http://dx.doi.org/10.1128/ CVI.00224-09 28.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Vaccine 2011; 29:3074-82; PMID:21320537; http://dx.doi.org/10.1016/j.vaccine.2011.01.075e1082705-12 S. JACCA ET AL.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Neuro-oncology 2012; 14:288- 301; PMID:22228853; http://dx.doi.org/10.1093/neuonc/nor219 30.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
PloS one2013; 8:e52758; PMID:23300989; http://dx.doi.org/10.1371/journal.,OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
J Virol Methods 2006; 136:126-36; PMID:16712963; http://dx.doi.org/ 10.1016/j.jviromet.2006.04.008 32.,OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Vaccine2011; 29:867-72; PMID:21115049; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
PloS one 2014; 9:e95779; PMID:24752229; http://dx.doi.org/10.1371/journal.pone.0095779 34.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
J Virol Methods 2010; 169:420-4; PMID:20705105; http://dx.doi.org/10.1016/j.jviromet.2010.08.002 36.,OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
PLoS Negl Trop Dis2015; 9:e0003850; PMID:26086739; http://dx.doi.org/10.1371/journal.pntd.0003850 37.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Curr Protoc Immunol 2008; Chapter 20:Unit 200 9 1- 9-10; PMID:18729063; http://dx.doi.org/10.1002/0471142735.im2009s82.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Vaccine 2013; 31:3906-14; PMID:23830977; http://dx.doi.org/ 10.1016/j.vaccine.2013.06.052 40.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Nucleic Acids Res 2005; 33:e36; PMID:15731329; http://dx.doi.org/ 10.1093/nar/gni035 4 1 .,OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
JImmunol 2000; 165:5133-42; PMID:11046045; http://dx.doi.org/ 10.4049/jimmunol.165.9.5133 42.,OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Cancer Cell 2008; 13:58-68; PMID:18167340; http://dx.doi.org/10.1016/j.ccr.2007.12.003 43.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Blood 2003; 102:2138-45; PMID:12750171; http://dx.doi.org/10.1182/blood-2003-01-0190 44.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
BioDrugs 2007; 21:145-56; PMID:17516710; http://dx.doi.org/10.2165/00063030-200721030-00002 46.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Nature 2003; 421:756-60; PMID:12610629; http://dx.doi.org/10.1038/nature01392 47.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Cancer Cell 2004; 5:317-28; PMID:15093539; http://dx.doi.org/10.1016/S1535-6108(04)00083-2 48.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
J Immunol 2010; 184:4170-7; PMID:20220087;http://dx.doi.org/10.4049/jimmunol.0903375 49.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
J Immunol 2005; 174:4228-36; PMID:15778385; http://dx.doi.org/10.4049/jimmunol.174.7.4228 50.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Cancer Res 2005; 65:5953-7; PMID:15994974; http://dx.doi.org/10.1158/0008-5472.CAN-05-0335 51.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Int J Cancer 2007; 120:574-84; PMID:17096348; http://dx.doi.org/ 10.1002/ijc.22274 52.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Clin Breast Cancer 2003; 3 Suppl 4:S173- 80; PMID:12620156; http://dx.doi.org/10.3816/CBC.2003.s.008 53.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Hum Gene Ther 2003; 14:1117-23; PMID:12885350; http://dx.doi.org/10.1089/104303403322124828 54.,OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
J Immun- other 2003; 26:163-70; PMID:12616108; http://dx.doi.org/10.1097/00002371-200303000-00009 55.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
J Clin Oncol 2007; 25:3680-7; PMID:17704416; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Clin Cancer Res 2014; 20:2910-21; PMID:24668647; http://dx.doi.org/10.1158/1078-0432.CCR-13-2663 57.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
2006; 12:7397-405; PMID:17189412; http://dx.doi.org/10.1158/1078- 0432.CCR-06-1546 58.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Cancer Immunol Immunother 2008; 57:1511-21; PMID:18536917; http://dx.doi.org/10.1007/s00262-008-0540-3 59.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Treat- ment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9.Clin Cancer Res 2009; 15:1575-84; PMID:19240169; http://dx.doi.org/10.1158/1078-0432.CCR-08-2628 60.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Int J Cancer 2009; 124:150-6; PMID:18839427; http://dx.doi.org/10.1002/ijc.23920 61.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Clin Cancer Res 2009; 15:924-32;PMID:19188163; http://dx.doi.org/10.1158/1078-0432.CCR-08-2283 62.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Cancer Immunol Immunother 2010; 59:1247-58; PMID:20364378; http://dx.doi.org/10.1007/s00262-010-0850-0 63.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
J Transl Med 2014; 12:122; PMID:24886178; http://dx.doi.org/10.1186/1479-5876-12-122 64.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Cancer Res 2008; 68:1979-87; PMID:18339880; http://dx.doi.org/10.1158/0008-5472.CAN-07-5688 65.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
"Donofrio G, Cavaggioni A, Bondi M, Cavirani S, Flammini CF, Mucignat-Caretta C. Outcome of bovine herpesvirus 4 infection fol-lowing direct viral injection in the lateral ventricle of the mouse brain.Microbes Infection 2006; 8:898-904; PMID:16503181; http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Cell Immunol 2006; 240:96-106; PMID:16930573; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Front Oncol 2013; 3:122; PMID:23675574; http://dx.doi.org/10.3389/fonc.2013.00122 68.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
J Exp Med1998; 188:589-96; PMID:9687535; http://dx.doi.org/10.1084/ jem.188.3.589 69.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
Oncoimmunology 2015; 4:e1005500; PMID:26155401; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c8/45/koni-05-03-1082705.PMC4839386.pdf
"The novelty extends to challenging the decision scientists to reason about building  This manuscript version is made available under the CC-BY-NC-ND 4.0 license: http://creativecommons.org/licenses/by-nc-nd/4.0/ cCorresponding author:  Dr. Anthony Constantinou, E-mail: anthony@constantinou.info.",Non-OADS,/arxiv_data1/oa_pdf/22/12/emss-67687.PMC4839499.pdf
1998. http://dslpitt.org/genie/index.php/about 43.,Non-OADS,/arxiv_data1/oa_pdf/22/12/emss-67687.PMC4839499.pdf
2015. http://www.agenarisk.com 50.,Non-OADS,/arxiv_data1/oa_pdf/22/12/emss-67687.PMC4839499.pdf
2014. https://www.eecs.qmul.ac.uk/~norman/ projects/B_Knowledge.htmlConstantinou et al.,Non-OADS,/arxiv_data1/oa_pdf/22/12/emss-67687.PMC4839499.pdf
"To view a copy of this license, visit http://creativecommons.org/ licenses/by-nc-sa/4.0/ Supplementary Information accompanies this paper on The I SME Journal website (http:/ /www.nature.",Non-OADS,/arxiv_data1/oa_pdf/61/58/ismej2015200a.PMC4839502.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ Supplementary Information accompanies the paper on the Neuropsychopharmacology website (http://www.nature.com/npp)Anemoside A3 enhances memory function FCF Ip et al 1887 Neuropsychopharmacology",Non-OADS,/arxiv_data1/oa_pdf/5e/02/npp201537a.PMC4839511.pdf
": Immunology Department, The Weizmann Institute of Science, Rehovot, Israel.The online-only Data Supplement is available with this article at http://stroke.ahajournals.org/lookup/suppl/doi:10.1161/STROKEAHA.",Non-OADS,/arxiv_data1/oa_pdf/0b/60/str-47-1354.PMC4839545.pdf
Stroke is available at http://stroke.ahajournals.org DOI: 10.1161/STROKEAHA.115.011800,Non-OADS,/arxiv_data1/oa_pdf/0b/60/str-47-1354.PMC4839545.pdf
The original data of this study is avail- able online: http://dx.doi.org/10.6084/m9.figshare.1476224.,OADS,/arxiv_data1/oa_pdf/0b/60/str-47-1354.PMC4839545.pdf
Available at: http://www.ncc- n.org.,Non-OADS,/arxiv_data1/oa_pdf/91/22/mpa-45-761.PMC4839740.pdf
https://www.youtube.com/yt/press/ en-GB/statistics.html.,Non-OADS,/arxiv_data1/oa_pdf/e8/6f/10.1177_2333794X15622333.PMC4839780.pdf
2011:1–134; http://www.phac-aspc.gc.ca/cd- mc/diabetes-diabete/index-fra.php.,Non-OADS,/arxiv_data1/oa_pdf/9b/33/medi-95-e2954.PMC4839786.pdf
"Cary, NC: SAS Institute Inc. 2012; http://support.sas.com/documentation/cdl/en/qcug/63964/PDF/default/qcug.pdf, 2013.",OADS,/arxiv_data1/oa_pdf/9b/33/medi-95-e2954.PMC4839786.pdf
"http://community.-cochrane.org/handbook (accessed January 15, 2015).",OADS,/arxiv_data1/oa_pdf/5f/d0/medi-95-e3009.PMC4839789.pdf
"http://www.who.int/transplantation/gkt/statistics/en/.Accessed November 21, 2015.",Non-OADS,/arxiv_data1/oa_pdf/b4/26/medi-95-e3119.PMC4839794.pdf
http://www.odt.nhs.uk/uk-transplant-registry/organ-specific-reports/.,Non-OADS,/arxiv_data1/oa_pdf/b4/26/medi-95-e3119.PMC4839794.pdf
"Among this population,17,541 individuals who participated in the laboratory examin-ation were finally included in the analyses (Supplementary Figure 1, http://links.lww.com/MD/A895).",OADS,/arxiv_data1/oa_pdf/cf/bb/medi-95-e3153.PMC4839797.pdf
URL: http://glaucomatoday.com/2009/08/GT0709_06.php/.,Non-OADS,/arxiv_data1/oa_pdf/fe/02/medi-95-e3212.PMC4839803.pdf
Available at: http://nhird.nhri.org.tw/en/index.html.,Non-OADS,/arxiv_data1/oa_pdf/10/58/medi-95-e3266.PMC4839807.pdf
BMI Classification in Global Database on Body Mass Index: an interactive surveillance tool for monitoringnutrition transition 2015; Available at: http://apps.who.int/bmi/index.jsp?introPage=intro_3.html.,OADS,/arxiv_data1/oa_pdf/b6/69/medi-95-e3286.PMC4839812.pdf
"The constant pis served for the correction of presumed random variation, which exists inevitably in the angle of section relative to the long axis of the podocyte.19,20The intraobserver variability of the FPW was assessed by thecoefficient of variation (the ratio of the SD to the mean) between 2 measurements of the same object by 1 observer.15The interobserver variability in this study was assessed by theintraclass correlation coefficient.21 Podocyte density per glomerulus [Nv(epi/glom)] was used to estimate podocyte detachment (detailed in the Supplementary Material, http://links.lww.com/MD/A887).",OADS,/arxiv_data1/oa_pdf/ea/1d/medi-95-e3294.PMC4839813.pdf
"The renal func- tion recovery was defined as complete recovery, partial recov- ery, and treatment failure, which has been detailed in theSupplementary Material, http://links.lww.com/MD/A887.3,27,28 Statistical Analysis Results were expressed as mean /C6SD (for data that were normally distributed), or median and interquartile range (IQR) (for data that were not normally distributed).",OADS,/arxiv_data1/oa_pdf/ea/1d/medi-95-e3294.PMC4839813.pdf
"For allcomparisons in the secondary prevention of stroke, the 95% CI of inconsistency factors from all cycles included zero (Table S1, http://links.lww.com/MD/A880), and the node-splittingmethod showed no significant inconsistency within the net-works for any of these outcomes, which suggested that the results in the network were consistent between direct and indirect evidence.",OADS,/arxiv_data1/oa_pdf/22/9e/medi-95-e3302.PMC4839815.pdf
"systolic blodd pressure (SBP) and between BP reductions and the risk reduction of 3 adverse outcomes were analyzed(Figure 4 and Figure S2 to S6, http://links.lww.com/MD/A880).",Non-OADS,/arxiv_data1/oa_pdf/22/9e/medi-95-e3302.PMC4839815.pdf
"Similarly, the meta-regression analysis revealed a trend toward protection against recurrent stroke through reduced BP (Figure S1, http://links.lww.com/MD/A880) with an adjustedR20.1995 ( P¼0.1618).",Non-OADS,/arxiv_data1/oa_pdf/22/9e/medi-95-e3302.PMC4839815.pdf
"risk of CHD and MACCE are provided in the appendix (Figure S2–S6, http://links.lww.com/MD/A880); all failed to reach statistical significance.",OADS,/arxiv_data1/oa_pdf/22/9e/medi-95-e3302.PMC4839815.pdf
"As shown in Figure 5 and S7,http://links.lww.com/MD/A880, the risk ratios for recurrent stroke and MACCE were comparable across the different subgroups except for the average BP reduction between treat-ment and control groups with a Pfor interaction of 0.01 for total stroke and 0.012 for MACCE.",Non-OADS,/arxiv_data1/oa_pdf/22/9e/medi-95-e3302.PMC4839815.pdf
The study was supported by National Natural Science Foundation of China (81370509) (http://www.nsfc.gov.cn/publish/portal1/).,Non-OADS,/arxiv_data1/oa_pdf/4e/26/medi-95-e3308.PMC4839816.pdf
ACKNOWLEDGMENTS The authors thank National Natural Science Foundation of China (81370509) (http://www.nsfc.gov.cn/publish/portal1/) forthe support.,Non-OADS,/arxiv_data1/oa_pdf/4e/26/medi-95-e3308.PMC4839816.pdf
"Gene Ontology and KEGG Pathway Enrichment Analysis To estimate the functions of DE miRNAs, we performed gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis using DA VIDweb application (https://david.ncifcrf.gov).",OADS,/arxiv_data1/oa_pdf/b3/63/medi-95-e3321.PMC4839821.pdf
"miRNA Targets and Relevant Biological Pathways A total of 2408 target genes were predicted for the 10 miRNAs, and the network of miRNA-target genes wasconstructed (Supplementary Figure 1, http://links.lww.com/ MD/A886).",OADS,/arxiv_data1/oa_pdf/b3/63/medi-95-e3321.PMC4839821.pdf
"NT-proBNP levels ( P¼0.053), echocardiography parameters including left ventricular end-diastolic diameter ( P¼0.988), and ejection fraction (p ¼0.190) were not associated with mtDNA copy number levels of leukocytes (Figure S2, http://links.lww.- com/MD/A892).",Non-OADS,/arxiv_data1/oa_pdf/0e/a5/medi-95-e3323.PMC4839823.pdf
"The clinical charac-teristics of these participants were summarized in Supple- mentary S2 and S3, http://links.lww.com/MD/A892.",OADS,/arxiv_data1/oa_pdf/0e/a5/medi-95-e3323.PMC4839823.pdf
"Available at: http://www.who.int/mediacentre/factsheets/fs310/en/.Accessed July 6, 2014.TABLE 3.",OADS,/arxiv_data1/oa_pdf/c4/fa/medi-95-e3327.PMC4839825.pdf
"Available at: http://www.qualityindicators.ahrq.gov/Modules/IQI_TechSpec.aspx.Accessed March 31, 2015.",OADS,/arxiv_data1/oa_pdf/c4/fa/medi-95-e3327.PMC4839825.pdf
"Available at: http://www.mohw.gov.tw/cht/DOMA/DM1_P.aspx?f_list_no=608&fod_list_no=772&doc_no=51568.Accessed January 6, 2016.",OADS,/arxiv_data1/oa_pdf/c4/fa/medi-95-e3327.PMC4839825.pdf
Available at: http://www.mohw.gov.tw/cht/DOMA/DM1.aspx?f_list_no=608&fod_list_no=774.,OADS,/arxiv_data1/oa_pdf/c4/fa/medi-95-e3327.PMC4839825.pdf
"Available at: http://www.nfa.gov.tw/main/Content.aspx?ID=2&MenuID=665.Accessed January 6, 2016.",Non-OADS,/arxiv_data1/oa_pdf/c4/fa/medi-95-e3327.PMC4839825.pdf
Available at: http://www.tjcha.org.tw/FrontStage/page.asp-x?ID=FF2E2252-F2AA-4573-9D7A-A00152BA9A63.,Non-OADS,/arxiv_data1/oa_pdf/c4/fa/medi-95-e3327.PMC4839825.pdf
Available at: http://www.mohw.gov.tw/cht/DOMA/DM1.aspx?f_list_no=608&fod_list_no=3785.,OADS,/arxiv_data1/oa_pdf/c4/fa/medi-95-e3327.PMC4839825.pdf
Available at: http://www.medicare.gov/hospitalcompare/about/timely-effective-care.html.,Non-OADS,/arxiv_data1/oa_pdf/c4/fa/medi-95-e3327.PMC4839825.pdf
Nutrition and Health Survey in Taiwan; 2010. http://nahsit.nhri.org.tw/node/7.,Non-OADS,/arxiv_data1/oa_pdf/9f/b0/medi-95-e3334.PMC4839828.pdf
"The concomitant variables corrected in the multivariate analysis of each studyhave list in Table S1 (Additional file 2, http://links.lww.com/MD/A894).",OADS,/arxiv_data1/oa_pdf/1f/28/medi-95-e3337.PMC4839831.pdf
"The result of sensitivity analysis indicatedthat the study published by Frank et al 54in CSS and Kruger et al59in PFS of univariate analysis were not stable and significantly influenced the pooled HR (Additional file 1:Figures S1–S2, http://links.lww.com/MD/A894).",OADS,/arxiv_data1/oa_pdf/1f/28/medi-95-e3337.PMC4839831.pdf
"After exclud-ing the study by Frank et al 54and Kruger et al,59the meta- analyses of the remained studies were stable (Additional file 1: Figures S3–S4, http://links.lww.com/MD/A894).",OADS,/arxiv_data1/oa_pdf/1f/28/medi-95-e3337.PMC4839831.pdf
"The main information of 23 excluded studies 97–119was listed in Table S2 (Additional file 2, http://links.lww.com/MD/A894), including 5 studies for CSS,5 for DFS, 9 for OS, 9 for PFS, and 10 for RFS.",Non-OADS,/arxiv_data1/oa_pdf/1f/28/medi-95-e3337.PMC4839831.pdf
http://www.picornas- tudygroup.com/taxa/taxa.htm.,OADS,/arxiv_data1/oa_pdf/74/a3/medi-95-e3347.PMC4839835.pdf
2013; http://nhird.nhri.org.tw/date_01.htm.,Non-OADS,/arxiv_data1/oa_pdf/74/a3/medi-95-e3347.PMC4839835.pdf
"In thisanalysis, the PBMC count was found to be significantly corre-lated with BMD after adjusting for the confounding factors from Model 1 to 4 ( b¼–0.049 to –0.037, P<0.000; Supplemental Table 1, http://links.lww.com/MD/A889).",Non-OADS,/arxiv_data1/oa_pdf/e3/0f/medi-95-e3357.PMC4839837.pdf
"Besides, in multiple linear regression analysis, the PBMC count was still found to be negativelycorrelated to T-scores after adjusting for variables from Model 1 to 4 (b¼/C00.500 to /C00.439, P<0.000; Supplemental Table 1, http://links.lww.com/MD/A889).",OADS,/arxiv_data1/oa_pdf/e3/0f/medi-95-e3357.PMC4839837.pdf
"As shown in Supplemental Table 2, http://links.lww.com/MD/A889 the univariate analysis revealed thatthe PBMC count was a risk factor for elderly men with at least osteopenia (OR ¼2.520, CI: 1.397–4.547; P¼0.002).",Non-OADS,/arxiv_data1/oa_pdf/e3/0f/medi-95-e3357.PMC4839837.pdf
"It was further confirmed by multivariate analysis after adjusting for allpotential confounding factors (OR ¼2.481, CI: 1.176–5.236; P¼0.017; Supplemental Table 2, http://links.lww.com/MD/ A889 and Figure 4).",Non-OADS,/arxiv_data1/oa_pdf/e3/0f/medi-95-e3357.PMC4839837.pdf
"Participants had a sig-nificantly high OR in the BMI <25 group after adjusting for all confounding variables (OR ¼2.798, CI: 1.122–6.973; P¼0.027; Supplemental Figure 1, http://links.lww.com/MD/ A889).",Non-OADS,/arxiv_data1/oa_pdf/e3/0f/medi-95-e3357.PMC4839837.pdf
"Consistently, subjects had a significantly high OR in theSBP<140 group after adjusting for all confounding variables (OR¼2.519, CI: 1.059–5.993; P¼0.037; Supplemental Figure 1, http://links.lww.com/MD/A889).",Non-OADS,/arxiv_data1/oa_pdf/e3/0f/medi-95-e3357.PMC4839837.pdf
"Taiwan, http://nhird.nhri.org.tw/en/Background.html 2015.",Non-OADS,/arxiv_data1/oa_pdf/2f/0c/medi-95-e3363.PMC4839840.pdf
"20. WHO Collaborating Center for Drugs Statistics Methodology:ATC/ DDD Index, http://www.whocc.no/atc_ddd_index/?code=A10BH.",OADS,/arxiv_data1/oa_pdf/2f/0c/medi-95-e3363.PMC4839840.pdf
2008; available at http://www.who.int/gho/ncd/risk_factors/blood_pressure_prevalence/en/.,Non-OADS,/arxiv_data1/oa_pdf/91/ea/medi-95-e3380.PMC4839848.pdf
"The characteristics of subjects with persistent phenotypes were not different fromthose of subjects categorized by baseline phenotypes (Table 1 and Supplemental Table 1, http://links.lww.com/MD/A903).",Non-OADS,/arxiv_data1/oa_pdf/19/4f/medi-95-e3384.PMC4839851.pdf
Available at: http://www.ginasthma.org/documents/4.,Non-OADS,/arxiv_data1/oa_pdf/df/12/medi-95-e3404.PMC4839862.pdf
"For details on the questionnaire items, please refer to the Supplementary Table 1, http://links.lww.com/MD/ A763.",Non-OADS,/arxiv_data1/oa_pdf/cf/1d/medi-95-e2814.PMC4839879.pdf
"See Supplementary Table 1, http://links.lww.com/MD/A763, for indicators of latent variables.",OADS,/arxiv_data1/oa_pdf/cf/1d/medi-95-e2814.PMC4839879.pdf
Available at: http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf?ua ¼1&ua¼1.,Non-OADS,/arxiv_data1/oa_pdf/cf/1d/medi-95-e2814.PMC4839879.pdf
Available at: http://www.moe.gov.cn/publicfiles/business/htmlfiles/moe/s8493/ 201412/181722.html.,Non-OADS,/arxiv_data1/oa_pdf/cf/1d/medi-95-e2814.PMC4839879.pdf
"For a 4-year investigation, the CVs of the PW sets for the 6 EDs areshown in Table 3 and Figure 5 (see eTable 1 and eTable 2, Supplemental Content, http://links.lww.com/MD/A768, which present the values of the R 2and PW in 2011–2013, respect- ively).",Non-OADS,/arxiv_data1/oa_pdf/ed/9a/medi-95-e2972.PMC4839888.pdf
"The R2of the linear regression lines of each ED for 4 years is shown in Table 2 andeTable 1 (see the Supplemental Content), http://links.lww.com/ MD/A768.",OADS,/arxiv_data1/oa_pdf/ed/9a/medi-95-e2972.PMC4839888.pdf
"In order to discover the impacts of the trucked time period in ED performance analysis, the ¯S 2-¯Vplots for the time period of 0 to 23 in 2010 are investigated and compared in eFigure 1, http://links.lww.com/MD/A768 in the Supplemental Content.",Non-OADS,/arxiv_data1/oa_pdf/ed/9a/medi-95-e2972.PMC4839888.pdf
"The eFigure 1, http://links.lww.com/MD/A768 can also indicate a specific interaction between ¯S2and ¯Vby a fair R2.",Non-OADS,/arxiv_data1/oa_pdf/ed/9a/medi-95-e2972.PMC4839888.pdf
"Available at: http://www.ahrq.gov/research/findings/final-reports/ptflow/index.html(accessed November 5, 2014).",OADS,/arxiv_data1/oa_pdf/ed/9a/medi-95-e2972.PMC4839888.pdf
"Washing-ton, DC: George Washington University; 2010:Available at: https://smhs.gwu.edu/urgentmatters/sites/urgentmatters/files/Standardized%20Performance%20Measurement%20and%20Reporting%20in%20ED.pdf (accessed October 10, 2015).",Non-OADS,/arxiv_data1/oa_pdf/ed/9a/medi-95-e2972.PMC4839888.pdf
"Washington, DC: ICDRM, GWU for VHA, US VA; 2010: Available at: https://www.gwu.edu/ /C24icdrm/ publications/PDF/EMP&P_Unit%201%202nd%20edition.pdf(accessed October 10, 2015).",Non-OADS,/arxiv_data1/oa_pdf/ed/9a/medi-95-e2972.PMC4839888.pdf
"Available at: http://www.ihi.org/resources/Pages/HowtoImprove/ScienceofImprovementFormingtheTeam.aspx(accessed October 18, 2014).14.",Non-OADS,/arxiv_data1/oa_pdf/ed/9a/medi-95-e2972.PMC4839888.pdf
"2006; Available at: http://www.jointcommission.org/assets/1/18/A_Comprehensive_Review_of_Development_for_Core_Measures.pdf (accessed October 10,2015).",OADS,/arxiv_data1/oa_pdf/ed/9a/medi-95-e2972.PMC4839888.pdf
Available at: http://www.doh.gov.tw/EN2006/DM/DM2.aspx?now_fod_list_no=12402&class_no=390&level_no=2).,OADS,/arxiv_data1/oa_pdf/d6/a2/medi-95-e2980.PMC4839891.pdf
Available at: http://www.whocc.no/atc_ddd_index/?code=A05AA02.).,OADS,/arxiv_data1/oa_pdf/d6/a2/medi-95-e2980.PMC4839891.pdf
Available at: http://www.interimhealthcare.com/services/home-care/information/coronary-artery-disease.,Non-OADS,/arxiv_data1/oa_pdf/22/01/medi-95-e2997.PMC4839893.pdf
"Of the 50 that underwent full-textevaluation, 40 met our inclusion criteria (see SupplementaryReferences, http://links.lww.com/MD/A765).",Non-OADS,/arxiv_data1/oa_pdf/3a/f6/medi-95-e3013.PMC4839895.pdf
"Qualitative Summary and Data Synthesis The clinical and methodological characteristics, as well as the main results of each study, are summarized in Tables 1 and2, and Supplementary Table 1, http://links.lww.com/MD/A765.We retrieved 40 studies that enrolled a total of 318,898 partici- pants from 14 countries.",Non-OADS,/arxiv_data1/oa_pdf/3a/f6/medi-95-e3013.PMC4839895.pdf
"Supplementary Table 3, http://links.lww.com/MD/A765, summarizes the adjusted effect sizes and results of statisticalTsai et al Medicine /C15Volume 95, Number 11, March 2016 2|www.md-journal.com Copyright #2016 Wolters Kluwer Health, Inc. All rights reserved.",Non-OADS,/arxiv_data1/oa_pdf/3a/f6/medi-95-e3013.PMC4839895.pdf
"Among the various study outcomes, only 19 studies could be classified into a specific range of CKD stages during follow-up (Supplementary Table 4, http://links.lww.com/MD/A765).",Non-OADS,/arxiv_data1/oa_pdf/3a/f6/medi-95-e3013.PMC4839895.pdf
"Effects of Male Sex on Progression of CKD The effects for male sex were assessed in 4 studies with patients of CKD stages 3 to 5 or 4 to 5 at baseline, and ESRD asthe study outcome (Supplementary Table 4, http://links.lww.-com/MD/A765).",OADS,/arxiv_data1/oa_pdf/3a/f6/medi-95-e3013.PMC4839895.pdf
"Effects of Baseline Proteinuria on Progression of CKD The influence of baseline proteinuria >1 g/day on the outcome of ESRD was evaluated in 3 studies with patients of CKD stages 3 to 5 or 4 to 5 at baseline (Supplementary Table4, http://links.lww.com/MD/A765).21,22,24A total of 6017 FIGURE 1.",OADS,/arxiv_data1/oa_pdf/3a/f6/medi-95-e3013.PMC4839895.pdf
"See supplementary references for studies included in the systematic review, http://links.lww.com/MD/A765.Tsai et al Medicine /C15Volume 95, Number 11, March 2016 4|www.md-journal.com Copyright #2016 Wolters Kluwer Health, Inc. All rights reserved.",Non-OADS,/arxiv_data1/oa_pdf/3a/f6/medi-95-e3013.PMC4839895.pdf
"See supplementary references for studies included in the systematic review, http://links.lww.com/MD/A765.Medicine /C15Volume 95, Number 11, March 2016 Risk Factors for CKD Copyright #2016 Wolters Kluwer Health, Inc. All rights reserved.",Non-OADS,/arxiv_data1/oa_pdf/3a/f6/medi-95-e3013.PMC4839895.pdf
"There was substantial heterogeneity ( I2¼89.5%; P<0.001) among the studies, but no publication bias ( P¼0.08) was found (Supplementary Figures 1B and 2B, http://links.lww.com/MD/A765).",OADS,/arxiv_data1/oa_pdf/3a/f6/medi-95-e3013.PMC4839895.pdf
"Effects of Diabetes on Progression of CKD The impacts of diabetes on the outcome of ESRD were analyzed in 4 studies with patients of CKD stages 3 to 5 or 4 to 5 at baseline (Supplementary Table 4, http://links.lww.com/MD/ A765).20–23A total of 7724 patients with a diabetes prevalence of 32% were assessed in the meta-analysis.",OADS,/arxiv_data1/oa_pdf/3a/f6/medi-95-e3013.PMC4839895.pdf
"There was low heterogeneity ( I 2¼28.2%; P¼0.24) and no evidence of publication bias ( P¼0.59) among the studies (Supplementary Figures 1C and 2C, http://links.lww.com/MD/A765).",Non-OADS,/arxiv_data1/oa_pdf/3a/f6/medi-95-e3013.PMC4839895.pdf
"http://www.ohri.ca/programs/clinical_epidemiology/nosgen.pdf (accessed January 18, 2016).",Non-OADS,/arxiv_data1/oa_pdf/3a/f6/medi-95-e3013.PMC4839895.pdf
"Notably, there were insufficient data for the type IV PVTT patients (Supplement Table 1, http://links.lww.com/ MD/A762), and the prognoses of the different treatments forthis group of patients were not analyzed.",Non-OADS,/arxiv_data1/oa_pdf/70/79/medi-95-e3015.PMC4839896.pdf
"Supplement Table 2, http://links.lww.com/MD/A762), and the results of this combinedtreatment were not compared with other treatments.",Non-OADS,/arxiv_data1/oa_pdf/70/79/medi-95-e3015.PMC4839896.pdf
"Supplement Tables 3 to 8, http://links.lww.com/MD/ A762, show the comparison between the groups of patients who underwent multiple treatments for each of the different types of PVTT.",Non-OADS,/arxiv_data1/oa_pdf/70/79/medi-95-e3015.PMC4839896.pdf
"Notably, no PS matching was carried out for the characteristics of type III PVTT patients who underwent TACE-Sor or TACE-RT because the raw data werewell balanced (Supplement Table 7, http://links.lww.com/MD/ A762).",Non-OADS,/arxiv_data1/oa_pdf/70/79/medi-95-e3015.PMC4839896.pdf
"Before PS matching, the survival profiles of the subtypes of PVTT patients are shown in Table 2 and Supplement Figure 1A http://links.lww.com/MD/A762.",Non-OADS,/arxiv_data1/oa_pdf/70/79/medi-95-e3015.PMC4839896.pdf
http://arxiv.org/ find/stat/1/au:+Thoemmes_F/0/1/0/all/0/1 or http://arxiv.org/abs/1201.6385 15.,OADS,/arxiv_data1/oa_pdf/70/79/medi-95-e3015.PMC4839896.pdf
"Survey Development and Instrument (I) Rehab-preference survey for studying the opinions and expectation on game-based rehabilitation systems The survey is conducted by a questionnaire (QN.I, see in supplementary document, http://links.lww.com/MD/A838) forpatients, which consists of 54 questions which are either multiple-choice or free-response questions.",Non-OADS,/arxiv_data1/oa_pdf/02/37/medi-95-e3032.PMC4839901.pdf
"We designed the questionnaire (QN.II, seein supplementary document, http://links.lww.com/MD/A838)consists of 8 rating components and is divided into 4 parts.",Non-OADS,/arxiv_data1/oa_pdf/02/37/medi-95-e3032.PMC4839901.pdf
The questionnaire was conducted by 7-point Likert-scale and built with Google Forms (http://goo.gl/fduXyw).,OADS,/arxiv_data1/oa_pdf/02/37/medi-95-e3032.PMC4839901.pdf
"Game Used in the Study Code Game Name Genre Download Link g01 Flow Frenzy Puzzle http://goo.gl/czem3E g02 Pudding Pop Mobile Puzzle http://goo.gl/6IsjBFg03 Jewels Star Casual http://goo.gl/nY7TlD g04 Candy Crush Saga Casual http://goo.gl/2DTnyo g05 Block Puzzle Puzzle http://goo.gl/VAJnz1g06 Kids Slide Puzzle Puzzle http://goo.gl/9qTrzjg07 Angry Birds Arcade http://goo.gl/Pz6RpY g08 Fruits Slice Action http://goo.gl/CU9Yz2 g09 3D Bowling Sports http://goo.gl/QInmUSg10 Basketball Shoot Sports http://goo.gl/GJrCWlg11 Temple Run Arcade http://goo.gl/WHXAtD g12 Subway Surfers Arcade http://goo.gl/n7xIO7 g13 Super Laser Arcade http://goo.gl/rWBjv8g14 Klondike Card http://goo.gl/2BGohk g15 Diamond Blast Arcade http://goo.gl/Ka6k06 g16 Kick Zombie Casual http://goo.gl/14PCxFg17 Tap the Frog Arcade http://goo.gl/G70lqrg18 Fruit Memory Game Puzzle http://goo.gl/LXycbj g19 Memory Games Puzzle http://goo.gl/cPnoHg g20 Mahjong Card http://goo.gl/ECS6yag21 Hunting Birds Arcade http://goo.gl/EYYkP9g22 Balloon Party Casual http://goo.gl/LPCpTx g23 Marble Blast 3 Casual http://goo.gl/FVQbBR g24 Piano Master Music http://goo.gl/K2fexLMedicine /C15Volume 95, Number 11, March 2016 Rehabilitation With Game Copyright #2016 Wolters Kluwer Health, Inc. All rights reserved.",Non-OADS,/arxiv_data1/oa_pdf/02/37/medi-95-e3032.PMC4839901.pdf
"To know their opinions on current game-basedrehabilitation systems, we ask them the following questions which are cited from the questionnaire for patients (QN.I, see in supplementary document, http://links.lww.com/MD/A838) inorder to see whether the OTs’ opinions are consistent with thestroke patients’ responses.",Non-OADS,/arxiv_data1/oa_pdf/02/37/medi-95-e3032.PMC4839901.pdf
"Finding 6: A Simple Rule, Based on Therapists’ Knowledge, of Selecting Commercial Games for Rehabilitation In rehab-compatibility survey, we obtained ratings of 6 features and 2 overall assessments, compatibility and difficulty, of each game from the questionnaire (QN.II, see in supple- mentary document, http://links.lww.com/MD/A838).",Non-OADS,/arxiv_data1/oa_pdf/02/37/medi-95-e3032.PMC4839901.pdf
"http://www.mohw.gov.tw/EN/Ministry/Statistic.aspx?f_list_no=474&fod_list_no=5653 (accessed March 2, 2016).",Non-OADS,/arxiv_data1/oa_pdf/02/37/medi-95-e3032.PMC4839901.pdf
http://www.asha.org/public/speech/dis- orders/Aphasia/.,Non-OADS,/arxiv_data1/oa_pdf/02/37/medi-95-e3032.PMC4839901.pdf
http://www.nintendo.com/wii/what-is-wii/.16.,Non-OADS,/arxiv_data1/oa_pdf/02/37/medi-95-e3032.PMC4839901.pdf
https://www.playstation.com/ en-us/home/.,Non-OADS,/arxiv_data1/oa_pdf/02/37/medi-95-e3032.PMC4839901.pdf
Kinect for Xbox 360. http://www.xbox.com/en-US/Kinect.18.,Non-OADS,/arxiv_data1/oa_pdf/02/37/medi-95-e3032.PMC4839901.pdf
Xperia TMTablet Z. http://www.sonymobile.com/ca-en/pro- ducts/tablets/xperia-tablet-z/.,Non-OADS,/arxiv_data1/oa_pdf/02/37/medi-95-e3032.PMC4839901.pdf
http://goo.gl/ 2F1EWs.,Non-OADS,/arxiv_data1/oa_pdf/02/37/medi-95-e3032.PMC4839901.pdf
http://goo.gl/st3YfO.32.,Non-OADS,/arxiv_data1/oa_pdf/02/37/medi-95-e3032.PMC4839901.pdf
http://goo.gl/5Txgfq.33.,Non-OADS,/arxiv_data1/oa_pdf/02/37/medi-95-e3032.PMC4839901.pdf
http://www.novint.com/index.php/ novintfalcon.,Non-OADS,/arxiv_data1/oa_pdf/02/37/medi-95-e3032.PMC4839901.pdf
http://www.reha-stim.de/cms/index.php?,Non-OADS,/arxiv_data1/oa_pdf/02/37/medi-95-e3032.PMC4839901.pdf
http://www.reha-stim.de/cms/index.php?,Non-OADS,/arxiv_data1/oa_pdf/02/37/medi-95-e3032.PMC4839901.pdf
http://kk14112.hi178.com/T5004ShowCmdy Data?&y_SketchName=Sketch1–2_Hi178&y_KindId=948115&y_HrefId=147919&y_CompId=215&&y_MuId=.,OADS,/arxiv_data1/oa_pdf/02/37/medi-95-e3032.PMC4839901.pdf
http://www.rehabfun.com/.,Non-OADS,/arxiv_data1/oa_pdf/02/37/medi-95-e3032.PMC4839901.pdf
http://www.pocket- gamer.biz/metrics/app-store/categories/.,Non-OADS,/arxiv_data1/oa_pdf/02/37/medi-95-e3032.PMC4839901.pdf
"http://www.app- brain.com/stats/android-market-app-categories.Hung et al Medicine /C15Volume 95, Number 11, March 2016 10 |www.md-journal.com Copyright #2016 Wolters Kluwer Health, Inc. All rights reserved.",Non-OADS,/arxiv_data1/oa_pdf/02/37/medi-95-e3032.PMC4839901.pdf
"Figure 1, http://links.lww.com/MD/A761).",Non-OADS,/arxiv_data1/oa_pdf/f2/d3/medi-95-e3038.PMC4839904.pdf
HGVS nomenclature (URL: http://www.hgvs.org/mutnomen/) was used for the sequence variations.,OADS,/arxiv_data1/oa_pdf/f2/d3/medi-95-e3038.PMC4839904.pdf
"Material, http://links.lww.com/MD/A761).",Non-OADS,/arxiv_data1/oa_pdf/f2/d3/medi-95-e3038.PMC4839904.pdf
The VWF gene mutations in our patients were screened in both the international literature (www.pubmed.com) and the databasesforVWF gene variations (Sheffield mutations database: http:// www.ragtimedesign.com/vwf/mutation/ and LOVD VWF data- base: https://grenada.lumc.nl/LOVD2/VWF/home.php?se-lect_db=VWF) to determine their deleterious or candidatestatus.,OADS,/arxiv_data1/oa_pdf/f2/d3/medi-95-e3038.PMC4839904.pdf
"Parts of the data collection in this study were published 2014 in Swedish in a public report from the Swedish Association of Local Authorities and Regions, Stockholm, Sweden (http://www.patientforsakring.se/resurser/ dokument/forskning/Skador-i-vaarden-skadepanorama-och-kostnader-foer-kirurgi.pdf).",OADS,/arxiv_data1/oa_pdf/fc/32/medi-95-e3047.PMC4839907.pdf
We first did direct pairwise meta-analyses with Review Manager v5.3.5(http://tech.cochrane.org/revman/download) using random- effect model to evaluate pooled relative risk and 95% confidence intervals.,OADS,/arxiv_data1/oa_pdf/f2/bd/medi-95-e3060.PMC4839911.pdf
"Where- after, we performed random-effect Bayesian network meta-analyses using Markov chain Monte Carlo methods with Aggre- gate Data Drug Information System20v1.16.6 (http://drugis.org/ software/addis1/addis1.16) and presented the estimates as oddratios and the corresponding 95% credible intervals (95% CrI).Aggregate Data Drug Information System software is pro- grammed using the prior distribution of all parameters in Baye- sian analyses.",OADS,/arxiv_data1/oa_pdf/f2/bd/medi-95-e3060.PMC4839911.pdf
"Quality of Evidence To appraise the quality of evidences of current direct and network meta-analysis for the primary outcome, we adopted the Grading of Recommendations Assessment, Development andEvaluation (GRADE) method24–31and summarized and pre- sented the information with the online application of Guideline Developing Tool (GDT, previously known as GRADEpro) (http://www.guidelinedevelopment.org/).",OADS,/arxiv_data1/oa_pdf/f2/bd/medi-95-e3060.PMC4839911.pdf
"Risk of bias assessments of overall and study level are summarized in Figure 3 and Supplementary Digital Content,Figure 2, http://links.lww.com/MD/A766, respectively.",Non-OADS,/arxiv_data1/oa_pdf/f2/bd/medi-95-e3060.PMC4839911.pdf
"Data for direct pairwise comparisons for primary outcome are shown as forest plots in Figure 4 and, for secondaryoutcomes, Supplementary Digital Content, Figures 3.1–3.4, http://links.lww.com/MD/A766.",OADS,/arxiv_data1/oa_pdf/f2/bd/medi-95-e3060.PMC4839911.pdf
"Estimated effects of biologic agent regimens in network meta-analysis on ASAS20 are shown as league table in Figure 5 and Supplementary Digital Content, Figures 4.1 to 4.4, http://links.lww.com/MD/A766.",OADS,/arxiv_data1/oa_pdf/f2/bd/medi-95-e3060.PMC4839911.pdf
"Figure 6 and Supplementary Digital Content, Figures 5.1 to 5.4, http://links.lww.com/MD/A766 showed the rank prob- ability plots for primary outcome and secondary outcomes, respectively.",OADS,/arxiv_data1/oa_pdf/f2/bd/medi-95-e3060.PMC4839911.pdf
"Second, SNPs with a known allele frequency <5% in Asian or Chinese populations were excluded, based on data in the NationalCenter for Biotechnology Information SNP database (http://www.ncbi.nlm.nih.gov/snp/ ).",OADS,/arxiv_data1/oa_pdf/80/1a/medi-95-e3064.PMC4839912.pdf
"A total of 89 SNPsof 49 genes were analyzed in 3 multiplex reactions (supple-mental Table 1, http://links.lww.com/MD/A767).",OADS,/arxiv_data1/oa_pdf/80/1a/medi-95-e3064.PMC4839912.pdf
"The testing for Hardy–Weinberg equi-librium, linkage disequilibrium, association, and descriptiveanalysis of SNPs were performed using the SNPstata web site (http://bioinfo.iconcologia.net/SNPstats).",OADS,/arxiv_data1/oa_pdf/80/1a/medi-95-e3064.PMC4839912.pdf
"Candidate SNPs Associated With HBV-RS The allele and genotype frequencies of the 89 SNPs were analyzed by iPLEX assay and are listed in supplemental Table2, http://links.lww.com/MD/A767.",OADS,/arxiv_data1/oa_pdf/80/1a/medi-95-e3064.PMC4839912.pdf
"The remaining 74 SNPs were included in the HBV-RS association analysis(supplemental Table 3, http://links.lww.com/MD/A767).",OADS,/arxiv_data1/oa_pdf/80/1a/medi-95-e3064.PMC4839912.pdf
"Haplotypes Associated with HBV-RS The LD analysis of these 9 candidate SNPs showed LD between IL4rs2243248 and IL4rs2243263 ( r2¼0.9178) and between TNFSF13B rs12583006 and TNFSF13B rs12428930 (r2¼0.9813) (supplemental Tables 4 and 5, http://links.lww.- com/MD/A767).",Non-OADS,/arxiv_data1/oa_pdf/80/1a/medi-95-e3064.PMC4839912.pdf
"The 18 patients (17.3% of 104) who had IL4 rs2243248 T/G and did not develop HBV-RS also had IL4 rs2243263 C/G (supplemental Tables 3 and 5, http://links.lww.- com/MD/A767).",Non-OADS,/arxiv_data1/oa_pdf/80/1a/medi-95-e3064.PMC4839912.pdf
"Candidate Single Nucleotide Polymorphisms Associated With HBsAg Reverse Seroconversion After Rituximab Therapy Gene symbol/C3SNP IDyGenotype HBV-RS, No HBV-RS, Yes ORz(95% CI)zPValuezAIC BIC CCL5 rs2107538 C/C-C/T 78 (86.7%) 14 (100%) 1.00 0.054 82.5 87.8 T/T 12 (13.3%) 0 (0%) 0.00 (0.00-NA) CD40 rs1883832 C/C 26 (29.2%) 1 (7.1%) 1.00 0.052 82.1 87.4 C/T-T/T 63 (70.1%) 13 (92.9%) 5.37 (0.69–43.15) IL4 rs2243248 T/T 72 (80%) 14 (100%) 1.00 0.016 80.4 85.7 T/G 18 (20%) 0 (0%) 0.00 (0.00-NA) IL4 rs2243263 G/G 69 (76.7%) 14 (100%) 1.00 0.0089 79.3 84.6 C/G 21 (23.3%) 0 (0%) 0.00 (0.00-NA) IL13 rs1295686 G/G-A/G 83 (92.2%) 10 (71.4%) 1.00 0.039 81.9 87.2 A/A 7 (7.8%) 4 (28.6%) 4.74 (1.18–19.09) IL18 rs243908 T/T 67 (76.1%) 7 (50%) 1.00 0.052 81.8 87.1 C/T-C/C 21 (23.9%) 7 (50%) 3.19 (1.00–10.14) IL20 rs1518108 C/C 58 (64.4%) 5 (35.7%) 1.00 0.043 82.1 87.4 C/T-T/T 32 (35.6%) 9 (64.3%) 3.26 (1.01–10.57) TNFSF13B rs12428930 A/A 32 (35.6%) 1 (7.1%) 1.00 0.018 80.6 85.9 A/C-C/C 32 (35.6%) 13 (92.9%) 7.17 (0.90–57.37) TNFSF13B rs12583006 T/T 31 (34.8%) 1 (7.1%) 1.00 0.02 80.5 85.8 A/T-A/A 58 (65.2%) 13 (92.9%) 6.95 (0.87–55.63) AIC¼Akaike Information Criterion, BIC ¼Bayesian Information Criterion, CI ¼conﬁdence interval, HBsAg ¼hepatitis B virus surface antigen, HBV-RS ¼reverse seroconversion of hepatitis B virus surface antigen, OR ¼odds ratio, SNP ¼single nucleotide polymorphism./C3Used in the gene resource (http://www.ncbi.nlm.nih.gov/gene/).",Non-OADS,/arxiv_data1/oa_pdf/80/1a/medi-95-e3064.PMC4839912.pdf
yUsed in the dbSNP resource (http://www.ncbi.nlm.nih.gov/snp/).,OADS,/arxiv_data1/oa_pdf/80/1a/medi-95-e3064.PMC4839912.pdf
"IL4 is produced by type 2 helper T (Th2) cells and can costimulate B-cell proliferation.27For possible mechanisms by which IL4 influences rituximab-associated HBV-RS, IL4could suppresses the expression and the replication of HBV in the hepatocellular carcinoma cell line Hep3B,28but rituximab was shown to cause a 12-fold peak-decrease of IL4mRNA in whole blood.29A lower IL4 level was associated with a lower anti-HBs level after HBV vaccination in HIV patients.30Total 6 SNPs of IL4 were genotyped in this study (supplemental Table 1, http://links.lww.com/MD/A767), including rs2243248located in the promoter region, rs2070874 in the 5 0untranslatedTABLE 3.",Non-OADS,/arxiv_data1/oa_pdf/80/1a/medi-95-e3064.PMC4839912.pdf
"39Two IL18 SNPs – rs243908 and rs187238 were geno- typed in this study (supplemental Table 1, http://links.lww.com/ MD/A767), based on the association of lymphoma40and HBV infection,41respectively.",Non-OADS,/arxiv_data1/oa_pdf/80/1a/medi-95-e3064.PMC4839912.pdf
"transcriptional activity of the IL18 promoter,42and even with serum IL18 levels.43IL18 rs187238 and several other IL18 SNPs were reported to be associated with chronic HBV infec-tion,44the development of hepatocellular hepatoma, and the clearance of HBV.45Unfortunately, we were unable to include rs187238 in our analysis because it showed a low call rate(supplemental Tables 1 and 2, http://links.lww.com/MD/A767).On the other hand, IL18 rs243908 was also located in 5 0 untranslated region, and the relationship with IL18 secretion was not understood.",Non-OADS,/arxiv_data1/oa_pdf/80/1a/medi-95-e3064.PMC4839912.pdf
"As shown in SupplementaryTables 1 and 2, http://links.lww.com/MD/A770, the risk of AKIwas significant for patients with NASDs (HR ¼1.47; 95% CI¼1.21–1.79, P<0.001).",Non-OADS,/arxiv_data1/oa_pdf/2e/16/medi-95-e3067.PMC4839913.pdf
Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.,Non-OADS,/arxiv_data1/oa_pdf/8f/d0/medi-95-e3070.PMC4839915.pdf
"the A1 allele increased PTSD risk (eTable 1, http://links.lww.",Non-OADS,/arxiv_data1/oa_pdf/e4/a8/medi-95-e3074.PMC4839917.pdf
"All studies seemed to indicate that the 9R increasedPTSD risk (eTable 2, http://links.lww.com/MD/A774).",Non-OADS,/arxiv_data1/oa_pdf/e4/a8/medi-95-e3074.PMC4839917.pdf
"Our meta-analysis did not find a significant association of homozygous TT with PTSD risk (OR ¼1.55, 95% CI: 0.39– 6.20; P¼0.536; eTable 4, http://links.lww.com/MD/A774).",OADS,/arxiv_data1/oa_pdf/e4/a8/medi-95-e3074.PMC4839917.pdf
"We did not find a significant association of rs1800497 with PTSD resilience (OR ¼5.23, 95% CI: 0.30– 90.03; P¼0.255; eTable 1, http://links.lww.com/MD/A774), probably due to larger variance owing to reduced sample size.",Non-OADS,/arxiv_data1/oa_pdf/e4/a8/medi-95-e3074.PMC4839917.pdf
"No significant difference in Remuzzi score was observed between the RGF and the IGF groups (data not shown).36 NGAL, KIM-1, and L-FABP were detected in 66.7%, 14.3%, and 95.2% of samples, respectively (Supplemental Figure 1, http://links.lww.com/MD/A779).",OADS,/arxiv_data1/oa_pdf/7a/9a/medi-95-e3076.PMC4839919.pdf
"Validation of the best-fit model with 1000 bootstrap resamples showed that the estimate of optimism was 0.064 and the bias-adjusted AUROC of the best-fit model was 0.752(Supplemental Figure 2, http://links.lww.com/MD/A779).The estimates of both models were generally linear and agreed well with the ideal line.",Non-OADS,/arxiv_data1/oa_pdf/7a/9a/medi-95-e3076.PMC4839919.pdf
"Data Analysis Processing Steps in Diffeomorphic Anatomical Registration Through the Exponentiated LieAlgebra (DARTEL)-Based T1 VBM T1-weighted structural MRI imaging data were analyzed using VBM, the VBM8 toolbox (htt p://dbm.neuro.uni-jena.de), and the Statistical Parametric M apping software program (SPM8, Wellcome Institute of Neurology, University College London, UK, http://www.fil.ion.ucl.ac.uk/ spm/) with default settings as described in the manual for the VBM8 toolbox.",OADS,/arxiv_data1/oa_pdf/ba/6d/medi-95-e3086.PMC4839925.pdf
"The Peak_nii toolbox (http://www.nitrc.org/pro- jects/peak_nii) was used to assess significant between-group main effects of cluster properties, including cluster size, maxi-mum Z-score, corresponding location of MNI coordinates, andanatomical structure.",OADS,/arxiv_data1/oa_pdf/ba/6d/medi-95-e3086.PMC4839925.pdf
"We also detected the expression of BAFF, which is a highly homologous member with APRIL in TNFSF family, in T- and B-lymphocytes, and we found that the upregulated BAFFexpression was also observed in B-lymphocytes, but not in T-lymphocytes (Supplementary Figure 1, http://links.lww.com/ MD/A825), which was consistent with the previous study thatthe expression of APRIL always positively correlated with thatof BAFF.",Non-OADS,/arxiv_data1/oa_pdf/b6/00/medi-95-e3099.PMC4839931.pdf
Data Preprocessing Functional image preprocessing was performed using the Data Processing Assistant for Resting-State fMRI (DPARSF)(http://www.restfmri.net)19and SPM8 tool kits (http://www.,OADS,/arxiv_data1/oa_pdf/18/c2/medi-95-e3101.PMC4839933.pdf
"We used the RESting-state fMRI data analysis Toolkit (REST) software(http://sourceforge.net/projects/resting-fmri) to calculate the time series of every voxel and its nearest voxels for regional homogeneity 1 by 1, to obtain the individual ReHo map.",OADS,/arxiv_data1/oa_pdf/18/c2/medi-95-e3101.PMC4839933.pdf
"The cut-off point of <400 copies/mL to define virological suppression was chosen to avoid exclusion of patients becauseof the occurrence of ‘‘blips,’’ defined as transient increases in plasma HIV-RNA, typically <400 copies/mL, which are not predictive of virologic failure (https://aidsinfo.nih.gov/guide-lines/html/1/adult-and-adolescent-treatment-guidelines/0).Exclusion criteria were antiretroviral regimens with only 1 follow-up visit, and those in which data about the CD4/CD8 cell ratio or the regimen composition were missing.",Non-OADS,/arxiv_data1/oa_pdf/eb/0c/medi-95-e3108.PMC4839936.pdf
"Statistical analyses of the data were performed in R,version 3.0.2 (R Foundation for Statistical Computing, Vienna, Austria, URL http://www.R-project.org/).",OADS,/arxiv_data1/oa_pdf/eb/0c/medi-95-e3108.PMC4839936.pdf
"From an age-adjusted model, physicalactivity (other than walking) at least once a week and over- weight were associated with decreased risk of all-cause demen- tia, while depression and higher levels of fasting glucose(/C215.6 mmol/L) were associated with an increased risk of dementia (see Table 1, Supplemental Content, which contains the results from the age-adjusted model, http://links.lww.com/MD/A780).",Non-OADS,/arxiv_data1/oa_pdf/c5/86/medi-95-e3112.PMC4839938.pdf
"The MEDLINE (through PubMed), CochraneLibrary, and Embase (through Ovid SP) databases were searched systematically from their inception to July 2015 (see eMethods, Supplemental Content 1, http://links.lww.com/MD/A803, foran illustration of the search strategies).",OADS,/arxiv_data1/oa_pdf/40/89/medi-95-e3117.PMC4839942.pdf
"9See Supplemental Content 2, http://links.lww.com/MD/A803 for further details.",Non-OADS,/arxiv_data1/oa_pdf/40/89/medi-95-e3117.PMC4839942.pdf
"The characteristics and quality assessment of the included studies are shown in Table 1 and in the Supplemental Table (seeTable, Supplemental Content 2, http://links.lww.com/MD/ A803, which illustrates the quality of the included studies).",Non-OADS,/arxiv_data1/oa_pdf/40/89/medi-95-e3117.PMC4839942.pdf
"The charac- teristics of the patients in the included studies are shown in theSupplemental Table, (see Table, Supplemental Content 3, http://links.lww.com/MD/A803, which illustrates the charac- teristics of the patients in the included studies and reference ofthose included studies).",Non-OADS,/arxiv_data1/oa_pdf/40/89/medi-95-e3117.PMC4839942.pdf
"There was a significantly higher incidence of the other individualoutcomes in the nonobstructive CAD group than in the normalartery group (see Table, Supplemental Content 4, http:// links.lww.com/MD/A803 which demonstrates the poorer prog- nosis of patients with nonobstructive CAD for all outcomes).The statistical sensitivity analysis obtained similar results (see Figure, Supplemental Content 5, http://links.lww.com/MD/ A803, which shows the similar results obtained for each mainoutcome when statistical sensitivity analyses were performed).",Non-OADS,/arxiv_data1/oa_pdf/40/89/medi-95-e3117.PMC4839942.pdf
"If revascularization was excluded from the combined endpoint,the pooled OR was 1.93 (95%CI, 1.72–2.16) in the fixed effects model and 1.88 (95% 1.67–2.11) in the random effects model.The statistical sensitivity analysis obtained similar results (see Figure, Supplemental Content 5, http://links.lww.com/MD/A803, which shows the similar results obtained in the statisticalsensitivity analyses performed for each main outcome).",OADS,/arxiv_data1/oa_pdf/40/89/medi-95-e3117.PMC4839942.pdf
"However, furtheranalysis of the individual events in the Supplemental Content 4 , http://links.lww.com/MD/A803 supported the conclusions reached above.",Non-OADS,/arxiv_data1/oa_pdf/40/89/medi-95-e3117.PMC4839942.pdf
"Available from: http://www.ohri.ca/programs/ clinical_epidemiology/oxford.asp (Accessed March 5, 2016).",Non-OADS,/arxiv_data1/oa_pdf/40/89/medi-95-e3117.PMC4839942.pdf
"24 MATERIALS AND METHODS This systematic review and meta-analysis was registered in http://www.crd.york.ac.uk/PROSPERO, and the registration number is CRD42015024184.",Non-OADS,/arxiv_data1/oa_pdf/35/18/medi-95-e3134.PMC4839950.pdf
National CancerInstitute; 2013. http://seer.cancer.gov/csr/1975_2010.,Non-OADS,/arxiv_data1/oa_pdf/35/18/medi-95-e3134.PMC4839950.pdf
2013;32:82http://www.jeccr.com/content/32/1/82.,Non-OADS,/arxiv_data1/oa_pdf/35/18/medi-95-e3134.PMC4839950.pdf
24. http://www.prisma-statement.org/25.,Non-OADS,/arxiv_data1/oa_pdf/35/18/medi-95-e3134.PMC4839950.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/32/c1/cia-11-423.PMC4839967.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2016:11 423–435Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  423RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S8946 5Multiple myeloma in the very elderly patient:  challenges and solutions John willan1 T oby A eyre1,2 Faye Sharpley1 Caroline watson1 Andrew J King1,3 Karthik Ramasamy1,4 1Department of Hematology, 2early  Phase Clinical Trial Unit, Oxford  University Hospitals National Health  Service (NHS) Foundation Trust,   Churchill Hospital, Oxford, UK;   3weatherall Institute of Molecular  Medicine, John Radcliffe Hospital,   Oxford, UK; 4National Institute for  Health Research (NIHR) Biomedical  Research Center Blood Theme,   Oxford, UKAbstract:  Diagnosis and management of myeloma in the very elderly patient is challenging.",Non-OADS,/arxiv_data1/oa_pdf/32/c1/cia-11-423.PMC4839967.pdf
"Stringent trial entry criteria typically exclude the majority of very elderly  patients due to reduced performance status, comorbidities, or organ dysfunction.9  Trial candidates over the age of 80, therefore, tend to be unusually fit and are not  representative of the typical very elderly patient.Correspondence: John willan Department of Hematology, Oxford  University Hospitals National Health  Service (NHS) Foundation Trust,  Churchill Hospital, Oxford OX3 7Le, UK Tel +44 1865 741 841 email john.willan@ouh.nhs.u k Journal name: Clinical Interventions in Aging Article Designation: Review Y ear: 2016 Volume: 11 Running head verso: Willan et al Running head recto: Myeloma in the very elderly DOI: http://dx.doi.org/10.2147/CIA.S89465",Non-OADS,/arxiv_data1/oa_pdf/32/c1/cia-11-423.PMC4839967.pdf
"Available from: http://seer.cancer.gov/csr/1975_2007/index.htm l.  Accessed February 4, 2016.",Non-OADS,/arxiv_data1/oa_pdf/32/c1/cia-11-423.PMC4839967.pdf
Available from: http://www.ncbi.nlm.nih.gov/ pubmed/1724267 0.,Non-OADS,/arxiv_data1/oa_pdf/32/c1/cia-11-423.PMC4839967.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/32/c1/cia-11-423.PMC4839967.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/32/c1/cia-11-423.PMC4839967.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a9/5a/dew044.PMC4840025.pdf
Available from: http://www.oecd.org/els/healthsystems/ Obesity-Update-2014.pdf.,Non-OADS,/arxiv_data1/oa_pdf/19/5a/WIITM-11-27162.PMC4840187.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/0c/7d/main.PMC4840235.pdf
Contents lists available at ScienceDirect Annals of Medicine and Surgery journal homepage: www.annalsjournal.com http://dx.doi.org/10.1016/j.amsu.2016.01.023 2049-0801/ ©2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/0c/7d/main.PMC4840235.pdf
http://www.vuoi.lt/index.php?1297062789 .,Non-OADS,/arxiv_data1/oa_pdf/0c/7d/main.PMC4840235.pdf
aNumber of different In ﬂuenza epitopes de ﬁned in the Immune Epitope Database and Analysis Resource (available online at http://www.iedb.org/home_v2.php).,OADS,/arxiv_data1/oa_pdf/c4/b5/icb201593a.PMC4840236.pdf
cAlleles that are unique to Indigenous Australians or particularly associated with this ethnic group (according to the IPD IMGT/HLA Database available online at http://www.ebi.ac.uk/ipd/imgt/hla/).,Non-OADS,/arxiv_data1/oa_pdf/c4/b5/icb201593a.PMC4840236.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by- nc-sa/4.0/ The Supplementary Information that accompanies this paper is available on the Immunology and Cel l Biology website (http://www.nature.com/icb)Indigenous Australians and in ﬂuenza EB Clemens et al 377 Immunology and Cell Biology",Non-OADS,/arxiv_data1/oa_pdf/c4/b5/icb201593a.PMC4840236.pdf
"The trial is registered at ClinicalTrial.gov, NCT01590316; the protocol is available in full at http://www.safeboosc.eu.",Non-OADS,/arxiv_data1/oa_pdf/08/e8/pr2015266a.PMC4840238.pdf
(http://www.crd.york.ac.uk/PROSPERO_REBRANDING/display_record.asp?ID=CRD42014010514).,Non-OADS,/arxiv_data1/oa_pdf/08/e8/pr2015266a.PMC4840238.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ Volume 79  |  N umber 4  |  april 2016       Pediatric RESEaRCH 535",Non-OADS,/arxiv_data1/oa_pdf/08/e8/pr2015266a.PMC4840238.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/),  which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/1b/f3/gev070.PMC4840262.pdf
PROAST version 50.8 (under development) was used to carry out  covariate BMD analysis for potency ranking (http://www.proast.nl) (29).,OADS,/arxiv_data1/oa_pdf/1b/f3/gev070.PMC4840262.pdf
"References  1. WHO (2015) Fact Sheet No 2012. http://www.who.int/mediacentre/ factsheets/fs102/en/ (accessed September 22, 2015).",OADS,/arxiv_data1/oa_pdf/1b/f3/gev070.PMC4840262.pdf
"Onchocerciasis—River Blindness, Fact Sheet No 95.  http://www.who.int/ mediacentre/factsheets/fs095/en/  3. WHO (2007) Onchocerciasis meeting of the International Task Force for Disease Education, Weekly Epidemiological Record, 1st June 2007, Nos 22/23, 82, pp.",Non-OADS,/arxiv_data1/oa_pdf/1b/f3/gev070.PMC4840262.pdf
"EMEA/CVMP/33128/2006- FINAL, http://www.ema.europa.eu/docs/ en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/ WC500014292.pdf.",Non-OADS,/arxiv_data1/oa_pdf/1b/f3/gev070.PMC4840262.pdf
https://www.gov.uk/government/uploads/system/ uploads/attachment_data/file/315698/assessment_of_threshold_for_in_ vivo_mutagens.pdf  12.,Non-OADS,/arxiv_data1/oa_pdf/1b/f3/gev070.PMC4840262.pdf
doi: http://dx.doi.org/10.1787/9789264091016-en  24.,Non-OADS,/arxiv_data1/oa_pdf/1b/f3/gev070.PMC4840262.pdf
"RIVM, http://www.rivm.nl/en/Library/Scien- tific/Models/PROAST (accessed September 22, 2015).",Non-OADS,/arxiv_data1/oa_pdf/1b/f3/gev070.PMC4840262.pdf
"http://CRAN.R-project.org/package=drsmooth   (accessed September 22, 2015).",Non-OADS,/arxiv_data1/oa_pdf/1b/f3/gev070.PMC4840262.pdf
"IPCS Inchem (1987) 770 Flubendazole (WHO Food Additive Series 31.  http://www.inchem.org/documents/jecfa/jecmono/v31je02.htm (accessed  September 22, 2015).",Non-OADS,/arxiv_data1/oa_pdf/1b/f3/gev070.PMC4840262.pdf
http://www.ema.,Non-OADS,/arxiv_data1/oa_pdf/1b/f3/gev070.PMC4840262.pdf
EMEA/CVMP (2001) Mebendazole Summary Report (2) EMEA/ MRL/781/01-FINAL March 2001. http://www.ema.europa.eu/docs/ en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500014873.pdf  44.,Non-OADS,/arxiv_data1/oa_pdf/1b/f3/gev070.PMC4840262.pdf
"http://www.fsc.go.jp/english/evalu- ationreports/vetmedicine/mebendazole_fs156_2010.pdf (accessed Sep- tember 22, 2015).Genotoxicity of flubendazole and its metabolites, 2016, Vol.",Non-OADS,/arxiv_data1/oa_pdf/1b/f3/gev070.PMC4840262.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/8a/3c/main.PMC4840266.pdf
Contents lists available at ScienceDirect International Journal for Parasitology: Parasites and Wildlife journal homepage: www.elsevier.com/locate/ijppaw http://dx.doi.org/10.1016/j.ijppaw.2015.11.004 2213-2244/ ©2015 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/8a/3c/main.PMC4840266.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/4a/a4/main.PMC4840267.pdf
Contents lists available at ScienceDirect International Journal for Parasitology: Parasites and Wildlife journal homepage: www.elsevier.com/locate/ijppaw http://dx.doi.org/10.1016/j.ijppaw.2015.12.002 2213-2244/ ©2015 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/4a/a4/main.PMC4840267.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ca/19/main.PMC4840268.pdf
Contents lists available at ScienceDirect International Journal for Parasitology: Parasites and Wildlife journal homepage: www.elsevier.com/locate/ijppaw http://dx.doi.org/10.1016/j.ijppaw.2015.11.003 2213-2244/ ©2015 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/ca/19/main.PMC4840268.pdf
"Consensus sequences were aligned to reference sequences obtained from NCBI ( http://www.ncbi.nlm.nih.gov/nuccore ) using MUSCLE or MAFFT ( Katoh et al., 2002; Edgar, 2004 ) with default parameters, followed by manual editing.",OADS,/arxiv_data1/oa_pdf/ca/19/main.PMC4840268.pdf
Individual sequences were analyzed using BLAST (Basic Local Alignment Search Tool) available on the NCBI website http://blast.ncbi.nlm.nih.gov/Blast.,OADS,/arxiv_data1/oa_pdf/ca/19/main.PMC4840268.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/ licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/07/d5/main.PMC4840270.pdf
1476-5586http://dx.doi.org/10.1016/j.neo.2016.02.004,OADS,/arxiv_data1/oa_pdf/07/d5/main.PMC4840270.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/ by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ef/d5/main.PMC4840271.pdf
1476-5586 http://dx.doi.org/10.1016/j.neo.2016.02.006,OADS,/arxiv_data1/oa_pdf/ef/d5/main.PMC4840271.pdf
http://dx.doi.org/10.1371/journal.pone.0031442 .,Non-OADS,/arxiv_data1/oa_pdf/ef/d5/main.PMC4840271.pdf
http://dx.doi.org/10.1111/neup.12244 [in press].,Non-OADS,/arxiv_data1/oa_pdf/ef/d5/main.PMC4840271.pdf
http://dx.doi.org/10.4161/21624011.2014.941734 .,Non-OADS,/arxiv_data1/oa_pdf/ef/d5/main.PMC4840271.pdf
http://dx.doi.org/10.1371/journal.pone.0145342 .,Non-OADS,/arxiv_data1/oa_pdf/ef/d5/main.PMC4840271.pdf
http://dx.doi.org/10.1186/s40425-014-0046-9 .,Non-OADS,/arxiv_data1/oa_pdf/ef/d5/main.PMC4840271.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/ by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/82/9b/main.PMC4840272.pdf
1476-5586http://dx.doi.org/10.1016/j.neo.2016.02.005,OADS,/arxiv_data1/oa_pdf/82/9b/main.PMC4840272.pdf
"4, 766–782http://dx.doi.org/10.3109/10428194.2015.1099647 REVIEW Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update Bruce D. Chesona, Wolfram Bruggerb, Gandhi Damajc, Martin Dreylingd, Brad Kahle, Eva Kimbyf, Michinori Ogurag, Eckhart Weidmannh, Clemens-Martin Wendtneriand Pier Luigi Zinzanij aLombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC, USA;bSchwarzwald-Baar Clinic, University of Freiburg, Villingen-Schwenningen, Germany;cUniversity Hospital, University of Basse-Normandie, Caen, France;dMedical Clinic, University Hospital of Munich, Munich, Germany;eUniversity of Wisconsin School of Medicine and Public Health, Madison, WI, USA;fCenter for Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden;gDepartment of Hematology, Tokai Central Hospital, Gifu, Japan;hDepartment of Oncology and Hematology, Krankenhaus Nordwest, Frankfurt, Germany;iKlinikum Schwabing, Academic Teaching Hospital of University of Munich, Munich, Germany;jInstitute of Hematology, University of Bologna, Bologna, Italy ABSTRACT Bendamustine has achieved widespread international regulatory approval and is a standard agent for the treatment for chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma and multiple myeloma.",Non-OADS,/arxiv_data1/oa_pdf/b2/92/ilal-57-766.PMC4840280.pdf
Available from: http://www.medicines.ie/medicine/14828/SPC/Levact+25mg+and+100+mg++powder+for+concentrate+for+solution+for+infusion/.OPTIMAL USE OF BENDAMUSTINE 781,Non-OADS,/arxiv_data1/oa_pdf/b2/92/ilal-57-766.PMC4840280.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b5/03/main.PMC4840285.pdf
Contents lists available at ScienceDirect Annals of Medicine and Surgery journal homepage: www.annalsjournal.com http://dx.doi.org/10.1016/j.amsu.2016.03.023 2049-0801/ ©2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/b5/03/main.PMC4840285.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/bf/f1/main.PMC4840287.pdf
Contents lists available at ScienceDirect Annals of Medicine and Surgery journal homepage: www.annalsjournal.com http://dx.doi.org/10.1016/j.amsu.2016.03.025 2049-0801/ ©2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/bf/f1/main.PMC4840287.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f8/5e/main.PMC4840288.pdf
1476-5586http://dx.doi.org/10.1016/j.neo.2016.03.002,OADS,/arxiv_data1/oa_pdf/f8/5e/main.PMC4840288.pdf
http://cancer.sanger.ac.uk/ cancergenome/projects/cosmic/ ; 2015.,Non-OADS,/arxiv_data1/oa_pdf/f8/5e/main.PMC4840288.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/f8/5e/main.PMC4840288.pdf
http://cancergenome.nih.gov/ .,Non-OADS,/arxiv_data1/oa_pdf/f8/5e/main.PMC4840288.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/8c/e9/main.PMC4840289.pdf
Contents lists available at ScienceDirect Annals of Medicine and Surgery journal homepage: www.annalsjournal.com http://dx.doi.org/10.1016/j.amsu.2016.03.024 2049-0801/ ©2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/8c/e9/main.PMC4840289.pdf
This is an open access article under the CC BY-NC-ND license(http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/34/b4/main.PMC4840290.pdf
1476-5586http://dx.doi.org/10.1016/j.neo.2016.03.001,OADS,/arxiv_data1/oa_pdf/34/b4/main.PMC4840290.pdf
Material and Methods Bioinformatics Analysis of Microarray Data Microarray data was obtained from NCBI-GEO ( http://www.ncbi.,OADS,/arxiv_data1/oa_pdf/34/b4/main.PMC4840290.pdf
The significantly up- and down-regulated genes were uploaded separately to DAVID Bioinfor- matics Resource ( https://david.ncifcrf.gov ).,OADS,/arxiv_data1/oa_pdf/34/b4/main.PMC4840290.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0 ).,Non-OADS,/arxiv_data1/oa_pdf/b0/c0/main.PMC4840291.pdf
1476-5586 http://dx.doi.org/10.1016/j.neo.2016.01.006,OADS,/arxiv_data1/oa_pdf/b0/c0/main.PMC4840291.pdf
While the genomic organization of spRAG1L andspRAG2L (RAG1L genes in S. purpuratus ) [Keywords : RAG; Transib; V(D)J recombination; evolution; transposition] Corresponding author: senra@mail.nih.govArticle is online at http://www.genesdev.org/cgi/doi/10.1101/gad.281014.116.This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (seehttp://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/78/6f/873.PMC4840292.pdf
"After six months, it isavailable under a Creative Commons License (Attribution-NonCommer-cial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.",Non-OADS,/arxiv_data1/oa_pdf/78/6f/873.PMC4840292.pdf
[Keywords : p53; tumor suppression; metabolism; ferroptosis; polymorphism; Ser46 phosphorylation]Corresponding author: dplane@p53lab.a-star.edu.sgArticle is online at http://www.genesdev.org/cgi/doi/10.1101/gad.281733.116.© 2016 Lane This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date(see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/ae/50/876.PMC4840293.pdf
"After six months, itis available under a Creative Commons License (Attribution-NonCom-mercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.",Non-OADS,/arxiv_data1/oa_pdf/ae/50/876.PMC4840293.pdf
"[Keywords : anti-apoptotic Bcl-2 proteins; BH3-only; Bax/Bak activation; outer mitochondrial membrane]Corresponding author: andreas.villunger@i-med.ac.atArticle is online at http://www.genesdev.org/cgi/doi/10.1101/gad.281519.116.© 2016 Sáez and Villunger This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).After six months, it is available under a Creative Commons License (At-tribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.",Non-OADS,/arxiv_data1/oa_pdf/6f/93/878.PMC4840294.pdf
"In other experiments, depletion of CTCF [Keywords : chromatin; insulators; topologically associated domains] Corresponding author: gary.felsenfeld@nih.govArticle is online at http://www.genesdev.org/cgi/doi/10.1101/gad.277863.116.This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (seehttp://genesdev.cshlp.org/site/misc/terms.xhtml).",Non-OADS,/arxiv_data1/oa_pdf/3d/80/881.PMC4840295.pdf
"After six months, it isavailable under a Creative Commons License (Attribution-NonCommer-cial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.",Non-OADS,/arxiv_data1/oa_pdf/3d/80/881.PMC4840295.pdf
Someconsensus regarding the hallmarks of MICs has started [Keywords : cancer metastasis; plasticity; epithelial –mesenchymal transition; metastasis-initiating cells; metastatic niche]Corresponding author: ykang@princeton.eduArticle is online at http://www.genesdev.org/cgi/doi/10.1101/gad.277681.116.© 2016 Celià-Terrassa and Kang This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/51/ff/892.PMC4840296.pdf
"After six months, it is available under a Creative Commons Li-cense (Attribution-NonCommercial 4.0 International), as described athttp://creativecommons.org/licenses/by-nc/4.0/.",Non-OADS,/arxiv_data1/oa_pdf/51/ff/892.PMC4840296.pdf
Article and publication date areonline at http://www.genesdev.org/cgi/doi/10.1101/gad.278432.116.© 2016 Carmona et al.,Non-OADS,/arxiv_data1/oa_pdf/f7/5f/909.PMC4840297.pdf
"This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).After six months, it is available under a Creative Commons License (At-tribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.",Non-OADS,/arxiv_data1/oa_pdf/f7/5f/909.PMC4840297.pdf
Article and publication date areonline at http://www.genesdev.org/cgi/doi/10.1101/gad.275891.115.© 2016 Jennis et al.,Non-OADS,/arxiv_data1/oa_pdf/6f/44/918.PMC4840298.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publi-cation date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/6f/44/918.PMC4840298.pdf
"Aftersix months, it is available under a Creative Commons License (At-tribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.",Non-OADS,/arxiv_data1/oa_pdf/6f/44/918.PMC4840298.pdf
"The S47 polymorphism appears to be restricted to Afri- can-descent populations, with a frequency of ∼1.5% in Af- rican Americans and between 6% and 8% in certainAfrican populations; in contrast, this variant has notbeen detected in Caucasian Americans (see http://evs.gs.washington.edu/EVS).",Non-OADS,/arxiv_data1/oa_pdf/6f/44/918.PMC4840298.pdf
"obtained from the Coriell Institute, which had been geno- typed as part of the 1000 Genomes Project (http://www.1000genomes.org) and identified and confirmed by us tobe homozygous S47 or wild type (see the Materials andMethods).",OADS,/arxiv_data1/oa_pdf/6f/44/918.PMC4840298.pdf
Article and publication date areonline at http://www.genesdev.org/cgi/doi/10.1101/gad.277665.116.© 2016 Horigome et al.,OADS,/arxiv_data1/oa_pdf/e9/78/931.PMC4840299.pdf
"This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).After six months, it is available under a Creative Commons License (At-tribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.",Non-OADS,/arxiv_data1/oa_pdf/e9/78/931.PMC4840299.pdf
Corresponding author: zhang.zhiguo@mayo.eduArticle is online at http://www.genesdev.org/cgi/doi/10.1101/gad.271841.115.© 2016 Wang et al.,OADS,/arxiv_data1/oa_pdf/c6/43/946.PMC4840300.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publi-cation date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/c6/43/946.PMC4840300.pdf
"Aftersix months, it is available under a Creative Commons License (At-tribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.",Non-OADS,/arxiv_data1/oa_pdf/c6/43/946.PMC4840300.pdf
Article and publication date areonline at http://www.genesdev.org/cgi/doi/10.1101/gad.276725.115.© 2016 O ’Neill et al.,Non-OADS,/arxiv_data1/oa_pdf/8f/05/973.PMC4840302.pdf
"This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).After six months, it is available under a Creative Commons License (At-tribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.",Non-OADS,/arxiv_data1/oa_pdf/8f/05/973.PMC4840302.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/OPEN",Non-OADS,/arxiv_data1/oa_pdf/c6/3a/srep24377.PMC4840343.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/9a/fa/main.PMC4840393.pdf
Contents lists available at ScienceDirect Annals of Medicine and Surgery journal homepage: www.annalsjournal.com http://dx.doi.org/10.1016/j.amsu.2016.03.039 2049-0801/ ©2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/9a/fa/main.PMC4840393.pdf
"55 (3) (2012) 340 e361, http://dx.doi.org/ 10.1097/MPG.0b013e3182662233 .",Non-OADS,/arxiv_data1/oa_pdf/9a/fa/main.PMC4840393.pdf
http://www.ncbi.nlm.,Non-OADS,/arxiv_data1/oa_pdf/9a/fa/main.PMC4840393.pdf
"28 (3) (2010) 501 e507, http://dx.doi.org/ 10.1159/000320409 .",Non-OADS,/arxiv_data1/oa_pdf/9a/fa/main.PMC4840393.pdf
"Colon Rectum 48 (11) (2005) 1997 e2009, http://dx.doi.org/10.1007/s10350-005-0180-z .",Non-OADS,/arxiv_data1/oa_pdf/9a/fa/main.PMC4840393.pdf
"106 (4) (2011) 574 e588, http://dx.doi.org/10.1038/ ajg.2010.481 .",Non-OADS,/arxiv_data1/oa_pdf/9a/fa/main.PMC4840393.pdf
"288 (4) (2005) G729 eG735, http://dx.doi.org/ 10.1152/ajpgi.00438.2004 .",Non-OADS,/arxiv_data1/oa_pdf/9a/fa/main.PMC4840393.pdf
http://www.ncbi.nlm.nih.gov/pubmed/15906768 (accessed 12.10.15).,Non-OADS,/arxiv_data1/oa_pdf/9a/fa/main.PMC4840393.pdf
"39 (2) (2004) 139 e143 discus- sion 139-143, http://www.ncbi.nlm.nih.gov/pubmed/14966727 (accessed 12.10.15).",Non-OADS,/arxiv_data1/oa_pdf/9a/fa/main.PMC4840393.pdf
"43(12) (2008) 2169 e2173, http://dx.doi.org/10.1016/j.jpedsurg.2008.08.045 .",OADS,/arxiv_data1/oa_pdf/9a/fa/main.PMC4840393.pdf
"37 (7) (2002) 1093 e 1097 discussion 1093-1097, http://www.ncbi.nlm.nih.gov/pubmed/12077779 (accessed 12.10.15).",Non-OADS,/arxiv_data1/oa_pdf/9a/fa/main.PMC4840393.pdf
"49 (1) (2009) 85 e89, http://dx.doi.org/10.1097/MPG.0b013e318198cd36 .",Non-OADS,/arxiv_data1/oa_pdf/9a/fa/main.PMC4840393.pdf
http://www.ncbi.nlm.nih.gov/pubmed/19815948 (accessed 12.10.15).,OADS,/arxiv_data1/oa_pdf/9a/fa/main.PMC4840393.pdf
http://www.ncbi.nlm.nih.gov/pubmed/20034235 (accessed 12.10.15).,OADS,/arxiv_data1/oa_pdf/9a/fa/main.PMC4840393.pdf
"[16] L.A. Coburn, X. Gong, K. Singh, et al., L-arginine supplementation improves responses to injury and in ﬂammation in dextran sulfate sodium colitis, PLoS One 7 (3) (2012) e33546, http://dx.doi.org/10.1371/journal.pone.0033546 .",Non-OADS,/arxiv_data1/oa_pdf/9a/fa/main.PMC4840393.pdf
http://www.pubmedcentral.nih.gov/articlerender.fcgi?,Non-OADS,/arxiv_data1/oa_pdf/9a/fa/main.PMC4840393.pdf
"32 (9) (1997) 920 e924, http://dx.doi.org/ 10.3109/00365529709011203 .",Non-OADS,/arxiv_data1/oa_pdf/9a/fa/main.PMC4840393.pdf
"Pain 7 (5) (2003) 397e406, http://dx.doi.org/10.1016/S1090-3801(02)00140-4 .",Non-OADS,/arxiv_data1/oa_pdf/9a/fa/main.PMC4840393.pdf
http://www.ncbi.nlm.nih.gov/pubmed/2159192 (accessed 12.10.15).,OADS,/arxiv_data1/oa_pdf/9a/fa/main.PMC4840393.pdf
https://www.nc3rs.org.uk/arrive-N.P.,Non-OADS,/arxiv_data1/oa_pdf/9a/fa/main.PMC4840393.pdf
http://www.ncbi.nlm.nih.gov/pubmed/8226803 (accessed 12.10.15).,OADS,/arxiv_data1/oa_pdf/9a/fa/main.PMC4840393.pdf
"277 (10) (2010) 2230 e2237, http://dx.doi.org/10.1111/j.1742-4658.2010.07640.x .",Non-OADS,/arxiv_data1/oa_pdf/9a/fa/main.PMC4840393.pdf
"277 (10) (2010) 2208 e2214, http://dx.doi.org/10.1111/j.1742-4658.2010.07637.x .N.P.",Non-OADS,/arxiv_data1/oa_pdf/9a/fa/main.PMC4840393.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/4d/f6/main.PMC4840394.pdf
Contents lists available at ScienceDirect Annals of Medicine and Surgery journal homepage: www.annalsjournal.com http://dx.doi.org/10.1016/j.amsu.2016.04.002 2049-0801/ ©2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/4d/f6/main.PMC4840394.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b6/d8/main.PMC4840395.pdf
Contents lists available at ScienceDirect Annals of Medicine and Surgery journal homepage: www.annalsjournal.com http://dx.doi.org/10.1016/j.amsu.2016.03.026 2049-0801/ ©2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/b6/d8/main.PMC4840395.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/3c/67/main.PMC4840396.pdf
Contents lists available at ScienceDirect Annals of Medicine and Surgery journal homepage: www.annalsjournal.com http://dx.doi.org/10.1016/j.amsu.2016.03.027 2049-0801/ ©2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/3c/67/main.PMC4840396.pdf
http://www.care-statement.org/ (accessed 22.03.16).,Non-OADS,/arxiv_data1/oa_pdf/3c/67/main.PMC4840396.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d6/43/main.PMC4840397.pdf
Contents lists available at ScienceDirect Annals of Medicine and Surgery journal homepage: www.annalsjournal.com http://dx.doi.org/10.1016/j.amsu.2016.03.028 2049-0801/ ©2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d6/43/main.PMC4840397.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ba/86/main.PMC4840398.pdf
Contents lists available at ScienceDirect Annals of Medicine and Surgery journal homepage: www.annalsjournal.com http://dx.doi.org/10.1016/j.amsu.2016.04.003 2049-0801/ ©2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/ba/86/main.PMC4840398.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/12/d3/main.PMC4840399.pdf
